Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/DK04/000922

International filing date: 28 December 2004 (28.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: DK
Number: PA 2003 01954
Filing date: 30 December 2003 (30.12.2003)

Date of receipt at the International Bureau: 11 February 2005 (11.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)

Kongeriget Danmark

Patent application No.: PA 2003 01954

Date of filing: 30 December 2003

Applicant:
(Name and address)

Københavns Universitet
Blegdamsvej 3B
DK-2200 København N
Denmark

Title: Compounds useful in the diagnosis and treatment of malaria

IPC: -

This is to certify that the attached documents are exact copies of the above mentioned patent application as originally filed.

Patent- og Varemærkestyrelsen
Økonomi- og Erhvervsministeriet

03 February 2005

Susanne Morsing

PATENT- OG VAREMÆRKESTYRELSEN

COMPOUNDS USEFUL IN THE DIAGNOSIS AND TREATMENT OF MALARIA

Field of the Invention

The present invention relates to the fields of preventing or treating malaria and it provides compounds, which are useful within these fields. These compounds may constitute parts of pharmaceutical compositions and vaccines and be used in methods of treatment, as medicaments and for the manufacture of compositions and/or these compounds may provide basis for a method of generating a vaccine against malaria. Furthermore, the invention relates to the use of these compounds as biotechnological tools and in *in vitro* diagnostic methods and kits.

General background

Malaria constitutes a permanent catastrophe. Annually, the disease kills between 1 and 2 million Africans and the economic losses due to malaria constitute a hindrance for economic development. In areas of stable malaria transmission the disease mainly affects children, because adults have acquired immunity. In these areas immunity to severe malaria and protection against malaria deaths is acquired early in life after a few clinical infections, whereas the acquisition of immunity that protect individuals from uncomplicated febrile malaria episodes is a much more sluggish process, requiring years of exposure. Thus, the epidemiological data indicate that immunity against severe disease is mediated through a different mechanism than immunity against uncomplicated disease, and that the targets on the parasites for these two kinds of malaria immunity are separate.

Malaria is caused by unicellular parasites living and multiplying asexually in the red blood cells (RBC). In each 48-hour cycle, the parasites invade RBC, multiply within them, and eventually burst them, before they go on to invade new RBC.

Plasmodium falciparum is the most virulent of the four species causing malaria and responsible for most malarial deaths. The particular virulence of *P. falciparum* is due to the ability of infected erythrocytes to adhere to a variety of host receptors on the endothelial lining such as ICAM-1, VCAM, thrombospondin, ELAM-1, and CD36, and avoid splenic clearance. Unchecked growth and the accumulation of sequestered parasites in vital organs such as the brain are crucial elements in the pathogenesis of severe malaria.

Sequestration is mediated through parasite-encoded, clonally variant surface antigens (VSA) inserted into the membrane of the infected RBC and is thought to be an immune evasion strategy evolved to avoid splenic clearance. The VSA expressed on infected

erythrocytes can be divided into serological types using plasma from individuals living in malaria endemic areas as typing reagents.

By flow cytometry analyses, two main serotypes have been defined, one, VSA_{SM} is mainly expressed by parasites causing severe and life-threatening *P. falciparum* malaria, and the other, VSA_{UM} is dominantly expressed during uncomplicated malaria infections in semi-immune individuals.

Naturally acquired immunity to malaria is mediated by plasma IgG, which control the growth of *P. falciparum*. VSAs are probably the main target of these antibodies, as acquisition of protection from *P. falciparum* malaria corresponds to a gradual accumulation of IgG with a broad range of VSA-specificities. Furthermore, VSA-specific immune responses steadily restrict the repertoire of VSA that are compatible with parasite survival, and drive VSA expression away from VSA_{SM} towards VSA_{UM} (Nielsen et al., 2002). VSA expression therefore is non-random as it depends on the degree of immunity in the infected host.

The best-characterised VSA are encoded by the *var* genes. This gene family, encompassing about 60 members per genome, encodes a highly polymorphic set of variant proteins, which collectively have been named *P. falciparum* erythrocyte membrane protein 1 (PfEMP1). These proteins are located on the surface of the *P. falciparum*-infected erythrocytes and have been shown to mediate adhesion to a number of host receptors.

The *var* genes contain a large variable 5' exon and a more conserved 3' exon separated by an intron. The 5' exon normally contains one or two Cysteine-rich Inter-Domain Regions (CIDR) and from two to seven domains designated DBL after their similarity to the Duffy Binding Ligand of *P. vivax* (Smith et al. 2000). A given parasite expresses only one PfEMP1 at a time, but in each generation a fraction of the daughter parasites may switch to expression of alternative PfEMP1 species through an unknown process. Different PfEMP1 molecules have different receptor specificities, and clonal switching between expression of the various *var* gene products in a mutually exclusive manner allows the parasite to modify its adhesion properties (Wahlgren et al., 1999).

Thus, the currently available data indicate that severe malaria is caused by parasites expressing a subset of PfEMP1 molecules and that antibodies directed against these are responsible for the protection against severe disease acquired early in life by children in endemic areas. It follows that the specific identification of the particular PfEMP1 molecules expressed by the parasites causing severe malaria is important for malaria vaccine development.

The obvious strategies followed in many laboratories are either to attempt to identify the *var* gene that is dominantly transcribed or to determine which PfEMP1 is expressed by parasites isolated from patients suffering from severe malaria.

Both strategies have been halted because the *var* genes show extensive intra- and inter-genomic variation.

Attempts to identify VSA_{SM}-type *var* gene transcription has been foiled because primer bias and concomitant transcription of several *var* genes makes it is impossible to quantify and compare transcription of these genes, when all the target nucleic acid sequences are not known. The proteomic approach has proved difficult, partly due to the variation in the repertoire already mentioned, partly because PfEMP1 is expressed at low levels on the surface of erythrocytes, and it has been difficult to obtain sufficient amounts of protein for a reliable mass spectrometry approach.

Frustrated by these efforts several laboratories has tried to identify the most relevant PfEMP1 by generating parasite lines with known adhesion phenotype using repeated rounds of panning and identifying the dominantly transcribed *var* genes. This approach has identified PfEMP1 molecules with a known receptor affinity, but since parasites causing severe malaria have never been shown to possess a common binding phenotype, the relevance of these PfEMP1 molecules in the pathogenesis of severe malaria is unclear.

The PfEMP1s constitute a large and polymorphic family. The proteins described in this application serve a unique function for the parasite in providing high growths rates in non-immune individuals and renders these parasites a unique serological phenotype. This discovery is of great potential importance because it makes it possible to design strategies that will specifically aim at reducing malaria deaths by preventing, diagnosing, and treating severe malaria.

The entire *P. falciparum* genome of one parasite isolate, 3D7, have previously been data-mined using bioinformatic tools. Based on both coding- and non-coding regions *var* genes have been found to group into three major groups (group A, B and C) and two intermediate groups B/A and B/C representing transitions between the three major groups. Group A consists of ten genes consistently identified as a distinct group by sequence analysis (Lavstsen et al. 2003).

Although the proposed grouping of *var* genes in 3D7 is common knowledge to a person skilled in the art and the sequence of the entire 3D7 *P. falciparum* genome is known as sequence submissions, information on function of SEQ ID 2, SEQ ID NO.: 4, and SEQ ID

NO.: 6 in the pathogenesis of malaria and their relevance for a vaccine against severe malaria has not previously been described.

In the 3D7 isolate, Group A contains 10 *var* genes of which we have identified three *var* genes, using a novel method, as being functionally relevant for development of a vaccine agasint severe malaria. However, the global repertoire of *var* genes is unknow, but estimated to encode more than 10^{27} possible variants PfEMP1.

Summary of the Invention

In essence, the inventive concept described herein is based on the observation that three genes, *PFD1235w/MAL7P1.1*, *PF11_0008*, and *PF13_0003* (referred to as SEQ ID NO.: 1, SEQ ID NO.: 3, and SEQ ID NO.: 5) are transcriptionally up-regulated in parasites of the species *Plasmodium falciparum*, when these parasites have been selected for increased antibody recognition by a novel selection method, described in the present application, using plasma from semi-immune children. This selection conway parasites a unique phenotype characteristic of parasites causing severe malaria. This phenotype is also obtained when parasites are selected for adhesion to a special kind of bone marrow derived endothelical cells and also results in the up-regulation of SEQ ID NO.: 1, SEQ ID NO.: 3, and SEQ ID NO.: 5. As the cytoadhesion to human endothelial cells and the antibody recognition of infected RBC is intimately linked to severe malaria, products of these genes provide for novel approaches to diagnosing and treating malaria prophylactically and/or therapeutically.

In the broadest sense, the present invention relates to the polypeptides, VAR4, VAR5, and VAR6 (referred to as SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6) encoded by SEQ ID NO.: 1, SEQ ID NO.: 3, and SEQ ID NO.: 5, respectively or parts hereof as well as polypeptides, which with respect to their sequence are identical in part to such sequences. In addition, the invention relates to the SEQ ID NO.: 1, SEQ ID NO.: 3, and SEQ ID NO.: 5 nucleic acid molecule or parts hereof as well as nucleic acid molecules, which with respect to their sequence are identical in part to such sequences.

A presently preferred embodiment relates to medical uses of any of the polypeptides and/or nucleic acids according to the present invention as well as methods of treatment of malaria comprising molecules of the invention.

Other aspects of the invention include pharmaceutical compositions and vaccines based on the molecules of the invention. In addition, the invention comprises polypeptides or nucleic acid molecules of the invention as medicaments, and the use of these polypeptides and nucleic acids for the manufacture of compositions, hereunder-immunogenic compositions

which are to administered in order to prophylactically or therapeutically reduce the incidence, prevalence or severity of malaria, especially severe malaria.

It is further within the scope of the present invention to provide a method of treatment and prevention of malaria, which comprises administering an effective amount of one or more of the described molecules of the invention to a subject.

It will appear that the mentioned polypeptides and nucleic acid molecules will also be useful as biotechnological tools. Therefore, the invention also relates to *in vitro* diagnostic methods, which comprise contacting a sample with polypeptides or nucleic acid molecules having the sequences described above, allowing *in vitro* reactions to occur and subsequently detecting any molecular complexes formed. These may for instance be complexes of antigens and antibodies. In some aspects of the invention, the polypeptides of the invention are parts of diagnostic kits. Alternatively, these kits may comprise antibodies, which specifically recognise such polypeptides. Kits may also compromise, but are not limited to oligonucleotides as part of diagnostic kits based on techniques such as array, PCR, and real-time quantitative PCR.

Detailed Description of the Invention

The new strategy

The present inventors have taken a novel approach and based their strategy on the hereby disclosed knowledge of the serological phenotype expressed by parasites causing severe malaria (VSA_{SM}) and the availability of all *var* genes sequences in the parasite line 3D7.

In culture 3D7 will normally express a typical VSA_{UM} serotype, thus the present inventors first developed a method to generate VSA_{SM} expressing 3D7 lines and then used quantitative real time PCR to identify the dominant *var* gene transcripts.

They hereafter made specific probes and antibodies, that allowed them to identify the PfEMP1 molecules expressed on the surface of the erythrocytes responsible for the serological phenotype carried by the selected parasite line.

This serological phenotype was also obtained when the 3D7 parasite line was selected for adhesion to bone marrow derived endothelial cells.

The relevance of the discovered PfEMP1 molecules were further substantiated by the fact that parasites expressing the molecules have a high growth rate in non-immune individuals, and that *var* genes with a high similarity to the discovered genes can be

identified in other parasites. Their approach is completely different from previous strategies of defining variant molecules responsible for binding to different receptors.

The strategy is based on both epidemiological studies showing that immunity to severe malaria is acquired more rapidly than protection from uncomplicated disease and sub-clinical infection findings indicating that VSA_{SM} constitute a restricted and antigenically conserved VSA subset, whereas VSA_{UM} are more diverse.

Together, these observations enabled developing of the disease-ameliorating strategies presented in the present application, which can protect against mortality and severe morbidity by accelerating acquisition of immunity to VSA_{SM}-expressing parasites and thereby forcing VSA expression away from VSA_{SM}.

As highlighted earlier *Plasmodium falciparum* erythrocyte membrane protein-1 (PfEMP1), are a highly polymorphic and diverse family of proteins. Every parasite genome carries about 60 genes encoding PfEMP1 and the repertoire of PfEMP1 genes differ from parasite genome to parasite genome. Thus, PfEMP1 genes show both intra- and inter-genomic variation, and the global repertoire of PfEMP1 proteins is unknown, but estimated to be very large, in fact the present inventors have estimated that there are more 10^{27} possible variants of this protein. The common features shared by the PfEMP1 family of genes and proteins are the organization of the genes (two exons and an intron), and the presence of domain structures that can be classified as Duffy Binding Ligand-like (DBL) or Cysteine-Rich Interdomain Region (CIDR).

In addition, the proteins share a relative conserved C-terminal tail consisting of a trans-membrane region and a relatively short intracellular domain. However, it must be stressed that the genes and the encoded proteins vary considerably between each other; both with regards to sequence (primary structure) and organization of the domains (Lavstsen et al., 2003).

It is also clear that expression of different PfEMP1 molecules confer parasite different functional (Smith et al., 2000; Robinson et al., 2003) and antigenic characteristics (Salanti et al., 2003). Within PfEMP1 domains classified as belonging to the same group and subgroup (i.e. DBLα, DBLβ, CIDRγ etc) short identity blocks of 2-14 amino acids can be identified between hyper variable blocks of varying lengths (of up to several hundred amino acids) in which there is no or very little homology between randomly chosen PfEMP1. Thus, PfEMP1 molecules constitute a very large and diverse family of proteins.

Inventive concept

The inventive concept disclosed in the present application is based on the unexpected observation that the transcription of 3 specific *Plasmodium falciparum var* genes, SEQ ID NO.: 1, SEQ ID NO.: 3, and SEQ ID NO.: 5, all members of Group A *var* genes, is up-regulated in parasite lines and clones carrying the VSA_{SM} phenotype. This up-regulation followed both after antibody-selection and selection for adhesion of infected RBC to bone marrow derived endothelial cells *in vitro*.

These observations shows that the proteins encoded by these three specific *var* genes are responsible for inducing the first IgG with specificity to PfEMP1 on iRBC and thus the dominant PfEMP1 expressed during *P. falciparum* infections in immunologically naïve individuals. Such proteins are useful as therapeutic and prophylactic agents as well as biological tools and diagnostic agents for the study, treatment and prevention of malaria, since these proteins described serve a unique function for the parasite in providing high growths rates in non-immune individuals and renders these parasites a unique serological phenotype. This is of great potential importance because it makes it possible to design strategies that will specifically aim at reducing malaria deaths by preventing, diagnosing, and treating malaria.

Polypeptide molecules of the invention

Thus, in its broadest aspect, the present invention relates to these 3 isolated polypeptides comprising at least one amino acid sequence selected from the group consisting of at least one of

a) SEQ ID NO.: 2, SEQ ID NO.: 4 or SEQ ID NO.: 6, and
b) a sequence having at least 80% sequence identity to a), and
c) sub-sequences of a) or b) with a minimum length of 10 amino acids, and
d) sub-sequences of a) b) comprising at least one B-cell epitope;

With the proviso that the Exon 2 of SEQ ID NO.: 2, SEQ ID NO.: 4 and/or SEQ ID NO.: 6 is excluded.

With the proviso that the "Fragment 1" and/or "Fragment 2" and/or "Fragment 3" and/or "Fragment 4" and /or "Fragment 5" and/or "Fragment 6" and/or "Fragment 7" and/or "Fragment 8" and/or "Fragment 9" and/or "Fragment 10" and/or "Fragment 11" and/or "Fragment 12" and/or "Fragment 13" and/or "Fragment 14" and/or "Fragment 15" and/or "Fragment 16" and/or "Fragment 17" "Fragment 18" and/or "Fragment 19" and/or

"Fragment 20" and/or "Fragment 21" and/or "Fragment 22" and/or "Fragment 23" and/or "Fragment 24" and/or "Fragment 25" and/or "Fragment 26" of SEQ ID NO.: 2, SEQ ID NO.: 4, and/or SEQ ID NO.: 6 is excluded.

With the proviso that the "Fragment 27" and/or "Fragment 28" and/or "Fragment 29" and/or "Fragment 30" and/or of SEQ ID NO.: 2 and/or SEQ ID NO.: 6 is excluded.

With the proviso that the "Fragment 31" and/or "Fragment 32" of SEQ ID NO.: 2 is excluded.

With the proviso that the amino acid sequence of SEQ ID NO.: 2, SEQ ID NO.: 4 and/or SEQ ID NO.: 6 is excluded.

For the present and any of the following aspects of the invention it applies that it is an object of preferred embodiments of the present invention to provide polypeptides, which are subject to antibody recognition by antibodies in sera from young children living in areas of high malaria transmission intensity and/or capable of mediating cyto-adhesion of intact erythrocyte infected by a parasite to endothelial cells, but not the CD36 receptor. The distinction to CD36 adhesion can be evaluated by the examples of the present invention, e.g. as described in example 4.

Length of the molecules

For all the aspects of the invention, it is apparent that the polypeptides of the invention, which form the basis of the described embodiments of the invention may be less or equal to any length between 6 - 3552 (SEQ ID NO.: 2), 6 - 2992 (SEQ ID NO.: 4) and 6 - 3344 (SEQ ID NO.: 6) amino acids, since these polypeptide all have great immunogenic capabilities and thus are especially great as candidates for the development for the treatment of malaria, particularly in the development of a vaccine.

Thus the present invention relates to any sub-sequence originating from any of the polypeptides having an amino acid length such as but not limited to less than or equal to 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 225, 250, 275, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1250 , 1500, 1750, 2000, 2250, 2500, 2750, or 2990 amino acids in length. In a further embodiment the length of a sub-sequence of SEQ ID NO.: 2 can be less than or equal to 3000, 3100, 3200, 3300, 3400, 3500 or 3550 amino

acids in length, whereas the length of a sub-sequence of SEQ ID NO.: 6 furthermore can be less than or equal to 3000, 3100, 3200, 3300 or 3340 amino acids in length.

In addition to these sequences, fragments or sub-sequences of the polypeptide of the invention, larger proteins/polypeptides comprising such sub-sequences as part of their sequence, are also embodiments of the present invention, thus with respect to all aspects of the invention it may be preferred that the polypeptides of the invention may have a length above the disclosed full length of 3553 (SEQ ID NO.: 2), 2994 (SEQ ID NO.: 4) or 3346 (SEQ ID NO.: 6) amino acids, if combined with other amino acids for e.g. preparation purposes.

Some characteristic lie within the polypeptide sequence of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6 such as B- and T-cell epitopes.
T-cell epitopes were defined using the SYFPEITHI server at Centre for Biological Sequence Analysis BioCentrum-DTU at the Technical University of Denmark (http://syfpeithi.bmi-heidelberg.com/Scripts/MHCServer.dll/ EpPredict.htm) with default settings. B-cell epitopes were defined using the Protean 4.0 software in the DNAstar package iwith default settings.
For SEQ ID NO.: 2 predicted T-cell epitopes are defined as, but not limited to amino acid no. 13-45, 93-107, 135-167, 201-236, 247-261, 302-316, 327-348, 394-409, 432-446, 457-473, 532-546, 573-589, 595-609, 625-639, 678-692, 870-890, 942-956, 986-1000, 1097-1111, 1130-1144, 1151-1165, 1196-1210, 1473-1492, 1508-1548, 1593-1630, 1633-1647, 1800-1814, 1830-1844, 1923-1937, 1943-1957, 1997-2025, 2235-2249, 2322-2336, 2378-2404, 2427-2441, 2464-2478, 2507-2521, 2533-2553, 2608-2637,26662-2683, 2693-2720, 2794-2808, 2851-2866, 2879-2904, 2965-2979, 3074-3088, 3092-3149, 3201-3216, 3236-3250, 3274-3288, 3297-3311, 3322-3336, 3350-3364, 3375-3395, 3488-3502, 3530-3544.

For SEQ ID NO.: 2 predicted B-cell epitopes are defined as, but not limited to amino acid no. 197-281, 365-470, 526-575, 631-772, 820-891, 905-933, 961-1003, 1024-1066, 1073-1188, 1206-1248, 1269-1367, 1402-1437, 1535-1731, 1991-2026, 2054-2096, 2124-2229, 2278-2313, 2404-2460, 2488-2530, 2663-2713, 2832-2965, 3014-3112, 3154-3210, 3322-3406.

For SEQ ID NO.: 4 predicted T-cell epitopes are defined as, but not limited to amino acid no. 117-131, 154-168, 177-213, 224-238, 258-272, 307-321, 332-346, 419-434, 454-468, 512-534, 561-595, 619-641, 645-680, 691-710, 781-795, 983-997, 1043-1057, 1065-1093, 1143-1185, 1296-1310, 1383-1397, 1453-1467, 1567-1597, 1653-1667, 1693-1707, 1740-1754, 1774-1836, 1855-1873, 1929-1943, 2066-2080, 2108-2122,

2130-2156, 2174-2188, 2206-2220, 2282-2296, 2309-2323, 2439-2453, 2552-2566, 2578-2592, 2625-2639, 2644-2673, 2697-2714, 2719-2733, 2744-2774, 2802-2816, 2918-2943, 2971-2985.

For SEQ ID NO.: 4 predicted B-cell epitopes are defined as, but not limited to amino acid no. 30-65, 89-113, 125-142, 213-272, 390-432, 491-514, 733-792, 833-851, 874-904, 1040-1069, 1128-1170, 1187-1211, 1258-1276, 1306-1365, 1394-1406, 1441-1499, 1542-1571, 1648-1678, 1884-1908, 1949-1979, 2268-2309, 2345.2369, 2392-2416, 2853-2906.

For SEQ ID NO.: 6 predicted T-cell epitopes are defined as, but not limited to amino acid no. 14-28, 43-57, 71-85, 222-248, 251-265, 301-315, 318-332, 359-373, 416-443, 446-460, 471-485, 518-532, 579-593, 624-643, 783-797, 949-967, 986-1000, 1016-1030, 1075-1093, 1141-1155, 1265-1279, 1340-1372, 1440-1471, 1505-1515, 1529-1556, 1634-1648, 1659-1673, 1687-1701, 1712-1726, 1813-1827, 1841-1855, 1875-1995, 2092-2110, 2137-2151, 2161-2171, 2249-2263, 2319-2333, 2379-2393, 2475-2495, 2502-2516, 2549-2564, 2591-2605, 2629-2643, 2650-2669, 2674-2688, 2734-2766, 2916-2930, 2989-3018, 3038-3052, 3115-3129, 3131-3145, 3167-3187, 3248-3262, 3323-3337.

For SEQ ID NO.: 6 predicted B-cell epitopes are defined as, but not limited to amino acid no. 7-27, 383-429, 627-786, 898-990, 1089-1221, 1307-1340, 1373-1525, 1670-1815, 1901-1934, 2007-2027, 2225-2251, 2363-2409, 2495-2528, 2614-2660, 2706-2911, 3221-3300.

Some characteristic structures lie within the polypeptide sequence of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6 and therefore also within the nucleotide sequence encoding these polypeptide sequences. Such structures comprise, but are not necessarily limited to DBL2, DBL5, and C2.

Preferred embodiments of the present invention include specific sub-sequences of the polypeptide of the invention having a minimum length of 10 amino acids such as sub-sequences that are at least 100 amino acids long. In even more preferred embodiments of the invention, these sub-sequences can be shown by known molecular biological techniques to be involved in the interaction with endothelial receptors and/or to be recognised by antibodies using plasma from young semi-immune children.

It is anticipated that relatively short sequences within the SEQ ID NO.: 2, SEQ ID NO.: 4 and/or SEQ ID NO.: 6 are responsible for mediating adhesion to endothelial receptors

other than CD36. In particular, it is possible that certain CIDR or DBL domains or parts hereof are responsible for the adhesion and/or for antibody recognition.

In other preferred embodiments of the invention, the sequences of the polypeptide of the invention can be shown to possess one or more antigen epitopes. In particular, such epitopes may be B-cell epitopes. Optionally, the sub-sequences may also comprise one or more T-cell epitopes alone or in combination with the B-cell epitopes. Finally, also larger polypeptides comprising the polypeptide of the invention or sub-sequences hereof with antigen epitopes and/or sequences involved in interaction with endothelial receptors are embodiments of the present invention.

It is also apparent that the polypeptide sequences of the invention can be present in the form of fusion proteins. In a further preferred embodiment, this fusion protein will comprise polypeptide sequences, which will facilitate the purification or detection of the protein. These polypeptide sequences may be but are not limited to tags that will facilitate purification and detection using commercially available systems such as the HA- ,-c-myc, His or GST tags.

The polypeptide embodiments of the present invention can therefore exhibit a vast degree of sequence identity to the full-length of SEQ ID NO.: 2, SEQ ID NO.: 4 and/or SEQ ID NO.: 6. It can for instance be appreciated that a fusion protein carrying within its sequence one or more B-cell epitopes and or regions of the polypeptide of the invention that are involved in adhesion to endothelial receptors will have a relatively low overall degree of sequence identity to full-length SEQ ID NO.: 2, SEQ ID NO.: 4 and/or SEQ ID NO.: 6.

Sequence identity of the polypeptide molecules

For all the aspects of the invention, it is thus apparent that the polypeptides of the invention may include sequences, which show anywhere between 40-100% sequence identity, such as at least 41%, at least 42%, at least 43%, at least 44%, at least 45%, at least 46%, at least 47%, at least 48%, at least 49% at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99 % or preferably 100% sequence identity to SEQ ID NO.: 2, SEQ ID NO.: 4 and/or SEQ ID NO.: 6 or a fragment or sub-sequence thereof.

As understood by the skilled adressee, the sequence identity of the polypeptide molecules of the present invention will be higher the smaller the fragments or sub-sequences in order to be unique, thus in some embodiments of the present invention, the fragments or sub-sequences are of 20-50 amino acid long and has a sequence identity of 80-100%, such as 20-50 amino acid long, 20-40 amino acid long, 20-30 amino acid long, 20-25 amino acid long, 30-50 amino acid long, 30-40 amino acid long, 30-35 amino acid long, 40-50 amino acid long, 40-45 or 45-50 amino acid long all with a sequence identity of 80-100%, such as 80% identical, 81% identical, 82% identical, 83% identical, 84% identical, 85% identical, 86% identical, 87% identical, 88% identical, 89% identical, 90% identical, 91% identical, 92% identical, 93% identical, 94% identical, 95% identical, 96% identical, 97% identical, 98% identical, 99% identical or even 100% identical.

In other embodiments of the present invention, the fragments or sub-sequences are of 51-750 amino acid long and has a sequence identity of 70-100%, such as 51-750 amino acid long, 60-700 amino acid long, 70-600 amino acid long, 80-500 amino acid long, 90-400 amino acid long, 100-250 amino acid long, 300-350 amino acid long, 400-500 amino acid long, 200-650 or 450-500 amino acid long all with a sequence identity of 70-100%, such as 70% identical, 71% identical, 72% identical, 73% identical, 74% identical, 75% identical, 80% identical, 85% identical, 88% identical, 89% identical, 90% identical, 91% identical, 92% identical, 93% identical, 94% identical, 95% identical, 96% identical, 97% identical, 98% identical, 99% identical or even 100% identical.

In yet other embodiments of the present invention, the fragments or sub-sequences are of more than 751 amino acid long and has a sequence identity of 60%-100%, such as more 751 amino acid long, more 800 amino acid long, more than 900 amino acid long, more than 1000 amino acid long, more than 1100 amino acid long, more than 1200 amino acid long, more than 1300 amino acid long, more than 1400 amino acid long, more than 2000 amino acids long or 2500 amino acid long all with a sequence identity of 60-100%, such as 60% identical, 61% identical, 62% identical, 63% identical, 64% identical, 65% identical, 70% identical, 75% identical, 77% identical, 80% identical, 85% identical, 88% identical, 92% identical, 93% identical, 94% identical, 95% identical, 96% identical, 97% identical, 98% identical, 99% identical or even 100% identical.

Additionally, variants are also an embodiment of the present invention and are determined based on a predetermined number of conservative amino acid substitutions as defined herein below. Conservative amino acid substitution as used herein relates to the substitution of one amino acid (within a predetermined group of amino acids) for another amino acid (within the same group), wherein the amino acids exhibit similar or substantially similar characteristics.

Within the meaning of the term "conservative amino acid substitution" as applied herein, one amino acid may be substituted for another within the groups of amino acids indicated herein below:

Amino acids having polar side chains (Asp, Glu, Lys, Arg, His, Asn, Gln, Ser, Thr, Tyr, and Cys,)
Amino acids having non-polar side chains (Gly, Ala, Val, Leu, Ile, Phe, Trp, Pro, and Met)
Amino acids having aliphatic side chains (Gly, Ala Val, Leu, Ile)
Amino acids having cyclic side chains (Phe, Tyr, Trp, His, Pro)
Amino acids having aromatic side chains (Phe, Tyr, Trp)
Amino acids having acidic side chains (Asp, Glu)
Amino acids having basic side chains (Lys, Arg, His)
Amino acids having amide side chains (Asn, Gln)
Amino acids having hydroxy side chains (Ser, Thr)
Amino acids having sulphor-containing side chains (Cys, Met),
Neutral, weakly hydrophobic amino acids (Pro, Ala, Gly, Ser, Thr)
Hydrophilic, acidic amino acids (Gln, Asn, Glu, Asp), and
Hydrophobic amino acids (Leu, Ile, Val)

Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.

Accordingly, a variant or a fragment thereof according to the invention may comprise, within the same variant of the sequence or fragments thereof, or among different variants of the sequence or fragments thereof, at least one substitution, such as a plurality of substitutions introduced independently of one another.

It is clear from the above outline that the same variant or fragment thereof may comprise more than one conservative amino acid substitution from more than one group of conservative amino acids as defined herein above.

The present invention further relates to addition or deletion of at least one amino acid in relation to any of the amino acid sequences according to the invention and may be an addition or deletion of from preferably 2 to 50 amino acids, such as from 10 to 20 amino acids, for example from 20 to 30 amino acids, such as from 40 to 50 amino acids.

However, additions or deletions of more than 50 amino acids, such as additions from 50 to 100 amino acids, addition of 100 to 150 amino acids, addition of 150-250 amino acids, are also comprised within the present invention. Even additions or deletions of 500-2000 amino acids are within the scope of the present invention. The deletion and/or the addition may - independently of one another - be a deletion and/or an addition within a sequence and/or at the end of a sequence.

The polypeptide fragments according to the present invention, including any functional equivalents thereof, may in one embodiment comprise less than 250 amino acid residues, such as less than 240 amino acid residues, for example less than 225 amino acid residues, such as less than 200 amino acid residues, for example less than 180 amino acid residues, such as less than 160 amino acid residues, for example less than 150 amino acid residues, such as less than 140 amino acid residues, for example less than 130 amino acid residues, such as less than 120 amino acid residues, for example less than 110 amino acid residues, such as less than 100 amino acid residues, for example less than 90 amino acid residues, such as less than 85 amino acid residues, for example less than 80 amino acid residues, such as less than 75 amino acid residues, for example less than 70 amino acid residues, such as less than 65 amino acid residues, for example less than 60 amino acid residues, such as less than 55 amino acid residues, for example less than 50 amino acid residues.

"Functional equivalency" as used in the present invention is according to one preferred embodiment established by means of reference to the corresponding functionality of a predetermined fragment of the sequence.

It is understood that the polypeptide fragments of the invention may possess one or more types of post-translational modifications when expressed on the cell surface. These modifications may comprise, but are not limited to, glycosylation, phosphorylation, acylation, cross-linking, proteolytic cleavage, linkage to an antibody molecule, a membrane molecule, or another ligand.

It is an object of presently preferred embodiments of the present invention that the polypeptide comprises the amino acid sequence shown in SEQ ID NO.: 2, SEQ ID NO.: 4 or SEQ ID NO.: 6.

It is an object of presently most preferred embodiments of the present invention that the polypeptide consists of the amino acid sequence shown in SEQ ID NO.: 2, SEQ ID NO.: 4 or SEQ ID NO.: 6.

Nucleic acid molecules

The embodiments of the present invention thus relate to polypeptides of the PfEMP1 class or sub-sequences hereof as well as nucleic acid molecules encoding such polypeptides or sub-sequences, wherein said polypeptides and sub-sequences comprise structures that are involved directly or indirectly in the binding to endothelial receptors and/or recognised by plasma antibodies from young semi-immune children.

The *PFD1235w/MAL7P1.1, PF11_0008, and PF13_0003* genes presented in SEQ ID NO.: 1, SEQ ID NO.: 3, and/or SEQ ID NO.: 5 are members of Group A *var* genes and, in their widest perspective, the embodiments of the invention thus relate to nucleic acid molecules, which are characteristic in that they do not belong to the *var1, var2* gene subfamily as

defined in Salanti et al. 2002 and Salanti et al. 2003 or Group B, Group C, and Group B/C, but does not exclude Group B/A *var* genes as defined in Lavstsen et al. 2003.

Furthermore, nucleic acid molecules, which are complementary to the nucleic acid molecules of the invention as described above as well as polypeptides encoded by these nucleic acid molecules are within the scope of the invention.

One embodiment of the present invention relates to a nucleic acid molecule comprising at least one nucleotide sequence selected from the group consisting of at least one of

a) SEQ IN NO.: 1, SEQ ID NO.: 3 and SEQ ID NO.: 5 or a sequence complementary thereof; and
b) a nucleotide sequence having at least 80% sequence identity to a); and
c) sub-sequences of a) or b) with a minimum length of 30 nucloetides; and
d) sub-sequences of a) or b) which comprises at least one sequence encoding a B-cell epitope;

As understood by the skilled adressee, the sequence identity of the nucleic acid molecules of the present invention will be higher the smaller the fragments or sub-sequences in order to be unique, thus in some embodiments of the present invention, the fragments or sub-sequences are of 60-150 nucleic acid long and has a sequence identity of 80-100%, such as 60-140 nucleic acid long, 60-130 nucleic acid long, 60-120 nucleic acid long, 60-110 nucleic acid long, 75-150 nucleic acid long, 80-140 nucleic acid long, 90-135 nucleic acid long, 90-150 nucleic acid long, 120-130 or 125-150 nucleic acid long all with a sequence identity of 80-100%, such as 80% identical, 81% identical, 82% identical, 83% identical, 84% identical, 85% identical, 86% identical, 87% identical, 88% identical, 89% identical, 90% identical, 91% identical, 92% identical, 93% identical, 94% identical, 95% identical, 96% identical, 97% identical, 98% identical, 99% identical or even 100% identical.

In other embodiments of the present invention, the fragments or sub-sequences are of 151-2200 nucleic acid long and has a sequence identity of 70-100%, such as 151-2100 nucleic acid long, 200-1700 nucleic acid long, 300-1600 nucleic acid long, 400-1500 nucleic acid long, 500-1400 nucleic acid long, 1000-1250 nucleic acid long, 1300-1350 nucleic acid long, 1400-1500 nucleic acid long, 200-1650 or 450-2000 nucleic acid long all with a sequence identity of 70-100%, such as 70% identical, 71% identical, 72% identical, 73% identical, 74% identical, 75% identical, 80% identical, 85% identical, 88% identical, 89% identical, 90% identical, 91% identical, 92% identical, 93% identical, 94% identical, 95% identical, 96% identical, 97% identical, 98% identical, 99% identical or even 100% identical.

In yet other embodiments of the present invention, the fragments or sub-sequences are of more than 2201 nucleic acid long and has a sequence identity of 60%-100%, such as more 2201 nucleic acid long, more 2300 nucleic acid long, more than 2400 nucleic acid long, more than 3500 nucleic acid long, more than 4000 nucleic acid long, more than 5000 nucleic acid long, more than 5500 nucleic acid long, more than 6000 nucleic acid long, more than 7000 nucleic acids long or 8500 nucleic acid long all with a sequence identity of 60-100%, such as 60% identical, 61% identical, 62% identical, 63% identical, 64% identical, 65% identical, 70% identical, 75% identical, 77% identical, 80% identical, 85% identical, 88% identical, 92% identical, 93% identical, 94% identical, 95% identical, 96% identical, 97% identical, 98% identical, 99% identical or even 100% identical.

With the proviso that the Exon 2 of SEQ ID NO.: 1, 3 and/or 5 is excluded

With the proviso that the "Fragment 1" and/or "Fragment 2" and/or "Fragment 3" and/or "Fragment 4" and /or "Fragment 5" and/or "Fragment 6" and/or "Fragment 7" and/or "Fragment 8" and/or "Fragment 9" and/or "Fragment 10" and/or "Fragment 11" and/or "Fragment 12" and/or "Fragment 13" and/or "Fragment 14" and/or "Fragment 15" and/or "Fragment 16" and/or "Fragment 17" "Fragment 18" and/or "Fragment 19" and/or "Fragment 20" and/or "Fragment 21" and/or "Fragment 22" and/or "Fragment 23" and/or "Fragment 24" and/or "Fragment 25" and/or "Fragment 26" of SEQ ID NO.: 1, SEQ ID NO.: 3, and/or SEQ ID NO.: 5 is excluded.

With the proviso that the "Fragment 27" and/or "Fragment 28" and/or "Fragment 29" and/or "Fragment 30" and/or of SEQ ID NO.: 1 and/or SEQ ID NO.: 5 is excluded.

With the proviso that the "Fragment 31" and/or "Fragment 32" of SEQ ID NO.: 1 is excluded.

With the proviso that the nucleotide sequence of SEQ ID NO.: 1, SEQ ID NO.: 3 and/or SEQ ID NO.: 5 is excluded.

The cDNA sequence encoding SEQ ID NO. 2, SEQ ID NO.: 4, and /or SEQ ID NO.: 6 in the parasite line 3D7 is provided in the sequence listing as SEQ ID NO.: 1, SEQ ID NO.: 3 and/or SEQ ID NO.: 5.

Again, it is apparent for all the aspects of the invention that the nucleic acid molecules of the invention may be less than or equal to any length between 30-10662 (SEQ ID NO.: 1), 30-8985 (SEQ ID NO.: 3) or 30-10041 (SEQ ID NO.: 5) nucleotides, such as less than or equal to 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50,

51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 225, 250, 275, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1250, 1500, 1750, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 6000, 7000, 8000, , 8100, 8200, 8300, 8400, 8500, 8600, 8700, 8800, 8900, 8955, 8956, 8957, 8958, 8959, 8960, 8961, 8962, 8963, 8964, 8965, 8966, 8967, 8968, 8969, 8970, 8971, 8972, 8973, 8974, 8975, 8976, 8977, 8978, 8979, 8980, 8981, 8982, 8983, 8984, 8985 nucleotides in length for SEQ ID NO.: 3 and further 9000, 9100, 9200, 9300, 9400, 9500, 9600, 9700, 9800, 9900, 10000, 10011, 10021, 10031, 10041 nucleotides in length for SEQ ID NO.: 5, and furthermore 10050, 10100, 10200, 10300, 10400, 10500, 10600, 10650, 10651, 10652, 10653, 10654, 10655, 10656, 10657, 10658, 10659, or 10660 nucleotides in length for SEQ ID NO.: 1.

Still with respect to all aspects of the invention it may be preferred that the nucleic acid molecules of the invention may have a length of 30 - 40, 30 - 50, 30 - 60, 30 - 70, 30 - 80, 30 - 90, 30 - 100, 30 - 200, 30 - 400, 30 - 500, 30 - 1000, 30 - 1200, 30 - 1300, 30 - 1400, 30 - 1500, 30 - 1600, 30 - 1700, 30 - 1800, 30 - 1900, 30 - 2000, 30 - 2250, 30 - 2500, 30 - 2750, 30 - 3000, 30 - 3500, 30 - 4000, 30 - 4500, 30 - 5000, 30 - 6000, 30 - 7000, 30 - 8000, 30 - 9000 nucleotides.

In preferred embodiments of the invention, sub-sequences of the nucleic acid molecules of the invention have a minimum length of 30 nucleotides and in even more preferred embodiments these sub-sequences are at least 300 nucleotides long.

Sequence identity of the nucleic acid molecules

Preferred nucleic acid embodiments further include nucleic acids encoding fragments of the polypeptide of the invention that are involved in interaction with endothelial receptors. In addition, it is an object of preferred embodiments that sub-sequences of the nucleic acid molecule of the invention comprise nucleotides encoding one or more B-cell epitopes and/or one or more T-cell epitopes.

Some characteristic structures lie within the peptide sequence of SEQ ID NO.: 2, SEQ ID NO.: 4 and/or SEQ ID NO.: 6 and therefore also within the nucleotide sequence encoding this peptide sequence. Such structures comprise, but are not necessarily limited to, a DBL2β domain followed by a C2 domain. On the other hand, some common features have been identified for proteins encoded by Group B, Group C, and Group B/C *var* genes including, but not limited to the DBL2δ domain. These features are not found within the amino acid sequence of SEQ ID NO.: 2, SEQ ID NO.: 4 and/or SEQ ID NO.: 6.

Further embodiments comprise nucleic acid molecules that complement full-length of SEQ ID NO.: 1, SEQ ID NO.: 3 and/or SEQ ID NO.: 5 or sequences identical in part hereto as well as nucleotide sequences that complement fragments of full-length SEQ ID NO.: 1, SEQ ID NO.: 3 and/or SEQ ID NO.: 5, or sequences identical in part hereto.

Preferred complementary nucleic acid molecules of the invention comprise nucleic acid molecules that are complementary to fragments of SEQ ID NO.: 1, SEQ ID NO.: 3 and/or SEQ ID NO.: 5, which have a nucleotide sequence that encodes a polypeptide or parts of a polypeptide that are involved in interaction with endothelial receptors. Additionally, preferred complementary nucleic acid molecules of the invention are complementary to sequences encoding one or more B-cell epitopes and/or one or more T-cell epitopes.

As discussed for the polypeptide-based compounds of the invention it is also apparent that the nucleotide based embodiments may represent only part of the full-length sequence. In addition these nucleotide sequences may be present in combination with exogenous sequences. For all the aspects of the invention, it is thus apparent that the nucleic acids molecules of the invention may include sequences that have anywhere between 1-100% sequence identity to the full-length sequence of SEQ ID NO.: 1, SEQ ID NO.: 3 and/or SEQ ID NO.: 5, such as at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or, preferably, 100% sequence identity to SEQ ID NO.: 1, SEQ ID NO.: 3 and/or SEQ ID NO.: 5, or a fragment or sub-sequence thereof.

It is to be understood that the nucleotide sequence of SEQ ID NO.: 1, SEQ ID NO.: 3 and/or SEQ ID NO.: 5, when present within the genome of the intact *Plasmodium falciparum* parasites as well as the polypeptide sequence of SEQ ID NO.: 2, SEQ ID NO.: 4 and/or SEQ ID NO.: 6, when present in or on the surface of intact red blood cells infected with *P. falciparum* are excluded from the scope of the present invention. This applies to all embodiments of the invention described in the present application. Compounds of the invention may however comprise sub-sequences of SEQ ID NO.: 1, SEQ ID NO.: 3 and/or SEQ ID NO.: 5 and sub-sequences of SEQ ID NO.: 2, SEQ ID NO.: 4 and/or SEQ ID NO.: 6 isolated and/or purified from the *Plasmodium* parasites or infected RBC.

Vectors

In addition, recombinant polypeptides comprising sub-sequences of the amino acid sequence of SEQ ID NO.: 2, SEQ ID NO.: 4 and/or SEQ ID NO.: 6 may be generated by use of the above-mentioned nucleic acid embodiments. These can be cloned into vectors by the use of cloning techniques known in the art. The sequence encoding the polypeptide

of interest is thereby linked to a heterologous promoter sequence. It may be preferred to optimise the codon context and codon pairing for the particular expression system. With respect to the polypeptide embodiments of the invention the incorporation of a secretory leader sequence may also be of use. The vector can be an expression vector in any of the mammalian, yeast, amphibian, insect, parasite, or bacterial expression systems known in the art. It is therefore apparent that, with the exception of *Plasmodium* infected RBC, prokaryotic and eukaryotic cells hereunder mammalian cells and transformed cell lines as well as cells in animals possessing nucleotide and/or amino acid embodiments described herein, are within the scope of the present invention.

Cells and cell lines

Propagation of such cells or cell lines may be performed with the intention of providing recombinant forms of one or more of the nucleic acid or polypeptide embodiments of the invention in amounts that are sufficient for further processing or purification. It is therefore within the scope of the present invention to provide preparations of compounds, which comprise polypeptides of the invention as well as nucleic acid molecules encoding these polypeptides. Preparations of such compounds may have a desired degree of purity referring to the relative amounts of the desired polypeptide and for instance whole cell proteins and unwanted variants of the desired polypeptide as defined above. The existence of a wide range of protein purification and concentration techniques is known to the skilled artisan. These techniques include gel electrophoresis, ion-exchange chromatography, affinity and immunoaffinity chromatography, ceramic hydroxyapatite chromatography, differential precipitation, molecular sieve chromatography, isoelectric focusing, gel filtration, and diafiltration.

For the various types of chromatography, the desired molecules are suspended in a buffer, which promotes adhesion of the molecules to the active surface of the resin and are then applied to the chromatography column. Removal of contaminants is performed by washing the resin in a buffer of intermediate ionic strength or pH. Elution of the desired molecules is performed by changing the ionic strength or pH of the buffer to values that will promote the dissociation of the molecules from the active surface of the resin used. In the case of immunoaffinity chromatography, the polypeptide may be purified by passage through a column containing a resin to which is bound antibodies which are specific for at least a portion of the polypeptide. Furthermore, His- or GST tags may be added to the polypeptides of the invention. Subsequently, the resulting fusion proteins can be purified by affinity chromatography on for instance glutathione sepharose 4B and HIS tag Metal Chelate Affinity Chromatography.

It is readily apparent that a person skilled in the art can create nucleic acid molecules of virtually any length by ligating a nucleic acid molecule encoding any of the amino acid sequences of the present invention or any part thereof to an exogenous nucleotide sequence. Recombinant nucleic acid molecules generated by this approach are embodiments of the invention. A recombinant construct can be capable of replicating autonomously within a host cell or, alternatively, it can become integrated into the chromosomal DNA. Such a recombinant nucleic acid molecule can comprise a sequence of genomic DNA, cDNA, synthetic or semi-synthetic origin. Again, it is preferred that such nucleic acid molecules are encoding one or more B-cell epitopes and/or one or more T-cell epitopes.

The nucleic acid embodiments of the present invention can be altered by genetic engineering so as to introduce substitutions, deletions and/or additions. In preferred embodiments of the invention, these alterations will provide for sequences encoding functionally equivalent molecules or molecules with the same or improved properties. Such changes of the polypeptide embodiments can be generated using techniques that are known to a person skilled in the art, including random mutagenesis and site-directed mutagenesis.

The use of recombinant polypeptides of the invention may be preferred when it is required that the preparations of these polypeptides are essentially free of any other antigen with which they are natively associated, *i.e.* free of any other antigen from *Plasmodium* parasites. As an alternative this may also be accomplished by synthesizing the polypeptide fragments by the well-known methods of solid or liquid phase peptide synthesis.

Pharmaceutical compositions

Additional aspects of the present invention relate to pharmaceutical compositions based on any of the polypeptide embodiments of the invention. In a presently preferred embodiment these pharmaceutical compositions relates to compositions capable of eliciting an immune response, which may or may not be in form of a vaccine. Preferably, such a composition comprises at least one amino acid sequence according to the present invention.

It is an object of presently preferred embodiments of the present invention to provide such an amino acid sequence selected from the group consisting of at least one of

a) SEQ ID NO.: 2, SEQ ID NO.: 4 and SEQ ID NO.: 6 and

b) a sequence having at least 80% sequence identity to a); and

c) sub-sequences of a) or b) with a minimum length of 30 amino acids; and

d) sub-sequences of a) or b) comprising at least one B-cell epitope.

Alternatively, the pharmaceutical composition according to the present invention may be based on any of the nucleotide embodiments of the invention. In a preferred embodiment, the pharmaceutical composition comprises at least one nucleotide sequence selected from the group consisting of at least one of

a) SEQ ID NO.: 1, SEQ ID NO.: 3 and SEQ ID NO.: 5 or a sequence complementary thereof; and

b) a nucleotide sequence having at least 80% sequence identity to a); and

c) sub-sequences of a) or b) with a minimum length of 30 nucleotides; and

d) sub-sequences of a) and b) which comprise at least one sequence encoding a B-cell epitope.

Such compositions may or may not further comprise a vector containing said amino acid or nucleotide sequence.

In a specially preferred embodiment, any of the pharmaceutical compositions described in the present application may further comprise a pharmaceutically acceptable carrier and/or an adjuvant.

Peptides, proteins and carbohydrates antigens are usually poorly immunogenic, or not immunogenic at all, when administered on their own. Better delivery systems and adjuvants may be needed to improve the ease of delivery and immunogenicity. In particular, *in vivo* immunisation with peptides and proteins to generate MHC class I specific response has been difficult. One possible technique to solve this is the use of ISCOMs, which are lipid carriers that act as adjuvants but have minimal toxicity, and they appear to load peptide and proteins into the cell cytoplasma, allowing MHC class I restricted T-cell response to these peptides, which make them useful in human immunisation.

Pharmaceutical compositions comprising the nucleotide and polypeptide embodiments of the invention can be produced by conventional techniques so that the said sequences are present as monomeric, multimeric or multimerised agents. Furthermore, antibodies generated from the polypeptide embodiments of the invention may constitute part of such pharmaceutical compositions. In addition to the active ingredients, pharmaceutical compositions may further comprise one or more physiologically acceptable carriers, proteins, supports, adjuvants as well as components that may facilitate the delivery of the active components of the compositions. As described above, a large number of adjuvants are available including but not limited to Freund's adjuvant, mineral gels such as

aluminium hydroxide, and surface-active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. As a pharmaceutical composition, the nucleic acid and peptide embodiments of the invention will be purified and processed through one or more formulation steps. A large variety of formulation buffers will be physiologically acceptable, such as phosphate, citrate, and other organic acids.

It is further understood that a pharmaceutical composition must be clinically safe. More specifically, it must be free of virus and bacteria that can cause infection upon administration of the composition to a subject. It may therefore be necessary to process the composition through on or more steps of virus filtration and/or inactivation. The removal of virus by filtration can be obtained by passing the composition through a nanofilter, whereas virus inactivation can be accomplished by the addition of various detergents and/or solvents or other antiviral compounds to the composition.

Antibodies

The polypeptide and/or nucleic acid embodiments of the invention may be used in their purified form to generate various types of antibodies, and it is understood that such antibodies will also be considered as compounds of the invention. These antibodies may include, but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments and fragments produced by a Fab expression library. A person skilled in the art knows that antibodies can be produced by e.g. immunisation of various hosts including goats, rabbits, rats, and mice. The term 'immunisation' refers to the injection of a polypeptide with immunogenic properties. Depending on the host species various types of adjuvants can be used in order to increase the immunological response including but not limited to Freund's adjuvant, mineral gels such as aluminium hydroxide, and surface-active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol.

It is preferred to use shorter sequences of the polypeptide of the invention fused to a powerful immunogenic molecule such as keyhole limpet hemocyanin resulting in the production of antibodies against this chimeric molecule. Accordingly, antibodies capable of recognising SEQ ID NO. 2, SEQ ID NO.: 4 and/or SEQ ID NO.: 6 can be produced by injection of synthetic peptides consisting of as little as 3 to 30 amino. Thus, it is an object of preferred embodiments of the present invention to provide such small synthetic peptides of3-250 amino acids, such as but not limited to 15-150 amino acids, 20-140 amino acids, 30-130 amino acids, 40-120 amino acids, 50-110 amino acids, 60-100 amino acids, 70-90 amino acids, 80-85 amino acids corresponding to a particular sequence of the SEQ ID NO.

2, SEQ ID NO.: 4 and/or SEQ ID NO.: 6 polypeptides. As an alternative, a more diverse set of antibodies can be generated by injection of a purified polypeptide embodiment of the invention.

Monoclonal antibodies directed against any of the polypeptides of the present invention, such as a purified polypeptide embodiment of the invention, can be produced using any of the conventional techniques that provide for the production of antibodies from cell lines in continuous culture. These techniques include the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique.

It will be readily appreciated that polypeptides of the invention can be incorporated into vaccines capable of inducing protective immunity against a specific subtype of malaria. In relation to the present invention it is preferred that the vaccine is directed specifically against the infectious activity of *Plasmodium falciparum* in the brain or adhesion to endothelial cells, which is characteristic of severe malaria.

One important aspect of the present invention therefore relates to a vaccine comprising one or more B-cell epitopes from a polypeptide encoded by any of the nucleotides according to the present invention. This vaccine is characterised in that it induces an antibody response wherein said antibody specifically recognises a molecule expressed on the surface of an intact erythrocyte infected by VSA_{SM} type parasites or parasites that have been selected for their ability to mediate adhesion to endothelial receptors. Generally, this molecule is recognised by the antibodies from semi-immune children or children suffering from severe malaria.

In preferred embodiments, antibodies directed against the polypeptides and/or nucleic acids of the invention can be administered to a subject in order to provide protection against the retention and sequestration of iRBC to endothelial cells which is characteristic of severe malaria.

Effective amounts of an agent that will promote an immune response against a compound of the present invention can be administered to subjects living in endemic areas so as to prevent the contraction of malaria.

In another embodiment, a subject believed to be at risk for contracting malaria may be identified either by conventional methods or by one of the *in vitro* diagnostic techniques, which constitute other embodiments of the present invention. An effective amount of an agent that inhibits SEQ ID NO.: 2, SEQ ID NO.: 4, SEQ ID NO.: 6 and/or homologues

hereof mediated sequestration or elicits an immune response in a subject can then be administered to this subject.

Another embodiment of the present invention relates to an isolated antibody or isolated antiserum induced in response to one or more polypeptides according to the invention and/or to one or more nucleic acids as defined in the present application.

Another embodiment of the present invention relates to an isolated antibody or isolated antiserum induced in response to one or more polypeptides according to the invention and/or to one or more nucleic acids as defined in the present application, wherein said antibody is capable of binding to a molecule expressed on the surface of an intact erythrocyte infected by a parasite causing malaria.

Another embodiment of the present invention relates to an isolated antibody or isolated antiserum induced in response to one or more polypeptides according to the invention and/or to one or more nucleic acids as defined in the present application, wherein said antibody is capable of recognising paracites selected *in vitro* for expression of VSA_{SM}.

A presently preferred embodiment relates to an antibody as described by the present application, wherein said antibody is capable of binding to a molecule expressed on the surface of an intact erythrocyte infected by a parasite capable of mediating cyto-adhesion of intact erythrocyte infected by a parasite to human endothelial cells, but not the CD36 receptor.

Vaccines

Additional aspects of the present invention relate to vaccines based on any of the embodiments of the invention, such as but not limited to a vaccine comprising any of the polypeptides, the nucleic acids or the recombinant vectors according to the present invention, said vaccine characterised in that it induces an immune response, wherein said immune response specifically recognises a molecule expressed on the surface of an intact erythrocyte infected by a parasites.

In one embodiment such a vaccine relates to a vaccine comprising one or more B-cell and/or T-cell epitopes originating from any of the polypeptides, the nucleic acids or the recombinant vectors of the present invention, said vaccine characterised in that it induces an immune response, wherein said immune response specifically recognises a molecule expressed on the surface of an intact erythrocyte infected by a parasites.

One presently preferred embodiment of the present invention relates to a polypeptide-based vaccine comprises at least one amino acid sequence selected from the group consisting of at least one of

a) SEQ ID NO.: 2, SEQ ID NO.: 4 and/or SEQ ID NO.: 6 and
b) a sequence having at least 80% sequence identity to a); and
c) sub-sequences of a) or b) with a minimum length of 30 amino acids; and
d) sub-sequences of a) or b) comprising at least one B-cell epitope.

Sub-sequences of the polypeptide of the invention used in a vaccine may be any of the above mentioned amino acid lengths and in addition to these fragments or sub-sequences of the polypeptide of the invention, larger polypeptides comprising sub-sequences of the invention as part of their sequence, are also embodiments of the present invention. It is preferred, however, that these sub-sequences have a minimum length of 30 amino acids and that they are at least 80% identical to a region of comparable length within the sequence of SEQ ID NO.: 2, SEQ ID NO.: 4 and/or SEQ ID NO.: 6.

In recent years there has been increased focus on nucleic acid vaccines. Other aspects of the present invention therefore concern genetic immunisation in which nucleotide based vaccines such as vaccines based on DNA molecules or on RNA molecules, which result in the expression of one or more B-cell and/or T-cell epitopes from a polypeptide encoded by a member of the SEQ ID NO.: 1, 3, and/or 5 gene family. As for the polypeptide based vaccine this vaccine is characterised in that it induces an antibody response wherein said antibody specifically recognises a molecule expressed on the surface of an intact erythrocyte infected by VSA_{SM} type parasites that have been selected for their ability to mediate adhesion to endothelial cells or for increased antibody recognition by plasma from young semi-immune children.

One embodiment of the present invention relates to a nucleotide based vaccine, such as a DNA vaccine, which results in the expression of a polypeptide comprising one or more B-cell and/or T cell epitopes from any of the polypeptide sequences of the present invention, wherein said vaccine is capable of inducing an immune respons which specifically recognises a molecule expressed on the surface of an intact erythrocyte infected by parasites, and wherein said parasites furthermore has a VSA_{SM} phenotype that have been selected for antibody recognition or adhesion to endothelial receptors *in vitro*, and wherein said molecule is recognised by antibodies from young children living in areas of high malaria transmission intensity.

One embodiment relates to a DNA vaccine comprising at least one nucleic acid sequences to the present invention, wherein said vaccine is capable of inducing an immune response, wherein said immune response specifically recognises a molecule expressed on the surface of an intact erythrocyte infected by parasites.

Another embodiment relates to a natural, synthetic or recombinant DNA or RNA vaccine having any nucleotide sequence according to the present invention, wherein the vaccine is capable of eliciting development of anti-*Plasmodium* antibodies.

In a preferred embodiment, the present invention relates to a nucleotide-based vaccine, which may be a DNA or RNA vaccine, comprising a vector comprising at least one nucleotide sequence selected from the group consisting of at least one of

a) SEQ ID NO.: 1, SEQ ID NO.: 3 and SEQ ID NO.: 5 or a sequence complementary thereof; and
b) a nucleotide sequence having at least 80% sequence identity to a); and
c) sub-sequences of a) or b) with a minimum length of 30 nucleotides; and
d) sub-sequences of a) and b) which comprise at least one sequence encoding a B-cell epitope.

The vaccine may thus comprise any of the sub-sequences of the nucleotide sequence of the invention, which may have any of the sequence identities described above. It is preferred, however, that these sub-sequences have a minimum length of 30 nucleotides and that they are at least 80% identical to a region of comparable length within the sequence of SEQ ID NO.: 1, SEQ ID NO.: 3 and/or SEQ ID NO.: 5.

According to this aspect of the invention one approach is to incorporate the DNA encoding a polypeptide of the invention or parts hereof into a viral or bacterial vector. The following organisms, among numerous others, may be employed for this purpose: Coxsackie virus, *vaccinia* virus, *Salmonella typhi* or *Salmonella typhimurium* (for oral administration). In each case the carrier organism must be acquired by the host cell and the relevant DNA sequences used for production of the polypeptide of the invention or parts hereof. These in turn are recognised as abnormal by the host or recipient and an immune response ensues.

Alternatively, the parasite nucleic acid sequence may be incorporated into an RNA virus or used to prepare viral replicons. This approach allows for the delivery of coding sequences, such as mRNA, to the host cell without risking a replicative, infectious process.

In order to obtain expression of immunogenic polypeptides it is required that elements of a nucleotide-based vaccine are capable of entering into the relevant target cells of the subject receiving such a vaccine. Therefore, preferred embodiments of the invention include vaccines, which further comprise one or more agents and/or vectors to facilitate such entry.

In a further preferred embodiment, the vector component of a nucleotide-based vaccine comprises a promoter for driving the expression in a mammalian cell line, a nucleotide sequence encoding a leader peptide for facilitating secretion/release of a polypeptide sequence from a mammalian cell, and a terminator.

The simple concept of a nucleotide-based vaccine is the inoculation of a recipient using the relevant DNA sequence alone. This 'naked DNA' approach avoids the administration of polypeptide directly, but its effectiveness depends on the ability of the host cell to utilise the injected DNA as a template for RNA and subsequent protein synthesis.

It is anticipated that the principal value of providing SM-specific protective immunity to sporozoite-induced infection will be, but not limited to individuals who have not previously been exposed to malaria or have only had a few cases of malaria. In the case of severe malaria such individuals will be infants and young children in endemic areas, travellers/tourists, soldiers or individuals from a non-malaria endemic area moving to or travelling in endemic areas.

While not being limited by way of theory it is believed that the protection against malaria obtained by the use of a vaccine is most likely a result of IgGs blocking the interaction between the iRBC and endothelial receptors in various organs of the body such as, but not limited to the brain. It is also possible, however, that opsonized erythrocytes are killed by macrophages or T-cells, either by fagocytosis or by other means.

In a preferred embodiment, the vaccine is therefore capable of inducing an IgG response and, accordingly, it comprises a polypeptide comprising one or more B-cell epitopes. It is desirable, however, that polypeptides comprising one or more T-cell epitopes are also part of the vaccine since assistance from T-cells may be required in order to obtain a good antibody response.

In another preferred embodiment of the invention, the vaccine is therefore based on the use of polypeptides of the invention wherein said polypeptides comprises one or more B-cell epitopes in combination with one or more T-cell epitopes. In a another preferred embodiment of the invention, the vaccine comprises B-cell epitopes in combination with T-

cell epitopes originating from an exogenous molecule, and in an further preferred embodiment, the peptides of the vaccine comprises only B-cell epitopes. In equally preferred embodiments of the invention, the vaccine is based on nucleotide sequences encoding polypeptides, which have the characteristics with respect to antigen epitopes described above.

Techniques exist for enhancing the antigenicity of immunogenic peptides including incorporation of these into a multimeric structure, binding to a highly immunogenic protein carrier, for example, keyhole limpet hemocyanin, or diptheria toxoid, and administration in combination with adjuvants or any other enhancers of immune response. Furthermore, it will be understood that polypeptides specific for a plurality of *Plasmodium* stages and species may be incorporated in the same vaccine composition to provide a multivalent vaccine. In addition, the vaccine composition may comprise antigens to provide immunity against other diseases in addition to malaria.

Immunogenic polypeptides of the invention as well as nucleic acid molecules encoding such polypeptides may be injected as is, or for convenience of administration, it can be added to pharmaceutically acceptable carriers or diluents. Suitable pharmaceutically acceptable carriers will be apparent to those skilled in the art, and include water and other polar substances, including lower molecular weight alkanols, polyalkanols such as ethylene glycol, polyethylene glycol, and propylene glycol as well as non-polar carriers.

Routes of administration, antigen dose, number and frequency of injections are all matters of optimisation within the scope of ordinary skill in the art, particularly in view of the fact that there is already experience in the art of providing protective immunity by the injection of irradiated sporozoites. Protective antibodies are usually best elicited by a series of 2 to 3 doses given about 2 to 3 weeks apart. The series can be repeated when concentrations of circulating antibodies in the vaccinee drops. The polypeptide is present in the vaccine in an amount sufficient to induce an immune response against the antigenic polypeptide and thus to protect against *Plasmodium* infection thereby protecting the subject against malaria.

Vaccination protocols can include the identification of a subject in need of a vaccine, for instance infants and young children living in regions populated with *P. falciparum* or non-immune individuals e.g. tourist/travellers and soldiers travelling through such regions, and administration of one or more effective doses of the vaccine to this subject.

In some aspects, the present invention can be used to both inhibit the adhesion of iRBC to endothelial receptors and to generate an immune response directed at SEQ ID NO. 2, SEQ

ID NO.: 4 and/or SEQ ID NO.: 6. It is therefore within the scope of the invention to provide uses of any of the polypeptides of the present invention as medicaments that are therapeutically or prophylactically useful or both.

Alternatively, such therapeutic and prophylactic effects can be obtained as a result of the expression of polypeptides of the invention within a diseased subject or a subject at risk for contracting malaria. Therefore, it is also within the scope of the invention to provide uses of any of the nucleic acid molecules of the present invention as medicaments that are therapeutically or prophylactically useful or both.

A currently particular preferred embodiment of the present invention relates to a vaccine comprising at least one nucleic acid according to the present invetion or at least one vector according to the present invention, the vaccine effecting *in vivo* expression of at least one antigen by a subject, to whom the vaccine has been administered, the amount of expressed antigen being effective to confer substantially increased resistance to malaria caused by *Plasmodium falciparum*.

Embodied in the invention is also a method for generating a vaccine against malaria comprising

a) injecting a sequence according to any of claims 1-14 and/or 15-28 in a subject
b) enabling said subject to generate antibodies specifically recognising any of the polypeptide sequences according to claim 1-14
c) purify said antibodies
d) selecting antibodies having cross-reactivity to parasites causing malaria
e) selecting antibodies having the ability to inhibit adhesion to endothelial cells.

Medical use

Polypeptides

One presently particular preferred aspect of the present invention relates to an isolated polypeptide comprising an amino acid sequence selected from the group consisting of at least one of SEQ ID NO.: 2, SEQ IN NO.: 4 and SEQ ID NO.: 6 for use as a medicament.

In a presently preferred embodiment the present invention relates to use of any of the amino acid sequences according to the present invention capable of mediating cyto-adhesion of intact erythrocyte infected by a parasite to human endothelial cells, but not to the CD36 receptor.

Such amino acid sequences can be segregated by an assay known to the skilled person comprising Chinese hamster ovary (CHO) cells transfected to express human CD36 and

cultured by standard methodology to measure iRBC adhesion to these receptors. In brief, parasites can be radiolabelled by incubating the cultures overnight in the presence of ^{3}H-phenylalanin (1 MBq for a standard culture containing 200 µl packed RBC). Wildtype and CD36-transfected CHO cells can be grown to a monolayer in 96-well microtitre plates (Nunc, Roskilde, Denmark). Late-stage-enriched iRBC (100 µl, 1x10^{7} RBC/ml) can be added to the CHO cell monolayer and incubated for one hour at 37°C before unbound iRBC can be washed away from the CHO cell monolayer. Finally, the number of CHO-adhering iRBC could be determined by liquid scintillation spectrometry.

In another presently preferred embodiment the present invention relates to use of any of the amino acid sequences according to the present invention, wherein said amino acid is consistently up-regulated after antibody selection-induced change from VSA_{UM} to VSA_{SM} expression or following selection for adhesion to bone marrow derived endothelial cells. Said amino acids do not belong to PfEMP1 groups B, C, B/C, *var1* or *var2* as defined by Lavstsen et al. 2003, and are further characterised lacking 1-2 cysteine residues in DBLα homology group G (Smith et al. 2000) compared to most PfEMP1 molecules in groups B and C.

For the present aspects of the invention it applies, as describe by the inventors, that it is an object of preferred embodiments of the present invention to provide any polypeptides, which are subject to antibody recognition by antibodies in sera from young children living in areas of high malaria transmission intensity and/or capable of mediating cyto-adhesion of intact erythrocyte infected by a parasite to endothelial cells, but not the CD36 receptor, for use as a medicament. Thus in one embodiment, the amino acid sequence may have at least 80% sequence identity to SEQ ID NO.: 2, SEQ ID NO.: 4 and SEQ ID NO.: 6.

It should be understood by the skilled addressee that any feature and/or aspect discussed above in connection with the sequence identity of the polypeptides according to the invention apply by analogy to antibodies according to the invention.

In another embodiment, the present invention relates to medical uses of an isolated polypeptide, wherein the amino acid sequence is a sub-sequence of with a minimum length of 10 amino acids.

Again, it should be understood that any lenght of an isolated polypetide described above by analogy applies to the present aspect of the invention.

A presently preferred embodiment relates to medical use of an isolated polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.

Another presently preferred embodiment relates to medical use of an isolated polypeptide comprising the amino acid sequence shown in SEQ ID NO:4.

Another presently preferred embodiment relates to medical use of an isolated polypeptide comprising the amino acid sequence shown in SEQ ID NO:6.

A particular presently preferred embodiment relates to medical use of an isolated polypeptide consisting of the amino acid sequence shown in SEQ ID NO:2.

Another particular presently preferred embodiment relates to medical use of an isolated polypeptide consisting of the amino acid sequence shown in SEQ ID NO:4.

Another particular presently preferred embodiment relates to medical use of an isolated polypeptide consisting of the amino acid sequence shown in SEQ ID NO:6.

One embodiment of the present invention relates to medial use of an isolated polypeptide according to the present invention, wherein the amino acid sequence has at least 80% sequence identity to SEQ ID NO:2.

Another embodiment of the present invention relates to medial use of an isolated polypeptide according to the present invention, wherein the amino acid sequence has at least 80% sequence identity to SEQ ID NO:4.

Yet another embodiment of the present invention relates to medial use of an isolated polypeptide according to the present invention wherein the amino acid sequence has at least 80% sequence identity to SEQ ID NO:6.

One specially preferred embodiment of the present invention relates to medical use of any of the polypeptides described herein, wherein the amino acid sequence is capable of mediating cyto-adhesion of intact erythrocyte infected by a parasite to human endothelial cells, but not to the CD36 receptor.

Another specially preferred embodiment of the present invention relates to medical use of any of the polypeptides described herein wherein the amino acid is consistently up-regulated after antibody selection-induced change from VSA_{UM} to VSA_{SM} expression.

Nucleic acids

The embodiments of the present invention thus relate to polypeptides of the PfEMP1 class or sub-sequences hereof as well as nucleic acid molecules encoding such polypeptides or sub-sequences, thus one aspect of the present invention relates to medical uses of an isolated nucleic acid comprising a nucleotide sequence selected from the group consisting of at least one of SEQ ID NO.: 1, SEQ ID NO.: 3 and SEQ ID NO.: 5 for use as a medicament.

As described by the present inventors the aim of the present invention is to provide a nucleic acid sequence encoding a polypeptide which is capable of mediating cyto-adhesion

of intact erythrocyte infected by a parasite to human endothelial cells and/or provide a nucleic acid sequence which is consistently upregulated after antibody selection-induced change from VSA_{UM} to VSA_{SM} expression.

This one embodiment relates to medical use of a nucleic acid, wherein the nucleotide sequence has at least 80% sequence identity to SEQ ID NO.: 1, SEQ ID NO.: 3 and/or SEQ ID NO.: 5.

Another presently preferred embodiment relates to medical use of a nucleic acid wherein the nucleotide sequence is a sub-sequence of with a minimum length of 30 nuclotides.

All the features described herein relating to the nucleic acid molecules of the present invention are also applicable as embodiments relating to the medical use of said nucleic acids, and vice versa.

Another presently preferred embodiment relates to medical use of a nucleic acid, wherein the nucleic acid comprises the nucleotide sequence shown in SEQ ID NO:1.

Another presently preferred embodiment relates to medical use of a nucleic acid, wherein the nucleic acid consists of the nucleotide sequence shown in SEQ ID NO:1.

Another presently preferred embodiment relates to medical use of a nucleic acid, wherein the nucleic acid comprises the nucleotide sequence shown in SEQ ID NO:3.

Another presently preferred embodiment relates to medical use of a nucleic acid, wherein the nucleic acid consists of the nucleotide sequence shown in SEQ ID NO:3.

Another presently preferred embodiment relates to medical use of a nucleic acid, wherein the nucleic acid comprises the nucleotide sequence shown in SEQ ID NO:5.

Another presently preferred embodiment relates to medical use of a nucleic acid, wherein the nucleic acid consists of the nucleotide sequence shown in SEQ ID NO:5.

Another presently preferred embodiment relates to medical use of a nucleic acid, wherein the nucleotide sequence has at least 80% sequence identity to SEQ ID NO:1.

Another presently preferred embodiment relates to medical use of a nucleic acid, wherein the nucleotide sequence has at least 80% sequence identity to SEQ ID NO:3.

Another presently preferred embodiment relates to medical use of a nucleic acid, wherein the nucleotide sequence has at least 80% sequence identity to SEQ ID NO:5.

Another presently preferred embodiment relates to medical use of a nucleic acid, wherein the sequence is consistently upregulated after antibody selection-induced change from VSA_{UM} to VSA_{SM} expression.

Another presently preferred embodiment relates to medical use of a nucleic acid, wherein the nucleic acid sequence encodes a polypeptide which is capable of mediating cyto-adhesion of intact erythrocyte infected by a parasite to human endothelial cells, but not the CD36 receptor.

Another presently preferred embodiment relates to medical use of a nucleic acid, wherein the nucleic acid sequence encodes a polypeptide which is recognised by plasma from young semi-immune children.

In a further preferred embodiment nucleic acid sequence is a re-codonised sequence. Particularly preferred are sequences that are recodonised in order to enhance or optimise expression of the resulting protein or polypeptide in a given expression system.

Vector

Another aspect of the present invention relates to a recombinant vector comprising any of the nucleic acids defined in the present application operably linked to one or more control sequences for use as a medicament.

Further medical uses

In another aspect, the present invention relates to use of any of the polypeptides according to the present invention for the manufacture of a composition to be administered in order to prophylactically or therapeutically reduce the incidence, prevalence or severity of malaria in a subject.

Thus, in one embodiment, the present invention relates to use of any of the polypeptides according to the present invention for the manufacture of a vaccine for prophylac of malaria.

In another embodiment the present invention relates to use of any of the polypeptides according to the present invention for the manufacture of a composition for vaccination against malaria.

As will be apparent, the present invention further relates to use of any nucleic acid according to the present invention for the manufacture of an composition to be administered in order to prophylactically or therapeutically reduce the incidence, prevalence or severity of malaria in a subject.

In one embodiment, the present invention relates to use of any nucleic acid according to the present invention for the manufacture of a vaccine for malaria prophylaxis .

In another embodiment the present invention relates to use of any nucleic acid according to the present invention for the manufacture of a composition for vaccination against malaria.

As the skilled adressee would recognise the present invention also relates to use of a recombinant vector according to the present invention for the manufacture of a composition to be administered in order to prophylactically or therapeutically reduce the incidence, prevalence or severity of malaria in a subject.

In one embodiment the present invention relates to use of a recombinant vector according to the present invention for the manufacture of a vaccine for prophylactic treatment of malaria.

In another embodiment the present invention relates to use of a recombinant vector according to the present invention for the manufacture of a composition for vaccination against malaria.

In a presently preferred embodiment of the present invention said malaria is caused by *Plasmodium falciparum*.

Treatment

It should be understood that any feature and/or aspect discussed above in connection with the uses according to the invention apply by analogy to methods of treatment according to the invention.

Thus, is one aspect the present invention relates to a method for prophylactically or therapeutically reduce the incidence, prevalence or severity of malaria in an subject said method comprising administering to said subject an effective amount of a polypeptide, a nucleic acid or a recombinant vector according to the present invention.

In one embodiment the present invention relates to a method for the prophylactic treatment of malaria in a subject, said method comprises administering to said subject an effective amount of a polypeptide, a nucleic or a recombinant vector according to the present invention.

In another embodiment the present invention relates to a vaccination method against malaria in a subject, said vaccination method comprising administering to said subject an effective amount of a polypeptide, a nucleic acid or a recombinant vector according to the present invention.

Composition

Another aspect of the present invention relates to use of the polypeptides and/or the nucleic acids as defined by the present application for the preparations of a composition. Thus in one embodiment the invention relates to a composition comprising a polypeptide according to the invention or a nucleic acid according to the invention and a pharmaceutically acceptable diluent, carrier or adjuvant.

In a presently preferred embodiment the composition is an immunogenic composition.

In a presently most preferred embodiment the composition induces an IgG/IgM antibody response.

Production of pharmaceuticals

Another aspect of the present invention may be the production of pharmaceuticals based on polypeptides of the invention or sub-sequences hereof or nucleic acid sequences encoding such molecules, as described above. Such pharmaceuticals may also include agents such as but not limited to other polypeptides and in particular antibodies, which are capable of modulating and/or inhibit the adhesion of SEQ ID NO.: 2, SEQ ID NO.:4, SEQ ID NO.:6 and/or homologous hereof to endothelial receptors.

Accordingly, it is within the scope of the invention to provide the use of any of the amino acid sequences according to the present invention for the manufacture of a composition, such as an immunogenic composition, which is to be administered in order to prophylactically or therapeutically reduce the incidence, prevalence or severity of severe malaria (SM) in an individual non-immune to SM causing parasites.

In addition, the invention also relates to the use of a nucleic acid molecule according to the present invention for the manufacture of a composition, such as an immunogenic composition, which is to be administered in order to prophylactically or therapeutically reduce the incidence, prevalence or severity of severe malaria in an individual non-immune to SM causing parasites.

Delivery of these pharmaceuticals can be performed by any conventional route including, but not limited to, transdermal, parenteral, gastrointestinal, transbronchial, and transalveolar administration.

Biotechnological tools

The use of the nucleic acid and polypeptide-based embodiments of the present invention can also extend to their use as biotechnological tools and as components of diagnostic assays.

Thus, one embodiment relates to an *in vitro* diagnostic method, said method comprising contacting a sample with any of the polypeptides according to the present invention under conditions allowing an *in vitro* immunological reaction to occur between said polypeptide and the antibodies possibly present in said sample, and *in vitro* detect the antigen-antibody complexes possibly formed.

In a presently preferred embodiment said diagnostic assay, further relates to an *in vitro* diagnostic method, wherein a disease-state profile for a tested subject is generated by determining the concentration or expression level in a sample of any of the polypeptide and/or nucleic acid sequences as defined in the present application.

Additional embodiments of the invention therefore include an *in vitro* diagnostic method, which comprises contacting a sample such as a tissue or biological fluid with a polypeptide comprising a sequence selected from the group consisting of at least one of

a) SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6; and
b) a sequence having at least 80% sequence identity to a); and
c) sub-sequences of a) or b) with a minimum length of 30 amino acids; and
d) sub-sequences of a) or b) comprising at least one B-cell epitope

under conditions allowing an *in vitro* immunological reaction to occur between said polypeptide composition and the antibodies possibly present in the biological sample, and the *in vitro* detection of the antigen-antibody complexes possibly formed. In one preferred embodiment the polypeptide is immobilised on a solid support.

Other embodiments include an *in vitro* diagnostic method, which comprises contacting a sample such as a tissue or biological fluid with a nucleotide composition comprising a sequence selected from the group consisting of at least one of

a) SEQ ID NO.: 1, SEQ ID NO.: 3, and SEQ ID NO.: 5 or a sequence complementary thereof; and

b) a nucleotide sequence having at least 80% sequence identity to a); and

c) sub-sequences of a) or b) with a minimum length of 18 nucleotides

under conditions allowing an *in vitro* reaction to occur between said nucleotide composition and e.g. primers and probes.

In some aspects, the nucleic acid embodiments are employed as nucleic acid probes in hybridisation assays, in cloning, or as primers for polymerase chain reaction (PCR). Similarly, the polypeptide-based embodiments can be used as components of immunological reactions such as ELISA, radio-immunoassays (RIA) and adhesion-blocking assays. The scope of such work can be, for example, to characterise SEQ ID NO.: 2, SEQ ID NO.: 4, and/or SEQ ID NO.: 6 or regions of SEQ ID NO.: 2, SEQ ID NO.: 4, and/or SEQ ID NO.: 6 involved in interaction with endothelial receptors or antibodies

In some diagnostic embodiments, nucleic acids complementary to the nucleic acid molecules of the invention or fragments hereof are used to identify SEQ ID NO.: 1, SEQ ID NO.: 3, and/or SEQ ID NO.: 5 nucleic acids (e.g. mRNA) present in a biological sample, for instance a tissue sample or a sample of body fluid such as blood or serum. In a preferred diagnostic embodiment, nucleic acid molecules complementary to fragments of SEQ ID NO.: 1, SEQ ID NO.: 3, and/or SEQ ID NO.: 5 comprising sequences, which are not found in nucleic acids encoding other SEQ ID NO.: 2, SEQ ID NO.: 4, and/ SEQ ID NO.: 6 proteins, are used to identify SEQ ID NO.: 1, SEQ ID NO.: 3, and/or SEQ ID NO.: 5 nucleic acids (e.g. mRNA) present in a biological sample.

In other diagnostic embodiments, nucleic acids identical to the nucleic acid molecules of the invention or fragments hereof are used to identify SEQ ID NO.: 1, SEQ ID NO.: 3, and/or SEQ ID NO.: 5 nucleic acids (e.g. mRNA) present in a biological sample, for instance a tissue sample or a sample of body fluid such as blood or serum. In a preferred diagnostic embodiment, nucleic acid molecules identical to fragments of SEQ ID NO.: 1, SEQ ID NO.: 3, and/or SEQ ID NO.: 5 comprising sequences, which are not found in nucleic acids encoding other SEQ ID NO.: 2, SEQ ID NO.: 4, and/ SEQ ID NO.: 6 proteins, are used to identify SEQ ID NO.: 1, SEQ ID NO.: 3, and/or SEQ ID NO.: 5 nucleic acids (e.g. mRNA) present in a biological sample.

The concentration or transcription level in the infected subject of SEQ ID NO.: 1, 3, and/or 5 nucleic acids or other nucleic acids, which encode proteins that can mediate adhesion to endothelial cells will differ depending on the type of *Plasmodium* infection. Thus, some

Plasmodium parasites will only cause the expression of low amounts of SEQ ID NO.: 2, SEQ ID NO.: 4, and/ or SEQ ID NO.: 6 or no expression at all. Likewise it will not be possible to detect any expression of SEQ ID NO.: 2, SEQ ID NO.: 4, and/or SEQ ID NO.: 6 in subjects that are not carrying a *Plasmodium* infection. Accordingly, malaria and, more specifically, severe malaria can be diagnosed by determining the concentration of SEQ ID NO.: 1, 3, and/or 5 gene transcripts in an individual at risk of contracting this disease. In the case of severe malaria such individuals may be e.g. infants or young children who live in endemic areas, and previously unexposed individuals travelling into endemic areas.

One embodiment of the present invention is therefore an *in vitro* diagnostic method whereby infection with Plasmodium and more specifically infection with *P. falciparum* can be detected. In a preferred embodiment, a disease state profile can be created by collecting data on the transcription level of SEQ ID NO.: 1, 3, and/or 5 in a large number of infected subjects and subsequent using these sets of data as reference. The concentration or transcription level of SEQ ID NO.: 1, 3, and/or 5 detected in a tested subject can then be compared to this reference material so as to predict or follow the disease-state of that particular individual. Thus, in some embodiments the term " SEQ ID NO.: 1, 3, and/or 5 disease-state profile" refers to the concentration or transcription level or concentration range or transcription level range of a nucleic acid sequence encoding SEQ ID NO.: 2, 4, and/or 6 or a part hereof that is detected in a biological sample. Arrays comprising nucleotide probes comprised by the nucleotide sequence of the invention or fragments hereof or real-time quantitative PCR can be used to create such disease-state profiles.

In a similar fashion to that discussed above, a SEQ ID NO.: 2, 4, and/or 6 disease-state profile comprising concentration levels or concentration range levels of SEQ ID NO.: 2, SEQ ID NO.: 4, and/or SEQ ID NO.: 6 amino acid sequences in healthy and diseased subjects can be created and used to follow the disease-state of an individual. Accordingly, in some embodiments the term " SEQ ID NO.: 2, SEQ ID NO.: 4, and/or SEQ ID NO.: 6 disease-state profile" refers to the concentration or concentration range or the expression level or expression level range of a polypeptide corresponding to SEQ ID NO.: 2, SEQ ID NO.: 4, and/or SEQ ID NO.: 6 or a part hereof in a biological sample. Preferred methods for detecting such proteins or polypeptides include radioactive or non-radioactive immune-based approaches such as ELISA or radio-immunoassays as well as standard membrane-blotting techniques.

The invention also relates to a method for the *in vitro* detection of antibodies, which correlate with malaria originating from the infection of an individual *P. falciparum* in a tissue or biological fluid likely to contain such antibodies. This procedure comprises

contacting a biological fluid or tissue sample as defined above with a preparation of antigens comprising the polypeptide of the invention or any part hereof under conditions, which allow an *in vitro* immunological reaction to occur between these antigens and the antibodies possibly present in the tissue or fluid. It further comprises the *in vitro* detection of the antigen-antibody complexes possibly formed by the use of conventional techniques. As an example, a preferred method involves the use of techniques such as ELISA, as well as immuno-fluorescent or radio-immunological assays (RIA) or equivalent procedures. Again, such techniques can be used for collecting data on the concentration of antibodies against the polypeptide of the invention or parts hereof in subjects infected with *Plasmodium* parasites. These data can serve as reference when compared to the concentration of antibodies against the polypeptide of the invention detected in a given subject and a disease-state profile can be generated on the basis hereof. Thus, in some embodiments the term " SEQ ID NO.: 2, SEQ ID NO.: 4, and/or SEQ ID NO.: 6 disease-state profile" refers to the concentration or concentration range of SEQ ID NO.: 2, SEQ ID NO.: 4, and/or SEQ ID NO.: 6 antibodies, which are detected in a biological sample.

Further, some aspects of the invention relate to the process of identifying compounds or compositions, which can be employed in the therapeutic treatment or prophylacxis of malaria. This may for instance be a method for identifying agents capable of modifying the SEQ ID NO.: 2, SEQ ID NO.: 4, and/or SEQ ID NO.: 6 dependent adhesion to human endothelial cells. When contacted with the agent(s) of interest, the adhesion of the iRBC to human endothelial cells is avoided. Alternatively, interaction of the agent(s) with the expressed polypeptides is avoided.

Kits

In other aspects of the invention, kits are provided which will simplify the use of the polypeptide and nucleotide embodiments of the invention for *in vitro* diagnostic purposes.

Such an *in vitro* diagnostic kit may comprise

a) any polypeptide and/or nucleic acid sequence as defined in the present application,

b) reagents for preparing a suitable medium for carrying out an immunological reaction between an antibody present in a sample of body fluid or tissue and said sequence; and

c) reagents allowing the detection of the antigen-antibody complexes formed, wherein said reagents may bear a radioactive or non-radioactive label.

In addition to this component, the kit may comprise reagents for preparing a suitable medium for carrying out an immunological reaction between an antibody present in a sample of body fluid and said sequence; and reagents allowing the detection of the antigen-antibody complexes formed, wherein said reagents may bear a radioactive or non-radioactive label.

Such an *in vitro* diagnostic kit may also comprise a cDNA chip with probes that have nucleotide sequences complementary to cDNA of the PfEMP1 described in the present application; primers for amplifying DNA obtained from clinical samples by PCR; and, means for labeling amplified DNA hybridized with the probes of the said cDNA chip. The cDNA chip may further comprise position markers to locate probes, and staining or labeling is performed by using, means for labeling comprising preferably biotin-binding material, most preferably, streptavidin-R-phycoerythrin which is a conjugate of a fluorophore and a protein with biotin-binding sites. The process for preparing cDNA chip contained in the kit comprises the steps of: preparing 5' terminal amine-linked DNA probes which have nucleotide sequences complementary to cDNA of the PfEMP1 described in the present application; affixing the DNA probes thus prepared to an aldehyde-derivatized solid surface; and, reducing excessive aldehydes not reacted with amine.

According to the present invention, *Plasmodium falciparum* in a cell or tissue can be detected by quantitatively measuring the level of one or more nucleic acids of the present invention using, e.g., real time polymerase chain reaction (PCR) with at least one oligonucleotide primer pair or oligonucleotide specific probe being capable of distinguishing between the PfEMP1 described by the present application and other polypeptides. In general, a quantitatively measured level in a biological sample from a subject, e.g., human of any of the nucleic acids described in the present application that is higher than the quantitatively measured level in a biological sample from a normal subject is indicative of malaria in the subject.

The kit of the invention is an implement that can detect malaria infection in a simple and accurate manner, as well as identify the types of infecting paracites, therefore, it may contribute to early diagnosis, prevention and treatment of malaria.

Alternatively, the *in vitro* diagnostic kit may comprise antibodies which specifically recognise a sequence selected from the group consisting of at least one of a) SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6; and b) a sequence having at least 80% sequence identity to a); and c) sub-sequences of a) or b) with a minimum length of 30 amino acids; and d) sub-sequences of a) or b) comprising at least one B-cell epitope as well as reagents for preparing a suitable medium for carrying out an immunological reaction between said

antibody and a sequence possibly present in a sample of body fluid or tissue and reagents allowing the detection of the antigen-antibody complexes formed. Said agents or said antibodies may optionally bear a radioactive or non-radioactive label.

A variety of assays can be utilized in order to detect antibodies that specifically bind to the desired polypeptide. Exemplary assays are described in detail in Antibodies: A Laboratory Manual, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988.

Representative examples of such assays include: countercurrent immuno-electrophoresis (CIEP), radioimmunoassays, radioimmunoprecipitations, enzyme-linked immuno-sorbent assays (ELISA), dot blot assays, inhibition or competition assays, and sandwich assays, immunostick (dipstick) assays, simultaneous immunoassays, immunochromatographic assays, immunofiltration assays, latex bead agglutination assays, immunofluorescent assays, biosensor assays, and low-light detection assays.

Still another aspect of the present invention provides antibodies, as discussed above, for detecting *Plasmodium falciparum* in diagnostic tests. Such antibodies are useful in a wide variety of antibody-based assays. As discussed above, exemplary assays are described in detail in Antibodies: A Laboratory Manual, (supra); U.S. Pat. No. 4,736,110 and U.S. Pat. No. 4,486,530.

These antibody-based diagnostic tests include but are not limited to the following tests:

A fluorescent antibody test (FA-test) uses a fluorescently-labeled antibody able to bind to one of the polypeptides of the invention. For detection, visual determinations are made by a technician using fluorescence microscopy, yielding a qualitative result. In a preferred embodiment, this assay is used for the examination of samples such as but not limited to blood samples.

FACS assay using fluorescently-labeled antibodies to bind one of the polypetides of the present invention expressed on the surface of RBC, yielding a quantitative result. In a preferred embodiment, this assay is used for the examination of samples such as but not limited to blood samples.

In latex bead agglutination assays, antibodies to one or more of the proteins of the present invention are conjugated to latex beads. The antibodies conjugated to the latex beads are then contacted with a sample under conditions permitting antibodies to bind to desired proteins in the sample, if any. The results are then read visually, yielding a qualitative result. In a preferred embodiment, this format can be used in the field for on-site testing.

Enzyme immunoassays (EIA) include a number of different assays able to utilize the antibodies provided by the present invention. For example, a heterogeneous indirect EIA uses a solid phase coupled with an antibody of the invention and an affinity purified, anti-IgG immunoglobulin preparation. Preferably, the solid phase is a polystyrene microtiter

plate. The antibodies and immunoglobulin preparation are then contacted with the sample under conditions permitting antibody binding, which conditions are well known in the art. The results of such an assay can be read visually, but are preferably read using a spectrophotometer, such as an ELISA plate reader, to yield a quantitative result.

An alternative solid phase EIA format includes a plastic-coated ferrous metal beads able to be moved during the procedures of the assay by means of a magnet. Yet another alternative is a low-light detection immunoassay format. In this highly sensitive format, the fight emission produced by appropriately labeled bound antibodies are quantitated automatically. Preferably, the reaction is performed using microtiter plates.

In a capture-antibody sandwich enzyme assay, the desired protein is bound between an antibody attached to a solid phase, preferably a polystyrene microtiter plate, and a labeled antibody. Preferably, the results are measured using a spectrophotometer, such as an ELISA plate reader.

In an alternative embodiment, a radioactive tracer is substituted for the enzyme mediated detection in an EIA to produce a radioimmunoassay (RIA).

In a sequential assay format, reagents are allowed to incubate with the capture antibody in a stepwise fashion. The test sample is first incubated with the capture antibody. Following a wash step, incubation with the labeled antibody occurs. In a simultaneous assay, the two incubation periods described in the sequential assay are combined. This eliminates one incubation period plus a wash step.

A dipstick/immunostick format is essentially an immunoassay except that the solid phase, instead of being a polystyrene microtiter plate, is a polystyrene paddle or dipstick. Reagents are the same and the format can either be simultaneous or sequential.

In a chromatographic strip test format, a capture antibody and a labeled antibody are dried onto a chromatographic strip, which is typically nitrocellulose or nylon of high porosity bonded to cellulose acetate. The capture antibody is usually spray dried as a line at one end of the strip. At this end there is an absorbent material that is in contact with the strip. At the other end of the strip the labeled antibody is deposited in a manner that prevents it from being absorbed into the membrane. Usually, the label attached to the antibody is a latex bead or colloidal gold. The assay may be initiated by applying the sample immediately in front of the labeled antibody.

Immunofiltration/immunoconcentration formats combine a large solid phase surface with directional flow of sample/reagents, which concentrates and accelerates the binding of antigen to antibody. In a preferred format, the test sample is preincubated with a labeled antibody then applied to a solid phase such as fiber filters or nitrocellulose membranes or the like. The solid phase can also be precoated with latex or glass beads coated with capture antibody. Detection of analyte is the same as standard immunoassay. The flow of

sample/reagents can be modulated by either vacuum or the wicking action of an underlying absorbent material.

A threshold biosensor assay is a sensitive, instrumented assay amenable to screening large number of samples at low cost. In one embodiment, such an assay comprises the use of light addressable potentiometric sensors wherein the reaction involves the detection of a pH change due to binding of the desired protein by capture antibodies, bridging antibodies and urease-conjugated antibodies. Upon binding, a pH change is effected that is measurable by translation into electrical potential (μvolts). The assay typically occurs in a very small reaction volume, and is very sensitive. Moreover, the reported detection limit of the assay is 1,000 molecules of urease per minute.

For diagnostic methods, which are based on detecting the presence of polypeptides of the invention sub-sequences with a low degree of sequence identity to polypeptides, which are unrelated to SEQ ID NO.: 2, SEQ ID NO.: 4, and/or SEQ ID NO.: 6 are preferred.

In a preferred embodiment, the kit comprises a solid support to which the antibodies of the kit are coupled. Such a support may for instance comprise an organic polymer.

In an additional embodiment, the kit comprises one or more doses of a vaccine in addition to the diagnostic components as described above. It is contemplated that such a kit may simplify the process of identifying and treating subjects in need of one of the therapeutic or prophylactic embodiments of the invention. Furthermore, the diagnostic components of a kit may be used to determine the presence of antibodies and thereby the efficiency of the vaccine in each individual subject.

In certain embodiments a kit comprises preparations of the polypeptide and/or nucleotide embodiments of the invention filled in a number of separate containers. The containers can be entirely separate or can be constituted by separate chambers of the same applicator device. Where the containers are separate, they could be provided in the form of a kit comprising separate dispensers or syringes. Where the containers form part of the same applicator, they could for example, be defined by separate barrels of a multi-barrel syringe. A kit may thus comprise containers and/or barrels, where one container or barrel contains an immunogenic substance and another container or barrel contains a diluent and/or a carrier and/or an adjuvant. Other containers or barrels may contain diagnostic components.

Novel agents

Within the scope of the present invention are also methods for identifying and/or designing novel agents useful in the prevention or treatment of malaria. Embodied in the invention is

therefore a method for testing an inhibitor-molecule capable of inhibiting binding of any of the polypeptides according to the present invention to a receptor expressed on endothelial cells comprising

a) *in vitro* cultures of endothelial cells
b) add potential inhibiting-molecule
c) add RBC infected with parasites, said iRBC expressing any of said polypeptide sequences on their surface of the RBC
d) measure the binding of the iRCB with said endothelial cells by microscopy or other means of quantifying binding as for instance liquid scintillation spectrometry.

Embodied in the invention is also a method for identifying an agent, which is capable of disrupting the *Plasmodium* life cycle, and an agent, which specifically modulates SEQ ID NO.: 2, SEQ ID NO.: 4, and/or SEQ ID NO.: 6 dependent adhesion to endothelial receptors, the method comprising providing a cell expressing an amino acid sequence selected from the group consisting of at least one of

a) SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6; and
b) a sequence having at least 80% sequence identity to a); and
c) sub-sequences of a) or b) with a minimum length of 30 amino acids; and
d) sub-sequences of a) or b) comprising at least one B-cell epitope

and contacting said cell with the agent and detecting adhesion of said cell to endothelial receptors.

By this approach, an agent, which inhibits adhesion of a polypeptide of the invention to endothelial receptors, can be identified by contacting endothelial receptors with polypeptides of the invention or sub-sequences thereof in the presence of the agent. Detection is accomplished and successful agents identified - according to their ability to induce a desired modulation of the formation of complexes of endothelial receptors and polypeptides of the invention.

In a preferred embodiment, this method is based on the detection of cells, which adhere to endothelial cells on a solid support. Again, such a support may for instance comprise a resin, a membrane, an organic polymer, a lipid or a cell or part thereof. According to another aspect of the invention a support comprising a polypeptide of the invention or a fragment thereof coupled to it can be used to capture endothelial receptors and thereby identify substances that are capable of modulating the interaction of endothelial receptors and a polypeptide of the invention. The method may be based on directly or indirectly

labelled endothelial receptors or a labelled polypeptide of the invention as well as the labelling of whole cells using radioactive as well as non-radioactive techniques.

Another possibility of using the polypeptide embodiments of the present invention is the development of a method for identifying an agent, which interacts with an amino acid sequence selected from the group consisting of at least one of

a) SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6; and
b) a sequence having at least 80% sequence identity to a); and
c) sub-sequences of a) or b) with a minimum length of 30 amino acids; and
d) sub-sequences of a) or b) comprising at least one B-cell epitope;

said method comprising providing a cell expressing one or more of said polypeptides; contacting said cell with the agent; and detecting the interaction of the agent with one or more of the said polypeptides.

In preferred embodiments, the agents identified by the use of these methods are monoclonal or polyclonal antibodies.

In addition, these methods can be used to identify compounds that will induce a desired immune response in a subject or patient and thereby serve as valuable tools in the development of novel medical compositions as for instance vaccines. Therefore, in a preferred embodiment of the invention, the methods described above are used for identifying polypeptides, which will induce a specific antibody response upon administration to a subject in need hereof, or nucleotide sequences encoding such amino acid sequences. Use of the methods for this purpose comprises injecting into a living organism one or more of the polypeptides defined above, contacting a tissue or a biological fluid sample from said organism with said polypeptides; allowing an *in vitro* reaction to occur between the polypeptides and antibodies possibly present in the biological tissue; and the *in vitro* detection of complexes possibly formed.

An additional preferred embodiment is a method as described above wherein said tissue or said biological fluid sample is contacted with polypeptides expressed on the surface of a cell.

An equally preferred embodiment is a method as described above wherein said tissue or said biological fluid sample is contacted with polypeptides expressed on the surface of erythrocytes selected for adhesion to endothelial cells or for increased antibody recognition.

Finally, another preferred embodiment of the invention is a method as described above wherein said tissue or biological fluid sample is contacted with polypeptides immobilised on a solid support.

In other embodiments, protein models of the polypeptides of the invention are constructed by the use of conventional techniques within molecular biology. Agents that interact with polypeptides of the invention are constructed and approaches in combinatorial chemistry are employed in the development of agents that modulate SEQ ID NO.: 2, SEQ ID NO.: 4, and/or SEQ ID NO.: 6 mediated interaction with endothelial receptors or are able to induce an immune response. Accordingly, novel agents that interact with SEQ ID NO.: 2, SEQ ID NO.: 4, and/or SEQ ID NO.: 6 are developed, screened in a SEQ ID NO.: 2, SEQ ID NO.: 4, and/or SEQ ID NO.: 6 characterisation assay, for instance a SEQ ID NO.: 2, SEQ ID NO.: 4, and/or SEQ ID NO.: 6 anti-adhesion assay as described above. The identity of each agent and its performance in the SEQ ID NO.: 2, SEQ ID NO.: 4, and/or SEQ ID NO.: 6 characterisation assay, its effect on the modulation of SEQ ID NO.: 2, SEQ ID NO.: 4, and/or SEQ ID NO.: 6-mediated adhesion to endothelial cells or its ability to induce an immune response is recorded on electronic or non-electronic media. These recorded data can serve as the basis for a library of SEQ ID NO.: 2, SEQ ID NO.: 4, and/or SEQ ID NO.: 6 modulating agents. Such a library can again be employed to further identify agents that modulate SEQ ID NO.: 2, SEQ ID NO.: 4, and/or SEQ ID NO.: 6-mediated adhesion to endothelial cells and can be valuable tools for selecting an appropriate pharmaceutical to treat a particular type of infection with *Plasmodium*. It is further expected that the high throughput screening techniques currently in use within the biotech and pharmaceutical industries can readily be applied to the procedures outlined above.

Host cells

With respect to the above embodiments, the invention further relates to host cells comprising the above-described nucleic acid molecules. The nucleic acid molecules may be transformed, stably transfected or transiently transfected into the host cell or infected into the host cell by a live attenuated virus. The preferred host cells may include, but are not limited to, prokaryotic cells, such as *Escherichia coli*, *Staphylococcus aureus*, and eukaryotic cells, such as *Sacchromyces cerevisiae* and *Pichia pastoris*, CHO and COS cells as well as Baculovirus infected hi-five or sf9 insect cells. Transformation with the recombinant molecules can be effected using methods well known in the art.

It should be understood that any feature and/or aspect discussed above in connection with the use according to the invention apply by analogy to methods of treatment or prevention of malaria according to the invention.

It should be understood that in a particular preferred embodiment of all the ascpects of the present invention, the malaria is severe malaria.

As will be apparent, preferred features and characteristics of one aspect of the invention may be applicable to other aspects of the invention.

Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

All patent and non-patent references cited in the present application, are hereby incorporated by reference in their entirety.

The invention will hereinafter be described by way of the following non-limiting Definitions, Figures and Examples.

Definitions

"Vaccine" refers to a preparation of SEQ ID NO.: 1, and/or SEQ ID NO.: 2, and/or SEQ ID NO.: 3, SEQ and/or ID NO.: 4, and/or SEQ ID NO.: 5, and/or SEQ ID NO.: and/or 6, which can induce protective immunity against severe malaria, but which does not itself cause disease.

"Medicament" relates to any composition comprising any of the polypeptides and/or nucleic acids describe herein for treatment of malaria and/or preventition of initiation of malaria and/or prophylaxis of malaria infection.

'VSA' refers to variant surface antigens expressed on the surface of RBC infected by *Plasmodium falciparum*. In the present context the variant surface antigen is PfEMP1.

'Serological phenotype' refers to the antibody profile obtained by FACS analysis of RBC infected by *P. falciparum* expressing VSA on the surface of said RBC.

3D7 refers to a specific laboratory isolate of a *Plasmodium falciparum* 3D7, which is a long-term clone derived from *P. falciparum* NF54 isolated from a Dutch malaria patient (Delemarre and Van der Kaay, 1979).

Unless otherwise defined herein or below in the remainder of the specification, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs.

'SEQ ID NO.: 1' is defined as the sequence of the two identical genes with the PlasmoDB accession numbers *PFD1235w* and *MAL7P1.1* (http://www.plasmodb.org) and the NCBI accession number NC_004318.

'SEQ ID NO.: 2' is defined as the protein product of the two identical genes with the PlasmoDB accession numbers *PFD1235w* and *MAL7P1.1* (http://www.plasmodb.org) and the NCBI accession number NC_004318.

The term 'VAR4' is defined as SEQ ID NO.: 2.

'SEQ ID NO.: 3' is defined as the sequence of the gene with the PlasmoDB accession number *PF11_0008* (http://www.plasmodb.org) and the NCBI accession number NC_004315.
'SEQ ID NO.: 4' is defined as the protein product of the gene with PlasmoDB accession number *PF11_0008* (http://www.plasmodb.org) and the NCBI accession number NC_004315.

The term 'VAR5' is defined as SEQ ID NO.: 4.

'SEQ ID NO.: 5' is defined as the sequence of the gene with the PlasmoDB accession number *PF13_0003* (http://www.plasmodb.org) and the NCBI accession number NC_004331.
'SEQ ID NO.: 6' is defined as the protein product of the gene with the PlasmoDB accession number *PF13_0003* (http://www.plasmodb.org) and the NCBI accession number NC_004331.

The term 'VAR6' is defined as SEQ ID NO.: 6.

The therm "*var*" 1 is defined as the DNA and amino acid sequence identified by the PlasmoDB accession numbers PFE1640w (http://www.plasmodb.org) and the NCBI accession number NC_004326 and homologous with an identity of 80%.

The term "*var2*" is defined as the DNA and amino acid sequences identified by the PlasmoDB accession numbers PL0030c (http://www.plasmodb.org) and the NCBI accession number NC_004316 and homologous with an identity of 80%.

The term "*var3*" is defined as three DNA and amino acid sequences identified by the PlasmoDB accession numbers PFA0015c, MAL6P1.314, and PFI1820w (http://www.plasmodb.org) and the NCBI accession numbers NC_004325, NC_004327, and NC_004330 respectively and homologous with an identity of 80%.

The term "Exon 2" refers to the nucleotides no. 9444–10662 of SEQ ID NO.: 1, the nucleotides no. 7722–8985 of SEQ ID NO.: 3, the nucleotides no. 8847-10041 of SEQ ID NO.: 5, amino acid no.3148–3553 of SEQ ID NO.: 2, amino acid no. 2574–2994 of SEQ ID NO.: 4, and amino acid no. 2949–3346 of SEQ ID NO.: 6.

The term "Fragment 1" of SEQ ID NO. 1, SEQ ID NO.: 3, and SEQ ID NO.: 5 refers to nucleotides no. 1-300 and amino acid no. 1-100 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 2" of SEQ ID NO. 1, SEQ ID NO.: 3, and SEQ ID NO.: 5 refers to nucleotides no. 301-600 and amino acid no. 101-200 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 3" of SEQ ID NO. 1, SEQ ID NO.: 3, and SEQ ID NO.: 5 refers to nucleotides no. 601-900 and amino acid no. 201-300 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 4" of SEQ ID NO.: 1, SEQ ID NO.: 3, and SEQ ID NO.: 5 refers to nucleotides no. 901-1200 and amino acid no. 301-400 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 5" of SEQ ID NO. 1, SEQ ID NO.: 3, and SEQ ID NO.: 5 refers to nucleotides no. 1201-1500 and amino acid no. 401-500 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 6" of SEQ ID NO. 1, SEQ ID NO.: 3, and SEQ ID NO.: 5 refers to nucleotides no. 1501-1800 and amino acid no. 501-600 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 7" of SEQ ID NO. 1, 3, and 5 refers to nucleotides no. 1801-2100 and amino acid no. 601-700 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 8" of SEQ ID NO. 1, 3, and 5 refers to nucleotides no. 2101-2400 and amino acid no. 701-800 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 9" of SEQ ID NO. 1, 3, and 5 refers to nucleotides no. 2401-2700 and amino acid no. 801-900 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 10" of SEQ ID NO. 1, 3, and 5 refers to nucleotides no. 2701-3000 and amino acid no. 901-1000 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 11" of SEQ ID NO. 1, SEQ ID NO.: 3, and SEQ ID NO.: 5 refers to nucleotides no. 3001-3300 and amino acid no. 1001-1100 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 12" of SEQ ID NO. 1, 3 SEQ ID NO.:, and SEQ ID NO.: 5 refers to nucleotides no. 3301-3600 and amino acid no. 1101-1200 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 13" of SEQ ID NO. 1, SEQ ID NO.: 3, and SEQ ID NO.: 5 refers to nucleotides no. 3601-3900 and amino acid no. 1201-1300 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 14" of SEQ ID NO. 1, SEQ ID NO.: 3, and SEQ ID NO.: 5 refers to nucleotides no. 3901-4200 and amino acid no. 1301-1400 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 15" of SEQ ID NO. 1, SEQ ID NO.: 3, and SEQ ID NO.: 5 refers to nucleotides no. 4201-4500 and amino acid no. 1401-1500 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 16" of SEQ ID NO. 1, SEQ ID NO.: 3, and SEQ ID NO.: 5 refers to nucleotides no. 4501-4800 and amino acid no. 1501-1600 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 17" of SEQ ID NO. 1, SEQ ID NO.: 3, and SEQ ID NO.: 5 refers to nucleotides no. 4801-5100 and amino acid no. 1601-1700 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 18" of SEQ ID NO. 1, SEQ ID NO.: 3, and SEQ ID NO.: 5 refers to nucleotides no. 5101-5400 and amino acid no. 1701-1800 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 19" of SEQ ID NO. 1, SEQ ID NO.: 3, and SEQ ID NO.: 5 refers to nucleotides no. 5401-5700 and amino acid no. 1801-1900 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 20" of SEQ ID NO. 1, SEQ ID NO.: 3, and SEQ ID NO.: 5 refers to nucleotides no. 5701-6000 and amino acid no. 1901-2000 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 21" of SEQ ID NO. 1, SEQ ID NO.: 3, and SEQ ID NO.: 5 refers to nucleotides no. 6001-6300 and amino acid no. 2001-2100 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 22" of SEQ ID NO. 1, SEQ ID NO.: 3, and SEQ ID NO.: 5 refers to nucleotides no. 6301-6600 and amino acid no. 2101-2200 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 23" of SEQ ID NO. 1, 3, and 5 refers to nucleotides no. 6601-6900 and amino acid no. 2201-2300 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 24" of SEQ ID NO. 1, SEQ ID NO.: 3, and 5 SEQ ID NO.: refers to nucleotides no. 6901-7200 and amino acid no. 2301-2400 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 25" of SEQ ID NO. 1, 3, and 5 refers to nucleotides no. 7201-7500 and amino acid no. 2401-2500 of SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6.

The term "Fragment 26" of SEQ ID NO. 1 and SEQ ID NO.: 5 refers to nucleotides no. 7501-7800 and amino acid no. 2501-2600 of SEQ ID NO.: 2 and SEQ ID NO.: 6.

The term "Fragment 26" of SEQ ID NO. 3 refers to nucleotides no. 7501-7719 and amino acid no. 2501-2573 of SEQ ID NO.: 4.

The term "Fragment 27" of SEQ ID NO. 1 and SEQ ID NO.: 5 refers to nucleotides no. 7801-8100 and amino acid no. 2601-2700 of SEQ ID NO.: 2 and 6.

The term "Fragment 28" of SEQ ID NO. 1 and SEQ ID NO.: 5 refers to nucleotides no. 8101-8400 and amino acid no. 2701-2800 of SEQ ID NO.: 2 and SEQ ID NO.: 6.

The term "Fragment 29" of SEQ ID NO. 1 and SEQ ID NO.: 5 refers to nucleotides no. 8401-8700 and amino acid no. 2801-2900 of SEQ ID NO.: 2 and SEQ ID NO.: 6.

The term "Fragment 30" of SEQ ID NO. 1 refers to nucleotides no. 8701-9000 and amino acid no. 2901-3000 of SEQ ID NO.: 2.

The term "Fragment 30" of SEQ ID NO. 5 refers to nucleotides no. 8701-8844 and amino acid no. 2901-2948 of SEQ ID NO.: 6.

The term "Fragment 31" of SEQ ID NO. 1 refers to nucleotides no. 9001-9300 and amino acid no. 3001-3100 of SEQ ID NO.: 2.

The term "Fragment 32" of SEQ ID NO. 1 refers to nucleotides no. 9301-9441 and amino acid no. 3101-3147 of SEQ ID NO.: 2.

The term 'adhesion to endothelial cells' or 'cytoadhesion' refers to the ability of erythrocytes infected by *P. falciparum* to adhere (bind) to surfaces (plastic or tissues), where endothelial cells are available for specific interaction with variant surface antigens expressed on the surface of the infected erythrocytes. The capacity of a given parasite isolate/line/clone for adhesion to endothelial cells *in vitro* is defined as the proportion of parasitised erythrocytes that can withstand washing after having been allowed to adhere (bind) to endothelial cells.

A "polypeptide" (e.g., a protein, polypeptide, peptide, etc.) is a polymer of amino acids comprising naturally occurring amino acids or artificial amino acid analogues, or a character string representing an amino acid polymer, depending on context. Given the degeneracy of the genetic code, one or more nucleic acids, or the complementary nucleic acids thereof, that encode a specific polypeptide sequence can be determined from the polypeptide sequence.

A "polynucleotide" (e.g., a nucleic acid, polynucleotide, oligonucleotide, etc.) is a polymer of nucleotides comprising nucleotides A,C,T,U,G, or other naturally occurring nucleotides or artificial nucleotide analogues, or a character string representing a nucleic acid, depending on context. Either the given nucleic acid or the complementary nucleic acid can be determined from any specified polynucleotide sequence.

Numbering of a given amino acid polymer or nucleotide polymer "corresponds to" or is "relative to" the numbering of a selected amino acid polymer or nucleic acid polymer when the position of any given polymer component (e.g., amino acid, nucleotide, also referred to generically as a "residue") is designated by reference to the same or an equivalent position in the selected amino acid or nucleotide polymer, rather than by the actual numerical position of the component in the given polymer. Thus, for example, the numbering of a given amino acid position in a given polypeptide sequence corresponds to the same or equivalent amino acid position in a selected polypeptide sequence used as a reference sequence.

An "equivalent position" (for example, an "equivalent amino acid position" or "equivalent residue position") is defined herein as a position (such as, an amino acid position or a residue position) of a test polypeptide sequence which aligns with a corresponding position of a reference polypeptide sequence, using for example an alignment algorithm as described herein such as, for example, the CLUSTALW alignment program using default parameters. The equivalent amino acid position of the test polypeptide sequence need not

have the same numerical position number as the corresponding position of the test polypeptide.

A "variant" is a polypeptide comprising a sequence, which differs (by deletion of an amino acid, insertion of an amino acid, and/or substitution of an amino acid for a different amino acid) in one or more amino acid positions from that of a parent polypeptide sequence. The variant sequence may be a non-naturally occurring sequence, i.e., a sequence not found in nature.

"Naturally occurring" as applied to an object refers to the fact that the object can be found in nature as distinct from being artificially produced by man. For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses, bacteria, protozoa, insects, plants or mammalian tissue) that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturally occurring. "Non-naturally occurring" as applied to an object means that the object is not naturally-occurring -- i.e., the object cannot be found in nature as distinct from being artificially produced by man.

"Binding" between two molecules, e.g., a ligand and a receptor, means a preferential binding of one molecule for another in a mixture of molecules. The binding of the molecules is typically considered specific if the binding affinity is about 1×10^4 M^{-1} to about 1×10^9 M^{-1} or greater (i.e., K_D of about 10^{-4} to 10^{-9} M or less). Binding affinity of a ligand and a receptor may be measured by standard techniques known to those of skill in the art. Non-limiting examples of well-known techniques for measuring binding affinities include Biacore® technology (Biacore AB, Sweden), isothermal titration microcalorimetry (MicroCal LLC, Northampton, MA USA), ELISA, and FACS. For example, FACS or other sorting methods may be used to select for populations of molecules (such as for example, cell surface-displayed ligands) which specifically bind to the associated binding pair member (such as a receptor, e.g., a soluble receptor). Ligand-receptor complexes may be detected and sorted e.g., by fluorescence (e.g., by reacting the complex with a fluorescent antibody that recognizes the complex). Molecules of interest which bind an associated binding pair member (e.g., receptor) are pooled and re-sorted in the presence of lower concentrations of receptor. By performing multiple rounds sorting in the presence of decreasing concentrations of receptor (an exemplary concentration range being on the order of 10^{-6} M down to 10^{-9} M, i.e., 1 micromolar (μM) down to 1 nanomolar (nM), or less, depending on the nature of the ligand-receptor interaction), populations of the molecule of interest exhibiting specific binding affinity for the receptor may be isolated.

A polypeptide, nucleic acid, or other component is "isolated" when it is partially or completely separated from components with which it is normally associated (other peptides, polypeptides, proteins (including complexes, e.g., polymerases and ribosomes which may accompany a native sequence), nucleic acids, cells, synthetic reagents, cellular contaminants, cellular components, etc.), e.g., such as from other components with which

it is normally associated in the cell from which it was originally derived. A polypeptide, nucleic acid, or other component is isolated when it is partially or completely recovered or separated from other components of its natural environment such that it is the predominant species present in a composition, mixture, or collection of components (i.e., on a molar basis it is more abundant than any other individual species in the composition). In some instances, the preparation consists of more than about 60%, 70% or 75%, typically more than about 80%, or preferably more than about 90% of the isolated species.

In one aspect, a "substantially pure" or "isolated" nucleic acid (e.g., RNA or DNA), polypeptide, protein, or composition also means where the object species (e.g., nucleic acid or polypeptide) comprises at least about 50, 60, or 70 percent by weight (on a molar basis) of all macromolecular species present. A substantially pure or isolated composition can also comprise at least about 80, 90, or 95 percent by weight of all macromolecular species present in the composition. An isolated object species can also be purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of derivatives of a single macromolecular species. The term "purified" generally denotes that a nucleic acid, polypeptide, or protein gives rise to essentially one band in an electrophoretic gel. It typically means that the nucleic acid, polypeptide, or protein is at least about 50% pure, 60% pure, 70% pure, 75% pure, more preferably at least about 85% pure, and most preferably at least about 99% pure.

The term "isolated nucleic acid" may refer to a nucleic acid (e.g., DNA or RNA) that is not immediately contiguous with both of the coding sequences with which it is immediately contiguous (i.e., one at the 5' and one at the 3' end) in the naturally occurring genome of the organism from which the nucleic acid of the invention is derived. Thus, this term includes, e.g., a cDNA or a genomic DNA fragment produced by polymerase chain reaction (PCR) or restriction endonuclease treatment, whether such cDNA or genomic DNA fragment is incorporated into a vector, integrated into the genome of the same or a different species than the organism, including, e.g., a virus, from which it was originally derived, linked to an additional coding sequence to form a hybrid gene encoding a chimeric polypeptide, or independent of any other DNA sequences. The DNA may be double-stranded or single-stranded, sense or anti-sense.

A "recombinant polynucleotide" or a "recombinant polypeptide" is a non-naturally occurring polynucleotide or polypeptide that includes nucleic acid or amino acid sequences, respectively, from more than one source nucleic acid or polypeptide, which source nucleic acid or polypeptide can be a naturally occurring nucleic acid or polypeptide, or can itself have been subjected to mutagenesis or other type of modification. A nucleic acid or polypeptide may be deemed "recombinant" when it is artificial or engineered, or derived from an artificial or engineered polypeptide or nucleic acid. A recombinant nucleic acid (e.g., DNA or RNA) can be made by the combination (e.g., artificial combination) of at least two segments of sequence that are not typically included together, not typically

associated with one another, or are otherwise typically separated from one another. A recombinant nucleic acid can comprise a nucleic acid molecule formed by the joining together or combination of nucleic acid segments from different sources and/or artificially synthesized. A "recombinant polypeptide" (or "recombinant protein") often refers to a polypeptide (or protein) that results from a cloned or recombinant nucleic acid or gene. The source polynucleotides or polypeptides from which the different nucleic acid or amino acid sequences are derived are sometimes homologous (i.e., have, or encode a polypeptide that encodes, the same or a similar structure and/or function), and are often from different isolates, serotypes, strains, species, of organism or from different disease states, for example.

The term "recombinant" when used with reference, e.g., to a cell, nucleotide, vector, protein, or polypeptide typically indicates that the cell, nucleotide, or vector has been modified by the introduction of a heterologous (or foreign) nucleic acid or the alteration of a native nucleic acid, or that the protein or polypeptide has been modified by the introduction of a heterologous amino acid, or that the cell is derived from a cell so modified. Recombinant cells express nucleic acid sequences (e.g., genes) that are not found in the native (non-recombinant) form of the cell or express native nucleic acid sequences (e.g., genes) that would be abnormally expressed under-expressed, or not expressed at all. The term "recombinant" when used with reference to a cell indicates that the cell replicates a heterologous nucleic acid, or expresses a peptide or protein encoded by a heterologous nucleic acid. Recombinant cells can contain genes that are not found within the native (non-recombinant) form of the cell. Recombinant cells can also contain genes found in the native form of the cell wherein the genes are modified and re-introduced into the cell by artificial means. The term also encompasses cells that contain a nucleic acid endogenous to the cell that has been modified without removing the nucleic acid from the cell; such modifications include those obtained by gene replacement, site-specific mutation, and related techniques.

The term "recombinantly produced" refers to an artificial combination usually accomplished by either chemical synthesis means, recursive sequence recombination of nucleic acid segments or other diversity generation methods (such as, e.g., shuffling) of nucleotides, or manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques known to those of ordinary skill in the art. "Recombinantly expressed" typically refers to techniques for the production of a recombinant nucleic acid in vitro and transfer of the recombinant nucleic acid into cells *in vivo, in vitro, or ex vivo* where it may be expressed or propagated.

The term "upregulated" in the aspects of the present invention refers to detection of a transcript by real-time quantitative PCR of any of the malaria parasite nucleotides of the present invention, wherein the nucleotide transcription level is evaluated, when compared to a housekeeping gene such as but not limited seryl-tRNA-transferase. When a transcription level of less than 100 times than that of the housekeeping gene, the evaluation is excluded. Any transcription level above this, wherein there is a difference of

at least 2 times between the transcription level of the malaria parasite *var* gene in the parasite culture of interest eg the antibody and/or endothelial cell selected 3D7 ($3D7_{SM1}$, $3D7_{endo}$) culture as compared to the control parasite culture eg the 3D7 parasite culture, said gene is upregulated.The assay of the present application is used for reference.

An "immunogen" refers to a substance capable of provoking an immune response, and includes, e.g., antigens, autoantigens that play a role in induction of autoimmune diseases, and tumor-associated antigens expressed on cancer cells. An immune response generally refers to the development of a cellular or antibody-mediated response to an agent, such as an antigen or fragment thereof or nucleic acid encoding such agent. In some instances, such a response comprises a production of at least one or a combination of CTLs, B cells, or various classes of T cells that are directed specifically to antigen-presenting cells expressing the antigen of interest.

An "antigen" refers to a substance that is capable of eliciting the formation of antibodies in a host or generating a specific population of lymphocytes reactive with that substance. Antigens are typically macromolecules (e.g., proteins and polysaccharides) that are foreign to the host.

An "adjuvant" refers to a substance that enhances an antigen's immune-stimulating properties or the pharmacological effect(s) of a drug. An adjuvant may non-specifically enhance the immune response to an antigen. "Freund's Complete Adjuvant," for example, is an emulsion of oil and water containing an immunogen, an emulsifying agent and mycobacteria. Another example, "Freund's incomplete adjuvant," is the same, but without mycobacteria.

An "immunogenic composition" refers to a composition that will evoke an immune response when administered to a subject possessing an immune system.

A "vector" is a component or composition for facilitating cell transduction or transfection by a selected nucleic acid, or expression of the nucleic acid in the cell. Vectors include, e.g., phages, plasmids, cosmids, viruses, YACs, bacteria, poly-lysine, etc. An "expression vector" is a nucleic acid construct or sequence, generated recombinantly or synthetically, with a series of specific nucleic acid elements that permit transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. The expression vector typically includes a nucleic acid to be transcribed operably linked to a promoter. The nucleic acid to be transcribed is typically under the direction or control of the promoter.

The term "immunoassay" includes an assay that uses an antibody or immunogen to bind or specifically bind an antigen. The immunoassay is typically characterized by the use of specific binding properties of a particular antibody to isolate, target, and/or quantify the antigen.

The term "homology" generally refers to the degree of similarity between two or more structures. The term "homologous sequences" refers to regions in macromolecules that have a similar order of monomers. When used in relation to nucleic acid sequences, the term "homology" refers to the degree of similarity between two or more nucleic acid sequences (e.g., genes) or fragments thereof. Typically, the degree of similarity between two or more nucleic acid sequences refers to the degree of similarity of the composition, order, or arrangement of two or more nucleotide bases (or other genotypic feature) of the two or more nucleic acid sequences. The term "homologous nucleic acids" generally refers to nucleic acids comprising nucleotide sequences having a degree of similarity in nucleotide base composition, arrangement, or order. The two or more nucleic acids may be of the same or different species or group. The term "percent homology" when used in relation to nucleic acid sequences, refers generally to a percent degree of similarity between the nucleotide sequences of two or more nucleic acids. When used in relation to polypeptide (or protein) sequences, the term "homology" refers to the degree of similarity between two or more polypeptide (or protein) sequences (e.g., genes) or fragments thereof. Typically, the degree of similarity between two or more polypeptide (or protein) sequences refers to the degree of similarity of the composition, order, or arrangement of two or more amino acid of the two or more polypeptides (or proteins). The two or more polypeptides (or proteins) may be of the same or different species or group. The term "percent homology" when used in relation to polypeptide (or protein) sequences, refers generally to a percent degree of similarity between the amino acid sequences of two or more polypeptide (or protein) sequences.

The term "homologous polypeptides" or "homologous proteins" generally refers to polypeptides or proteins, respectively, that have amino acid sequences and functions that are similar. Such homologous polypeptides or proteins may be related by having amino acid sequences and functions that are similar, but are derived or evolved from different or the same species using the techniques described herein.

The term "subject" as used herein includes, but is not limited to, an organism; a mammal, including, e.g., a human, non-human primate (e.g., baboon, orangutan, monkey), mouse, pig, cow, goat, cat, rabbit, rat, guinea pig, hamster, horse, monkey, sheep, or other non-human mammal; a non-mammal, including, e.g., a non-mammalian vertebrate, such as a bird (e.g., a chicken or duck) or a fish, and a non-mammalian invertebrate.

The term "pharmaceutical composition" means a composition suitable for pharmaceutical use in a subject, including an animal or human. A pharmaceutical composition generally comprises an effective amount of an active agent and a carrier, including, e.g., a pharmaceutically acceptable carrier.

The term "effective amount" means a dosage or amount sufficient to produce a desired result. The desired result may comprise an objective or subjective improvement in the recipient of the dosage or amount.

A "prophylactic treatment" is a treatment administered to a subject who does not display signs or symptoms of a disease, pathology, or medical disorder, or displays only early signs or symptoms of a disease, pathology, or disorder, such that treatment is administered for the purpose of diminishing, preventing, or decreasing the risk of developing the disease, pathology, or medical disorder. A prophylactic treatment functions as a preventative treatment against a disease or disorder. A "prophylactic activity" is an activity of an agent, such as a nucleic acid, vector, gene, polypeptide, protein, substance, or composition thereof that, when administered to a subject who does not display signs or symptoms of pathology, disease or disorder, or who displays only early signs or symptoms of pathology, disease, or disorder, diminishes, prevents, or decreases the risk of the subject developing a pathology, disease, or disorder.

A "prophylactically useful" agent or compound (e.g., nucleic acid or polypeptide) refers to an agent or compound that is useful in diminishing, preventing, treating, or decreasing development of pathology, disease or disorder.

A "therapeutic treatment" is a treatment administered to a subject who displays symptoms or signs of pathology, disease, or disorder, in which treatment is administered to the subject for the purpose of diminishing or eliminating those signs or symptoms of pathology, disease, or disorder. A "therapeutic activity" is an activity of an agent, such as a nucleic acid, vector, gene, polypeptide, protein, substance, or composition thereof, that eliminates or diminishes signs or symptoms of pathology, disease or disorder, when administered to a subject suffering from such signs or symptoms. A "therapeutically useful" agent or compound (e.g., nucleic acid or polypeptide) indicates that an agent or compound is useful in diminishing, treating, or eliminating such signs or symptoms of a pathology, disease or disorder.

The term "gene" broadly refers to any segment of DNA associated with a biological function. Genes include coding sequences and/or regulatory sequences required for their expression. Genes also include non-expressed DNA nucleic acid segments that, e.g., form recognition sequences for other proteins (e.g., promoter, enhancer, or other regulatory regions). Genes can be obtained from a variety of sources, including cloning from a source of interest or synthesizing from known or predicted sequence information, and may include sequences designed to have desired parameters.

Generally, the nomenclature used hereafter and the laboratory procedures in cell culture, molecular genetics, molecular biology, nucleic acid chemistry, and protein chemistry described below are those well known and commonly employed by those of ordinary skill in the art. Standard techniques, such as described in Sambrook et al., Molecular Cloning - A Laboratory Manual (2nd Ed.), Vols. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989 (hereinafter "Sambrook") and Current Protocols in Molecular Biology, F. M. Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc. (1994, supplemented through 1999) (hereinafter "Ausubel"), are used for recombinant nucleic acid methods, nucleic acid

synthesis, cell culture methods, and transgene incorporation, e.g., electroporation, injection, gene gun, impressing through the skin, and lipofection. Generally, oligonucleotide synthesis and purification steps are performed according to specifications. The techniques and procedures are generally performed according to conventional methods in the art and various general references, which are provided throughout this document. The procedures therein are believed to be well known to those of ordinary skill in the art and are provided for the convenience of the reader.

As used herein, an "antibody, Ab" refers to a protein comprising one or more polypeptides substantially or partially encoded by immunoglobulin genes or fragments of immunoglobulin genes. The term antibody is used to mean whole antibodies and binding fragments thereof. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG (1-4), IgM, IgA, IgD and IgE, respectively. A typical immunoglobulin (e.g., antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 KDa) and one "heavy" chain (about 50-70 KDa). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chains, respectively.

Antibodies exist as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, for example, pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)'2, a dimer of Fab which itself is a light chain joined to VH-CH1 by a disulfide bond. The F(ab)'2 may be reduced under mild conditions to break the disulfide linkage in the hinge region thereby converting the (Fab')2 dimer into an Fab' monomer. The Fab' monomer is essentially an Fab with part of the hinge region. The Fc portion of the antibody molecule corresponds largely to the constant region of the immunoglobulin heavy chain, and is responsible for the antibody's effector function (*see*, Fundamental Immunology, W.E. Paul, ed., Raven Press, N.Y. (1993), for a more detailed description of other antibody fragments). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such Fab' fragments may be synthesized de novo either chemically or by utilizing recombinant DNA methodology. Thus, the term antibody, as used herein also includes antibody fragments either produced by the modification of whole antibodies or synthesized *de novo* using recombinant DNA methodologies.

Antibodies also include single-armed composite monoclonal antibodies, single chain antibodies, including single chain Fv (sFv) antibodies in which a variable heavy and a variable light chain are joined together (directly or through a peptide linker) to form a continuous polypeptide, as well as diabodies, tribodies, and tetrabodies (Pack et al. (1995) J Mol Biol 246:28; Biotechnol 11:1271; and Biochemistry 31:1579). The antibodies are,

e.g., polyclonal, monoclonal, chimeric, humanized, single chain, Fab fragments, fragments produced by an Fab expression library, or the like.

The term "epitope" means a protein determinant capable of specific binding to an antibody. Epitopes usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. Conformational and nonconformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents.

An "antigen-binding fragment" of an antibody is a peptide or polypeptide fragment of the antibody that binds an antigen. An antigen-binding site is formed by those amino acids of the antibody that contribute to, are involved in, or affect the binding of the antigen. See Scott, T.A. and Mercer, E.I., Concise Encyclopedia: Biochemistry and Molecular Biology (de Gruyter, 3d ed. 1997), and Watson, J.D. et al., Recombinant DNA (2d ed. 1992) [hereinafter "Watson, Recombinant DNA"], each of which is incorporated herein by reference in its entirety for all purposes.

The term "screening" describes, in general, a process that identifies optimal molecules of the present invention, such as, e.g., the polypeptides and fragments and variants thereof, and related fusion polypeptides and proteins including the same, and nucleic acids encoding all such molecules. Several properties of these respective molecules can be used in selection and screening, for example: an ability of a respective molecule to bind a ligand or to a receptor, to inhibit cell proliferation, , to alter an immune response, e.g., induce or inhibit a desired immune response, in a test system or an *in vitro, ex vivo* or *in vivo* application. In the case of antigens, several properties of the antigen can be used in selection and screening including antigen expression, folding, stability, immunogenicity and presence of epitopes from several related antigens.

"Selection" is a form of screening in which identification and physical separation are achieved simultaneously by, e.g., expression of a selection marker, which, in some genetic circumstances, allows cells expressing the marker to survive while other cells die (or vice versa). Screening markers include, for example, luciferase, beta-galactosidase and green fluorescent protein, and the like. Selection markers include drug and toxin resistance genes, and the like. Another mode of selection involves physical sorting based on a detectable event, such as binding of a ligand to a receptor, reaction of a substrate with an enzyme, or any other physical process which can generate a detectable signal either directly (e.g., by utilizing a chromogenic substrate or ligand) or indirectly (e.g., by reacting with a chromogenic secondary antibody). Selection by physical sorting can by accomplished by a variety of methods, such as by FACS in whole cell or microdroplet formats.

An "exogenous" nucleic acid," "exogenous DNA segment," "heterologous sequence," or "heterologous nucleic acid," as used herein, is one that originates from a source foreign to

the particular host cell, or, if from the same source, is modified from its original form. Thus, a heterologous gene in a host cell includes a gene that is endogenous to the particular host cell, but has been modified. Modification of a heterologous sequence in the applications described herein typically occurs through the use of recursive sequence recombination. The terms refer to a DNA segment which is foreign or heterologous to the cell, or homologous to the cell but in a position within the host cell nucleic acid in which the element is not ordinarily found. Exogenous DNA segments are expressed to yield exogenous polypeptides.

The term "nucleic acid" refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form. Unless specifically limited, the term encompasses nucleic acids containing known analogues of natural nucleotides which have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences and as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al. (1991) Nucleic Acid Res 19:5081; Ohtsuka et al. (1985) J Biol Chem 260:2605-2608; Cassol et al. (1992) ; Rossolini et al. (1994) Mol Cell Probes 8:91-98). The term nucleic acid is used interchangeably with gene, cDNA, and mRNA encoded by a gene.

"Nucleic acid derived from a gene" refers to a nucleic acid for whose synthesis the gene, or a subsequence thereof, has ultimately served as a template. Thus, an mRNA, a cDNA reverse transcribed from an mRNA, an RNA transcribed from that cDNA, a DNA amplified from the cDNA, an RNA transcribed from the amplified DNA, *etc.*, are all derived from the gene and detection of such derived products is indicative of the presence and/or abundance of the original gene and/or gene transcript in a sample.

A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter or enhancer is operably linked to a coding sequence if it increases the transcription of the coding sequence. Operably linked means that the DNA sequences being linked are typically contiguous and, where necessary to join two protein coding regions, contiguous and in reading frame. However, since enhancers generally function when separated from the promoter by several kilobases and intronic sequences may be of variable lengths, some polynucleotide elements may be operably linked but not contiguous.

The term "identical" or "identity," in the context of two or more nucleic acid or polypeptide sequences, refers to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection.

"Sequence identity" is a measure of identity between polypeptides at the amino acid level and a measure of identity between nucleic acids at nucleotide level. The protein sequence identity may be determined by comparing the amino acid sequence in a given position in each sequence when the sequences are aligned. Similarly, the nucleic acid sequence identity may be determined by comparing the nucleotide sequence in a given position in each sequence when the sequences are aligned

To determine the percent identity of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity # of identical positions/total # of positions (e.g., overlapping positions) x 100). In one embodiment the two sequences are the same length.

Alignment of two sequences for the determination of percent identity is to be accomplished by using a mathematical algorithm published (Tatusova and Madden, 1999). BLAST nucleotide alignments is be performed with the blastn program, with the parameters "Reward for a match" = 1, "Penalty for a mismatch" = -2, "Strand option" = both strands, "Open gap" = 5, "Extension gap" = 2, "gapx_dropoff" = 50, "expect" = 10.0, "word size" = 11 and "Fliter" = on.

BLAST protein searches can be performed with the blastp program applying the "BLOSUM26" matrix, with the parameters "Reward for a match" = 1, "Penalty for a mismatch" = -2, "Open gap" = 11, "Extension gap" = 1, "gapx_dropoff" = 50, "expect" = 10.0, "word size" = 3 and "Fliter" = on.

Both programs can be accessed from National Center for Biotechnological Information's web page at http://www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html

In all polypeptide or amino acid based embodiments of the invention the percentage of sequence identity between one or more sequences is based on alignment of the respective sequences as performed by clustalW software (http:/www.ebi.ac.uk/clustalW/index.html) using the default settings of the program. These settings are as follows: Alignment=3Dfull, Gap Open 10.00, Gap Ext. 0.20, Gap separation Dist. 4, Protein weight matrix: Gonnet. With respect to the nucleotide-based embodiments of the invention, the percentage of sequence identity between one or more sequences is also based on alignments using the clustalW software with default settings. For nucleotide sequence alignments these settings

are: Alignment=3Dfull, Gap Open 10.00, Gap Ext. 0.20, Gap separation Dist. 4, DNA weight matrix: identity (IUB).

The term "serum" is used in its normal meaning, i.e. as blood plasma without fibrinogen and other clotting factors. The term "plasma" is used in its normal meaning, i.e. as blood plasma. Both terms are use interchangeable.

In the present context "complementary sequence" refers to nucleotide sequences, which will hybridise to a nucleic acid molecule of the invention under stringent conditions. The term "stringent conditions" in refers to general conditions of high stringency. The term "stringency" is well known in the art and is used in reference to the conditions (temperature, ionic strength and the presence of other compounds such as organic solvents) under which nucleic acid hybridisations are conducted. With "high stringency" conditions, nucleic acid base pairing will occur only between nucleic acid fragments that have a high frequency of complementary base sequences, as compared to conditions of "weak" or "low" stringency.

As an example, high stringency hybridisation conditions comprise (1) low ionic strength and high temperature for washing, such as 0.015 M NaCl/0.0015 M sodium citrate, pH 7.0 (0.1xSSC) with 0.1% sodium dodecyl sulfate (SDS) at 50°C; (2) hybridisation in 50% (vol/vol) formamide with 5 x Denhardt's solution (0.1% (wt/vol) highly purified bovine serum albumin/0.1% (wt/vol) Ficoll/0.1% (wt/vol) polyvinylpyrrolidone), 50 mM sodium phosphate buffer at pH 30.5 and 5 x SSC at 42°C; or (3) hybridisation in 50% formamide, 5 x SSC, 50 mM sodium phosphate (pH 30.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C with washes at 42°C in 0.2 x SSC and 0.1% SDS.

The term "effective amount" refers to an amount or concentration of a substance such as an amino acid sequence, nucleotide sequence or an antibody, which is effective to produce a protective prophylactic or therapeutic response with respect to the disease malaria. In general, an effective amount of the substance, which is administered to a human subject, will vary depending upon a number of factors associated with that subject, including whether the subject has previously been exposed to *Plasmodium falciparum*. The person of ordinary skill in the art can determine an effective amount of the substance by varying the dosage of the product and measuring the resulting cellular and humoral immune and/or therapeutic responses subsequent to administration. In particular, the concentration range of an immunogenic substance is chosen so as to enhance the likelihood of eliciting an immunogenic response e.g. vaccinating the recipient for a long period of time, without causing a malaria infection in the vaccine recipient.

"Endemic areas" refers to areas where transmission of *P. falciparum* parasites occurs repeatedly over the years. Depending on the intensity of transmission, endemic areas are often divided (in order of decreasing intensity) into holo- (intense, perennial transmission), hyper- (intense, seasonal transmission), meso- (less intense, locally and temporally

varying transmission), hypo-endemic (little transmission with little effect at the population level) areas.

A "B-cell epitope" is defined as an antigenic determinant, which functionally is the portion of an antigen, which combines with the antibody paratope. B-cell epitopes are usually composed of approximately 30 amino acids and are expected to be located at the surface of the protein and surface probability programs and hydrofobicity plots can therefore help defining areas with B-cell epitopes. With respect to the present invention the Protean 4.0 software in the DNAstar package is used with default settings when defining such areas. Specific B-cell epitopes should preferably be determined experimentally, which can be done by methods well known to the person of ordinary skill in the art.

In the present context the term "DNA vaccine" refers to vaccines based on any species of nucleic acid molecules, comprising species of DNA or RNA.

The term "T cell epitope" refers to a sequence of about ten amino acids that are part of a much longer, folded chain of amino acids and can lead to activation of a T-cell when presented on the surface of a cell in complex with Major Histocompatibility Complex II (MHC) and/or MHCI. Probability values for putative T-cell epitopes within a polypeptide may be obtained with the use of computers, neural networks and prediction servers such as SYFPEITHI server at Centre for Biological Sequence Analysis BioCentrum-DTU, Technical University of Denmark (http://syfpeithi.bmi-heidelberg.com/Scripts/MHCServer.dll/EpPredict.htm), which is used with, default unchangeable settings.

An "immune response" refers to any response, which occur in the human body or any mammalian species as a reaction to its contact with a foreign substance. An immune response can for example cause activation of B-lymphocytes and/or T-cells. Activation of B-lymphocytes can result in production of antibodies that can target said foreign substance or antigen. Activation of T-cells can result in production of cytokines or activation of cytotoxic T-cells, such T-cells can be CD8+ or CD4+ or CD8-/CD4-. Activation of an immune response can furthermore result in activation of macrophages, NK cells and/or result in the production of specific T- and B- memory cells

The term 'fusion protein' is to be interpreted as the product of a SEQ ID NO.: 1, SEQ ID NO.: 3, and/or SEQ ID NO.: 5 nucleic acid sequence to which an exogenous nucleic acid sequence that may be of virtually any length has been added.

"*In vitro* panning" refers to a procedure by which erythrocytes infected by a particular isolate/line/clone of *P. falciparum* is selected for dominant expression of a variant surface antigen (VSA) with defined adhesion characteristics. To select for expression of VSA that can adhere to human endothelial cells *in vitro* by *in vitro* panning, erythrocytes infected by mature stages of the isolate/line/clone in question are allowed to adhere to culture dishes previously containing human endothelial cells. Unbound (non-adhering) erythrocytes are removed by washing, and only the remaining bound (adhering) are used to propagate the

isolate/line/clone further. The process of *in vitro* panning is usually repeated at a minimum of three times to ensure uniform expression of the VSA with the desired adhesion characteristics.

"Expression systems" refers to eucaryotic and/or prokaryotic systems for expression of VAR4, VAR5, and/or VAR6 protein or homologues hereof. The DNA sequence that forms the basis for expression in these systems may be either non-recodonised and/or recodonised. As an example the sequence could be optimised for expression in different yeast systems, *in vitro* systems using human cells, and/or insect cell systems. In such systems it would be of advantage to purify the protein before using it therapeutically and/or as a vaccine. In another example, the sequences could be optimised for expression in plant derived systems. Such whole transgenic plants might be ingested to activate the immune system against parasites causing severe malaria, or the proteins could be purified from such transgenic plants. Plant expression systems could be, but are not limited to transgenic potatoes, Soya been, tobacco, banana, and/or crops used for animal feeding that can be made transgenic with known methods. SEQ ID NO.: 1, SEQ ID NO.: 3, and/or SEQ ID NO.: 5 or homologues hereof can be delivered to plants by different means. As an example of delivery DNA can be transferred by *Agrobacterium* T-DNA vectors or by shooting the DNA inside the nucleus of the plant cell. Transient expression can be obtained with different virus vectors transfecting the plant cell.

The term 'nucleic acid molecule' refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes molecules composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as molecules having non-naturally occurring nucleobases, sugars and covalent internucleoside (backbone) linkages which function similarly or combinations thereof. Such modified or substituted nucleic acids are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases and other enzymes, and are in the present context described by the terms "nucleic acid analogues" or "nucleic acid mimics". Preferred examples of nucleic acid mimetics are peptide nucleic acid (PNA-), Locked Nucleic Acid (LNA-) , xylo-LNA-, phosphorothioate-, 2'-methoxy-, 2'-methoxyethoxy-, morpholino- and phosphoramidate-containing molecules or the like.

By 'real time quantitative PCR' is meant a method including a fluorescent DNA intercalating dye in a PCR reaction mix. This method measures incorporated fluorescens at the end of each cycle making it possible to calculate the copy number of mRNA molecules in the original starting sample.

By "Enzyme-linked-immunosorbent assay (ELISA)" is meant an assay for determining the amount, level or titre of protein, antigen or antibody in a given sample by means of an enzyme-catalysed colour reaction. One variant of ELISA is the two-antibody "sandwich"

ELISA. This assay is used to determine the antigen concentration in unknown samples. The assay is done by coating a microtiter plate with antibody, antigen is then added and allowed to complex with the bound antibody. Unbound products are removed by washing, and a labelled secondary antibody (the "detection" antibody) is allowed to bind to the antigen, thus completing the "sandwich". The assay is then quantitated by measuring the amount of labelled secondary antibody bound to the antigen, through the use of a colorimetric substrate. In a second variant of the ELISA method, plates are coated with antigen and specific antibodies are used for the detection by incubating the plate with a biological fluid. Unbound antibodies are then removed by washing, and a labelled secondary antibody (the "detection" antibody) is allowed to bind to the primary antibody. The level of binding between antigen and antibody is then quantitated by measuring the amount of labelled secondary antibody bound to the matrix, through the use of a colorimetric substrate

By "radioimmunoassay (RIA)" is meant a method that utilises radiolabelled Antibody (Ab) or Antigen (Ag) to detect Ag:Ab reactions. The Abs or Ags are labelled with ^{125}I (iodine-125) and the presence of Ag:Ab complexes are detected using a gamma counter. RIA can be done in solution as well on filters. In solution the Ag:Ab complexes are precipitated and the amount of radioactivity in the supernatant measured.

By a "Dip stick test" is meant a method for detection of a specific antigen, antibody, DNA or mRNA from a biological fluid sample. A nucleic acid, antigen or antibody is bound to the membrane of the dip stick and contact to a labelled or unlabelled bodily fluid is allowed for a given time. The nucleic acid, antigen or antibody bound on the membrane can then be hybridised to nucleic acid, antigen or antibody labelled with a dye.

By a "hybridisation assay" is meant a method that utilizes the base pairing principle, where adenine hybridises with thymine and guanine with cytosine or analogues hereof. Biological (e.g. tissue, blood, or serum) samples can be tested for the presence of RNA or DNA by hybridisation with a probe, labelled or unlabelled, solid phase or liquid phase.

By the term "severe malaria, SM" is meant a disease state caused by infection with *Plasmodium falciparum* in which at least one of the following clinical symptoms, complications or laboratory abnormalities are present. Clinical symptoms/complications: Prostration, impaired consciousness, respiratory distress, acidotic breathing, multiple convulsions, circulatory collapse, pulmonary oedema, abnormal bleeding, jaundice, haemoglobinuria. Laboratory findings: B-haemoglobin <5g/dL; B-glucose <2.2mmol/L; P-bicarbonate <15mmol/L; P-lactate >5mmol/L; P-creatinine >265µmol/L; parasitaemia >4%.

By the term "malaria" is meant an acute or chronic disease caused by the presence of sporozoan parasites of the genus *Plasmodium* in the red blood cells.

By the term "semi-immune" is meant an an individual who have been exposed to *Plasmodium falciparum* infection and developed an immune response to the parasite. The immune response is not necessarily fully protective. Thus, a semi-immune subject is protected against severe malaria, but might still be infected with malaria parasites or in risk of becoming infected with parasites causing non-severe malaria.

By "in vitro diagnosis" is meant detection of *P falciparum* derived compounds related to SEQ ID NO.: 1, SEQ ID NO.: 2, SEQ ID NO.: 3, SEQ ID NO.: 4, SEQ ID NO.: 5, and/or SEQ ID NO.: 6 in a biological fluid or sample. These SEQ ID NO.: 1, SEQ ID NO.: 3, and/or SEQ ID NO.: 5 related compounds can for example be mRNA, DNA, or for SEQ ID NO.: 2, SEQ ID NO.: 4, and/or SEQ ID NO.: 6 protein-antigen, peptide-antigen or antibody being of any subclass. The methods for *in vitro* diagnosis of severe malaria could be, but are not limited to PCR, RT-PCR, real-time quantitative PCR, ELISA, RIA, Dip stick test or any Hybridisation assay.

By "VSA_{SM}" is meant a limited and conserved set of VSA that are both stronger and more commonly recognised by IgG in the plasma of malaria-exposed young semi-immune individuals than VSA (VSA_{UM}) expressed by parasites causing uncomplicated malaria (UM) in older semi-immune children. To test for VSA_{SM} expression on the surface of erythrocytes infected by a *P. falciparum* isolate/line/clone, the level of specific recognition of VSA expressed by the isolate/line/clone in question is tested again a panel of plasma by flow cytometry. (Staalsoe et al. 1999, Staalsoe et al. 2003). Plasma is collected from children (aged 1-10 years) living in an area of very high malaria transmission intensity. The children are classified as responders or non-responders according to the reactivity of their plasma in comparison with that of plasma collected from individuals living in areas where malaria transmission never occurs. The percentage of responders in age groups defined by year is plotted against age. The tested parasite isolate/line/clone is classified as a VSA_{SM} if the percentage of responders is higher than 80% in 2-year-old children. A parasite isolate/line/clone is classified as VSA_{UM} if the percentage of responders aged 2 years is lower than 50% and increases steadily by age.

By "VSA_{UM}" is meant less well conserved set of VSA that are less well and less commonly recognised by IgG in the plasma of malaria-exposed young semi-immune individuals, but well and more commonly recognised by immune adults from malaria endemic areas. To test for VSA_{UM} expression on the surface of erythrocytes infected by a *P. falciparum* isolate/line/clone, the level of specific recognition of VSA expressed by the isolate/line/clone in question is tested again a panel of plasma by flow cytometry. (Staalsoe et al. 1999, Staalsoe et al. 2003). Plasma is collected from children (aged 1-10 years) living in an area of very high malaria transmission intensity. The children are classified as responders or non-responders according to the reactivity of their plasma in comparison with that of plasma collected from individuals living in areas where malaria transmission never occurs. The percentage of responders in age groups defined by year is plotted against age. The tested parasite isolate/line/clone is classified as a VSA_{SM} if the percentage of responders is higher than 80% in 2-year-old children. A parasite

isolate/line/clone is classified as VSA_{UM} if the percentage of responders aged 2 years is lower than 50% and increases steadily by age.

With respect to the present invention the term 'polypeptide' refers to an amino acid chain of any length, including a full-length protein, oligopeptides, short peptides and fragments thereof, wherein the amino acid residues are linked by covalent bonds.

"Isolated" and "purified": The term "isolated" requires the material to be removed from the environment in which it was present originally. For example, a polypeptide or nucleic acid, which is expressed in a cell, is not isolated. However, the same polypeptide or nucleic acid, when separated from some or all of the coexisting material occurring in the original environment, will be considered as isolated. It is in accordance with this definition to regard polypeptides and nucleic acids present in cell lysates as isolated. By "purifying"' a compound such as a polypeptide or a nucleic acid is meant increasing the degree of purity of a preparation of the compound by removing completely or partially at least one contaminant from the preparation. When applied to a preparation of a compound the term "degree of purity" refers to its relative content by weight of the compound of interest, based on the total weight of the preparation. The degree of purity of a compound may be within the range of 1 - 100%, such as from 1 - 100%, 10 - 100%, 20 - 100%, 30 - 100%, 40 - 100%, 50 - 100%, 300 - 100%, 70 - 100%, 80 - 100% and 90 - 100%. 'Substantially pure' is herein used to describe a polypeptide or a nucleic acid with a degree of purity of at least 70%, such as at least 75%, at least 80%, at least 85%, at least 90% at least 95%, at least 99% or preferably substantially pure from other components. The % value herein indicates % (w/w).

Figure Legends

Figure 1
Quantitative fluorometric measurements (*m1-3*) of plasma Ab recognition of VSA expressed by *P. falciparum* isolates. Parasites (columns) were obtained from 68 pediatric patients from Ghana (parasite donors). Plasma samples (rows) were obtained from 96 healthy children from the same area as the patients. Small squares represent specific parasite/plasma combinations. For each such combination, Ab levels are indicated by the shading of the square (*m1-4*). The healthy plasma donors (rows) are sorted by age, and within each of the two clinical categories the parasite isolates (columns) are sorted according to the age of the parasite donors (malaria patients). Within parasite donor age groups, individual isolates are sorted according to level of VSA IgG recognition (sum of scores). Small numbers along the *right* and *bottom edges* are for enumeration of plasma samples and parasites, respectively.

Figure 2
Age dependency of Ab recognition of VSA expressed by 68 *P. falciparum* isolates. For each parasite/plasma combination, the Ab recognition was scored on a six-level scale, according to Ab recognition of the isolate by 2-fold dilutions of a pool of plasma from adult, parasite-

exposed Ghanaians. The overall Ab recognition of individual isolate was subsequently calculated as the sum of scores obtained with each of the 96 plasma samples. The dependency upon the age of the parasite donors (malaria patients) is shown in *A* and *B*, whereas the dependency upon the age of the healthy plasma donors is shown in *C* and *D*. Parasite isolates obtained from patients with severe *P. falciparum* malaria are shown in *A* and *C*, whereas parasites from patients with nonsevere malaria are shown in *B* and *D*. In all panels, means and 95% confidence intervals are indicated.

Figure 3

Distribution of patient age (*A*) and VSA Ab fluorescence sum of scores (*B*) according to cluster assignment of the infecting *P. falciparum* isolate. Median (center line), 25th and 75th percentiles (box), 10th and 90th percentiles (vertical lines), and outliers (•) are shown for each cluster.

Figure 4

Plasma Ab recognition of VSA expressed by parasite isolates obtained from 68 Ghanaian children with *P. falciparum* malaria. The level of fluorescence (mean and 95% confidence intervals) obtained with 2-fold dilutions of a plasma pool from parasite-exposed adult Ghanaians is shown, including the regression line (solid line) and its 95% confidence interval (dashed lines). *A*, Ab recognition of isolates according to their origin from patients with severe (•) or nonsevere (O) *P. falciparum* malaria. *B*, Ab recognition of isolates according to their origin from young (•; 3–4 years of age) or older (O; 5–11 years of age) *P. falciparum* malaria patients.

Figure 5

Levels of IgG with specificity for variant surface antigens in *P. falciparum* 3D7 before (panels A-B) and after (C-D) *in vitro* selection by iRBC reactivity with IgG in the plasma of semi-immune Ghanaian children. Open histograms show VSA-specific IgG reactivity in plasma from semi-immune Ghanaian children (A, C) or clinically immune Ghanaian adults (B, D). Shaded histograms show corresponding reactivity in plasma from donors without *P. falciparum* exposure (negative control).

Figure 6

An *in vitro* culture of ethidium bromide-labelled *P. falciparum* 3D7-infected RBC following sequential exposure to the SM1 plasma pool, biotinylated secondary anti-human IgG, and streptavidin-coated DynaBeads (*m3-1, m3-2*). Uninfected RBC (white left-arrows), and iRBC coated (white down-arrows) or not coated (white up-arrows) with DynaBeads, as well as free DynaBeads (black arrows) can be seen in the micrograph.

Figure 7

Plasma levels of IgG with specificity for variant surface antigens expressed by 3D7, $3D7_{SM1}$, and five *P. falciparum* field isolates from Sudan. Plasma was obtained from Sudanese (A)

and Tanzanian (B) individuals, and levels are given on a semi-quantitative scale determined by recognition of intact iRBC by IgG in plasma pools from non-exposed donors (negative control pool) and highly exposed donors (positive control pool), respectively. IgG reactivity in plasma from the five parasite donors to the autologous *P. falciparum* isolates are indicated by heavy lines.

Figure 8
Adhesion of 3D7- and $3D7_{SM1}$-infected RBC to wild-type (CHO-0) and CD36-transfected (CHO-CD36) Chinese hamster ovary (CHO) cells (*m4-1*).

Figure 9
A) Schematic presentation of all 3D7 *var* gene sequence analyses (*m2-1, m2-2, m2-3).* Gene names, chromosomal location, transcriptional direction and domain structure are shown along with the cluster to which each gene was assigned by the sequences analyses. Sequences that could not be assigned to any cluster were named X. Three major *var* gene groups (group A-C), two intermediate groups group B/A and group B/C and two unique genes representing *var1* and *var2 var* gene families were defined (framed). B) Sequence analyses of *var* genes from other *P. falciparum* strains than 3D7. Protein accession numbers, originating strain, domain structure and the closest related 3D7 *var* 5' sequence are shown along with sequence group allocations as defined in 3D7. *) The genes were assigned to group A, as their DBL1α sequences clustered together with other group A sequences in analysis of DBLα sequences. **) Pseudogene, belongs to the *var1* family ^) Upstream sequences with atypically low similarity to upsB or upsC sequences.

Figure 10
Schematic representation of head-to-head genomic organisation of *rif* and upsA flanked *var* genes. Nine genes are flanked by a *rif* gene, which has its initiation codon approximately 3 or 4 kb upstream from the *var* initiation codon, and one *var* gene by another *var* gene at -2 kb. Punctured lines represent upsA, dotted lines upsA-*rif* and full line upsBsh. The diamond marks the putative termination site of upsA characterised by a stretch of TA repeats. Sizes of genes are not in scale.

Figure 11
Distance tree of 3D7 *var* gene 500 bp 3' region generated using the p-distance/NJ method (*m2-3).* The four dense clusters A through D were supported by both bootstrapping and maximum parsimony (MP) tree (not shown). The relationship of the remaining sequences could not be verified by the MP tree making method. Numbers at the nodes represent bootstrap proportions (BP) on 1000 replicates. The scale bar represents the proportion of different nucleotide compared. PlasmoDB accession numbers are shown. Genes with assigned cluster are collected in Figure 9.

Figure 12
Distance tree of DBLαCIDR1 domains of 3D7 PfEMP1 and pseudogene PFE1640w generated using the p-distance/NJ method (*m2-3)*. The clusters A through E were supported by both bootstrapping and maximum parsimony tree (not shown). Numbers at the nodes represent bootstrap proportions (BP) on 1000 replicates. The scale bar represents the proportion of different amino acids compared. PlasmoDB accession numbers are shown.

Figure 13
Fold changes in *var* gene transcription by late-stage *P. falciparum* 3D7 before and after antibody-selection of parasites for selection of VSA_{SM}-type antigens using DynaBeads coated with plasma IgG from three different pools of plasma from semi-immune African children (SM1, SM2, SM3) (*m3-2*). Transcription levels were measured using real-time PCR and primers specific for 59 *var* genes and one pseudogene (Salanti et al., 2003) (*m5-2*). Panel A shows mean fold changes (± SD; 5 experiments) in *var* gene transcription related to selection using the SM1 pool. Panel B shows fold change values in one experiment using the SM2 pool, while Panel C summarizes one experiment using the SM3 pool. Black bars indicate the 15 most highly transcribed *var* genes in selected and/or unselected 3D7. A 3-fold change in *var* gene transcription (dashed lines) was arbitrarily defined as the cut-off for biologically significant changes in *var* gene transcription. Primers see Table 1. Grouping of *var* genes is as described in (Lavstsen et al., 2003).

Figure 14
Changes in *var* gene transcription in synchronised ring-stage (30 hr) *Plasmodium falciparum* 3D7 *in vitro* selected with a pool of plasma antibodies from children from semi-immune African children (SM1, SM2) (se legend to Fig 13). Panel A shows mean fold changes (± SD; 5 experiments) in *var* gene transcription related to selection using the SM1 pool. Panel B shows fold change values in one experiment using the SM2 pool. A fold change of 2 (dotted lines) was defined as the cut-off for biological interesting changes in *var* gene transcription.

Figure 15
Relative levels of *var* transcripts in 10 µg of total RNA obtained from 3D7 (lane 1) and antibody-selected 3D7 (lane 2) ring stage iRBC. Northern blots (*m7-1*) probed with DIG labelled RNA probes targeting (Panel A) *PFD1235w/MAL7P1.1* (SEQ ID NO.: 1). Transcript size is 12.5kb. (Panel B) Ethidium bromide-stained gel shown to allow comparison of total RNA amounts.

Figure 16
Expression of PfEMP1 in 3D7 and antibody-selected 3D7 trophozoite/schizont stage iRBC. Western blots (*m10-5, m10-6*) of SDS-extracts obtained before (Lane A) and following (Lane B) antibody selection. Samples were run in 5% SDS-PAGE gels, blotted and probed with antibodies to a relatively conserved sequence of the intracellular acidic segment ATS/Exon2 (lanes A-B) and a specific antibody raised against DBL5-δ of VAR4 (SEQ ID

NO.: 2)(Lanes C-D). The antibody-selected parasite expressed the product of *PFD1235w/MAL7P1.1* (***)(SEQ ID NO.: 2) and a PfEMP1 with molecular weight (MW) corresponding to the predicted MW of MAL6P1.316 (**). Both selected and unselected parasites expressed a PfEMP1 of a MW corresponding to the predicted MW of PF08_0107 (*). SDS-extracts of RBC infected by NF54 obtained from a Dutch volunteer (Hermsen et al., 2001). Extracts were obtained on day 8, 9, and 10 (Lanes E-G) and the blot probed with the DBL5-δ antibody used in Lanes C-D.

Figure 17

Surface expression of antigens in *P. falciparum* 3D7 before (A1-5) and after (B1-5) antibody selection (*m3-2, m10-6*). Murine plasma antibodies against recombinant DBL5-δ of VAR4 (SEQ ID NO.: 2) reacted with the surface of most antibody-selected 3D7 iRBC in FACS (B1; green line) and fluorescence microscopy (B2; green dots). The antibodies only reacted with a minority of unselected 3D7 (A1, A2), and with none of the trypsin-treated iRBC from antibody-selected 3D7 (B1; purple line). Shaded histograms show flow cytometry reactivity in pre-vaccination mouse plasma. VSA-specific IgG (A3, B3) reactivity in plasma from a semi-immune African child (red line) and a clinically immune African adult (blue line) confirming the VSA_{UM} phenotype of unselected 3D7 and the VSA_{SM} phenotype of antibody-selected 3D7. Localization of the VAR4 (SEQ ID NO.: 2) using confocal microscopy and murine plasma anti-DBL5-δ antibodies (A4, A5, B4, B5). Ethidium-bromide staining of DNA in the nuclei is red/orange and staining of VAR4 (SEQ ID NO.: 2) using FITC-labeled antibodies is green. Pre-vaccination mouse plasma did not stain iRBC (data not shown).

Figure 18

Plasma antibody levels to recombinant DBL5-δ (A), CIDR1-α (B), DBL3-β (C), and NTS (D) domains of the VAR4 (SEQ ID NO.: 2) in Tanzanian children and adults, and in Danish donors without *P. falciparum* exposure (DK) (*m12-1*). For competition ELISA experiments (*m12-2*), plates were coated with recombinant CIDR1-α domains of the proteins encoded by *PFD1235w/MAL7P1.1* (SEQ ID NO.: 1 and SEQ ID NO.: 2) (E) and PFE1644w/*var*1 (F), and ELISA reactivity measured in three different plasma samples, which had been pre-incubated with increasing concentrations of homologous or heterologous fusion protein as indicated in the top part of each panel. Non-depleted (ND) plasma was included for comparison.

Figure 19

Similarity of the *PFD1235w/MAL7P1.1* encoded protein (SEQ ID NO.: 2) homologues in genotypically distinct parasite isolates. Alignment of DBL1-α/CIDR1-α from two peripheral blood parasites from children (BM021 and BM48) and the protein product of *PFD1235w/MAL7P1.1* (SEQ ID NO.: 2) from 3D7 covering amino acids 842-1602 in 3D7 SEQ ID NO. 2. Identical residues appear on black background, conserved amino acid changes on grey, and radical changes on white background.

Figure 20
Fold changes in *var* gene transcription in ring-stage (30 hr) (Panel A) and by late-stage (Panel B) *P. falciparum* 3D7 before and after *in vitro* selection on human endothelial cells for selection of parasites expressing VSA_{SM}-type antigens (*m6-1, m6-2*). Transcription levels were measured using real-time PCR and primers specific for 59 *var* genes and one pseudogene (Salanti et al., 2003). The two panels shows fold change values in one experiment. Black bars indicate the 15 most highly transcribed *var* genes in selected and/or unselected 3D7. A 3-fold change in *var* gene transcription (dashed lines) was arbitrarily defined as the cut-off for biologically significant changes in *var* gene transcription. Primers see Table 1. Grouping of *var* genes is as described in (Lavstsen et al., 2003).

Examples

Example 1:

Erythrocytes infected by P. falciparum *parasites causing severe malaria (SM) are stronger and more commonly recognised by IgG in plasma of malaria-exposed individuals than erythrocytes infected by other* P. falciparum *parasites*

P. falciparum-infected red blood cells (iRBC) adhere to endothelial host receptors through parasite-encoded, clonally variant surface antigens (VSA). The VSA-mediated iRBC adhesion and the acquired VSA-specific antibody response is linked to disease severity. Parasites isolated from young children with severe malaria (SM) express a limited and conserved set of VSA (VSA_{SM}) that are both stronger and more commonly recognised by IgG in the plasma of malaria-exposed individuals than VSA (VSA_{UM}) expressed by parasites causing uncomplicated malaria (UM) in older semi-immune children. It is therefore likely that the SM-specific protective immunity acquired in young children in areas of intense parasite transmission is based on antibodies to VSA_{SM} that inhibits the adhesion to endothelial cells of parasites expressing VSA_{SM} on the surface of infected erythrocytes.

Materials and methods

m1-1. Isolation of iRBC from malaria patients: Circulating human erythrocytes infected with *Plasmodium falciparum* (iRBC) were collected in vacutainers containing either heparin or citrate-phosphate-dextrose (CPD) as anticoagulant. Plasma and white blood cells were removed upon centrifugation at 800xg, and the erythrocyte pellet resuspended in an equal volume of freezing solution (28%(v/v) glycerol in 4.2%(w/v) sorbitol and 0.9%(w/v) NaCl in H_2O) and snap-frozen in liquid Nitrogen.

In vitro culture of P. falciparum parasites: Cryopreserved iRBC were restored by thawing at 37°C followed by washing in 3.5% $NaCl_2$ and washing twice in RPMI 1640 culture medium (http://www.lifetech.com). Parasites were maintained

in a 5% suspension culture of uninfected human O^+ erythrocytes in RPMI 1640, supplemented with Albumax, hypoxanthin, glutamine, gentamycin (all http://www.lifetech.com), and non-immune human serum. Culture medium was changed and Giemsa-stained smears were prepared for microscopy on a daily basis.

m1-2. Purification of iRBC *from cultures:* iRBC with haemozoin-containing trophozoites and schizonts were purified from *in vitro* cultures (*m1-1*) by magnet-activated cell sorting (MACS; http://www.miltenyibiotec.com), exploiting the magnetic properties of haemozoin. In short, iRBC were passed through a size-C MACS column mounted with a 0.9 mm x 40 mm needle. The column was washed with phosphate buffered saline (PBS) supplemented with 2% foetal calf serum (FCS; PBS-S) until no erythrocytes could be seen in the eluate. The column was removed from the magnet, and the trophozoite- and schizont-containing iRBC retained in the column were then released by further washing. A purity of trophozoite-/schizont-infected iRBC >90% was usually reached by this procedure .

m1-3. Detection of human VSA-specific IgG: Purified iRBC (*m1-2*) were labelled with 1 µl ethidium bromide (EB; http://www.sigma-aldrich.com) solution (0.1 mg/ml) per 10^5 erythrocytes to allow discrimination between nucleic acid-containing iRBC and uninfected erythrocytes devoid of DNA/RNA. For each sample, 2 x 10^5 erythrocytes in 100 µl PBS-S (m1-3) were used. EB-labelled iRBC were mixed with 1–5 µl of human plasma or antibody preparation, followed by goat anti-human IgG (http://www.dako.com), diluted 1:200 and by fluorescein isothiocyanate (FITC)-conjugated rabbit anti-goat Ig (http://www.dako.com), diluted 1:25. The antibodies were diluted in PBS-S, and 100 µl of the dilution was added per sample. At each step, samples were incubated for 30 min at 5°C. The samples were washed twice in 3 ml PBS-S between each incubation step and once after the last. Samples were kept overnight at 5°C before analysis on a Coulter EPICS XL-MCL flow cytometer (http://beckman.com).

m1-4. For quantification of FITC fluorescence, the mean fluorescence intensity (MFI) of the ethidium bromide positive red blood cells was calculated using WinList software (http://www.vsh.com). Plasma from Danish donors never exposed to falciparum malaria did not label uninfected erythrocytes or iRBC above the level of the secondary and tertiary antibodies alone. In contrast, the plasma pool prepared from hyper-immune Ghanaians selectively labelled iRBC but not uninfected erythrocytes.

m1-5. Human plasma samples tested: The individual human plasma samples were obtained from the following groups of individuals:
Plasma from Danish adults without exposure to *P. falciparum* parasites were obtained at the Copenhagen University Hospital (Rigshospitalet) from laboratory staff and blood donors being screened for the presence of anti-RhD antibodies.
Plasma from 96 Ghanaian children living in Dodowa Town, 50 km northeast of Accra. The area is characterized by hyperendemic, seasonal transmission of *P. falciparum* parasites. All children were healthy at the time of blood sampling.

A pool of plasma from healthy, parasite-exposed adults from the village of Gomoa Onyadze, 80 km west of Accra (Nielsen et al. 2002).

To corroborate the above hypothesis levels of antibodies in plasma from 96 healthy children, aged 3–8 years, with specificity for each of the 68 parasite isolates (Fig. 1) were measured (*m1-4*). Overall, antibody (Ab) recognition of the parasite VSA differed widely among plasma donors. While plasma samples from some children contained barely detectable levels of Abs specific for VSA expressed by any of the isolates (e.g., plasma donors 15, 34, and 59; see Fig. 1), others had high levels and a broad range of VSA-specific Ab (e.g., plasma donors 14, 41, and 84; Fig. 1). By analyzing the parasite-specific sum of scores from the 96 x 68 recognition matrix, we found that recognition of VSA was independently associated with both the age of the malaria patient (3–4, 5–30, and 7–11 years; $p = 0.005$) and the clinical picture (severe or nonsevere; $p = 0.006$, by two-factor ANOVA). There was no significant interaction between these two sources of variation ($p = 0.26$). Pair wise multiple comparison procedures (Tukey's post-hoc test) showed that while the VSA sum of scores of parasites from the youngest patient group was significantly different from that from either of the two other age groups ($p < 0.05$), the latter two were not significantly different from each other ($p \geq 0.05$). The relationship between severity and age of the parasite donor is illustrated in Fig.2, *A* and *B*. These results show that Ab recognition of parasite VSA was independently affected by both the age and the clinical severity of the malaria patient from whom the parasite was obtained. This is important, because disease severity is inversely correlated with age in areas of endemic parasite transmission, which in all likelihood reflects age-dependent acquisition of protective immunity (reviewed in Riley et al. 1994). Protective immunity appears to involve acquisition of Ab responses to a broad range of VSA (Bull et al. 1998), and consistent with this observation we found that VSA Ab levels correlated with the age of the healthy plasma donors (Fig.2, *C* and *D*). The authenticity of our finding of independent effects of patient age and disease severity is supported by the fact that the age distributions of children with severe and nonsevere disease were similar (by *t* test, $p = 0.5$) in the present study (5.30 ± 0.4 and 30.0 ± 0.5 years, respectively; mean ± SD), due to the exclusion of children <3 years of age.

To further substantiate our findings and to investigate whether parasites from patients with severe *P. falciparum* malaria expressed particular VSA, we used the 96 x 68 recognition matrix (Fig. 1) to search for patterns of similarity in the VSA Ab recognition of the parasite isolates. Hierarchical cluster analysis identified three main clusters (data not shown). In one of these (cluster I), all but one (90%) of the isolates were from severe cases, whereas this was the case for only 5 of 20 (25%) in cluster II. The third and largest cluster (III) showed an intermediate pattern, with 21 of 38 (55%) isolates from patients with severe malaria (Fig. 3). The proportion of isolates from severe patients in the three clusters was thus quite different (by X^2 test, $p = 0.009$). When we analyzed the age distribution of the patients donating the parasites within the clusters, cluster I was composed of parasites from young patients, whereas the other two clusters contained parasites from older patients (Fig. 3A). The cluster-specific differences in patient age composition did not quite

reach conventional statistical significance (by Kruskal-Wallis test, $p = 0.06$). The distribution of the parasite-specific sum of scores among the clusters showed that cluster I was composed entirely of parasites expressing very well-recognized VSA, whereas the opposite was true for cluster II. Again, cluster III formed an intermediate group (Fig. 3*B*). The distribution of sum of scores was significantly different among the three clusters (by Kruskal-Wallis test, $p < 0.001$), with all pairwise differences being significant (by Dunn's post-hoc test, $p < 0.01$ in all cases).

We have used flow cytometry to measure VSA-specific IgG to provide evidence of modulation of VSA expression by acquired immunity. Our method is particularly suited to this type of analysis, as it allows unbiased and quantitative analysis of large matrixes of VSA and corresponding Abs of specified isotype. We found that the level of plasma IgG recognition of VSA expressed by *P. falciparum* isolates obtained from patients with severe malaria was approximately twice that of VSA from nonsevere isolates (Fig. 4*A*). In a similar way we found that VSA Ab recognition of isolates from young patients (3–4 years of age) was ~2-fold that of isolates from older patients (5–11 years of age; Fig. 4*B*).

Thus, the VSA antibody recognition of parasites from severe patients is broader and more intense than recognition of VSA expressed by parasites from other malaria patients (Figs. 1 and 2), independently of the age of the patient. Thus, our data suggest that acquisition of VSA-specific Ab responses gradually restricts the repertoire of VSA that are compatible with parasite survival in the semi-immune host. Furthermore, it appears to limit the risk of severe disease by preventing the expression of VSA likely to cause life-threatening complications, such as cerebral malaria and severe anaemia.

Example 2:

Sub-grouping of Plasmodium falciparum *3D7* var *genes based on sequence analysis of coding and non-coding regions*

PfEMP1 is a polymorphic family of high molecular weight adhesion antigens expressed on the surface of infected erythrocytes. PfEMP1 is an important target for protective immunity and is implicated in the pathology of malaria through its ability to adhere to host endothelial receptors. The accumulation of antibodies against a broad repertoire of PfEMP1s is probably the functional basis for the natural acquisition of immunity to malaria (Bull et al. 1998)

All *var* genes are characterised by a two-exon structure. Exon 1 encodes a large extra-erythrocytic and highly variable region containing two to seven Duffy-binding like (DBL) domains and mostly one or two cysteine-rich inter-domain region (CIDR) domains. Based on sequence homologies, the DBL domains can be sub-divided into α, β, γ, δ, and ε types and the CIDR domains into CIDRα other (CIDR-O) types. A subset of *var* genes furthermore contains a second cysteine-rich domain called C2. Exon 2 encodes the intra-erythrocytic (cytoplasmic) and conserved part of the protein.

The entire genome of the *P. falciparum* clone 3D7 genome is now known, including its complete *var* gene repertoire. Figure 9 shows the domain structure of each of the 59 *var* genes as well as the truncated pseudo-gene *PFE1640*w.

Methods

m2-1. Nucleotide and deduced amino acid sequences as well as location and transcriptional directions of 3D7 *var* and *rif* genes were obtained from the *Plasmodium* Genome Resource – http://www.plasmodb.org.

m2-2. Alignments were performed using the ClustalW multiple alignment method, European Molecular Biology Laboratory, Heidelberg, Germany at default parameters (Gap Open: 10.00; Gap Extention: 0.20, Gap Separation Distance: 4, Protein weight matrix: Gonnet, DNA weight matrix: identity (IUB)). Alignments were corrected by hand using Bioedit (Hall, 1999) to assure homologous sequences for sequence analysis and tree-building. For distance tree-building, the *var* gene 5' flanking regions were defined as the 600 bp, 1.4 kb or 2.0 kb upstream of the translation initiation codon and the 3' flanking region as the 500 bp downstream of the translation stop codon. The available *var* flanking sequences from other strains than 3D7 varied between 250 and 2100 bp in length. For the most part 3' sequences were those retrieved by Mercereau-Puijalon *et al* (Mercereau-Puijalon et al. 2002) . *Var* gene domain structures were defined using definitions described in Smith *et al.* (Smith et al. 2000) . DBLαCIDR1 domains were aligned from Pro-Cys (PC) of DBLα homology block A to the conserved Glu-Trp (EW) motif of CIDR M2 area, resulting in sequence lengths of 550 to 650 aa. For analysis of DBL relationships sequences covering Pro-X-Arg-Arg (PXRR) of DBL homology block B to Glu-Trp (EW) of homology block H were aligned.

m2-3. Distance trees were constructed the by p-distance/neighbour-joining (NJ) method as well as maximum parsimony (MP) using MEGA version 2.1 (Kumar et al. 2001). Trees were bootstrapped 1000 times and compared between NJ and MP tree-building methods to assure confidence in topology. Observed clusters from each tree were confirmed visually on alignments.

The 1.5 kb 5' region of 3D7 *var* genes has previously been described to group into three major sequence groups, *upsA, upsB* and *upsC* (Gardner et al. 2002) . To further investigate sequence similarities in this region, we analysed the 2 kb upstream sequences of all 3D7 *var* genes and the pseudo *var* gene PFE1640w. In agreement with Gardner *et al.* (Gardner et al. 2002) the alignments revealed three major sequence groups with high similarity between sequences of each group. However, two sequences did not align well with any of the groups and within the groups, subgroups could be identified. Thus, each of the groups were analysed separately.

Ten *var* genes had 5' regions belonging to the *upsA* group and all but one were positioned head-to-head with a *rif* gene, the exception PF08_0141 was head-to-head with another *var* gene (Fig. 10). Using a primer set targeting *upsA* 3D7 sequences around -900 bp from the

translation initiation codon, we could PCR amplify products of the expected sizes in 3D7 genomic DNA, as well as in five of five field-isolates tested (data not shown). These data suggests that *upsA* regions not are unique to 3D7.

Alignments and tree-building (Fig. 11) of the 500 bp *var* 3' regions divided most sequences into four clusters (A-D). 13 sequences fell outside these clusters, and the relationship between these sequences could not be confirmed by bootstrapping or comparison the two tree-building methods used.

Because most PfEMP1 molecules contain a semi-conserved head structure comprising of DBL1α and CIDR1, we restricted the analysis of coding sequences to these domains. In 3D7 all but one *var* gene encode a DBLlα as the first domain and in all but four genes DBL1 is followed by a CIDR1. Since alignment and tree constructions of DBL1 and CIDR1 domains individually yielded almost identical clusters, we decided to analyse the head structure sequences from the N-terminal region of DBL1 to a conserved motif in the C-terminal region of CIDR1 (Fig. 12). Fifty-two sequences, including that of pseudogene PFE1640w, could be grouped into five clusters, and four sequences could not be assigned any of these. When all CIDR sequences are aligned most CIDR1s fall into separate clusters of CIDRα or CIDRα1 domains (Robinson et al. 2003). The exceptions are three sequences (PF08_0141, PF11_0008, PF13_0003), which fall into a CIDRγ cluster. In Figure 12, the head structures of these genes fall into group A. Robinson *et al.* (Robinson et al. 2003) found that most CIDR domains bind CD36 but identified nine, which did not. These constitute cluster A.

Figure 9 schematically sums up the findings of all the *var* gene sequence analyses. The combination of clusters and chromosomal organization of the *var* genes indicate that *var* genes can be grouped into three major subgroups, *var* group A, B and C and two intermediate groups group B/A and group B/C, which appear to represent transitions between these three groups. The two genes previously shown to belong to conserved *var* families, *var1* and var2, fell outside these groups. Group A *var* genes were most easily defined, whereas the borders of the proposed group B and C were less clear (Fig. 9A). The grouping was supported by analyses of both coding and non-coding sequences. However, the best predictors for the groups were the upstream region and chromosomal organization. Thus, genes placed near the telomere and with a transcriptional direction towards the telomere all had upsA sequences and formed group A. Group B were dominated by telomeric located but centromeric transcribed genes flanked by upsB and finally group C harboured all centromeric located genes with a upsC 5'region.

Group A comprise most large PfEMP1s with a domain structure different from the most common 4-domain type, which is the predominant domain structure of Group B and C. Two genes PF08_0140 and MAL6P1.316 were classified as B/A because they had upsBsh 5' regions and chromosomal characteristics in common with group B genes, but had DBLα-CIDR1 sequences and domain structure characteristic for group A genes. Interestingly, these two genes are adjacent to a group A *var* or a pseudo *var* gene with an upsA region

both transcribed in the opposite direction, thereby merging their 5'regions. Adding the DBL1α-CIDR1 of the flanking pseudogene MAL6P1.317 to the alignments placed this pseudogene within DBLα-CIDR1 cluster A.

The fact that 5' regions predict *var* gene chromosomal organisation and domain structure, and sequence similarities in coding and non-coding regions several thousand bases downstream from the translation initiation site implies that recombination, or other mechanisms of homogenizing exchange is much more likely to occur between *var* genes within a group than between *var* genes of different groupings. It can be proposed that an original ancestral *var* gene has been duplicated and diverged in the three main types, and each of these have then diverged into the genes of each group. In this process information may also have been exchanged between genes of different groupings. The data suggests that some exchange have taken place between groups B and C and some characteristics of group A have leaked into these groups, but that characteristics from groups B and C have not gained access to group A.

In conclusion, var genes can be sub-grouped into three major groups (group A, B and C) and two intermediate groups B/A and B/C representing transitions between the three major groups. The best defined var group, group A, comprises telomeric genes transcribed towards the telomere encoding PfEMP1s with complex domain structures different from the 4-domain type dominant of groups B and C. A rif subgroup transcribed towards the centromere was found neighbouring var genes of group A such that the rif and var 5' regions merged. This organization appeared to be unique for the group A var genes.

Example 3:

Selection of P. falciparum *isolate 3D7 for expression of well recognised VSA* in vitro

Establishment of the genetic control of changes in VSA expression in response to *in vitro* selection is now possible because of the availability of the entire genomic sequence of the *P. falciparum* clone 3D7, which is a long-term clone derived from *P. falciparum* NF54 isolated from a Dutch malaria patient (Delemarre and Van der Kaay, 1979).

As a first step towards direct molecular identification of VSA_{SM}-encoding genes in 3D7, we established a method to enforce expression of VSA_{SM}-like antigens in this parasite clone by a novel selection method using plasma from semi-immune children with low levels of VSA_{UM}-IgG but high levels of VSA_{SM}-IgG (Fig. 5).

Materials and methods

m3-1. To enrich 3D7 for iRBC expressing VSA well recognized by IgG in the SM1 plasma pool, 1×10^8 RBC infected with late trophozoite-stage parasites purified by gelatine flotation) were mixed with 200 µL pooled plasma in 3 mL culture medium, and incubated the mixture at room temperature (20-25°c) for 15 min. Antibodies not

reactive with intact iRBC were removed by washing × 2 (800 g, 30 min). The iRBC were then resuspended in 3 mL culture medium and incubated as above with 100 µL biotinylated secondary antibody recognizing human IgG (Dako, Glostrup, Denmark). The iRBC were washed twice and resuspended as above and subsequently mixed with 100 µL streptavidin-coated DynaBeads (Dynal, Oslo, Norway). Finally, we isolated DynaBeads-coated iRBC by placing the IRBC suspension in a magnet field until all DynaBeads had settled at the magnet. The culture medium containing RBC and iRBC not covered with DynaBeads was removed by decantation. This procedure was repeated once before the DynaBeads-covered iRBC were transferred to a new culture bottle with medium and uninfected RBC for continuation of *in vitro* culturing.

m3-2. *Human plasma samples used for selection:* We used repeated rounds of panning on DynaBeads coated by IgG from two plasma pools (SM1, SM2) from semi-immune Ghanaian children and one plasma pool (SM3) from semi-immune Tanzanian children to select 3D7 parasites expressing VSA that were highly recognized by IgG in these plasma pools (Staalsoe et al., 2003).

Flow cytometry analysis of unselected 3D7 indicated that its VSA expression was heterogeneous but that the majority of the iRBC expressed VSA that were poorly recognised by IgG in the plasma of individuals living in areas of endemic *P. falciparum* transmission (Fig. 5). In particular, only few iRBC were specifically labelled by IgG in the plasma of semi-immune children with documented high levels of IgG with specificity for VSA expressed by *P. falciparum* isolated from patients with severe malaria (VSA_{SM}) and low levels of VSA expressed by patients with uncomplicated malaria (VSA_{UM}) (Fig. 5A). Although IgG levels in the plasma of sympatric adults were higher than in children, they were still moderate (Fig. 5B). Taken together, these data indicate that the VSA expressed by unselected 3D7 were of the VSA_{UM} type.

Only a minority of RBC infected by unselected 3D7 expressed VSA_{SM}-type antigens. To increase the proportion of iRBC expressing VSA_{SM}-type molecules in the culture, we first incubated 3D7 with the SM1 pool of plasma from semi-immune children, then with biotinylated anti-human IgG and finally with streptavidin-coated DynaBeads. As expected from the heterogeneous IgG recognition of VSA expressed by unselected 3D7, this resulted in some iRBC being covered by multiple DynaBeads while most were devoid of any beads (Fig. 6). We subsequently isolated the DynaBeads-covered iRBC by exposing the culture to a strong magnetic field, and used only these to propagate the culture further. Flow cytometry analysis showed that the IgG recognition of the VSA expressed by the $3D7_{SM1}$ sub-clone obtained by three rounds of selection in this manner was much stronger than that of VSA expressed by the unselected 3D7 parental clone (Fig. 5C-D). The biggest increase in IgG recognition of VSA following selection was seen in the plasma from children with documented high levels of VSA_{SM}-type IgG and low IgG levels with specificity for VSA_{UM}-type antigens (Fig. 5A and 5C). This, and the fact that the level of IgG recognition of $3D7_{SM1}$ iRBC was both high and similar in children (Fig. 5C) and adults (Fig. 5D) show

that the applied selection method had caused a change from predominantly VSA_{UM}-type antigens being expressed in unselected 3D7 to VSA_{SM}-type expression in $3D7_{SM1}$.

The $3D7_{SM1}$ VSA_{SM}-expressing sub-clone was selected by its reactivity to IgG in a plasma pool from West African children living in an area of hyperendemic, seasonal *P. falciparum* transmission. To investigate whether the high VSA-specific IgG reactivity against $3D7_{SM1}$ extended beyond this region and in a variety of epidemiological settings, we measured levels of IgG with specificity for the VSA expressed by $3D7_{SM1}$ in series of plasma samples obtained from individuals (8 to 42 years of age) living in an area of hypoendemic, highly seasonal transmission in Sudan (Fig. 7A) and from children aged 3-11 years living in area of very intense transmission in Tanzania (Fig. 7B). All 20 Tanzanian children had medium-to-high levels of IgG unselected 3D7 iRBC and to all of five local parasite isolates, reflecting the high endemicity in their area of residence (Fig. 7B). Nevertheless, levels of IgG with specificity for the $3D7_{SM1}$ VSA were higher than those with specificity for unselected 3D7 (Fig. 7B). Importantly, levels of $3D7_{SM1}$ VSA-specific IgG were higher than IgG with specificity for VSA expressed by any of the local isolates, although $3D7_{SM1}$ was selected on IgG from West Africa. Taken together, these data suggest the existence of substantial conservation in time and space of the commonly and highly recognised VSA_{SM}-type iRBC surface antigens.

In conclusion, these findings open the possibility of identifying VSA of importance in the pathogenesis of severe disease (VSA_{SM}) by comparing VSA gene expression in isogenic parasites expressing VSA_{UM}- and VSA_{SM}-type iRBC surface molecules that are characterised by their differential IgG recognition pattern rather than by their adhesion specificity.

Example 4:

3D7 parasite expressing VSA_{SM} does not adhere to CD36

Most members of the PfEMP1 family of 3D7 posses the capacity to bind CD36 and the binding motives have been mapped to the N-terminal part of the molecules. PfEMP1 that bind CD36 are structurally and functionally related (Robinson et al 2003) and belong to Groups B, C, or B/C (Lavstsen et al. 2003) and Example 2. In this example we show that 3D7 expressing a VSA_{UM} phenotype bind CD36, whereas 3D7 expressing the VSA_{SM} phenotype does not.

Materials and methods:

m4-1. We used Chinese hamster ovary (CHO) cells transfected to express human CD36 and cultured by standard methodology to measure iRBC adhesion to these receptors (Staalsoe et al. 1999; Hasler et al. 1993; Rogerson et al. 1995). In brief, parasites were radiolabelled by incubating the cultures overnight in the presence of ^{3}H-phenylalanin (1 MBq for a standard culture containing 200 µl packed RBC). Wildtype and CD36 transfected CHO cells were grown to a monolayer in 96-well

microtitre plates (Nunc, Roskilde, Denmark). Late-stage-enriched iRBC (100 µl, $1x10^7$ RBC/ml) were added to the CHO cell monolayer and incubated for one hour at 37°C before unbound iRBC were washed away from the CHO cell monolayer. Finally, the number of CHO-adhering iRBC was determined by liquid scintillation spectrometry.

To investigate the relationship between VSA_{SM} expression and iRBC adhesion to CD36, we compared the ability of RBC infected by 3D7 and $3D7_{SM1}$ to adhere to CD36-transfected (CD36-CHO) CHO cells (Fig. 8). While 3D7 showed four- to 10-fold higher adhesion to CHO-CD36 cells than to wild-type CHO-0 cells, adhesion of $3D7_{SM1}$ to the transfected cells was never more than twice that to wild-type cells (Fig. 8). The average adhesion ratio was 30·3 for 3D7 and 1·4 for $3D7_{SM1}$, corresponding to a difference of 4·9 [95% confidence interval: (1·9-7·9)]. These results indicate that there is a relationship between VSA_{SM} expression and the loss of ability of iRBC to adhere to CD36.

In conclusion, these results indicate that parasites expressing the VSA_{SM} phenotype do not adhere to CD36.

Example 5:

Selection of P. falciparum *isolate 3D7 for expression of well recognised VSA* in vitro *results in selective up-regulation of Group A* var genes

Parasite-encoded PfEMP1 proteins expressed on the surface membrane of iRBC mediate the adhesion of such erythrocytes to a range of host receptors. The PfEMP1 proteins are encoded by the *var* gene family containing 50-60 members per haploid parasite genome. Different PfEMP1 molecules have different receptor specificities, and clonal switching between expression of the various *var* gene products in a mutually exclusive manner allows the parasite to modify its adhesion properties. Gene expression and switching can be examined using gene-specific primers and real-time PCR.
Using real-time quantitative PCR we compared *var* gene expression in the parasite line 3D7 before ($3D7_{UM}$) and after ($3D7_{SM}$) selection for antibody recognition (Example 3),

m5-1. RNA was purified from $3D7_{UM}$ and $3D7_{SM}$ and used for the synthesis of cDNA. Total RNA was prepared with Trizol LS (http://www.invitrogen.com) as recommended by the manufacturer, and treated with DNAse1 (http://www.invitrogen.com). Absence of DNA in RNA samples was confirmed by stable base fluorescence after 40 cycles of real-time PCR with *seryl-tRNA synthetase* primers (Salanti et al., 2003)) (Table 1). One µg of DNA-free RNA was reversed transcribed using Superscript II and random hexamer primers ((http://www.invitrogen.com)) at 25°C for 10 min, 42°C for 50 min followed by 70°C for 15 min in a total volume of 40 µl.

Table 1

Primer sets used in real-time PCR assays to specifically amplify 59 *var* genes and one pseudogenes (underlined). Where several genes are listed next to a single primer set, primer targets in the listed genes were identical.

Primer set	Forward primer	Reverse primer	Target gene(s)
1	TGCGCTGATAACTCACAACA	AGGGGTTCATCGTCATCTTC	PFA0005w
4	GACGAGGAGTCGGAAAAGAC	TGGACAGGCTTGTTTGAGAG	PF10_0001
5	GTGCACCAAAAGAAGCTCAA	ACAAAACTCCTCTGCCCATT	PF10_0406
6	GAGGCTTATGGGAAACCAGA	AGGCAGTCTTTGGCATCTTT	PF11_0007
7	GACGGCTACCACAGAGACAA	CGTCATCATCGTCTTCGTTT	PF11_0008 (SEQ ID NO.: 3)
8	TGCTGAAGACCAAATTGAGC	TTGTTGTGGTGGTTGTTGTG	PF11_0521
9	TCGATTATGTGCCGCAGTAT	TTCCCGTACAATCGTATCCA	PFL0020w
10	TGGTGATGGTACTGCTGGAT	TTTATTTTCGGCAGCATTTG	PFL0030c
11	GACGCCTGCACTCTCAAATA	TTGGAGAGCACCACCATTTA	PFL0935c
12	AGCAAAATCCGAAGCAGAAT	CCCACAGATCTTTTCCTCGT	PFL1950w
15	CATCCATTACGCAGGATACG	AAATAGGGTGGGCGTAACAC	PFL1960w
17	GGCACGAAGTTTTGCAGATA	TTTGTGCGTCTTTCTTCGTC	PFL2665c
18	CGGAGGAGGAAAAACAAGAG	TGCCGTATTTGAGACCACAT	PFL0005w
19	CGGAATTAGTTGCCTTCACA	CATTGGCCACCAAGTGTATC	PF13_0364
20	CACAGGTATGGGAAGCAATG	CCATACAGCCGTGACTGTTC	PF13_0003 (SEQ ID NO.: 5)
21	CAATTTTGGGTGTGGAATCA	CACTGGCCACCAAGTGTATC	PFB1055c
22	ATGTGCGCTACAAGAAGCTG	TTGATCTCCCCATTCAGTCA	PFB0010w
23	CAATCTGCGGCAATAGAGAC	CCACTGTTGAGGGGTTTTCT	PFC1120c/PFC0005w
25	ATATGGGAAGGGATGCTCTG	TGAACCATCGAAGGAATTGA	PFD0020c
26	ACCGCCCCATCTAGTGATAG	CACTTGGTGATGTGGTGTCA	PFD0615c
27	TAAAAGACGCCAACAGATGC	TCATCGTCTTCGTCTTCGTC	PFD0625c
28	ACTTTCTGGTGGGGAATCAG	TTCACCGCCACTTACTTCAG	PFD0630c/PFD0635c
30	GACGACGATGAAGACGAAGA	AGATCTCCGCATTTCCAATC	PFD0005w
32	ACCTAATGGCGAAAACCAAG	ACACTTGCCTTCATCCACTG	PFD1000c
34	TGCAACGAAACATTAGCACA	AGCAGGGGATGATGCTTTAC	PFD1015c
35	AAACACGTTGAATGGCGATA	GACGCCGAGGAGGTAAATAG	PFD1235w/MAL7P1.1 (SEQ ID NO.: 1)
36	TGACGACTCCTCAGACGAAG	CTCCACTGACGGATCTGTTG	PFD1245c
37	AAGAAAGTGCCACAACATGC	GTTCGTACGCCTGTCGTTTA	PFE1640w
38	GAAGCTGGTGGTACTGACGA	TATTTTCCCACCAGGAGGAG	PFE0005w
39	ATTTGTCGCACATGAAGGAA	AACTTCGTGCCAATGCTGTA	MAL6P1.252
41	GGTGTCAAGGCAGCTAATGA	TATGTCCTGCGCTATTTTGC	PF08_0141
43	GTCGTGGAAAAACGAAAGGT	TATCTATCCAGGGCCCAAAG	PF08_0142
44	ATGTGTGCGAGAAGGTGAAG	TGCCTTCTAGGTGGCATACA	MAL6P1.4
45	CAATTTTTCCGACGCTTGTA	CACATATAGCGCCGTCCTTA	PF07_0048
46	GCGACGCTCAAAAACATTTA	TCATCCAACGCAATCTTTGT	PF07_0050
49	GTTGAGTCTGCGGCAATAGA	CTGGGGTTTGTTCAACACTG	PF07_0049
50	CACACATGTCCACCACAAGA	ACCCTTCTGTGGTGTCTTCC	MAL7P1.56
51	ACGTGGTGGAGACGTAAACA	CCTTTGTTGTTGCCACTTTG	MAL7P1.55
52	CGTGGTAGTGAAGCACCATC	CCCACCTTCTTGTGGTTTCT	PF07_0051
53	TGACGACGATAAATGGGAAA	TTCTTTTGGAGCAGGGAGTT	PF07_0139
54	ACCAAGTGGTGACAAAGCAG	GGGTGGCACACAAACACTAC	PFD1005c/PFD1015c
55	TTTGTCCGGAAGACGATACA	ATCTGGGGCAGAATTACCAC	PF08_0106

Primer set	Forward primer	Reverse primer	Target gene(s)
58	CACACGTGGACCTCAAGAAC	AAAACCGATGCCAATACTCC	PFI1830c
66	CCTAAAAAGGACGCAGAAGG	CCAGCAACACTACCACCAGT	PF08_0107
67	AAGGGAAGATTGGTGGACAG	AGGGGGATCAGTATCACGTC	MAL6P1.314
91	ACAAAGGAACGTCCATCTCC	GCCAATACTCCACATGATCG	PF13_0001
92	TGCAAGGGTGCTAATGGTAA	CCTGCATTTTGACATTCGTC	PF08_0103
93	GACAAATACGGCGACTACGA	TGTTTCACCCCATTCTTCAA	MAL6P1.1
94	TGGAAAGAACATGGACCTGA	TTCCTCGAGGGAAGAATCAC	MAL6P1.316
95	TCACAACCTGACCCCCTACT	TCTTCGTCGTTGTCATCCTC	PFD0995c
96	TGACCAAGACGAAGTATGGAA	TTGATCTCTGTTCGCTGTCC	PFI1820w
97	TCATTATGGGAAGCACGATT	TGATTTCTACCATCGCAAGG	PFA0015c
98	ATGGTGGCAAACTTGTGAGA	TCCAATTGGTCTCCTTGACA	PF08_0140
99	AGGGAGCATCAGGTGGTAGT	GCTGTGCATGCTTTTTCATT	MAL7P1.50
100	GATCAAAAGAGGCGGAGAAG	TTCCAATTGGGGAATTTTTC	PFI0005w
101	CAAGAGACACAACCGGAAGA	CACTTCCAATTGGGGAATTT	PFA0765c
60*	AAGTAGCAGGTCATCGTGGTT	TTCGGCACATTCTTCCATAA	PF07_0073

*Endogenous control gene: *seryl-tRNA synthetase* (PF07_0073)

To study gene expression of individual *var* genes a specific primer set for each of 59 *var* genes and one pseudogenes in the 3D7 genome was designed (Table 1), and real-time PCR was performed on cDNA from $3D7_{UM}$ and $3D7_{SM}$.

m5-2. Real-time PCR was done using a Rotorgene thermal cycler system (http://www.corbettresearch.com). Change in *PFD1235w/MAL7P1.1* (SEQ ID NO.: 1), *PF11_0008* (SEQ ID NO.: 3) , and *PF13_0003* (SEQ ID NO.: 5) gene transcription after selection for antibody recognition. Specific primers targeting SEQ ID NO.: 1, SEQ ID NO.: 3, and SEQ ID NO.: 5 (Figs. 13 and 14) were used to measure transcription before ($3D7_{UM}$) and after antibody selection ($3D7_{SM}$). The fold change in transcription levels, normalised against seryl-tRNA synthetase, was calculated for each primer set by the ΔΔCt method (User Bulletin #2, Applied Biosystems, http://www.appliedbiosystems.com). Reactions were performed in 20 µl volumes using QuantiTect SYBR Green PCR master mix and 0.5 mM primers, according to manufacturer's instructions (http://www.qiagen.com). PCR cycling conditions optimised for *P. falciparum* cDNA were 95°C for 15 min followed by 40 cycles of 94°C for 30 sec, 54°C for 40 sec, and 68°C for 50 sec with a final extension at 68°C for 10 min. Data acquisition was done at the end of elongation of each cycle. Specificity of amplification was ascertained by melting-curve analysis of each PCR product. Electrophoresis of PCR products and EB staining was performed and revealed no bands from no-template controls and single bands for all targets in cDNA PCR products. Quantification was done using the Rotorgene software version 4.30 (http://www.qiagen.com). Transcription levels of the endogenous *P. falciparum* genes *actin*, *seryl-tRNA synthetase* and *aldolase* were analysed in order to determine the most accurate endogenous control. *P. falciparum seryl-tRNA synthetase* displayed the most uniform transcription profile in different parasite

isolates and an unchanged pattern throughout the parasite life and was thus used for calculations of fold changes in *var* gene transcription by the ΔCT method (described in User Bulletin #2, Applied Biosystems, http://www.appliedbiosystems.com).

m5.3. Genes (*PF11_0521, PFL0030c, PFL1950w, PFL005w, PF13_003* (SEQ ID NO.: 5), *PFB1055c, PFD1235w/MAL7P1.1* (SEQ ID NO.: 1), *PFE1640w, PFI1830, PF08_0107, MAL6P1.314, MAL6P1.316, PFD0995c, PFA0015c, seryl-tRNA synthetase*) used for absolute quantification were PCR amplified, ligated into the pCR2.1 TOPO vector and transformed into *Eschericia coli* TOPO10 cells (TA cloning System, Invitrogen). Plasmids were purified using Qiagen Miniprep spin columns (Qiagen, Merck Eurolab, Albertslund, Denmark) and the identity of inserts verified by subsequent sequencing on an ABI Prism 310 (Perkin-Elmer) using the Big Dye terminator reaction mix, ABI Prism proofreading and translation software, and the *P. falciparum* 3D7 genome database (http://www.plasmodb.org). Plasmid concentrations were determined by spectrophotometry and serial 10-fold Tris-EDTA buffer (pH=7.5) dilutions ranging from $5x10^8$ to $5x10^0$ template copies per real-time PCR reaction. Triplicate real-time measurements were made for each dilution and a best-fit standard curve was generated using the RotorGene 2000 software. The standard curves were linear across a range of seven logs of DNA concentrations with correlation coefficients between 0.9779 and 0.9969. The detection limit of the system was ≥ 20 copies (data not shown). The coefficient of variance (CV) was calculated as 100*(standard deviation/mean). RT-PCR was performed as described using 1 µg total RNA in a total volume of 40 µl of which 0.5 µl was subsequently used for real-time PCR. Absolute values were calculated from the standard curves.

Real-time PCR followed by calculating fold change in $3D7_{UM}$ compared to $3D7_{SM}$ demonstrated marked upregulation of three Group A *var* genes *PFD1235/MAL7P1.1w* (SEQ ID NO.: 1), *PF11_0008* (SEQ ID NO.: 3), and *PF13_0003* (SEQ ID NO.: 5). The transcription of Group B, C or B/C *var* genes was either downregulated or not regulated in the $3D7_{SM}$ compared to $3D7_{UM}$ (Figs. 13 and 14, Table 2). The up-regulated *var* genes *PFD1235w/MAL7P1.1* (SEQ ID NO.: 1), *PF11_0008* (SEQ ID NO.: 3), and *PF13_0003* (SEQ ID NO.: 5) were also the most dominant *var* transcript when doing absolute quantification (Table 2) with *var* gene-specific primers. The upregulated and dominant *PFD1235w/MAL7P1.1* , *PF11_0008* (SEQ ID NO.: 3), and *PF13_0003* (SEQ ID NO.: 5) gene showed 3 to 10-fold higher level of expression following antibody selection both in ring-stage and trophozoite/schizont-stage 3D7 parasites (Table 2).

Table 2: **Copy number of selected *var* genes and *seryl-tRNA synthetase* transcripts in unselected and VSA_{UM}-expressing 3D7 and 3D7 after antibody-selection for VSA_{SM} expression**

Cluster[a]	Primer[b]	Gene	Trophozoite/schizont-stage parasites					Ring-stage parasites				
			Unselected		Antibody-selected		Fold change	Unselected		Antibody-selected		Fold change
			Copies	CV[c]	Copies	CV[c]		Copies	CV[c]	Copies	CV[c]	
A	8	PF11_0521	426	11	7,119	27	16.7	12,570	31	84,341	29	6.7
	20	PF13_0003	1,797	7	6,129	20	3.4	77,934	13	179,746	9	2.3
	35	PFD1235w/MAL7P1.1	2,931	20	29,941	13	10.2	101,417	27	1,152,758	12	11.4
	67	MAL6P1.314	3,145	13	19,356	14	6.2	87,130	19	767,747	8	8.8
	97	PFA0015c	77,890	12	1,333	30	58.4	155,151	21	18,419	14	8.4
B/A	94	MAL6P1.316	13,742	15	36,637	24	2.7	247,156	29	1,057,056	28	4.3
B	18	PFL0005w	15	21	1,106	23	73.7	928	12	13,769	23	14.8
	21	PFB1055c	64	16	2,533	12	39.6	5,272	22	26,070	5	4.9
	58	PFI1830c	79,111	39	59,860	22	1.3	18,600	15	13,124	12	1.4
B/C	12	PFL1950w	226	22	524	8	2.3	13,236	19	19,053	24	1.4
C	66	PF08_0107	865,266	33	58,833	28	14.7	10,459,156	21	611,814	15	17.1
	95	PFD0995c	23,415	19	491	12	47.7	567,205	19	9,148	19	62
var2	10	PFL0030c	907	14	12,562	19	14	12,905	30	127,631	30	9.9
var1	37	PFE1640w	12,279	21	14,239	10	1.2	8,224	17	9,111	30	1.1
		seryl-tRNA synthetase	609,533	130	609,533	130	1	643,271	20	643,271	20	1

[a]: As described in Lavstsen *et al.*, 2003; [b]: Salanti *et al.* 2003 and Table 1; Coefficient of variation (%) between three different quantification experiments

In conclusion, IgG selection resulted in marked upregulation of SEQ ID NO.: 1, 3, and 5.

Example 6:

Selection of P. falciparum *isolate 3D7 for adhesion to human endothelial cells* in vitro *results in selective up-regulation of Group A* var genes

The particular virulence of *P. falciparum* is due to the ability of infected erythrocytes to adhere to a variety of host receptors on the endothelial lining such as ICAM-1, VCAM, thrombospondin, ELAM-1, and CD36, and avoid splenic clearance. To show that selection of 3D7 on human endothelial cells leads to a serological phenotype and a transcription profile similar to $3D7_{SM1}$ we did several rounds of selection on bone marrow derived endothelial cells generating $3D7_{endo}$.

m6-1. We used human endothelial cells to select 3D7 for increased VSA_{SM} expression. Human endothelial cells were cultured by standard methodology to measure iRBC adhesion to receptors on the endothelial cells. In brief, parasites were radiolabelled by incubating the cultures overnight in the presence of ^{3}H-phenylalanin (1 MBq for a standard culture containing 200 µl packed RBC). Late-stage-enriched iRBC (100 µl, $1x10^{7}$ RBC/ml) were added to the endothelial cell monolayer and incubated for one hour at 37°C before unbound iRBC were washed away from the endothelial cell monolayer. Finally, the number of endothelial cell-adhering iRBC was determined by liquid scintillation spectrometry.

m6-2. Real-time PCR was done using a Rotorgene thermal cycler system (http://www.corbettresearch.com). Change in *PFD1235w/MAL7P1.1* (SEQ ID NO.: 1), *PF11_0008* (SEQ ID NO.: 3) , and *PF13_0003* (SEQ ID NO.: 5) gene transcription after selection for antibody recognition. Specific primers targeting SEQ ID NO.: 1, 3, and 5 (Fig. 20) were used to measure transcription before ($3D7_{UM}$) and after antibody selection ($3D7_{SM}$). The fold change in transcription levels, normalised against seryl-tRNA synthetase, was calculated for each primer set by the ΔΔCt method (User Bulletin #2, Applied Biosystems, http://www.appliedbiosystems.com). Reactions were performed in 20 µl volumes using QuantiTect SYBR Green PCR master mix and 0.5 mM primers, according to manufacturer's instructions (http://www.qiagen.com). PCR cycling conditions optimised for *P. falciparum* cDNA were 95°C for 15 min followed by 40 cycles of 94°C for 30 sec, 54°C for 40 sec, and 68°C for 50 sec with a final extension at 68°C for 10 min. Data acquisition was done at the end of elongation of each cycle. Specificity of amplification was ascertained by melting-curve analysis of each PCR product. Electrophoresis of PCR products and EB staining was performed and revealed no bands from no-template controls and single bands for all targets in cDNA PCR products. Quantification was done using the Rotorgene software version 4.30 (http://www.qiagen.com). *P. falciparum seryl-tRNA synthetase* was used for

calculations of fold changes in *var* gene transcription by the ΔCT method (described in User Bulletin #2, Applied Biosystems, http://www.appliedbiosystems.com).

The resulting cell line $3D7_{endo}$ showed a FACS profile similar to that of $3D7_{SM1}$ (Example 3 and Fig. 5) and a marked up-regulation of the *PFD1235w/MAL7P1.1* (SEQ ID NO.: 1), *PF11_0008* (SEQ ID NO.: 3), and *PF13_0003* (SEQ ID NO.: 5) *var* genes as analysed by real-time quantitative PCR (Fig. 20).

In conclusion, we find that selection of 3D7 for adhesion to human endothelial cells confer a serological phenotype, VSA_{SM} similar to that of parasites causing severe malaria and to 3D7 selected with childrens plasma. As in $3D7_{SM1}$ the acquisition of the VSA_{SM} phenotype in $3D7_{endo}$ is accompanied by marked upregulation of the PFD1235w/MAL7P1.1 (SEQ ID NO.: 1), PF11_0008 (SEQ ID NO.: 3), and PF13_0003 (SEQ ID NO.: 5) var genes.

Example 7:

Northern blots of antibody-selected, ring-stage 3D7 showed strong hybridization signals corresponding to full-length transcripts of PFD1235w/MAL7P1.1 *(SEQ ID NO.: 1)*

Materials and methods:

m7-1. For Northern blotting, we used 10 μg of total RNA separated in a standard denaturing MOPS-formaldehyde agarose gel and transferred to positively charged nylon membranes overnight (Sambrook et al., 1989). RNA was cross-linked to the membrane by baking for 30 min at 120°C. DIG-labeled RNA probes were generated using the DIG RNA labeling kit (Roche, Hvidovre, Denmark). Hybridization, washing, and detection were done according to the manufacturer's recommendations with a hybridization temperature of 65°C in DIG Easy Hyb buffer (Roche).

Northern blots of antibody-selected, ring-stage 3D7 showed strong hybridization signals corresponding to full-length transcripts of the upregulated *var* gene *PFD1235w/MAL7P1.1* (SEQ ID NO.: 1) (Fig.15A). The corresponding signals were either absent or much weaker in Northern blots of unselected 3D7. Similarly, *PF11_0008* (SEQ ID NO.: 3) and *PF13_0003* (SEQ ID NO.: 5) were found to be present as full-length transcripts in antibody-selected 3D7, but not in 3D7 (data not shown).

Taken together, these results shows that antibody-selected 3D7 expressing VSA_{SM}-type antigens transcribe full-length PFD1235w/MAL7P1.*1 (SEQ ID NO.: 1),* PF11_0008 (SEQ ID NO.: 3) and PF13_0003 (SEQ ID NO.: 5).

Example 8:

The PFD1235w/MAL7P1.1 *(SEQ ID NO.: 1),* PF11_0008 *(SEQ ID NO.: 3), and* PF13_0003 *(SEQ ID NO.: 5) genes that is selectively upregulated in* P. falciparum *isolate 3D7 following selection for antibody recognition* in vitro *belong to the Group A* var *genes and share their characteristics*

From Example 3, 4, 5, and 6 it appears that the Group A *PFD1235w/MAL7P1.1* (SEQ ID NO.: 1), *PF11_0008* (SEQ ID NO.: 3) and *PF13_0003* (SEQ ID NO.: 5) genes encodes VSA_{SM}-like proteins, and that this protein is involved in the acquisition of the VSA_{SM} phenotype following antibody-selection of VSA_{UM}-expressing 3D7 ($3D7_{SM}$). The fact that almost identical results were obtained using plasma pools from children living in West Africa (pools SM1 and SM2) and East Africa (plasma pool SM3) indicate that a PfEMP1 similar to that encoded by *PFD1235w/MAL7P1.*1 (SEQ ID NO.: 1), *PF11_0008* (SEQ ID NO.: 3) and *PF13_0003* (SEQ ID NO.: 5) are present in *P. falciparum* parasites transmitted on both sides of this vast continent.

In conclusion, PFD1235w/MAL7P1.1 (SEQ ID NO.: 1), PF11_0008 (SEQ ID NO.: 3) and *PF13_0003* (SEQ ID NO.: 5) *seems to belong to a sub-group of var genes, with a constrained ability to recombine, that are functionally conserved and commonly recognised by* VSA_{SM}*-antibodies.*

Example 9:

PFD1235w/MAL7P1.1 *(SEQ ID NO.: 1),* PF11_0008 *(SEQ ID NO.: 3) and* PF13_0003 *(SEQ ID NO.: 5) belongs to a var sub-family that is common and highly conserved in* P. falciparum *isolates*

PFD1235w/MAL7P1.1 (SEQ ID NO.: 1), *PF11_0008* (SEQ ID NO.: 3) and *PF13_0003* (SEQ ID NO.: 5) are the dominant transcript and is highly upregulated in the *P. falciparum* isolate 3D7 following selection for antibody selection and adhesion to human endothelial cells ($3D7_{SM}$ and $3D7_{endo}$; Example 3, 4, 5, and 6) . All the 3D7 *var* genes differ from each other, but smaller blocks of sequences with high similarity are found in various *var* genes. To date, only three sub-families of PfEMP1 have been defined (*var1-3*) (Salanti et al. 2002; Salanti et al. 2003; Kraemer and Smith, 2003). Apart from the *var1*–3 sub-families, all PfEMP1 genes described so far from other parasite isolates differ from each other, and from the 3D7 *var* genes. It has therefore been assumed that the global repertoire of *var* genes is very large. This constitutes an obvious obstacle for the development of vaccines based on *var* genes and their products, as a high degree of conservation is a prerequisite for vaccine pan-reactivity.

To test the degree of inter-genomic diversity of *PFD1235w/MAL7P1.1*(SEQ ID NO.: 1), *PF11_0008* (SEQ ID NO.: 3) and *PF13_0003* (SEQ ID NO.: 5) ; 60 different Ghanaian parasite isolates obtained from the peripheral blood of *P. falciparum* malaria patients were tested.

m9-1. Genomic DNA was isolated (http://www.clontech.com) using the NucleoSpin purification kits according to the manufacturer's recommendations. PCR was carried out in 0.2-ml microfuge tubes in a reaction volume of 20 µl using a PE2400 PCR machine (http://www.perkin-elmer.com). Final concentrations of the PCR reagents were as follows: Hotstart Taq polymerase (http://www.qiagen.com): 0.1 U; primers: 1 µM; dNTP: 2.5 mM, each; and $MgCl_2$: 1.5 mM). Cycling conditions were optimised for *P. falciparum* DNA: 15 min at 95°C followed by 30 cycles of 30 sec at 94°C, 30 sec at 50°C, and 4 min at 68°C, with a final extension for 15 min at 68°C. The PCR products were visualised and size was determined in a 1% agarose gel containing EB. PCR amplification using *PFD1235w/MAL7P1.1, PF11_0008,* and *PF13_0003* specific primers (Table 1) on genomic DNA from 60 isolates from Ghanaian children yielded a definite band of the expected size of 160 bp in 10, 3, 20, respectively of the isolates.

m9-2. To demonstrate the extent of sequence similarity, 2304 bp corresponding to 768 amino acids were cloned and sequenced. Gene-specific primers for *PFD1235w/MAL7P1.1* (SEQ ID NO.: 1) were used to perform PCR on genomic DNA from PCR positive isolates. PCR products were gel-purified using the Qiagen gel purification kit according to the manufacturer's instructions (http://www.qiagen.com). Purified PCR fragments were ligated into the pCRII TOPO vector using TOPO TA cloning kit, and transformed into TOP10 competent cells (http://www.invitrogen.com). Positive clones were selected and propagated. Plasmid preparations were made using MiniPrep spin columns (http://www.qiagen.com). Sequencing was performed on an ABI Prism 377 using the Big Dye terminator reaction mix (http://www.perkin-elmer.com). Proofreading and translation were done with ABI Prism software.

From the sequencing it was found that 556/768 cloned from BM021 and BM048 were identical to the *PFD1235w/MAL7P1.1* (SEQ ID NO.: 1) sequence (Fig. 19). Alignments were done using ClustalW and default settings.

Taken together, these data show that PFD1235w/MAL7P1.1 *(SEQ ID NO.: 1) belongs to a conserved and common gene sub-family and thus fulfils two required criteria for any candidate gene in vaccine development. Similarly* PF11_0008 *(SEQ ID NO.: 3) and* PF13_0003 *(SEQ ID NO.: 5) were found to belong to* var *gene sub-families families with similar identities.*

Example 10:

$3D7_{SM1}$ expresses VAR4 (SEQ ID NO.: 2) on the surface of infected erythrocytes

To generate recombinant proteins of VAR4 (SEQ ID NO.: 2) domains were cloned into the pBAD-TOPO vector (Invitrogen) by PCR using the following domain-specific oligonucleotide primers and subsequently into the Baculovirus transfer vector pAcGP67:

NTS.Fw:	5´-GAATTCATGGGGAATGCATCATCA-3´
NTS.Rv:	5´-ATTTCTATCTTCTGCGTT-3´
DBL1-α.Fw:	5´-GAATTCAACGCAGAAGATAGAAATC-3´
DBL1-α..Rv:	5´-CTTCGATGTATATGTCTG-3´
CIDR1-α.Fw:	5´-GAATTCGACGCTAAAACTGATAGTA-3´
CIDR1-α.Rv:	5´-ACATATATCGCCATTCAACG-3´
DBL2-β.Fw:	5´-GAATTCTTGAATGGCGATATATGTA-3´
DBL2-β.Rv:	5´-GTATATAGCTGATACTGT-3´
C2.Fw:	5´-GAATTCACAGTATCAGCTATATACC-3´
C2.Rv:	5´-ATAACATGGTTGTTGTGA-3´
DBL3-β..Fw:	5´-GAATTCTCACAACAACCATGTTATG-3´
DBL3-β..Rv:	5´-ATCTATTCCACCTGTAGT-3´
DBL4-γ.Fw:	5´-GAATTCACTACAGGTGGAATAGATCA-3´
DBL4-γ.Rv:	5´-ACATGCGGCATTGAGACT-3´
DBL5-δ.Fw:	5´-GAATTCAGTCTCAATGCCGCATGTG-3´
DBL5-δ.Rv:	5´-TCTACAATGTCTGGCACA-3´
CIDR2-β Fw:	5´-GAATTCTGTGCCAGACATTGTAGATC-3´
CIDR2-β.Rv:	5´-TTTGCCACTAGGTACGT-3´

m10-1. For production of carboxy-terminally V5 epitope and histidine-tagged protein the PCR amplified inserts were excised from pBAD-TOPO constructs by *Eco*RI and *Pme*I digestion and subsequently sub-cloned into the *Eco*RI and blunt-ended *Bgl*II sites of the *Baculovirus* transfer vector pAcGP67-A (BD Biosciences, Brøndby, Denmark). Recombinant *Baculovirus* were generated by co-transfection of the pAcGP307-A-NTS, pAcGP67-A-DBL1-α, pAcGP67-A-CIDR15-α, pAcGP67-A-DBL2-β, pAcGP67-A-C2, pAcGP67-A-DBL3-β, pAcGP67-A-DBL4-γ, pAcGP67-A-DBL5-δ, or pAcGP67-A-CIDR2-β D construct genes and *Bsu*330I linearized Bakpak6 *Baculovirus* DNA (BD Biosciences Clontech) into insect Sf9 cells. Recombinant products were expressed by infection of insect High-Five cells with recombinant *Baculovirus* using a multiplicity of infection of ten. Recombinant proteins were purified from culture supernatants on Co2+ metal-chelate agarose column and eluted with 25 mM HEPES-KOH (pH=7.30), 0.5 mM $MgCl_2$, 0.5 mM DTT, 100 mM NaCl, 10% glycerol, and 100 mM imidazole.

m10-2. For production of GST fusion protein a conserved sequence of the intracellular acidic segment ATS/Exon2 was sub-cloned into the pGEX-4T1 vector by PCR using the following oligonucleotide primers ATS-Fw: 5′-CGGAATTCAAAACAAAATCATCAGTAG-3′, ATS-Rv: 5′-*ATAAGAATGCGGCCGC*GTTGATTACCACTTAATGTG-3′. The proteins were expressed as fusion proteins at the carboxy-terminus of glutathione S-transferase

from *Schistosoma japonicum* and purified by affinity chromatography on glutathione sepharose 4B (Amersham Pharmacia Biotech).

m10-3. To generate murine antibodies against VAR4 domains and ATS/Exon2 the recombinant proteins were used to immunize Balb/c mice (5 µg) and rabbit s (50 µg) (given subcutaneously in Freund's complete adjuvant) followed by two booster injections in Freund's incomplete adjuvant.

A DNA vaccination approach to generate antibodies to VAR4 (SEQ ID NO.: 2) domains were also used. All domains was cloned into the Eucaryotic TA expression vector pCR3.1 (Invitrogen) using the following primers:

DBL1-α.Fw: 5'-GCCRCCATGGACGCAGAAGATAGAAATC-3'
DBL1-α..Rv: 5'-CTACTTCGATGTATATGTCT-3'
CIDR1-α.Fw: 5'-GCCRCCATGGACGCTAAAACTGATAGTA-3'
CIDR1-α.Rv: 5'-CTAACATATATCGCCATTCAACG-3'
DBL2-β.Fw: 5'-GCCRCCATGGTGAATGGCGATATATGTA-3'
DBL2-β.Rv: 5'-CTAGTATATAGCTGATACTGT-3'
C2.Fw: 5'-GCCRCCATGGCAGTATCAGCTATATACC-3'
C2.Rv: 5'-CTAATAACATGGTTGTTGTGA-3'
DBL3-β..Fw: 5'-GCCRCCATGGCACAACAACCATGTTATG-3'
DBL3-β..Rv: 5'-CTAATCTATTCCACCTGTAGT-3'
DBL4-γ.Fw: 5'-GCCRCCATGGCTACAGGTGGAATAGATCA-3'
DBL4-γ.Rv: 5'-CTAACATGCGGCATTGAGACT-3'
DBL5-δ.Fw: 5'-GCCRCCATGGGTCTCAATGCCGCATGTG-3'
DBL5-δ.Rv: 5'-CTATCTACAATGTCTGGCACA-3'
CIDR2-β.Fw: 5'-GCCRCCATGGGTGCCAGACATTGTAGATC-3'
CIDR2-β.Rv: 5'-CTATTTGCCACTAGGTACGT-3'

m10-4. Plasmids were propagated in TOP10 cells (Invitrogen) and plasmid was purified using Plasmid GIGA prep kit (Qiagen). Plasmid DNA was injected IM to mice 4 times with 2 weeks intervals and finally boosted with the recombinant protein corresponding to the domain.

m10-5. SDS-extracted trophozoite/schizont-stage iRBC were reduced by boiling in the presence of L-mercaptoethanol and electrophoresed in the Laemmli sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) system (Sambrook et al., 1989). Immunoblots were prepared on PVDF membranes by semidry blotting using standard methods. All available binding sites on membranes were blocked in Tris-buffered-saline-Tween (TBS-T) containing 5% skimmed milk. Blots were probed with an antiserum raised against a recombinant protein of the highly conserved intracellular acidic segment ATS/Exon2 conserved among most *var* genes in 3D7, DBL5-δ of *PFD1235w/MAL7P1.1* (SEQ ID NO.: 1), and pre-immune mouse sera diluted 1:100 in TBS-T. Bound antibody was detected with relevant IgG alkaline phosphatase-conjugated antibody (Dako, Glostrup, Denmark). All washes were

done using TBS-T. Blots were developed by standard methods using p-nitroblue tetrazolium phosphate (NBT, Sigma) and 5-bromo-4-chloro-3-indolylphosphate (BCIP, Sigma) as substrates.

m10-6. Immunostaining and flow cytometry were performed as described (Staalsoe et al., 1999; Nielsen et al., 2002) with some modifications. Briefly, 2.5 x 10^5 of MACS purified, ethidium bromide labeled iRBC were incubated for 1 hr in 20 µl of murine sera or for 30 min in 5 uL of human sera. All murine sera had been depleted of anti-human erythrocyte antibodies by absorption. For immunostaining with murine sera, iRBC were sequentially exposed to 100 µL of 1:25 diluted goat anti-mouse Ig (Dako), biotinylated anti-goat Ig (Dako) and 1:200 diluted FITC-conjugated streptavidin (Dako) for 30 minutes each. For immunostaining with human sera, iRBC were incubated in 100 uL of 1:25 diluted biotinylated anti-human IgG (Dako) then in 1:2000 diluted FITC-conjugated streptavidin for 30 min each time. For fluorescence and confocal microscopy, wet mounts of immunostained parasites were prepared and images were obtained using a Leica DM LB2 and a Carl Zeiss Scanning Microscope, respectively. For both microscopes, suitable filters and channels were used to detect FITC and ethidium-bromide staining.
When appropriate, trypsin treatment was performed as described (Fernandez et al., 1999) with modifications. Cells were washed once in PBS, incubated in 10 volumes of 100 µg/ml TPCK-treated trypsin (Amersham Pharmacia Biotech) in PBS for 10 min at 37°C. The reaction was stopped with 1 volume of 2 mg/ml soybean trypsin inhibitor (Sigma-Aldrich) in RPMI 1640/5% Albumax. Cells were washed twice in PBS then used for immunostaining and flow cytometry.

We next used Western blotting to investigate the protein translation of VAR4 (SEQ ID NO.: 2) (*m10-5*). Analysis of PfEMP1 expression of unselected late trophozoite/schizont stage 3D7 using antiserum against the conserved intracellular ATS/Exon2 *var* domain showed a single band with an estimated molecular weight of 260 kDa (Fig. 17, Lane A). This indicates that most of these parasites expressed a PfEMP1 with a four-domain structure, in correspondence to the results of the absolute quantification (Example 5, Table 2) that showed a dominant group C gene transcript encoding a PfEMP1 molecule of this size. Antibody-selected 3D7 expressed a PfEMP1 species of 260 kDa, but also expressed additional high-molecular weight bands (Fig. 17, Lane B). Again, these data agree with the results of the absolute quantification showing that the three most highly transcribed *var* genes in antibody-selected 3D7 were PF08_0107, MAL6P1.316, and more specifically *PFD1235w/MAL7P1.1* (SEQ ID NO.: 1), which encode proteins with predicted molecular weights of approximately 260, 330, and 400 kDa, respectively. Furthermore, an antiserum against Baculovirus-derived DBL5-δ of the *PFD1235w/MAL7P1.1* (SEQ ID NO.: 1) gene product revealed a high-molecular weight band (Fig. 17, Lane D) corresponding to the top band in the ATS/Exon2-probed blot (Fig. 17, Lane B). This indicates that *PFD1235w/MAL7P1.1* (SEQ ID NO.: 1) is not only a major transcript in antibody-selected 3D7, but that this *var* gene is also translated into protein.

Antibodies to Baculovirus-derived DBL5-δ of the *PFD1235w/MAL7P1.1* (SEQ ID NO.: 1) gene product were tested on iRBC by flow cytometry, immuno-fluorescence and confocal microscopy (*m9-6)*. Only a small percentage of RBC infected by unselected 3D7 reacted with the murine DBL5-δ antibodies (Fig. 18A1), although these iRBC did express VSA detectable by flow cytometry with human plasma (Fig. 18A3). By contrast, a large proportion of RBC infected with antibody-selected 3D7 were recognized by the murine antibodies, and this reactivity was abrogated by prior trypsin treatment of the iRBC (Fig. 18B1). Fluorescence and confocal microscopy using the DBL5-δ murine antibodies showed a distinct punctate pattern on the surface of intact RBC infected by antibody-selected 3D7 (Figs. 18B2, 18B5), but not by unselected 3D7 (Figs. 18A2, 18A5).

Taken together, these results indicate that the product of PFD1235w/MAL7P1.1 *(SEQ ID NO.: 1 and 2) is expressed on the surface of antibody-selected 3D7 and that the protein confers a* VSA_{SM} *phenotype. Similar results were obtained for* PF11_0008 *(SEQ ID NO.: 3 and 4) and* PF13_0003 *(SEQ ID NO.: 5 and 6) (data not shown).*

Example 11:

Monoclonal antibodies to VAR4 (SEQ ID NO.: 2), VAR5 (SEQ ID NO.: 4), VAR6 (SEQ ID NO.: 6)

For production of monoclonal antibodies (mAb) mice were immunized by injection of different domains of VAR4, VAR5, and/or VAR6 to stimulate the production of antibodies targeting these domains.

m11-1. The antibody forming cells were isolated from the spleen of the mice. Monoclonal antibodies were produced by fusing single antibody-forming cells to cancer cells (such as cells from myeloma) to make them immortal. The cells were grown using *in vitro* cell-culture techniques and cloned by limiting dilution. mAb secreted from the hybridomas were purified and used for identification by flow-cytometry of field *P. falciparum* isolates expressing VAR4, VAR5, and/or VAR6 or homologous hereof.

This strategy resulted in mAb with different specificities and different avidity and the resulting mAb were used to identify epitopes involved in adhesion to receptors on human endothelial cells and to discriminate between even quite similar epitopes.

Example 12:

VAR4 (SEQ ID NO.: 2) recombinant fusion proteins are commonly and specifically recognised

If VAR4 (SEQ ID NO 2) mediates a VSA_{SM} phenotype, it would be predicted that a high proportion of children in malaria endemic areas have acquired antibodies to this protein. To test this hypothesis we measured plasma levels of IgG against recombinant domains of

the VAR4 protein by ELISA in asymptomatic individuals living under high malaria transmission intensity in Tanzania.

To make recombinant proteins of VAR4 (SEQ ID NO.: 2) the *PFD1235w/MAL7P1.1* (SEQ ID NO.: 1) NTS, DBL1-α, CIDR1-α, DBL2-β, C2, DBL3-β, DBL4-γ, DBL5-δ, and CIDR2-β were sub-cloned into the pGEX-4T1 vector by PCR using the following domain-specific oligonucleotide primers and a hot start taq polymerase (Qiagen) and PfuTurbo (Stratagene):

NTS.Fw: 5´-GAATTCATGGGGAATGCATCATCA-3´
NTS.Rv: 5´-ATAAGAATGCGGCCGCATTTCTATCTTCTGCGTT-3´
DBL1-α.Fw: 5´-GAATTCAACGCAGAAGATAGAAATC-3´
DBL1-α..Rv: 5´-ATAAGAATGCGGCCGCCTTCGATGTATATGTCTG-3´
CIDR1-α.Fw: 5´-GAATTCGACGCTAAAACTGATAGTA-3´
CIDR1-α.Rv: 5´-ATAAGAATGCGGCCGCACATATATCGCCATTCAACG-3´
DBL2-β.Fw: 5´-GAATTCTTGAATGGCGATATATGTA-3´
DBL2-β.Rv: 5´-ATAAGAATGCGGCCGCGTATATAGCTGATACTGT-3´
C2.Fw: 5´-GAATTCACAGTATCAGCTATATACC-3´
C2.Rv: 5´-ATAAGAATGCGGCCGCATAACATGGTTGTTGTGA-3´
DBL3-β..Fw: 5´-GAATTCTCACAACAACCATGTTATG-3´
DBL3-β..Rv: 5´-ATAAGAATGCGGCCGCATCTATTCCACCTGTAGT -3´
DBL4-γ.Fw: 5´-GAATTCACTACAGGTGGAATAGATCA-3´
DBL4-γ.Rv: 5´-ATAAGAATGCGGCCGCACATGCGGCATTGAGACT-3´
DBL5-δ.Fw: 5´-GAATTCAGTCTCAATGCCGCATGTG-3´
DBL5-δ.Rv: 5´-ATAAGAATGCGGCCGCTCTACAATGTCTGGCACA-3´
CIDR2-β.Fw: 5´-TCCCCCGGGTGTGCCAGACATTGTAGATC-3´
CIDR2-β.Rv: 5´-ATAAGAATGCGGCCGCTTTGCCACTAGGTACGT-3´

The proteins encoding single domains were expressed as fusion proteins (*E. coli strain BL21*) at the carboxyterminus of glutathione S-transferase from *Schistosoma japonicum*, and purified by affinity chromatography on glutathione sepharose 4B (Amersham Pharmacia Biotech)

Materials and methods

m12-1. We used plasma samples from 20 children (3-4 and 10-11 years of age) and 10 young adults (18-19 years of age) living in Mgome village in the Tanga region of Tanzania for ELISA analysis of antibody responses to purified recombinant NTS, DBL3-β, CIDR1-α and DBL5-δ of VAR4-GST domains as previously described. Briefly, proteins were diluted in 0.1 M glycine/HCl (pH 2.75). The wells of Maxisorp micro titre plates (Nunc, Roskilde, Denmark) were coated with antigen by overnight incubation at 4°C. The plates were emptied, and any residual binding capacity was blocked with 100 µl of blocking buffer (1% bovine serum albumin, 0.5 M NaCl, 1% Triton-X-100 in phosphate-buffered saline (PBS), pH 7.2) per well. After incubation for 0.5 hr at room temperature, the plates were washed four times with washing

buffer (PBS, 0.5 M NaCl, 1% Triton-X-100, pH 7.4) and 100 µl of plasma diluted 1:200 in blocking buffer was added to each well. The plates were then incubated for one hour at room temperature, and then washed and incubated for one more hour at room temperature with peroxidase-conjugated rabbit anti-human immunoglobulin G (IgG) (Dako, Glostrup, Denmark) diluted 1:1000 in blocking buffer. Subsequently, the plates were washed and 100 µl of o-phenylenediamine substrate (0.30%, Dako) diluted in 0.1 M sodium citrate buffer (pH 5.0) with 0.05% (v/v) H_2O_2, was added to each well. Finally, the plates were incubated at room temperature in the dark before the addition of 100 µl of 2.5 M H_2SO_4 and the optical density (OD) was measured at 492 nm. Control plates were coated with GST alone. Cut-off values were calculated as the mean ELISA unit plus 2 standard deviations obtained with sera of 13 Danish blood donors without malaria exposure as described in (Jakobsen et al., 1993).

m12-2. Competition ELISA was done using recombinant CIDR1-α domains of VAR4 (SEQ ID NO.: 2) and *var*1 (*PFE1640w*) using three different plasma samples of high, medium, and low reactivity with the proteins from two children aged 3 years and one child aged 11 years. Blocking of plasma was done using 0.1, 1, 5, and 10 µg/ml of recombinant protein for 2 hr at room temperature. The test plasma samples were diluted 1:50 and tested as described above.

Most parasite-exposed children and adults had IgG directed against DBL5-δ (Fig. 18A), CIDR1-α (Fig. 18B), DBL3-β (Fig. 18C), and NTS (Fig. 18D), with comparable levels in young children and adults. To test the antigen specificity of the antibody recognition, we performed competition ELISA using the CIDR1-α domains of the VAR4 (SEQ ID NO.: 2) and *var*1 (*PFE1640w*) proteins. Pre-incubation of the plasma with homologous recombinant protein caused a dose-dependent reduction in OD_{492} values (Figs. 18E, 18F), whereas the heterologous protein (Figs. 18E, 18F) did not change the plasma reactivity.

These result showing that a high proportion of young children recognises recombinant domains of VAR4 and the demonstration that our DBL5-δ antiserum did not cross react with products of *MAL6P1.316*, and *PF08_0107* in Western blotting, suggest that the plasma antibody reactivity to recombinant VAR4 (SEQ ID NO.: 2) protein was the result of exposure to parasites expressing PfEMP1 resembling that encoded by *PFD1235w/MAL7P1.1* (SEQ ID NO.: 1), rather than being due to a broad cross-reactivity between different CIDR or DBL domains. Similar results were obtained when using VAR5 (SEQ ID NO.: 4) and VAR6 (SEQ ID NO.: 6) (data not shown).

Example 13:

Experimental infection of humans results in transcription and translation of PFD1235w/MAL7P1.1 *(SEQ ID NO.: 1 and 2)*

We have proposed that the dominance of parasites expressing VSA_{SM}-type antigens among non-immune patients is related to their higher growth rate in such individuals, and that the shift towards VSA_{UM}-type antigens occurs as this strong selective advantage of VSA_{SM}-expressing parasites gradually disappears as VSA_{SM}-specific immunity is acquired.

Materials and methods:

m13-1. We used parasites isolated on days 8, 9, and 10 from a Dutch volunteer exposed on day 0 to mosquitoes infected by *P. falciparum* isolate NF54 as part of ongoing studies of experimental *P. falciparum* infections (Hermsen et al., 2001). These parasites were cultured *in vitro* for 27 (day 8 and day 9 isolates) or 33 days (day 10 isolate) to obtain sufficient parasites for DNA/RNA analysis.

m13-2. SDS-extracted trophozoite/schizont-stage iRBC were reduced by boiling in the presence of L-mercaptoethanol and electrophoresed in the Laemmli sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) system (Sambrook et al., 1989). Immunoblots were prepared on PVDF membranes by semidry blotting using standard methods. All available binding sites on membranes were blocked in Tris-buffered-saline-Tween (TBS-T) containing 5% skimmed milk. Blots were probed with an antiserum raised against a recombinant protein of the highly conserved intracellular acidic segment ATS/Exon2 conserved among most *var* genes in 3D7, DBL5-δ of VAR4 (SEQ ID NO.: 2), and pre-immune mouse sera diluted 1:100 in TBS-T. Bound antibody was detected with relevant IgG alkaline phosphatase-conjugated antibody (Dako, Glostrup, Denmark). All washes were done using TBS-T. Blots were developed by standard methods using p-nitroblue tetrazolium phosphate (NBT, Sigma) and 5-bromo-4-chloro-3-indolylphosphate (BCIP, Sigma) as substrates.

To further study this hypothesis we studied parasites rescued on days 8, 9, and 10 from a Dutch volunteer receiving a mosquito-transmitted *P. falciparum* NF54 infection on day 0. NF54 was originally isolated from a non-immune Dutch malaria patient, and isogenic with the 3D7 parasites cloned from it (Salanti et al., 2003). Western blots of Day 10 parasites probed with antiserum against the DBL5-δ domain of the *PFD1235w/MAL7P1.1* gene product, detected a high-molecular weight band (Fig. 17, Lane G), which corresponded in size to that observed in antibody-selected 3D7 (Fig. 17, Lane B). This band was not detected in similar blots of parasites obtained on Day 8 and Day 9 (Fig. 17, Lanes E-F). In line with these findings, we observed high *PFD1235w/MAL7P1.1* (SEQ ID NO.: 1) copy numbers relative to those of the *seryl tRNA synthetase* gene on Day 10, but not on Day 8, corresponding to a 38.30 and 8.4 fold increase in mRNA copies of this *var* gene relative to the copy number of *seryl-tRNA synthetase* mRNA between Day 8 and Day 10 in rings and trophozoites, respectively (data not shown). Judged by comparison of Ct-values, ring-stage transcription of *PFD1235w/MAL7P1.1* (SEQ ID NO.: 1) was relatively low on Day 8 (rank: 55/60), but high on Day 10 (rank: 9/60). The corresponding rankings in trophozoites were 48 on Day 8 and 18 on Day 10.

Taken together, these data show that PFD1235w/MAL7P1.1 (SEQ ID NO.: 1) is translated into a functional protein in vivo, and indicate that this protein may be associated with fast-growing parasites dominating acute P. falciparum malaria in non-immune patients. Similar results were obtained for PF11_0008 *(SEQ ID NO.: 3) and* PF13_0003 *(SEQ ID NO.: 5) (data not shown).*

Example 14:

Anti-adhesion assay

It is becoming increasingly apparent that acquired protective immunity to *P. falciparum* infection relies on antibodies (Abs) specifically recognizing variant parasite antigens expressed on the surface of late stage-infected erythrocytes. In this scenario, only parasites expressing variant antigens to which the host does not possess adequate specific Ab are likely to cause disease, and immunity is likely to depend on the accumulation of a large panel of Ab specificities recognizing different variants of such antigens. Severe malaria is often associated with sequestration of large quantities of parasites in the brain. Parasites causing severe malaria have been shown to adhere receptors on endothelial cells. To show that VAR4, VAR5, and VAR6 are responsible for *in vitro* adhesion of $3D7_{SM1}$ and $3D7_{endo}$ parasites to endothelial receptors, an antibody adhesion assay with murine antibodies against VAR4, VAR5, and VAR6 were performed.

Materials and methods:

m14-1. Antiadhesion was measured by ^3H labeled parasites: For use in adhesion assays, parasite cultures with a parasitemia of ~1% late trophozoites and schizonts were first transferred from Albumax II medium (Life Technologies), with a high concentration of hypoxanthine (Hpx), into RPMI 1640 plus 5% normal human serum (low Hpx) and maintained for 24 h. The parasites then were labeled by exposure to [3H]Hpx (Amersham; 8.75 MBq/mL of RBCs) for another 24 h. Finally, the cultures were enriched for late-stage iRBCs and incubated for 30 min, with or without test plasma. Endothelial cells were grown on Microtiter plates (Falcon; Becton Dickinson) then blocked with bovine serum albumin (BSA; 20 mg/mL, 100 µL/well) in PBS at room temperature for 30 min. We added enriched [^{3}H]Hpx-labeled late-stage iRBCs to wells containing endothelial cells (2×10^6 cells/well) and incubated the wells at 37°C for 1 h. Nonadherent iRBCs were removed by 4 washes in RPMI 1640. Adherent iRBCs were harvested onto glass fiber pads, and the [^{3}H]Hpx activity was measured in a liquid scintillation counter (Beckman Coulter). Inhibition of iRBC adhesion by plasma was calculated as 1 - (testEndothelialCell - controlBSA)/controlEndothelialCell - controlBSA), where testEndothelial is counts per minute of iRBCs preincubated with plasma and adhering to wells containing endothelial cells, and controlEnothelial cells and controlBSA refer to counts per minute of iRBCs not preincubated with plasma and adhering to endothelial cells and BSA-coated wells, respectively.

Cytoadhesion of endothelial cells were significantly inhibited by plasma from individuals suffering from severe malaria, and more importantly binding of $3D7_{SM1}$ and $3D7_{endo}$ to endothelial cells were strongly inhibited by the murine anti-VAR4, -VAR5, and -VAR6 antibodiesAntibodies raised against recombinant VAR4, -VAR5, and –VAR6 inhibit parasite adhesion to endothelial cells *in vitro* (data not shown).

An obvious consequence of this finding is that vaccine induced antibodies against SEQ ID NO.: 2, 4, and/or 6 constructs can hinder binding of parasites to endothelial tissue and thus prevent severe malaria.

Example 15:

Identification of receptors and VAR4 (SEQ ID NO.: 2), VAR5 (SEQ ID NO.: 4), and/or VAR6 (SEQ ID NO.: 6) sites binding receptors on endothelial cells in vitro

To further study endothelial cell adhesion all domains were cloned into the pDISPLAY vector (Invitrogen) using the following primers as examplified for VAR4:

NTS.Fw: 5´-TCCCCCGGGATGGGGAATGCATCATCA-3´
NTS.Rv: 5´-TCCCCGCGGATTTCTATCTTCTGCGTT-3´
DBL1-α.Fw: 5´-TCCCCCGGGAACGCAGAAGATAGAAATC-3´
DBL1-α..Rv: 5´-TCCCCGCGGCTTCGATGTATATGTCT-3´
CIDR1-α.Fw: 5´-TCCCCCGGGGACGCTAAAACTGATAGTA-3´
CIDR1-α.Rv: 5´-TCCCCGCGGACATATATCGCCATTCAACG-3´
DBL2-β.Fw: 5´-TCCCCCGGGTTGAATGGCGATATATGTA-3´
DBL2-β.Rv: 5´-TCCCCGCGGGTATATAGCTGATACTGT-3´
C2.Fw: 5´-TCCCCCGGGACAGTATCAGCTATATACC-3´
C2.Rv: 5´-TCCCCGCGGATAACATGGTTGTTGTGA-3´
DBL3-β..Fw: 5´-TCCCCCGGGTCACAACAACCATGTTATG-3´
DBL3-β..Rv: 5´-TCCCCGCGGATCTATTCCACCTGTAGT-3´
DBL4-γ.Fw: 5´-TCCCCCGGGACTACAGGTGGAATAGATCA-3´
DBL4-γ.Rv: 5´-TCCCCGCGGACATGCGGCATTGAGACT-3´
DBL5-δ.Fw: 5´-TCCCCCGGGAGTCTCAATGCCGCATGTG-3´
DBL5-δ.Rv: 5´-TCCCCGCGGTCTACAATGTCTGGCACA-3´
CIDR2-β.Fw: 5´-TCCCCCGGGTGTGCCAGACATTGTAGATC-3´
CIDR2-β.Rv: 5´-TCCCCGCGGTTTGCCACTAGGTACGT-3´

The ability of the different domains to bind directly to endothelial cells was in this example assayed using a mammalian expression system.

m15-1. Domains were cloned into the pDisplay vector (Invitrogen). This vector allows display of cloned proteins on the cell surface. Each domain was fused at the N-terminus to the murine Ig κ-chain leader sequence, which targets the protein to the cell surface, and at the C-terminus to the platelet derived growth factor receptor (PDGFR) transmembrane domain, which anchors the protein to the cell membrane.

A human non-adherent T cell and a CHO cell line was used for transient expression of the recombinant proteins. This approach has enabled us to study cell adhesion to endothelial cells. Blockage of this binding was studied using relevant recombinant domains expressed in the Baculovirus system (Example 10) and commercial antibodies directed against specific endothelial receptors.
VAR4 (SEQ ID NO.: 2), VAR5 (SEQ ID NO.: 4), and/or VAR6 (SEQ ID NO.: 6) regions responsible for receptor binding were identified using random mutagenesis.

Example 16:

To express VAR4 (SEQ ID NO.: 2), VAR5 (SEQ ID NO.: 4), and/or VAR6 (SEQ ID NO.: 6) in eucaryotic organisms the Exon 1 ranging from nt 1 to 9444 (SEQ ID NO.: 1), 7719 (SEQ ID NO.: 3), and 8844 (SEQ ID NO.: 5) were subjected to a full recodonisation:

An artificial codon table was generated by combining the codon usage of *Trichoplusia ni* and *Homo sapiens* genes. The codon bias of the synthetic genes were adapted to this "artificial" codon usage. In addition, regions of very high (> 80%) or very low (<30%) GC content was avoided and the GC-content was adjusted to 50% where possible. During the optimization process following cis-acting sequence motifs were avoided: internal TATA-boxes, chi-sites and ribosomal entry sites, AT-rich or GC-rich sequence stretches,repeat sequences and RNA secondary structures, and
(cryptic) splice donor and acceptor sites, branch points

No reverse-complementary sequence identities longer than 20 nucleotides are found when the optimized sequence is aligned to the transcriptom of *Homo sapiens*. No RNA interference should therefore be expected. The entire gene was divided into and constructed as four ~2kb long fragments using PstI (2028), KasI (3759) and PvuII (5899) and cloned into pCR-Script-Amp (Stratagene, CA, USA) Kpn1 and Sac1 restriction sites.

The recodonised *PFD1235w/MAL7P1.1, PF11_0008,* and *PF13_0003* NTS,
DBL1-α, CIDR1-α, CIDR1-γ, DBL2-β, DBL2-γ, C2,
DBL3-β, DBL3-γ, DBL4-γ, DBL4-δ, DBL4-β, DBL5-δ, DBL5-β, and CIDR2β were expressed in Baculovirus infected hi-five insect cells and purified by HIS tag Metal Chelate Affinity Chromatography purification by cloning the domains into the pAcGP307-A (BD Biosciences, Brøndby, Denmark) and Eucaryotic TA expression vector pCR3.1 (Invitrogen).

Example 17:

Field isolates of P. falciparum *causing severe malaria shows high transcription of* PFD1235w/MAL7P1.1 *(SEQ ID NO. 1),* PF11_0008 *(SEQ ID NO.: 3), and/or* PF13_0003 *(SEQ ID NO.: 5)* or homologues hereof.

From Example 3, 4, 5, and 6 it appears that the Group A *PFD1235w/MAL7P1.1* (SEQ ID NO. 1), *PF11_0008* (SEQ ID NO.: 3), and/or *PF13_0003* (SEQ ID 5) gene encodes VSA_{SM}-like proteins, and that these proteins are involved in the acquisition of the VSA_{SM} phenotype following antibody-selection of VSA_{UM}-expressing 3D7 ($3D7_{SM}$) and adhesion to endothelial cells ($3D7_{endo}$).

Materials and methods

m17.1. Real-time PCR was done using a Rotorgene thermal cycler system (http://www.corbettresearch.com) following purification of RNA and synthesis of cDNA (*m5.1*). The transcription level of *PFD1235w/MAL7P1.1* (SEQ ID NO. 1), *PF11_0008* (SEQ ID NO.: 3), and *PF13_0003* (SEQ ID NO.: 5) or homologues of *hereof* were measured using primers targeting this sequence. The absolute copy number was calculated (*m5.3*) and compared to the absolute copy number of other *var* genes present in the field isolates as well as housekeeping genes such as seryl-tRNA synthetase. Reactions were performed as in (*m5.2*)

The transcription of PFD1235w/MAL7P1.1 (SEQ ID NO. 1), PF11_0008 (SEQ ID NO.: 3), and/or PF13_0003 (SEQ ID NO.: 5) or homologues hereof were found to be higher than other var genes in parasites causing severe malaria, but low in parasites causing uncomplicated malaria (data not shown).

Example 18:

Plasmodium falciparum *field isolates causing severe malaria expresses VAR4 (SEQ ID NO.: 2) on the surface of infected erythrocytes*

Analysis of VAR4 (SEQ ID NO.: 2) expression of RBC infected with parasites causing severe malaria using antibodies to Baculovirus-derived DBL5-δ of the *PFD1235w/MAL7P1.1* gene product revealed a high-molecular weight band of approximately 400 kDA corresponding to the size of the VAR4 expressed by $3D7_{SM}$ (Example 5), which was absent in parasites with a VSA_{UM} phenotype (data not shown).

Taken together, the results of Example 17 and 18 indicates that PFD1235w/MAL7P1.1 (SEQ ID NO.: 1) or homologues hereof are not only transcribed, but also expressed on the surface of RBC infected with parasites having a VSA_{SM} phenotype and causing severe malaria, but not parasites causing uncomplicated malaria and having a VSA_{UM} phenotype. Similar results were obtained for PF11_0008 (SEQ ID NO.: 3), and PF13_0003 (SEQ ID NO.: 5) (data not shown).

Example 19:

Plasmodium falciparum *field isolates causing severe malaria adhere to endothelial cells and adhesion is inhibited by SEQ ID NO. 2, 4, and/or 6 specific antibodies*

To show that VAR4, VAR5, and/or VAR6 are responsible for *in vitro* adhesion of field isolates to endothelial receptors, an antibody adhesion assay with murine antibodies against VAR4, VAR5, and VAR6 were performed.

Materials and methods:

m19-1. Antiadhesion was measured by ^{3}H labeled parasites: For use in adhesion assays, parasite cultures with a parasitemia of ~1% late trophozoites and schizonts were first transferred from Albumax II medium (Life Technologies), with a high concentration of hypoxanthine (Hpx), into RPMI 1640 plus 5% normal human serum (low Hpx) and maintained for 24 h. The parasites then were labeled by exposure to [3H]Hpx (Amersham; 8.75 MBq/mL of RBCs) for another 24 h. Finally, the cultures were enriched for late-stage iRBCs and incubated for 30 min, with or without test plasma. Endothelial cells were grown on Microtiter plates (Falcon; Becton Dickinson) then blocked with bovine serum albumin (BSA; 20 mg/mL, 100 µL/well) in PBS at room temperature for 30 min. We added enriched [^{3}H]Hpx-labeled late-stage iRBCs to wells containing endothelial cells (2×10^{6} cells/well) and incubated the wells at 37°C for 1 h. Nonadherent iRBCs were removed by 4 washes in RPMI 1640. Adherent iRBCs were harvested onto glass fiber pads, and the [^{3}H]Hpx activity was measured in a liquid scintillation counter (Beckman Coulter). Inhibition of iRBC adhesion by plasma was calculated as 1 - (testEndothelialCell - controlBSA)/controlEndothelialCell - controlBSA), where testEndothelial is counts per minute of iRBCs preincubated with plasma and adhering to wells containing endothelial cells, and controlEnothelial cells and controlBSA refer to counts per minute of iRBCs not preincubated with plasma and adhering to endothelial cells and BSA-coated wells, respectively.

Cytoadhesion to endothelial cells were significantly inhibited by plasma from young semi-immune children, and more importantly binding of field isolates to endothelial cells were strongly inhibited by the murine anti-VAR4, -VAR5, and –VAR6 antibodies. In this example it is shown that antibodies raised against recombinant VAR4, -VAR5, and –VAR6 inhibit field parasite isolate adhesion to endothelial cells *in vitro.*

An obvious consequence of this finding is that vaccine induced antibodies against SEQ ID NO.: 2, 4, and/or 6 constructs can hinder binding of parasites to endothelial tissue and thus prevent severe malaria.

Example 20:

A novel DynaBead based method and adhesion to endothelial cells selects for RBC infected with parasites having a VSA_{SM} phenotype and which transcribes var *genes with similar characteristics*

Selection of parasites using a novel antibody-DynaBead based method (Example 3) and adhesion to endothelial cells (Example 6) leads to changes in the serological phenotype of

the 3D7 parasites from being of a VSA_{UM}- to a VSA_{SM}-type (Example 3 and Figs. 5C-D). This VSA_{SM} phenotype resembles that of parasites causing severe malaria (Example 1 and Fig. 1). Thus, this method and results provided by it forms the basis for identification of PfEMP1 molecules that could be used as part of a vaccine against severe malaria.

Using this method we were able to identify three different *var* genes *PFD1235w/MAL7P1.1* (SEQ ID NO.: 1), *PF11_0008* (SEQ ID NO.: 3), and *PF13_0003* (SEQ ID NO.: 5) that were highly transcribed and upregulated in $3D7_{SM}$ (Figs. 13, 14, and 20, Example 5 and 6, Table 2). The protein products of these three genes are responsible for the serological phenotype and adhesive properties of $3D7_{SM}$. Interestingly, these three genes do not belong to the *var1*, *var2* gene subfamily as defined previously (Salanti et al. 2002, Salanti et al. 2003) or Group B, Group C, and Group B/C *var* genes as defined recently (Lavstsen et al. 2003). They lack 1-2 cysteine residues in DBLα homology group G (Smith et al. 2000) compared to most PfEMP1 molecules in Group B, C, and B/C. Additionally, they posses a CIDR1α distinctly different from the CIDR1α domain of the *MCvar1* PfEMP1 gene product expressed by Malayan Camp parasites and of the A4VAR expressed by A4 parasites that have been shown to bind CD36 (Baruch et al. 1997; Cooke et al. 1998; Bryan et al. 2003; Smith et al. 1998). By contrast, $3D7_{SM}$ that transcribes *PFD1235w/MAL7P1.1* (SEQ ID NO.: 1), *PF11_0008* (SEQ ID NO.: 3), and/or *PF13_0003* (SEQ ID NO.: 5) do not bind to CD36 (Example 3).

In conclusion, the three genes are present and expressed in field isolates causing severe malaria, but not in parasites with a VSA_{UM} phenotype (Example 17, 18, and 19) indicating that the serve similar functions and might be responsible for the pathogenesis of severe malaria.

References

Baruch DI, Ma XC, Singh HB, Bi X, Pasloske BL, Howard RJ. (1997). Identification of a region of PfEMP1 that mediates adherence of *Plasmodium falciparum* infected erythrocytes to CD36: conserved function with variant sequence. Blood 90, 3766-3775

Bian Z, Wang G, Tian X and Fan J. (1999). Expression of *Plasmodium falciparum*-infected erythrocyte membrane protein from cerebral malaria patients. *Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong* 17, 359-362.

Bian,Z.Q. and Wang,G.Z. (2000). Antigenic variation and cytoadherence of PfEMP1 of *Plasmodium falciparum*-infected erythrocyte from malaria patients. Chinese Medical Journal *113*, 981-984.

Bryan YG., Dror BI, Ciaran B, Allan MG., Sornchai L, Kubes,P., and Ho, M. (2003). Recombinant PfEMP1 peptide inhibits and reverses cytoadherence of clinical *Plasmodium falciparum* isolates *in vivo*. Blood 101, 331-337.

Cooke BM, Nicoll CL, Baruch DI, Coppel RL. (1998). A recombinant peptide based on PfEMP-1 blocks and reverses adhesion of malaria-infected red blood cells to CD36 under flow. Mol Microbiol. 30, 83-90

Delemarre BJ & Van der Kaay HJ. (1979). Malaria tropica op natuurlijke wijze verkregen in Nederland. *Ned Tijdschr Geneeskd* 123, 1981-1982.

Dodoo,D., Staalsoe,T., Giha,H., Kurtzhals,J.A., Akanmori,B.D., Koram,K., Dunyo,S., Nkrumah,F.K., Hviid,L., and Theander,T.G. (2001). Antibodies to variant antigens on the surfaces of infected erythrocytes are associated with protection from malaria in Ghanaian children. Infect. Immun. 309, 3713-3718.

Fernandez,V., Hommel,M., Chen,Q., Hagblom,P., Wahlgren,M. (1999). Small, clonally variant antigens expresed on the surface of the *Plasmodium falciparum*-infected erythrocyte are encoded by the *rif* gene family and are the target of human immune responses. J. Exp. Med. *190,* 1393-1403.

Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan MS, Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin DMA, Fairlamb AH, Fraunholz MJ, Roos DS, Ralph SA, Mcfadden GI, Cummings LM, Subramanian GM, Mungall C, Venter JC, Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser CM, Barrell B. (2002) Genome sequence of the human malaria parasite *Plasmodium falciparum*. *Nature* 419, 498-511.

Gupta,S., Snow,R., Donnelly,C., Marsh,K., and Newbold,C. (1999). Immunity to non-cerebral malaria is acquired after one or two infections. Nature Medicin. *5*, 340-343.

Hall TA: (1999). BioEdit:a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. *Nucl Acids Symp Ser* 41, 95-98.

Hasler T, Albrecht GR, Van Schravendijk MR *et al.* (1993). An improved microassay for *Plasmodium falciparum* cytoadherence using stable transformants of Chinese hamster ovary cells expressing CD36 or intercellular adhesion molecule-1. *Am J Trop Med Hyg* 48, 332-347.

Hermsen,C.C., Telgt,D.S.C., Linders,E.H.P., Van de Locht,L.A.T.F., Eling,W.M.C., Mensink,E.J.B.M., and Sauerwein,R.W. (2001). Detection of *Plasmodium falciparum* malaria parasites *in vivo* by real-time quantitative PCR. Mol. Biochem. Parasitol. *118*, 247-251.

Howard,R.J. and Barnwell,J.W. (1984). Roles of surface antigens on malaria-infected red blood cells in evasion of immunity. Contemp. Top. Immunobiol. *12*, 127-191.

Kumar S, Tamura K, Jakobsen I and Nei M. (2001). MEGA2 : Molecular Evolutionary Genetics Analysis. Ver. 2.1. *Bioinformatics* 17, 1244-1245.

Jakobsen,P.H., Hviid,L., Theander,T.G., Afare,E.A., Ridley,R.G., Heegard,P.M.H., Stuber,D., Dalsgaard,K., and Nkrumah,F.K. (1993). Specific T-cell recognition of the merozoite proteins rhoptry- associated protein 1 and erythrocyte-binding antigen 1 of *Plasmodium falciparum*. Infect. Immun. *61*, 268-273.

Kraemer SM, Smith JD. (2003). Evidence for the importance of genetic structuring to the structural and functional specialization of the Plasmodium falciparum var gene family. Mol Microbiol. 50, 1527-38.

Kirchgatter,K. and Del Portillo,H.A. (2002). Association of severe non-cerebral *Plasmodium falciparum* malaria in Brazil with expressed PfEMP1 DBL1α sequences lacking cysteine residues. Mol. Med. *8*, 16-23.

Lavstsen,T., Salanti,A., Jensen,A.T.R., Arnot,D.E., and Theander,T.G. (2003). Sub-grouping of *Plasmodium falciparum* 3D7 *var* genes based on sequence analysis of coding and non-coding regions. Malar. J. *2*.

McGregor,I.A., Carrington,S.P., and Cohen,S. (19303). Treatment of East African *P. falciparum* malaria with West African human g-globulin. Trans. R. Soc. Trop. Med. Hyg. *57*, 170-175.

Mercereau-Puijalon O, Barale JC, Bischoff E. (2002). Three multigene families in Plasmodium parasites: facts and questions. *Int J Parasitol.* 32, 1323-1344.

Newbold,C.I., Craig,A.G., Kyes,S., Berendt,A.R., Snow,R.W., Peshu,N., and Marsh,K. (1997). PfEMP1, polymorphism and pathogenesis. Ann. Trop. Med. Parasitol. *91* , 551-557.

Nielsen,M.A., Staalsoe,T., Kurtzhals,J.A., Goka,B.Q., Dodoo,D., Alifrangis,M., Theander,T.G., Akanmori,B.D., and Hviid,L. (2002). Plasmodium falciparum variant surface antigen expression varies between isolates causing severe and nonsevere malaria and is modified by acquired immunity. J. Immunol. *1308*, 3444-3450.

Riley,E.M., L.Hviid, T.G. Theander. (1994). Malaria. F. Kierszenbaum, ed. Parasitic Infections and the Immune System 119. Academic, New York.

Robinson,B.A., Welch,T.L., and Smith,J.D. (2003). Widespread functional specialization of Plasmodium falciparum erythrocyte membrane protein 1 family members to bind CD330 analysed across a parasite genome. Mol. Microbiol. *47*, 12305-1278.

Rogerson SJ, Chaiyaroj SC, Ng K, Reeder JC & Brown GV. (1995). Chondroitin sulfate A is a cell surface receptor for *Plasmodium falciparum*-infected erythrocytes. *J Exp Med.* 182, 15-20.

Salanti A, Jensen ATR, Zornig HD, Staalsoe T, Joergensen L, Nielsen MA, Khattab A, Arnot DE, Klinkert MQ, Hviid L and Theander TG. (2002). A sub-family of common and highly conserved *Plasmodium falciparum var* genes. Mol Biochem Parasitol *122*, 111-115.

Salanti,A., Staalsoe,T., Lavstsen,T., Jensen,A.T., Sowa,M.P., Arnot,D.E., Hviid,L., and Theander,T.G. (2003). Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Mol Microbiol 2003. Jul. ;49. (1):179. -91. *49*, 179-191.

Sambrook,J., Fritsch,E.F., and Maniatis,T. (1989). Molecular cloning: a laboratory manual. (Cold Spring Harbor: Cold Spring Harbor Laboratory Press).

Silamut,K., Phu,N.H., Whitty,C., Turner,G.D.H., Louwrier,K., Mai,N.T.H., Simpson,J.A., Hien,T.T., and White,N.J. (1999). A quantitative analysis of the microvascular sequestration of malaria parasites in the human brain. Am. J. Pathol. *155*, 395-410.

Smith JD, Kyes S, Craig AG, Fagan T, Hudson-Taylor D, Miller LH, Baruch DI, Newbold CI. (1998). Analysis of adhesive domains from the A4VAR Plasmodium falciparum erythrocyte membrane protein-1 identifies a CD36 binding domain. Mol Biochem Parasitol. 97, 133-48.

Smith,J.D., Subramanian,G., Gamain,B., Baruch,D.I., and Miller,L.H. (2000). Classification of adhesive domains in the Plasmodium falciparum erythrocyte membrane protein 1 family. Mol Biochem. Parasitol. 2000. Oct. ;110. (2):293. -

Staalsoe T, Giha HA, Dodoo D, Theander TG and Hviid L. (1999) Detection of antibodies to variant antigens on *Plasmodium falciparum* infected erythrocytes by flow cytometry. Cytometry *35,* 329-336.

Staalsoe T, Nielsen MA, Vestergaard LS, Jensen ATR, Theander TG and Hviid L. (2003). *In vitro* selection of *Plasmodium falciparum* 3D7 for expression of variant surface antigens associated with severe malaria in African children. Parasite Immunol *25,* 421-427.

Tatusova TA and Madden TL. (1999). FEMS Microbiol Lett. 174, 247-50.

Wahlgren,M., Fernandez,V., Chen,Q., Svard,S., and Hagblom,P. (1999). Waves of malarial variations . Cell *96*, 3003-3006.

Claims

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of at least one of

SEQ ID NO.: 2, SEQ ID NO.: 4 and SEQ ID NO.: 6

for use as a medicament.

2. An isolated polypeptide according to claim 1, wherein said amino acid sequence has at least 80% sequence identity to SEQ ID NO.: 2, SEQ IN NO.: 4 and SEQ ID NO.: 6.

3. An isolated polypeptide according to claim 1 or 2, wherein said amino acid sequence is a sub-sequence of with a minimum length of 10 amino acids.

4. A polypeptide according to claim 1, wherein said polypeptide comprises the amino acid sequence shown in SEQ ID NO:2.

5. A polypeptide according to claim 4, wherein said polypeptide consists of the amino acid sequence shown in SEQ ID NO:2.

6. A polypeptide according to claim 1, wherein said polypeptide comprises the amino acid sequence shown in SEQ ID NO:4.

7. A polypeptide according to claim 6, wherein said polypeptide consists of the amino acid sequence shown in SEQ ID NO:4.

8. A polypeptide according to claim 1, wherein said polypeptide comprises the amino acid sequence shown in SEQ ID NO:6.

9. A polypeptide according to claim 8, wherein said polypeptide consists of the amino acid sequence shown in SEQ ID NO:6.

10. A polypeptide according to claim 1, wherein said amino acid sequence has at least 80% sequence identity to SEQ ID NO:2.

11. A polypeptide according to claim 1, wherein said amino acid sequence has at least 80% sequence identity to SEQ ID NO:4.

12. A polypeptide according to claim 1, wherein said amino acid sequence has at least 80% sequence identity to SEQ ID NO:6.

13. An polypeptide to claim 1-12, wherein said amino acid is consistently up-regulated after antibody selection-induced change from VSA_{UM} to VSA_{SM} expression.

14. An polypeptide according to claim 1-13, wherein said amino acid sequence is capable of mediating cyto-adhesion of intact erythrocyte infected by a parasite to human endothelial cells, but not to the CD36 receptor.

15. An isolated nucleic acid comprising a nucleotide sequence selected from the group consisting of at least one of

a) SEQ ID NO.: 1, SEQ ID NO.: 3 and SEQ ID NO.: 5

for use as a medicament.

16. A nucleic acid according to claim 15, wherein said nucleotide sequence has at least 80% sequence identity to SEQ ID NO.: 1, SEQ ID NO.: 3 or SEQ ID NO.: 5.

17. A nucleic acid according to claim 15-16, wherein said nucleotide sequence is a sub-sequence of with a minimum length of 30 nucleotides.

18. A nucleic acid according to claim 15, wherein said nucleic acid comprises the nucleotide sequence shown in SEQ ID NO:1.

19. A nucleic acid according to claim 18, wherein said nucleic acid consists of the nucleotide sequence shown in SEQ ID NO:1.

20. A nucleic acid according to claim 15, wherein said nucleic acid comprises the nucleotide sequence shown in SEQ ID NO:3.

21. A nucleic acid according to claim 20, wherein said nucleic acid consists of the nucleotide sequence shown in SEQ ID NO:3.

22. A nucleic acid according to claim 15, wherein said nucleic acid comprises the nucleotide sequence shown in SEQ ID NO:5.

23. A nucleic acid according to claim 22, wherein said nucleic acid consists of the nucleotide sequence shown in SEQ ID NO:5.

24. A nucleic acid according to claim 15, wherein said nucleotide sequence has at least 80% sequence identity to SEQ ID NO:1.

25. A nucleic acid according to claim 15, wherein said nucleotide sequence has at least 80% sequence identity to SEQ ID NO:3.

26. A nucleic acid according to claim 15, wherein said nucleotide sequence has at least 80% sequence identity to SEQ ID NO:5.

27. A nucleic acid sequence according to claim 15-26, wherein said sequence is consistently upregulated after antibody selection-induced change from VSA_{UM} to VSA_{SM} expression.

28. A nucleic acid according to claim 15-17, wherein said nucleic acid sequence encodes a polypeptide which is capable of mediating cyto-adhesion of intact erythrocyte infected by a parasite to human endothelial cells, but not the CD36 receptor.

29. A recombinant vector comprising the nucleic acid defined in any of claims 15-28 operably linked to one or more control sequences for use as a medicament

30. A composition comprising a polypeptide according to any of claims 1-14 or a nucleic acid according to any of claims 15-28 and a pharmaceutically acceptable diluent, carrier or adjuvant.

31. A composition according to claim 30, wherein said composition is an immunogenic composition.

32. A composition according to claim 31, wherein said composition induces an IgG/IgM antibody response.

33. An isolated antibody or isolated antiserum induced in response to one or more polypeptides as defined in any of claims 1-14 and/or to one or more nucleic acids as defined in any of claims 15-28.

34. An antibody according to claim 33, wherein said antibody is capable of binding to a molecule expressed on the surface of an intact erythrocyte infected by a parasite causing malaria.

35. An antibody according to claim 33, wherein said antibody is capable of recognising parasites selected *in vitro* for expression of VSA_{SM}.

36. An antibody according to claim 33, wherein said antibody is capable of binding to a molecule expressed on the surface of an intact erythrocyte infected by a parasite capable of mediating cyto-adhesion of intact erythrocyte infected by a parasite to human endothelial cells, but not the CD36 receptor.

36. A vaccine comprising at least one nucleic acid according to any of claims 15-28 or at least one vector according to claim 29, the vaccine effecting *in vivo* expression of at least one antigen by a subject, to whom the vaccine has been administered, the amount of expressed antigen being effective to confer substantially increased resistance to malaria caused by *Plasmodium falciparum*.

37. Use of a polypeptide according to any of claims 1-14 for the manufacture of a composition to be administered in order to prophylactically or therapeutically reduce the incidence, prevalence or severity of malaria in a subject.

38. Use of a polypeptide according to any of claims 1-14 for the manufacture of a vaccine for malaria prophylaxis.

39. Use of a polypeptide according to any of claims 1-12 for the manufacture of a composition for vaccination against malaria.

40. Use of a nucleic acid according to any of claims 15-28 for the manufacture of an composition to be administered in order to prophylactically or therapeutically reduce the incidence, prevalence or severity of malaria in a subject.

41. Use of a nucleic acid according to any of claims 1-28 for the manufacture of a vaccine for malaria prophylaxis.

42. Use of a nucleic acid according to any of claims 15-28 for the manufacture of a composition for vaccination against malaria.

43. Use of a recombinant vector according to claim 29 for the manufacture of a composition to be administered in order to prophylactically or therapeutically reduce the incidence, prevalence or severity of malaria in a subject.

44. Use of a recombinant vector according to claim 29 for the manufacture of a vaccine for prophylactic treatment of severe malaria.

45. Use of a recombinant vector according to claim 29 for the manufacture of a composition for vaccination against severe malaria.

46. Use according to any of claims 37-45, wherein said malaria is caused by *Plasmodium falciparum.*

47. A method for prophylactically or therapeutically reduce the incidence, prevalence or severity of malaria in an subject said method comprising administering to said subject an effective amount of a polypeptide according to any of claims 1-14, a nucleic acid according to any of claims 15-28 or a recombinant vector according to claim 29.

48. A method for the prophylactic treatment of severe malaria in an subject, said method comprising administering to said subject an effective amount of a polypeptide according to any of claims 1-14, a nucleic acid according to any of claims 15-28 or a recombinant vector according to claim 29.

49. A vaccination method against severe malaria in an subject, said vaccination method comprising administering to said subject an effective amount of a polypeptide according to any of claims 1-14, a nucleic acid according to any of claims 15-28 or a recombinant vector according to claim 29.

50. A vaccine comprising any of the polypeptides according to any of claims 1-14, the nucleic acids according to any of claims 15-28 or the recombinant vector according to claim 29, said vaccine characterised in that it induces an immune response, wherein said immune response specifically recognises a molecule expressed on the surface of an intact erythrocyte infected by a parasites.

51. A vaccine comprising one or more B-cell and/or T-cell epitopes originating from any of the polypeptides according to any of claims 1-14, the nucleic acids according to any of claims 15-28 or the recombinant vector according to claim 29, said vaccine characterised in that it induces an immune response, wherein said immune response specifically

recognises a molecule expressed on the surface of an intact erythrocyte infected by a parasites.

52. A DNA vaccine, which results in the expression of a polypeptide comprising one or more B-cell and/or T cell epitopes from any of the polypeptide sequences according to claim 1-14, wherein said vaccine is capable of inducing an immune response, wherein said immune response specifically recognises a molecule expressed on the surface of an intact erythrocyte infected by parasites.

53. A DNA vaccine comprising at least one nucleic acid sequences according 15-28, wherein said vaccine is capable of inducing an immune response, wherein said immune response specifically recognises a molecule expressed on the surface of an intact erythrocyte infected by parasites.

54. An *in vitro* diagnostic method, said method comprising contacting a sample with a polypeptide according to any of claims 1-14 under conditions allowing an *in vitro* immunological reaction to occur between said polypeptide and the antibodies possibly present in said sample, and *in vitro* detect the antigen-antibody complexes possibly formed.

55. An *in vitro* diagnostic method according to claim 54, wherein a disease-state profile for a tested subject is generated by determining the concentration or expression level in a sample of sequences as defined in any of claims 1-14 and/or 15-28.

56. An *in vitro* diagnostic kit comprising

a) a sequence as defined in any of claims 1-14 and/or 15-28
b) reagents for preparing a suitable medium for carrying out an immunological reaction between an antibody present in a sample of body fluid or tissue and said sequence; and
c) reagents allowing the detection of the antigen-antibody complexes formed, wherein said reagents may bear a radioactive or non-radioactive label.

57. A method for generating a vaccine against severe malaria comprising

a) injecting a sequence according to any of claims 1-14 in a subject
b) enabling said subject to generate antibodies specifically recognising any of the polypeptide sequences according to claim 1-14
c) purify said antibodies
d) selecting antibodies having cross-reactivityto parasites causing severe malaria

e) selecting antibodies having the ability to inhibit adhesion to endothelial cells.

58. A method for testing an inhibitor-molecule capable of inhibiting binding of any of the polypeptides according to claim 1-14 to a receptor expressed on endothelia cells comprising

a) *in vitro* cultures of endothelial cells

b) add potential inhibiting-molecule

c) add RBC infected with parasites, said iRBC expressing any of said polypeptide sequences on their surface of the RBC

d) measure the binding of the iRCB with said endothelia cells by microscopy or other means of quantifying binding as for instance liquid scintillation spectrometry.

Abstract

The present invention relates to nucleic acid molecules related to the *PFD1235w/MAL7P1.1*, *PF11_0008*, and *PF13_0003* gene families as well as amino acid sequences encoded by such nucleic acid molecules with respect to their role in mediating adhesion of infected red blood cells to endothelial cells, which is characteristic for the pathogenesis of severe malaria (SM). Accordingly, the invention provides pharmaceutical compositions and vaccines, hereunder nucleotide-based vaccines comprising compounds that are related to VAR4, VAR5, and/or VAR6 polypeptides and *PFD1235w/MAL7P1.1* *PF11_0008*, and/or *PF13_0003* nucleic acid molecules. The invention further relates to the use of these compounds as medicaments and for the manufacture of compositions, such as immunogenic compositions. In addition, the invention relates to methods of treatment and prevention of severe malaria wherein these methods are based on the nucleic acid molecules and polypeptides of the invention. As these compounds can also be used as biotechnological tools the invention provides *in vitro* diagnostic methods and kits comprising reagents and IgGs/antibodies designated to the use in such methods. The invention also relates to methods of identifying agents capable of modulating the VAR4, VAR5, and/or VAR6 dependent adhesion to endothelial cells and agent capable of interacting with VAR4, VAR5, and/or VAR6. Finally, a method for identifying polypeptides, which will induce a specific IgG/ antibody response upon administration to a subject is provided by the invention.



Fig. 1

PA 2003 00195



Fig. 2



Fig. 3



Fig. 4



Fig. 5



Fig. 6



Fig. 7



Fig. 8



Gene	Location	Orientation (transcribed towards)	5' region	DBL1-CIDR1	Intron	ATS	3' region	Domain structure	
PFE1640w**	Telomeric	Telomere	upsD	A	None	None	None	DBL1-α CIDR1-α DBL2-β1 C2 DBL3-γ DBL4-ε DBL5-γ DBL6-β DBL7-κ	var1
PFL0030c	Near telomere	Telomere	upsE	None	AI	D	X	DBL1-x DBL2-α DBL3-x DBL4-κ DBL5-ε DBL6-ε ATS	var2
PFD1235w	Near telomere	Telomere	upsA	A	AI	A	A	DBL1-α CIDR1-α DBL2-β1 C2 DBL3-β1 C2 DBL4-γ DBL5-δ CIDR-β ATS	
MAL7P1.1	Telomeric	Telomere	upsA	A	AI	A	A	DBL1-α CIDR1-α DBL2-β1 C2 DBL3-β1 C2 DBL4-γ DBL5-δ CIDR-β ATS	
PF11_0521	Telomeric	Telomere	upsA	A	AI	A	A	DBL1-α CIDR1-α DBL2-β1 C2 DBL3-β1 C2 DBL4-δ CIDR-γ ATS	
PF13_0003	Near telomere	Telomere	upsA	A	AI	A	A	DBL1-α CIDR-γ DBL2 β C2 DBL3-γ DBL4-δ CIDR β DBL5-β C2 ATS	
PF08_0141	Near telomere	Telomere	upsA	A	X	A	A	DBL1-α CIDR-γ DBL2-β C2 DBL3-γ DBL4-ζ DBL5-ε ATS	var group A
PF11_0008	Near telomere	Telomere	upsA	A	X	A	A	DBL1-α CIDR-γ DBL2-γ DBL3-δ CIDR-β DBL4-β C2 ATS	
PFD0020c	Near telomere	Telomere	upsA	A	X	A	A	DBL1-α CIDR1-α DBL2-β C2 DBL3-γ DBL4-γ DBL5-δ CIDR-γ ATS	
PFA0015c	Near telomere	Telomere	upsA	A*	All	A	A	DBL1-α DBL2-ε ATS	
MAL6P1.314	Near telomere	Telomere	upsA	A*	All	A	A	DBL1-α DBL2-ε ATS	
PFI1820w	Near telomere	Telomere	upsA	A*	All	A	A	DBL1-α DBL2-ε ATS	
PF08_0140	Near telomere	Centromere	upsBsh	A	B	B	B	DBL1-α CIDR1-α DBL2-β1 C2 DBL3-γ DBL4-ε CIDR β ATS	
MAL6P1.316	Near telomere	Centromere	upsBsh^	A	X	X	X	DBL1-α CIDR β DBL2 β C2 DBL3-γ DBL4-ζ DBL5-ε ATS	var group B/A
PFL0020w	Near telomere	Centromere	upsBsh	X	X	X	B	DBL1-α CIDR β DBL2 β C2 DBL3-γ DBL4-ζ DBL5-ε ATS	
MAL6P1.4	Telomeric	Centromere	upsB	C	X	X	B	DBL1-α CIDR1-α DBL2 β C2 DBL3-γ DBL4-δ CIDR-γ DBL5-γ DBL6-ε DBL7-ε ATS	
PF11_0007	Telomeric	Centromere	upsB	X	B	B	D	DBL1-α CIDR1-α DBL2-ε CIDR β ATS	
PF08_0142	Telomeric	Centromere	upsB	B	B	B	D	DBL1-α CIDR1-α DBL2 δ CIDR β ATS	
PFE0005w	Telomeric	Centromere	upsB	B	B	B	D	DBL1-α CIDR1-α DBL2-δ CIDR-β ATS	
PFA0005w	Telomeric	Centromere	upsB	B	B	C	B	DBL1-α CIDR1-α DBL2-δ CIDR-β ATS	
PFA0765c	Telomeric	Centromere	upsB	B	B	B	B	DBL1-α CIDR1-α DBL2-δ CIDR-β ATS	
PFC1120c	Telomeric	Centromere	upsB	B	B	B	B	DBL1-α CIDR1-α DBL2-δ CIDR-β ATS	
PFD0005w	Telomeric	Centromere	upsB	B	B	B	B	DBL1-α CIDR1-α DBL2-γ DBL3-x CIDR-β ATS	
PFI0005w	Telomeric	Centromere	upsB	D	B	B	B	DBL1-α CIDR1-α DBL2-δ CIDR-γ ATS	
PF13_0364	Telomeric	Centromere	upsB	D	B	B	B	DBL1 α CIDR1 α DBL2-δ CIDR-β ATS	
PF07_0139	Telomeric	Centromere	upsB	D	X	B	B	DBL1 α CIDR1α DBL2-δ CIDR-β DBL3-ε ATS	
PFB1055c	Telomeric	Centromere	upsB	D	X	B	B	DBL1-α CIDR1 α DBL2-δ CIDR-β ATS	
PF10_0406	Telomeric	Centromere	upsB	B	X	B	B	DBL1 α CIDR1 α DBL2 δ CIDR-β ATS	
PFL0005w	Telomeric	Centromere	upsB	B	X	B	B	DBL1 α CIDR1 α DBL2 δ CIDR-β ATS	var group B
PFB0010w	Telomeric	Centromere	upsB	B	X	B	B	DBL1 α CIDR1α DBL2-γ ATS	
PFC0005w	Telomeric	Centromere	upsB	B	X	B	B	DBL1 α CIDR1 α DBL2 δ CIDR β ATS	
PFL2665c	Telomeric	Centromere	upsB	B	X	B	B	DBL1-α CIDR1-α DBL2-δ CIDR-β ATS	
PF13_0001	Telomeric	Centromere	upsB	B	X	B	B	DBL1-α CIDR1-α DBL2-δ CIDR-β ATS	
MAL6P1.1	Telomeric	Centromere	upsB	E	B	B	B	DBL1-α CIDR1-α DBL2-δ CIDR-β ATS	
PFD1245c	Telomeric	Centromere	upsB	X	X	C	B	DBL1-α CIDR1-α DBL2-δ CIDR-β ATS	
PFI1830c	Telomeric	Centromere	upsB	C	X	B	B	DBL1-α CIDR1-α DBL2-δ CIDR-γ ATS	
PF10_0001	Telomeric	Centromere	upsB	C	X	B	B	DBL1-α CIDR1-α DBL2-δ CIDR-γ ATS	
PFL0935c	Centromeric	Telomere	upsB	D	X	C	B	DBL1-α CIDR1-α DBL2-δ CIDR-γ ATS	
PFD0835c	Centromeric	Telomere	upsBsh	C	B	C	C	DBL1-α CIDR1-α DBL2 δ CIDR-β ATS	
PFL1955w	Centromeric	Telomere	upsBsh	C	B	C	C	DBL1-α CIDR1-α DBL2 δ CIDR-β ATS	
PF08_0106	Centromeric	Telomere	upsBsh	C	B	C	X	DBL1 α CIDR1-α DBL2 δ CIDR-β ATS	
MAL7P1.50	Centromeric	Telomere	upsBsh	C	X	C	X	DBL1 α CIDR1-α DBL2-δ CIDR-γ ATS	
PF08_0103	Centromeric	Telomere	upsBsh	B	X	C	X	DBL1 α CIDR1 α DBL2 δ CIDR β ATS	var group B/C
MAL7P1.55	Centromeric	Telomere	upsBsh	B	X	C	C	DBL1 α CIDR1-α DBL2-δ CIDR-γ ATS	
PF07_0050	Centromeric	Telomere	upsBsh	B	AI	B	D	DBL1 α CIDR1 α DBL2 β C2 DBL3-γ ATS	
PFD1005c	Centromeric	Telomere	upsBsh	E	B	B	C	DBL1 α CIDR1 α DBL2 δ CIDR-γ ATS	
PFL1950w	Centromeric	Telomere	upsB^	E	X	B	D	DBL1-α CIDR1-α DBL2-β1 C2 DBL3-δ CIDR-β ATS	
MAL6P1.252	Centromeric	Telomere	upsC	B	B	D	X	DBL1-α CIDR1-α DBL2-β1 C2 DBL3-δ CIDR-β ATS	
PFD0995c	Centromeric	Telomere	upsC	C	X	D	X	DBL1 α CIDR1-α DBL2 δ CIDR-γ ATS	
MAL7P1.56	Centromeric	Telomere	upsC	C	X	B	D	DBL1-α CIDR1-α DBL2-δ CIDR-β ATS	
PF08_0107	Centromeric	Telomere	upsC	X	B	B	D	DBL1-α CIDR1-α DBL2 δ CIDR-γ ATS	
PF07_0049	Centromeric	Telomere	upsC	C	B	C	X	DBL1-α CIDR1-α DBL2 δ CIDR-γ ATS	
PFD0630c	Centromeric	Telomere	upsC	C	B	C	C	DBL1-α CIDR1-α DBL2-δ CIDR-γ ATS	
PFD1000c	Centromeric	Telomere	upsC	C	B	B	C	DBL1-α CIDR1-α DBL2 δ CIDR-γ ATS	
PFD1015c	Centromeric	Telomere	upsC	D	B	B	X	DBL1-α CIDR1-α DBL2-δ CIDR-β ATS	var group C
PFD0615c	Centromeric	Telomere	upsC	C	X	X	X	DBL1-α CIDR1-α DBL2-δ CIDR β ATS	
PF07_0051	Centromeric	Telomere	upsC	C	AI	D	X	DBL1-α CIDR1-α DBL2 δ CIDR β ATS	
PF07_0048	Centromeric	Telomere	upsC	C	X	C	C	DBL1-α CIDR1-α DBL2 δ CIDR β ATS	
PFL1960w	Centromeric	Telomere	upsC	C	X	C	X	DBL1-α CIDR1-α DBL2 δ CIDR β ATS	
PFD0625c	Centromeric	Telomere	upsC	C	X	C	X	DBL1-α CIDR1-α DBL2 δ CIDR-β ATS	

B PfEMP1	Strain	3D7 gene with closest related 5' sequence	5' region	DBL1-CIDR1	Intron	ATS	3' region	Known domain structure
var1 family	3D7 homologue	PFE1640w	Both 5' region and coding sequences are conserved [42]					
var2 family	3D7 homologue	PFL0030c	Both 5' region and coding sequences are conserved [35]					
AAA75397	FCR3	MAL6P1.316	upsBsh^	A	nd	C	D	DBL1-α CIDR1-α DBL2-β C2 DBL3-γ DBL4-ε CIDR β ATS
AAA75396	Dd2	PF07_0050	upsB	C	nd	B	X	DBL1-α CIDR1-α DBL2-β C2 DBL3-γ DBL4-ε CIDR β ATS
AAA75398	FCR3	PF07_0139	upsB	E	nd	B	X	DBL1 α CIDR1-α DBL2-β C2 DBL3-ε CIDR-β ATS
AAD03351	It	PFL2665c	upsB	X	nd	nd	nd	DBL1-α CIDR1-α DBL2-β C2 DBL3-ε CIDR-β DBL4-γ DBL5-β
AF193424	It	PF08_0142	upsB	X	nd	nd	nd	DBL1-α CIDR1-α DBL2-β C2 DBL3-γ
AAB60251	MC	-	nd	B	nd	B	D	DBL1-α CIDR1-α DBL2-δ CIDR-γ DBL3-β DBL4-ε ATS
AAC05220	-	PFD0005w	upsB	B	nd	nd	nd	DBL1 α CIDR1α DBL2-δ C2 DBL3-δ
AAC47438	FCR3	PFB1055c	upsB	X	nd	B	nd	DBL1-α CIDR1α DBL2 β C2 DBL3-δ CIDR β ATS
AAB06961	II	PFL0020w	upsBsh	X	nd	nd	nd	DBL1-α CIDR1-α DBL2-β1 C2 DBL3-δ CIDR β
AAA75399	Dd2	PFD1015c	upsC	B	nd	C	X	DBL1-α CIDR1 α DBL2-δ CIDR-β ATS
AAC05730	FCR3	-	nd	C	nd	C	nd	DBL1-α CIDR1-α DBL2-δ CIDR-β ATS

Fig. 9



Fig. 10



Fig. 11



Fig. 12



Fig. 13



Fig. 14



Fig. 15



Fig. 16



Fig. 17



Fig. 18



Fig. 19



Fig. 20

SEQUENCE LISTING

<110> Københavns Universitet
Louise Jørgensen
Pamela Magistrado
Thomas Lavstsen
Ali Salanti
Morten A. Nielsen
Trine Staalsø
Lars Hviid
Thor Theander
Anja Jensen

<120> COMPOUNDS USEFUL IN THE DIAGNOSIS AND TREATMENT OF MALARIA

<130> P36017DK01

<160> 6

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 10662
<212> DNA
<213> Plasmodium falciparum

<220>
<221> gene
<222> (0)...(0)
<223> var gene PFD1235w

<400> 1
atggggaatg catcatcatc agagggggag gctaaaaccc ctagtttaac agaaagtcac 60
aacagtgcaa gaaatatttt ggaaggttat gccgaaagta taaaggaaca ggcatcaaaa 120
gatgcaaaaa tacatggaca tcatttgaaa ggagatttgg cgaaagcagt atttcgtcat 180
ccatttttctg catatagacc taactatgga aatccgtgcg aacttgatta taggtttcat 240
actaatgtat ggcatcgtaa cgcagaagat agaaatcctt gtctttttag tcgtgcaaaa 300
cgtttttcaa atgaaggtga agcagaatgt aatggtggta taataactgg taataaaggt 360
gaatgtgggg catgtgcacc gtataggaga agacatatat gtgactataa tttgcaccat 420
ataaacgaaa ataatataag gaatactcat gatttattgg ggaatttgtt agttatggca 480
aggagtgaag gtgaatctat tgtgaaaagt catgaatata caggttatgg tatatacaaa 540
tcaggtatat gtacttctct tgctcgcagt tttgcagata taggagatat tattcgagga 600
aaagatctgt atcgtcgtga tagtagaaca gataaattag aagagaattt aagaaaaatt 660
ttcgcgaata tatataaaga attgaagaat gggaagaagt gggcggaagc aaaagagtac 720
taccaagatg atggaactgg aaattattat aaattaaggg aagcttggtg ggcacttaac 780
agaaaagatg tgtggaaagc attaacatgt agtgcgccaa gggatgctca atatttcata 840
aaatcaagcg tcagggatca aacattttca aatgattatt gtggccatgg tgaacatgag 900
gttcttacaa atttagatta tgtccctcaa tttttacgat ggtttgaaga atgggcagaa 960
gagttttgta gaataaaaaa aataaaatta ggaaaggtta aggaagcatg tcgtgatgac 1020
tcaaaaaaat tatattgtag tcataatgga tatgactgta cgaaaactat tcgaaataaa 1080
gatattttgt ctgataatcc taaatgtact gggtgttctg ttaaatgcaa agtttatgaa 1140
ctttggttaa ggaatcaacg aaatgaattt gaaaaacaaa aaaaaaaata ttataaggaa 1200
atacagacat atacatcgaa ggacgctaaa actgatagta atattaataa cgaatattat 1260
aaggaatttt atgacaaact taaaaatgag ggctatgaaa cattgaacaa atttataaaa 1320
ttactaaatg aaggaaggta ttgtaaagaa aaaatatcag gagaaaggaa tattgatttt 1380
actatgactg gtgataaaga cgcgttttat cgctcagact attgccaaat atgtcctgaa 1440

tgtggagtcc aatgtagcgg tacaacatgc acaccaaaaa aagtgataca tccgaattgc 1500
aaagataaag aaacttatga gcctggtgat gcaaaaacca ctgatattac tgtcctttat 1560
agtggtgatg aagaaggtga tattgcacaa aaattacaag atttttgtaa tgataaaaat 1620
aaagaaaatg atgaaaacta tgaaaaatgg caatgctatt ataaaagtag tgagattaat 1680
aaatgtcaaa tgacaccatc atcacacaaa gttccaaaac atggttacat tatgtcattt 1740
tatgcttttt ttgatttgtg ggttaagaat ttattaatag atagtataaa ttggaagaac 1800
gatcttacga attgtataaa taatactaat gttacggatt gtaaaaatga ttgtaacaca 1860
aattgtaaat gttttgaaaa ttgggctaaa acaaaagaaa atgagtggaa aaaagtgaag 1920
acgatataca aaaatgaaaa cggaaacacg aacaattatt ataaaaaact taataaccat 1980
tttcaaggtt atttttttca cgttatgaaa gagcttaaca aagaagaaaa atggtataaa 2040
cttatggaag atttaaaaga aaaaattgat tcttccaatt tgaaaaatgg tacgaaagat 2100
tcagaaggcg caataaaagt gttgttcgat cacttaaaag atatagctga aagatgcata 2160
gacaataatt caaaagattc atgtccacct tcagtggata cgaaaacaaa cccctgtgct 2220
aaacctcctg gtagtaaacc cactaaaagt gtaaaacaat tagcggaaca tatgcaacag 2280
aaggcacaaa aacttttggg tactcgtggt ggtgaaagta aattgaaggg ggatgcaaca 2340
agagggacgt ataaccttgg aggtcaagga aacacgttga atggcgatat atgtaaaata 2400
acaaaaaatc ataccaatga tagtcgtcct aatggtgaac catgtacagg taaagataaa 2460
gttaaaaacg ggtttcgctt gaaaatagga accccgtgga caaatattgt acaaaaaaaa 2520
aaaaaaaagt catacaaaga cttctattta cctcctcggc gtcaacatat gtgtacatca 2580
aatttagaaa atttgagcac gagtagcaaa ggacttagta atggtagttt tgctagtcac 2640
tcattattag gtgatgtatt gctcgcagca aaatttgaag cacaaaagat aatactagtg 2700
tataaaaata agaataatat aaatatcaga aaaagaataa ctgacccaaa tgatcaagct 2760
actgtatgtc gtgctatacg ttacagtttc gccgatctag gagatattat acgaggaaaa 2820
gacatgtgga atataaacag tgatgcaaaa gatcttcaag atcgtttaga aaaaatattt 2880
aaaaccatta atgaaaaact tcctaatgaa atccaaaaaa gatatacgaa ccgtgaaaat 2940
aaacatttag atttacgttc agactggtgg gaagctaata gacatcaagt ttggagagct 3000
atgaaatgtg caacaaaagg catcagcaat aacaattgta atggtatccc aatagaagat 3060
tacatcccac aacgattaag atggatgacg gaatgggccg aatggtattg caaaaagcag 3120
tcacaggaat atgagaagtt ggaggagaag tgtgggatgt gtacgggtaa gggtcagggt 3180
gatggtaaag attgtacaca gaaggataaa gaatgtagtc cgtgcaagaa agcatgtgat 3240
gcatataaga aggaaataga aaaatgggaa aaacaatgga aaacagtatc agctatatac 3300
caaatattat acgcaaaagc acgaattgtt gctagtaatg gcggtcctgg gtattataat 3360
acggaagtac agaagaaaga ccgatccgtg tatgacttct tgtacgagtt acatttacaa 3420
aatggtggca aaaaaggtcc tcctcctgct acacatcctt ataaatctgt taacacacgt 3480
gataaacgtg atgccactga tgatacaaca cccactgtgt atagtactgc tgcaggatat 3540
gtacaccaag aagcacatat tggtgattgt aaggaacaac acgttttttg tgataataac 3600
ggcaacaagg agaagtatgc ttttaagaat ccaccaaatg tatatgttga ggcgtgtaag 3660
tgtatgacga gggaggcacc accaccacca acaactcctt ctactccaaa tccgtgtgct 3720
gaaactggtg gtgtacatac cattaaaact gtgactgatg tcgcaaaaat attacagggg 3780
gaggcaaatg aaacaatgct aaaaaatagt tccaatggta atgataagga tgagagtaaa 3840
ttgaaaggta aggcagaaga aggggattat agtcgtggag gtacgccaag tgacttcaac 3900
aacaatttat gtggtataac acaaaagcat tccaatgctc ataatgattc acaacaacca 3960
tgttatggaa aagatcaaaa aaggttcaat gtaggaacgg aatggtcatt taaggataat 4020
catagaaaac ggacacaccc tgaggcatat atgcctccaa gaagggaaca tatatgtaca 4080
tcaaatttgg aatatttaat tcataagaga aaaaaaccaa ttatagaagg tgatcctaac 4140
aagattattc attccttatt gggcgatgtg ttacttgcag caaaatatga agcagaaaac 4200
ataaagaaac tgtatgaaga aaataacaac cgaaaagatc aggaaggtat atgtcgagct 4260
atgaaatata gttttgcaga tataggggat attattcgag gaaaagatat gtggatagaa 4320
aacaatgatg ctaagagatt acaaacaaat ttgaaagaaa tatttactaa aattaaagaa 4380
aaaactggag gcaccacata taatgaagat aacgatccgt atttaaaatt acgtgcagat 4440
tggtgggaag ctaatagagc caaagtatgg aaagcaatga aatgtaaaac aaatggcgta 4500
gatatcactt gtgatagtga tcatacacca ttggatgatt atatccccca aagattaaga 4560
tggatgactg aatgggcaga atggtattgt aaagcgcaat cacaggagta taagaagttg 4620
gaggagaagt gtagtcaatg caagagtaag ggtaaaggtg ggaatgagtg ttacagagaa 4680
acgaaggaat gtaacgattg caagcaagca tgtgaagaat ataaaaggaa aataaaaaca 4740
tgggcagatc aatggaaggt aatatcaaat aaatacgagg atttatacaa aaaagcccaa 4800
aatcctacta atgctgttct caaagataac aaagatgaga aagacaagaa tgtgattgat 4860
tttttgacac aattacaaaa agcaaataat ggcgaaaaaa ctggtgtgca caccgtgtat 4920
tctactgctg caggatatat acatcaagag gcacgtacac gtgaatgcca ggaacaaagg 4980

gagttttgtg ataaaaaaaa tggcattgac aacacaagtt atgcttttaa ggatccacct 5040
catgggtatg ctacagcgtg tgattgcata aataggtcgc aaacagagga gccgaagaaa 5100
aaggaagaaa atgtagagag tgcgtgcaaa atagtggaag aagttctttc gaaaccacga 5160
gataaaacta caggtggaat agatcattgt aatccaaagt attatccaag aaaagaaaat 5220
tatcctggat ggaattgtac tccaggtcag tttaaatcag gtcatgctgg agcatgtatg 5280
cctccaagaa gaataaaatt atgtgtaatt aatttacaat atttgaatga gaagaaatca 5340
ccagaagaat tgagaaaagc ttttattcaa tgcgctgcaa tagaaacgta ttggttatgg 5400
caaaaataca aaaaggataa gaatggtggt gttgcacaag caaaattaaa tagtggtacc 5460
atcgctgatg actttaagcg tcaaatgttc tatacgtttg gagattatag agatttatgt 5520
ttagatactg atatatcatc aaaagcagat acaagtacag gtgtaggtaa agtaaaaatt 5580
aatatagatt ctgttttcca aaaaattgac ataactaatg tcgaacaacg taaaccttgg 5640
tggggaaaaa acgcagaagc tatttgggat ggaatgttat gtgctttaag ttataatact 5700
acaaacaaaa atatggatta caatgcacac acaaaattaa atcccacgta cggctacaac 5760
gccataaaat ctgaactgga agactttgtg aacagacctc aattccttcg atggttcact 5820
gaatggagtg acgaattttg tacagaacgt agtataaaga tcaaggagtt ggaaacaaaa 5880
tgtaacgatt gtactgttag tgagagtggt actagtgatg ctacgggtaa taaaacatgt 5940
gatgataaag ataaatgtga cgagtgcaaa agagcatgta caacatataa aacttggctt 6000
aaaaattgga aaactcaata taaaacacaa agcaaaaaat attttgatga taaaagaaaa 6060
gaactatata aaagtatcga tgacgtcgcc agttctacac aagcctatca atatttacat 6120
gcacaattaa aaaaactttg tggtaatgct gattgcaagt gtatggatgg tgagtccaaa 6180
gaaacaaccg gacagcctga taactcccac gattcccata tgcctgcatc attagatgat 6240
gaacccgaag aagtgaatgg aaagtgtaat tgtaaagtga aacatcgtcc acaacctccg 6300
ctagcacttc caccaccagc accatcggga cctccagctg aagaccaaat tgagcatgac 6360
aatagaggac gatcggaacg tggtgaccaa ggcccactac cagcgcgacc tcctcctccc 6420
ccacaagctg cacaaccacc acaaccaaaa ccaaaacgca ctggagaagg cctcggtcgt 6480
aatctaccac cagctgacag aaataccaat ctctccgatt ccgaagaaga agacgacgaa 6540
gatgacgacg aagtccagga ggaggaggaa acgccaccgt cggaggcgga ggaaggtgaa 6600
ggacacgtcg agacagagga ggagacgaag ccggtgaagg aaaagacgga aggggcgggg 6660
gccacagaag tcacaaaaca ggggtcggca ccaacggcaa caacaccaac agtagaagat 6720
atttgcgcca cagtggccaa agcacttaag ggcgacaaaa gtctcaatgc cgcatgtgcc 6780
ctcaaatatg gcaaaaacaa ctcacgttta ggttggaaat gtataccaac tagtggtgac 6840
aaaacagaca caagtgagaa tggtgcccca cgtcgtgctc gtagtgccca tggtggtaaa 6900
agtgatagtg aaaaaggttc catatgtgtg ccgccgcgaa gacgacgatt atatataaaa 6960
aagatagtag attgggcgga atcacagtcg aagacagtaa caagtgttaa tggagatggt 7020
aatgggtcac aggaagtagt tagtgttaat ggagctagtg agagtggtgg tagtggtagt 7080
ggtactgagt cacaggcgag tgatgtgtca caaggtaacg gcgcgtcgac atcgccacaa 7140
gtggctctcc tccacgcctt tgtgaagtcc gctgcaatag agacgttttt tgcttggcat 7200
aaatataaag tggataaaga aatagaggaa aaggaaaaac aggcagcaca aaatcatcta 7260
gttcaacgta aaacaagcga gaacccccaa aagaaattag aaggtggtga aatacctgaa 7320
gattttaagc gtcaaatgtt ctatacttta ggagattata gggatatttt agtgggggac 7380
aagactatga ttgaggcgtt agaaaagagt ggtgacacga aaatagaaga tatatcggaa 7440
aaaataccaa aaattttaga tggtgagaac aacaaagctg ctggtggtgg ccccaaacaa 7500
ccaaatagtg gtaaaacacc acaagaatgg tggaaagaaa acgcaaaaca catttggcat 7560
ggaatgatat gtgctttaac atacaacaca gacagtaatg gaaaggacaa aaaaatacaa 7620
caggttaaag ctacggacaa cacagatctt ttccaaaaac tgaaaaaaga caacgactac 7680
gaaactgtgt catttggtgc tagtggtacc ggcgccaaaa gcaacgacga taccaaatta 7740
aaaaattttg tggtacgccc cacatatttt cgttggttag aggaatgggg agaagagttt 7800
tgtcgaaaac aaaaacataa gttatatata attaaaaaag attgtcgtga taataagttt 7860
tgtagtggtg atggcttgcg ttgtgacgaa aaagttccag ataagaaaga tatttttaag 7920
catttcgatt gtcccagttg tgccagacat tgtagatctt atagaaaatg gatagaaaga 7980
aaaaaaacag aatatgagaa acaagaaagc gcatatagta aacaaaaaag taattacgta 8040
aatggaagta atggtgatgg aggtaataat aatgataaag aattttacac aaaactagaa 8100
acgtgcacta aagcaacaaa ctttttagaa tcattaaaag gacaatgtat tggtaataat 8160
aatggaggca ctgacataaa atttagtaat acaaatataa catttggatc tgcagaagat 8220
tgtaaacctt gttctgaatt taaagtaaat tgtgaaaatg gtagttgtgg gagtgctaag 8280
caaaaggatt gcccaaataa tacgattact tcacaaaata ttaaaggtct tactgaccaa 8340
gtagatatgc gtgttagtga taacactgaa agtggatttg aaggtgattt aggcatttgt 8400
cagggtgcag gtatatttaa aggtattaga aaagatgaat ggaaatgtgg tgatttctgt 8460
ggtatagata tatgtactct ggaaaaaacc aataatggga aagaaagcga taaaaaatat 8520

```
atcataatga aagaattcgt taaaagatgg ctagaatatt tttttgaaga ttataataga 8580
attcaaaaaa aattaaagac atgtaaagaa aatggtaaag gatccacatg tataagaagt 8640
tgtgtagatg aatggataaa gctgaaaaag gatgaatggc aaaaaattaa cagtaattac 8700
cttgaccaaa atacaaaaga aaatcctgaa ggtaataatt taagctcttt tttggaggat 8760
ggaccgttta agaatgaggt tgataaagct ataaaacctt gtggtaattt aactgatttc 8820
aagaagtcaa agaaatgtaa tggcacttcc agatcaggaa atagtgaaga gagcacaaaa 8880
tatgatggtg ttatatgttt gcttgataat cttaaaaaca taataaaaac ttgtcaaaac 8940
gtacctagtg gcaaaccaga tacaccgtgt caaaaatccc ccgcccccgt tggagacgat 9000
gatgatcccc ttgaagagga aaacccagta acacaaccga acatttgtcc gcaaacatca 9060
gtggaagaaa aaaaaaaaga ggaagaagaa aagtgtgatg aaaaggagga agaagaagaa 9120
aaagaggagg aaaaagataa aggagatgag gaagtaaaag aagaagaaaa agataaagga 9180
gatgaggaag aagaagcaga agaagaagaa gaagaagaag aggaaacaga tagtcacatt 9240
tatgaagact actctgattc agacgcagag gaagatgatg aagatgaagc tgttacagaa 9300
tccttatcac cttcagagtc acaaccaaaa cgattgctac gagaatttcc atcccccgaa 9360
ttaaaaaatg ccatgttatt ttctaccatc ctctggatgg taggtatcgg ttttgcggcg 9420
ttcacttatt ttttttctaaa gaaaaaaccg aaatcacctg ttgacctctt acgtgtactt 9480
gacatccata aaggcgatta tggaacacct accccgaaat caaaaaatag atatatcccc 9540
tatgtgagtg atacatataa agggaaaaca tacttatatg ttgaaggaga tacagacgaa 9600
gagaaatata tgtttctgtc tgatactact gatataacct cttccgaaag tgagtatgaa 9660
gaattggata ttaatgatat atatgtacca ggtagtccta aatataaaac attgatagaa 9720
gtagtattgg aaccatcaaa aagtgatggt aacacaccag gtaagggtga tggtaacaca 9780
ctaggtgatg atatggtacc taccacgaat acatttacag atgaggaatg gaatgaactg 9840
aaacaggatt ttgtatcaca atatatacaa agtagattac caatggatgt accacaatat 9900
gatgtatcaa cggagagtcc aatgaatata ggaggtaatg ttttagatga tggtatggat 9960
gaaaaacctt ttattacttc tattcatgat agggatttaa atagtggaga agaaattagt 10020
tataatattc atatgagtac taacactaat aatgatattc caaaatatgt atcaaataat 10080
gtatattctg gtatagattt aattaatgat acattaagtg ataacaaaca tattgatata 10140
tatgatgaag tgctaaaaag aaaagaaaat gaattatttg gaacaaatta taagaaaaat 10200
acatcaaaca atagtgtagc aaaaaatact aatagtgatc caattatgaa ccaattagat 10260
ttgttacata aatggttaga tagacataga gatatatgtg aaaattgggg gaaaaaagaa 10320
gatattttga ataaattgaa tgaacaatgg aataaagata atgatggtgg tgatatacca 10380
aatgataaca aaaagttgaa tacggatgtt tcgatacaaa tagatatgga tgaaactaaa 10440
ggaaagaagg aatttagtaa tatggatact atcttggatg atatggaaga tgatatatat 10500
tatgatgtaa atgatgaaaa cccatctgta gatgatatac ctatggatca taataaagta 10560
gatgtaccaa agaaagtaca tgttgaaatg aaaatcctta ataatacatc taatggatcg 10620
ttggaacaac aatttcctat atcggatgta tggaatatat aa                    10662
```

<210> 2
<211> 3553
<212> PRT
<213> Plasmodium falciparum

<400> 2

```
Met Gly Asn Ala Ser Ser Ser Glu Gly Glu Ala Lys Thr Pro Ser Leu
 1               5                  10                  15
Thr Glu Ser His Asn Ser Ala Arg Asn Ile Leu Glu Gly Tyr Ala Glu
            20                  25                  30
Ser Ile Lys Glu Gln Ala Ser Lys Asp Ala Lys Ile His Gly His His
        35                  40                  45
Leu Lys Gly Asp Leu Ala Lys Ala Val Phe Arg His Pro Phe Ser Ala
    50                  55                  60
Tyr Arg Pro Asn Tyr Gly Asn Pro Cys Glu Leu Asp Tyr Arg Phe His
65                  70                  75                  80
Thr Asn Val Trp His Arg Asn Ala Glu Asp Arg Asn Pro Cys Leu Phe
                85                  90                  95
Ser Arg Ala Lys Arg Phe Ser Asn Glu Gly Glu Ala Glu Cys Asn Gly
            100                 105                 110
```

Gly Ile Ile Thr Gly Asn Lys Gly Glu Cys Gly Ala Cys Ala Pro Tyr
115 120 125
Arg Arg Arg His Ile Cys Asp Tyr Asn Leu His His Ile Asn Glu Asn
130 135 140
Asn Ile Arg Asn Thr His Asp Leu Leu Gly Asn Leu Leu Val Met Ala
145 150 155 160
Arg Ser Glu Gly Glu Ser Ile Val Lys Ser His Glu Tyr Thr Gly Tyr
165 170 175
Gly Ile Tyr Lys Ser Gly Ile Cys Thr Ser Leu Ala Arg Ser Phe Ala
180 185 190
Asp Ile Gly Asp Ile Ile Arg Gly Lys Asp Leu Tyr Arg Arg Asp Ser
195 200 205
Arg Thr Asp Lys Leu Glu Glu Asn Leu Arg Lys Ile Phe Ala Asn Ile
210 215 220
Tyr Lys Glu Leu Lys Asn Gly Lys Lys Trp Ala Glu Ala Lys Glu Tyr
225 230 235 240
Tyr Gln Asp Asp Gly Thr Gly Asn Tyr Tyr Lys Leu Arg Glu Ala Trp
245 250 255
Trp Ala Leu Asn Arg Lys Asp Val Trp Lys Ala Leu Thr Cys Ser Ala
260 265 270
Pro Arg Asp Ala Gln Tyr Phe Ile Lys Ser Ser Val Arg Asp Gln Thr
275 280 285
Phe Ser Asn Asp Tyr Cys Gly His Gly Glu His Glu Val Leu Thr Asn
290 295 300
Leu Asp Tyr Val Pro Gln Phe Leu Arg Trp Phe Glu Glu Trp Ala Glu
305 310 315 320
Glu Phe Cys Arg Ile Lys Lys Ile Lys Leu Gly Lys Val Lys Glu Ala
325 330 335
Cys Arg Asp Asp Ser Lys Lys Leu Tyr Cys Ser His Asn Gly Tyr Asp
340 345 350
Cys Thr Lys Thr Ile Arg Asn Lys Asp Ile Leu Ser Asp Asn Pro Lys
355 360 365
Cys Thr Gly Cys Ser Val Lys Cys Lys Val Tyr Glu Leu Trp Leu Arg
370 375 380
Asn Gln Arg Asn Glu Phe Glu Lys Gln Lys Lys Lys Tyr Tyr Lys Glu
385 390 395 400
Ile Gln Thr Tyr Thr Ser Lys Asp Ala Lys Thr Asp Ser Asn Ile Asn
405 410 415
Asn Glu Tyr Tyr Lys Glu Phe Tyr Asp Lys Leu Lys Asn Glu Gly Tyr
420 425 430
Glu Thr Leu Asn Lys Phe Ile Lys Leu Leu Asn Glu Gly Arg Tyr Cys
435 440 445
Lys Glu Lys Ile Ser Gly Glu Arg Asn Ile Asp Phe Thr Met Thr Gly
450 455 460
Asp Lys Asp Ala Phe Tyr Arg Ser Asp Tyr Cys Gln Ile Cys Pro Glu
465 470 475 480
Cys Gly Val Gln Cys Ser Gly Thr Thr Cys Thr Pro Lys Lys Val Ile
485 490 495
His Pro Asn Cys Lys Asp Lys Glu Thr Tyr Glu Pro Gly Asp Ala Lys
500 505 510
Thr Thr Asp Ile Thr Val Leu Tyr Ser Gly Asp Glu Glu Gly Asp Ile
515 520 525
Ala Gln Lys Leu Gln Asp Phe Cys Asn Asp Lys Asn Lys Glu Asn Asp
530 535 540
Glu Asn Tyr Glu Lys Trp Gln Cys Tyr Tyr Lys Ser Ser Glu Ile Asn
545 550 555 560
Lys Cys Gln Met Thr Pro Ser Ser His Lys Val Pro Lys His Gly Tyr
565 570 575
Ile Met Ser Phe Tyr Ala Phe Phe Asp Leu Trp Val Lys Asn Leu Leu

580 585 590
Ile Asp Ser Ile Asn Trp Lys Asn Asp Leu Thr Asn Cys Ile Asn Asn
595 600 605
Thr Asn Val Thr Asp Cys Lys Asn Asp Cys Asn Thr Asn Cys Lys Cys
610 615 620
Phe Glu Asn Trp Ala Lys Thr Lys Glu Asn Glu Trp Lys Lys Val Lys
625 630 635 640
Thr Ile Tyr Lys Asn Glu Asn Gly Asn Thr Asn Asn Tyr Tyr Lys Lys
645 650 655
Leu Asn Asn His Phe Gln Gly Tyr Phe Phe His Val Met Lys Glu Leu
660 665 670
Asn Lys Glu Glu Lys Trp Tyr Lys Leu Met Glu Asp Leu Lys Glu Lys
675 680 685
Ile Asp Ser Ser Asn Leu Lys Asn Gly Thr Lys Asp Ser Glu Gly Ala
690 695 700
Ile Lys Val Leu Phe Asp His Leu Lys Asp Ile Ala Glu Arg Cys Ile
705 710 715 720
Asp Asn Asn Ser Lys Asp Ser Cys Pro Pro Ser Val Asp Thr Lys Thr
725 730 735
Asn Pro Cys Ala Lys Pro Pro Gly Ser Lys Pro Thr Lys Ser Val Lys
740 745 750
Gln Leu Ala Glu His Met Gln Gln Lys Ala Gln Lys Leu Leu Gly Thr
755 760 765
Arg Gly Gly Glu Ser Lys Leu Lys Gly Asp Ala Thr Arg Gly Thr Tyr
770 775 780
Asn Leu Gly Gly Gln Gly Asn Thr Leu Asn Gly Asp Ile Cys Lys Ile
785 790 795 800
Thr Lys Asn His Thr Asn Asp Ser Arg Pro Asn Gly Glu Pro Cys Thr
805 810 815
Gly Lys Asp Lys Val Lys Asn Gly Phe Arg Leu Lys Ile Gly Thr Pro
820 825 830
Trp Thr Asn Ile Val Gln Lys Lys Lys Lys Lys Ser Tyr Lys Asp Phe
835 840 845
Tyr Leu Pro Pro Arg Arg Gln His Met Cys Thr Ser Asn Leu Glu Asn
850 855 860
Leu Ser Thr Ser Ser Lys Gly Leu Ser Asn Gly Ser Phe Ala Ser His
865 870 875 880
Ser Leu Leu Gly Asp Val Leu Leu Ala Ala Lys Phe Glu Ala Gln Lys
885 890 895
Ile Ile Leu Val Tyr Lys Asn Lys Asn Asn Ile Asn Ile Arg Lys Arg
900 905 910
Ile Thr Asp Pro Asn Asp Gln Ala Thr Val Cys Arg Ala Ile Arg Tyr
915 920 925
Ser Phe Ala Asp Leu Gly Asp Ile Ile Arg Gly Lys Asp Met Trp Asn
930 935 940
Ile Asn Ser Asp Ala Lys Asp Leu Gln Asp Arg Leu Glu Lys Ile Phe
945 950 955 960
Lys Thr Ile Asn Glu Lys Leu Pro Asn Glu Ile Gln Lys Arg Tyr Thr
965 970 975
Asn Arg Glu Asn Lys His Leu Asp Leu Arg Ser Asp Trp Trp Glu Ala
980 985 990
Asn Arg His Gln Val Trp Arg Ala Met Lys Cys Ala Thr Lys Gly Ile
995 1000 1005
Ser Asn Asn Asn Cys Asn Gly Ile Pro Ile Glu Asp Tyr Ile Pro Gln
1010 1015 1020
Arg Leu Arg Trp Met Thr Glu Trp Ala Glu Trp Tyr Cys Lys Lys Gln
1025 1030 1035 1040
Ser Gln Glu Tyr Glu Lys Leu Glu Glu Lys Cys Gly Met Cys Thr Gly
1045 1050 1055

Lys Gly Gln Gly Asp Gly Lys Asp Cys Thr Gln Lys Asp Lys Glu Cys
1060 1065 1070
Ser Pro Cys Lys Lys Ala Cys Asp Ala Tyr Lys Lys Glu Ile Glu Lys
1075 1080 1085
Trp Glu Lys Gln Trp Lys Thr Val Ser Ala Ile Tyr Gln Ile Leu Tyr
1090 1095 1100
Ala Lys Ala Arg Ile Val Ala Ser Asn Gly Gly Pro Gly Tyr Tyr Asn
1105 1110 1115 1120
Thr Glu Val Gln Lys Lys Asp Arg Ser Val Tyr Asp Phe Leu Tyr Glu
1125 1130 1135
Leu His Leu Gln Asn Gly Gly Lys Lys Gly Pro Pro Pro Ala Thr His
1140 1145 1150
Pro Tyr Lys Ser Val Asn Thr Arg Asp Lys Arg Asp Ala Thr Asp Asp
1155 1160 1165
Thr Thr Pro Thr Val Tyr Ser Thr Ala Ala Gly Tyr Val His Gln Glu
1170 1175 1180
Ala His Ile Gly Asp Cys Lys Glu Gln His Val Phe Cys Asp Asn Asn
1185 1190 1195 1200
Gly Asn Lys Glu Lys Tyr Ala Phe Lys Asn Pro Pro Asn Val Tyr Val
1205 1210 1215
Glu Ala Cys Lys Cys Met Thr Arg Glu Ala Pro Pro Pro Pro Thr Thr
1220 1225 1230
Pro Ser Thr Pro Asn Pro Cys Ala Glu Thr Gly Gly Val His Thr Ile
1235 1240 1245
Lys Thr Val Thr Asp Val Ala Lys Ile Leu Gln Gly Glu Ala Asn Glu
1250 1255 1260
Thr Met Leu Lys Asn Ser Ser Asn Gly Asn Asp Lys Asp Glu Ser Lys
1265 1270 1275 1280
Leu Lys Gly Lys Ala Glu Glu Gly Asp Tyr Ser Arg Gly Gly Thr Pro
1285 1290 1295
Ser Asp Phe Asn Asn Asn Leu Cys Gly Ile Thr Gln Lys His Ser Asn
1300 1305 1310
Ala His Asn Asp Ser Gln Gln Pro Cys Tyr Gly Lys Asp Gln Lys Arg
1315 1320 1325
Phe Asn Val Gly Thr Glu Trp Ser Phe Lys Asp Asn His Arg Lys Arg
1330 1335 1340
Thr His Pro Glu Ala Tyr Met Pro Pro Arg Arg Glu His Ile Cys Thr
1345 1350 1355 1360
Ser Asn Leu Glu Tyr Leu Ile His Lys Arg Lys Lys Pro Ile Ile Glu
1365 1370 1375
Gly Asp Pro Asn Lys Ile Ile His Ser Leu Leu Gly Asp Val Leu Leu
1380 1385 1390
Ala Ala Lys Tyr Glu Ala Glu Asn Ile Lys Lys Leu Tyr Glu Glu Asn
1395 1400 1405
Asn Asn Arg Lys Asp Gln Glu Gly Ile Cys Arg Ala Met Lys Tyr Ser
1410 1415 1420
Phe Ala Asp Ile Gly Asp Ile Ile Arg Gly Lys Asp Met Trp Ile Glu
1425 1430 1435 1440
Asn Asn Asp Ala Lys Arg Leu Gln Thr Asn Leu Lys Glu Ile Phe Thr
1445 1450 1455
Lys Ile Lys Glu Lys Thr Gly Gly Thr Thr Tyr Asn Glu Asp Asn Asp
1460 1465 1470
Pro Tyr Leu Lys Leu Arg Ala Asp Trp Trp Glu Ala Asn Arg Ala Lys
1475 1480 1485
Val Trp Lys Ala Met Lys Cys Lys Thr Asn Gly Val Asp Ile Thr Cys
1490 1495 1500
Asp Ser Asp His Thr Pro Leu Asp Asp Tyr Ile Pro Gln Arg Leu Arg
1505 1510 1515 1520
Trp Met Thr Glu Trp Ala Glu Trp Tyr Cys Lys Ala Gln Ser Gln Glu

1525 1530 1535
Tyr Lys Lys Leu Glu Glu Lys Cys Ser Gln Cys Lys Ser Lys Gly Lys
1540 1545 1550
Gly Gly Asn Glu Cys Tyr Arg Glu Thr Lys Glu Cys Asn Asp Cys Lys
1555 1560 1565
Gln Ala Cys Glu Glu Tyr Lys Arg Lys Ile Lys Thr Trp Ala Asp Gln
1570 1575 1580
Trp Lys Val Ile Ser Asn Lys Tyr Glu Asp Leu Tyr Lys Lys Ala Gln
1585 1590 1595 1600
Asn Pro Thr Asn Ala Val Leu Lys Asp Asn Lys Asp Glu Lys Asp Lys
1605 1610 1615
Asn Val Ile Asp Phe Leu Thr Gln Leu Gln Lys Ala Asn Asn Gly Glu
1620 1625 1630
Lys Thr Gly Val His Thr Val Tyr Ser Thr Ala Ala Gly Tyr Ile His
1635 1640 1645
Gln Glu Ala Arg Thr Arg Glu Cys Gln Glu Gln Arg Glu Phe Cys Asp
1650 1655 1660
Lys Lys Asn Gly Ile Asp Asn Thr Ser Tyr Ala Phe Lys Asp Pro Pro
1665 1670 1675 1680
His Gly Tyr Ala Thr Ala Cys Asp Cys Ile Asn Arg Ser Gln Thr Glu
1685 1690 1695
Glu Pro Lys Lys Lys Glu Glu Asn Val Glu Ser Ala Cys Lys Ile Val
1700 1705 1710
Glu Glu Val Leu Ser Lys Pro Arg Asp Lys Thr Thr Gly Gly Ile Asp
1715 1720 1725
His Cys Asn Pro Lys Tyr Tyr Pro Arg Lys Glu Asn Tyr Pro Gly Trp
1730 1735 1740
Asn Cys Thr Pro Gly Gln Phe Lys Ser Gly His Ala Gly Ala Cys Met
1745 1750 1755 1760
Pro Pro Arg Arg Ile Lys Leu Cys Val Ile Asn Leu Gln Tyr Leu Asn
1765 1770 1775
Glu Lys Lys Ser Pro Glu Glu Leu Arg Lys Ala Phe Ile Gln Cys Ala
1780 1785 1790
Ala Ile Glu Thr Tyr Trp Leu Trp Gln Lys Tyr Lys Lys Asp Lys Asn
1795 1800 1805
Gly Gly Val Ala Gln Ala Lys Leu Asn Ser Gly Thr Ile Pro Asp Asp
1810 1815 1820
Phe Lys Arg Gln Met Phe Tyr Thr Phe Gly Asp Tyr Arg Asp Leu Cys
1825 1830 1835 1840
Leu Asp Thr Asp Ile Ser Ser Lys Ala Asp Thr Ser Thr Gly Val Gly
1845 1850 1855
Lys Val Lys Ile Asn Ile Asp Ser Val Phe Gln Lys Ile Asp Ile Thr
1860 1865 1870
Asn Val Glu Gln Arg Lys Pro Trp Trp Gly Lys Asn Ala Glu Ala Ile
1875 1880 1885
Trp Asp Gly Met Leu Cys Ala Leu Ser Tyr Asn Thr Thr Asn Lys Asn
1890 1895 1900
Met Asp Tyr Asn Ala His Thr Lys Leu Asn Pro Thr Tyr Gly Tyr Asn
1905 1910 1915 1920
Ala Ile Lys Ser Glu Leu Glu Asp Phe Val Asn Arg Pro Gln Phe Leu
1925 1930 1935
Arg Trp Phe Thr Glu Trp Ser Asp Glu Phe Cys Thr Glu Arg Ser Ile
1940 1945 1950
Lys Ile Lys Glu Leu Glu Thr Lys Cys Asn Asp Cys Thr Val Ser Glu
1955 1960 1965
Ser Gly Thr Ser Asp Ala Thr Gly Asn Lys Thr Cys Asp Asp Lys Asp
1970 1975 1980
Lys Cys Asp Glu Cys Lys Arg Ala Cys Thr Thr Tyr Lys Thr Trp Leu
1985 1990 1995 2000

Lys Asn Trp Lys Thr Gln Tyr Lys Thr Gln Ser Lys Lys Tyr Phe Asp
2005 2010 2015
Asp Lys Arg Lys Glu Leu Tyr Lys Ser Ile Asp Asp Val Ala Ser Ser
2020 2025 2030
Thr Gln Ala Tyr Gln Tyr Leu His Ala Gln Leu Lys Lys Leu Cys Gly
2035 2040 2045
Asn Ala Asp Cys Lys Cys Met Asp Gly Glu Ser Lys Glu Thr Thr Gly
2050 2055 2060
Gln Pro Asp Asn Ser His Asp Ser His Met Pro Ala Ser Leu Asp Asp
2065 2070 2075 2080
Glu Pro Glu Glu Val Asn Gly Lys Cys Asn Cys Lys Val Lys His Arg
2085 2090 2095
Pro Gln Pro Pro Leu Ala Leu Pro Pro Pro Ala Pro Ser Gly Pro Pro
2100 2105 2110
Ala Glu Asp Gln Ile Glu His Asp Asn Arg Gly Arg Ser Glu Arg Gly
2115 2120 2125
Asp Gln Gly Pro Leu Pro Ala Arg Pro Pro Pro Pro Pro Gln Ala Ala
2130 2135 2140
Gln Pro Pro Gln Pro Lys Pro Lys Arg Thr Gly Glu Gly Leu Gly Arg
2145 2150 2155 2160
Asn Leu Pro Pro Ala Asp Arg Asn Thr Asn Leu Ser Asp Ser Glu Glu
2165 2170 2175
Glu Asp Asp Glu Asp Asp Asp Glu Val Gln Glu Glu Glu Glu Thr Pro
2180 2185 2190
Pro Ser Glu Ala Glu Glu Gly Glu Gly His Val Glu Thr Glu Glu Glu
2195 2200 2205
Thr Lys Pro Val Lys Glu Lys Thr Glu Gly Ala Gly Ala Thr Glu Val
2210 2215 2220
Thr Lys Gln Gly Ser Ala Pro Thr Ala Thr Thr Pro Thr Val Glu Asp
2225 2230 2235 2240
Ile Cys Ala Thr Val Ala Lys Ala Leu Lys Gly Asp Lys Ser Leu Asn
2245 2250 2255
Ala Ala Cys Ala Leu Lys Tyr Gly Lys Asn Asn Ser Arg Leu Gly Trp
2260 2265 2270
Lys Cys Ile Pro Thr Ser Gly Asp Lys Thr Asp Thr Ser Glu Asn Gly
2275 2280 2285
Ala Pro Arg Arg Ala Arg Ser Ala His Gly Gly Lys Ser Asp Ser Glu
2290 2295 2300
Lys Gly Ser Ile Cys Val Pro Pro Arg Arg Arg Arg Leu Tyr Ile Lys
2305 2310 2315 2320
Lys Ile Val Asp Trp Ala Glu Ser Gln Ser Lys Thr Val Thr Ser Val
2325 2330 2335
Asn Gly Asp Gly Asn Gly Ser Gln Glu Val Val Ser Val Asn Gly Ala
2340 2345 2350
Ser Glu Ser Gly Gly Ser Gly Ser Gly Thr Glu Ser Gln Ala Ser Asp
2355 2360 2365
Val Ser Gln Gly Asn Gly Ala Ser Thr Ser Pro Gln Val Ala Leu Leu
2370 2375 2380
His Ala Phe Val Lys Ser Ala Ala Ile Glu Thr Phe Phe Ala Trp His
2385 2390 2395 2400
Lys Tyr Lys Val Asp Lys Glu Ile Glu Glu Lys Glu Lys Gln Ala Ala
2405 2410 2415
Gln Asn His Leu Val Gln Arg Lys Thr Ser Glu Asn Pro Gln Lys Lys
2420 2425 2430
Leu Glu Gly Gly Glu Ile Pro Glu Asp Phe Lys Arg Gln Met Phe Tyr
2435 2440 2445
Thr Leu Gly Asp Tyr Arg Asp Ile Leu Val Gly Asp Lys Thr Met Ile
2450 2455 2460
Glu Ala Leu Glu Lys Ser Gly Asp Thr Lys Ile Glu Asp Ile Ser Glu

2465 2470 2475 2480
Lys Ile Pro Lys Ile Leu Asp Gly Glu Asn Asn Lys Ala Ala Gly Gly
2485 2490 2495
Gly Pro Lys Gln Pro Asn Ser Gly Lys Thr Pro Gln Glu Trp Trp Lys
2500 2505 2510
Glu Asn Ala Lys His Ile Trp His Gly Met Ile Cys Ala Leu Thr Tyr
2515 2520 2525
Asn Thr Asp Ser Asn Gly Lys Asp Lys Lys Ile Gln Gln Val Lys Ala
2530 2535 2540
Thr Asp Asn Thr Asp Leu Phe Gln Lys Leu Lys Lys Asp Asn Asp Tyr
2545 2550 2555 2560
Glu Thr Val Ser Phe Gly Ala Ser Gly Thr Gly Ala Lys Ser Asn Asp
2565 2570 2575
Asp Thr Lys Leu Lys Asn Phe Val Val Arg Pro Thr Tyr Phe Arg Trp
2580 2585 2590
Leu Glu Glu Trp Gly Glu Glu Phe Cys Arg Lys Gln Lys His Lys Leu
2595 2600 2605
Tyr Ile Ile Lys Lys Asp Cys Arg Asp Asn Lys Phe Cys Ser Gly Asp
2610 2615 2620
Gly Leu Arg Cys Asp Glu Lys Val Pro Asp Lys Lys Asp Ile Phe Lys
2625 2630 2635 2640
His Phe Asp Cys Pro Ser Cys Ala Arg His Cys Arg Ser Tyr Arg Lys
2645 2650 2655
Trp Ile Glu Arg Lys Lys Thr Glu Tyr Glu Lys Gln Glu Ser Ala Tyr
2660 2665 2670
Ser Lys Gln Lys Ser Asn Tyr Val Asn Gly Ser Asn Gly Asp Gly Gly
2675 2680 2685
Asn Asn Asn Asp Lys Glu Phe Tyr Thr Lys Leu Glu Thr Cys Thr Lys
2690 2695 2700
Ala Thr Asn Phe Leu Glu Ser Leu Lys Gly Gln Cys Ile Gly Asn Asn
2705 2710 2715 2720
Asn Gly Gly Thr Asp Ile Lys Phe Ser Asn Thr Asn Ile Thr Phe Gly
2725 2730 2735
Ser Ala Glu Asp Cys Lys Pro Cys Ser Glu Phe Lys Val Asn Cys Glu
2740 2745 2750
Asn Gly Ser Cys Gly Ser Ala Lys Gln Lys Asp Cys Pro Asn Asn Thr
2755 2760 2765
Ile Thr Ser Gln Asn Ile Lys Gly Leu Thr Asp Gln Val Asp Met Arg
2770 2775 2780
Val Ser Asp Asn Thr Glu Ser Gly Phe Glu Gly Asp Leu Gly Ile Cys
2785 2790 2795 2800
Gln Gly Ala Gly Ile Phe Lys Gly Ile Arg Lys Asp Glu Trp Lys Cys
2805 2810 2815
Gly Asp Phe Cys Gly Ile Asp Ile Cys Thr Leu Glu Lys Thr Asn Asn
2820 2825 2830
Gly Lys Glu Ser Asp Lys Lys Tyr Ile Ile Met Lys Glu Phe Val Lys
2835 2840 2845
Arg Trp Leu Glu Tyr Phe Phe Glu Asp Tyr Asn Arg Ile Gln Lys Lys
2850 2855 2860
Leu Lys Thr Cys Lys Glu Asn Gly Lys Gly Ser Thr Cys Ile Arg Ser
2865 2870 2875 2880
Cys Val Asp Glu Trp Ile Lys Leu Lys Lys Asp Glu Trp Gln Lys Ile
2885 2890 2895
Asn Ser Asn Tyr Leu Asp Gln Asn Thr Lys Glu Asn Pro Glu Gly Asn
2900 2905 2910
Asn Leu Ser Ser Phe Leu Glu Asp Gly Pro Phe Lys Asn Glu Val Asp
2915 2920 2925
Lys Ala Ile Lys Pro Cys Gly Asn Leu Thr Asp Phe Lys Lys Ser Lys
2930 2935 2940

Lys Cys Asn Gly Thr Ser Arg Ser Gly Asn Ser Glu Glu Ser Thr Lys
2945 2950 2955 2960
Tyr Asp Gly Val Ile Cys Leu Leu Asp Asn Leu Lys Asn Ile Ile Lys
2965 2970 2975
Thr Cys Gln Asn Val Pro Ser Gly Lys Pro Asp Thr Pro Cys Gln Lys
2980 2985 2990
Ser Pro Ala Pro Val Gly Asp Asp Asp Asp Pro Leu Glu Glu Glu Asn
2995 3000 3005
Pro Val Thr Gln Pro Asn Ile Cys Pro Gln Thr Ser Val Glu Glu Lys
3010 3015 3020
Lys Lys Glu Glu Glu Glu Lys Cys Asp Glu Lys Glu Glu Glu Glu Glu
3025 3030 3035 3040
Lys Glu Glu Glu Lys Asp Lys Gly Asp Glu Glu Val Lys Glu Glu Glu
3045 3050 3055
Lys Asp Lys Gly Asp Glu Glu Glu Glu Ala Glu Glu Glu Glu Glu Glu
3060 3065 3070
Glu Glu Glu Thr Asp Ser His Ile Tyr Glu Asp Tyr Ser Asp Ser Asp
3075 3080 3085
Ala Glu Glu Asp Asp Glu Asp Glu Ala Val Thr Glu Ser Leu Ser Pro
3090 3095 3100
Ser Glu Ser Gln Pro Lys Arg Leu Leu Arg Glu Phe Pro Ser Pro Glu
3105 3110 3115 3120
Leu Lys Asn Ala Met Leu Phe Ser Thr Ile Leu Trp Met Val Gly Ile
3125 3130 3135
Gly Phe Ala Ala Phe Thr Tyr Phe Phe Leu Lys Lys Lys Pro Lys Ser
3140 3145 3150
Pro Val Asp Leu Leu Arg Val Leu Asp Ile His Lys Gly Asp Tyr Gly
3155 3160 3165
Thr Pro Thr Pro Lys Ser Lys Asn Arg Tyr Ile Pro Tyr Val Ser Asp
3170 3175 3180
Thr Tyr Lys Gly Lys Thr Tyr Leu Tyr Val Glu Gly Asp Thr Asp Glu
3185 3190 3195 3200
Glu Lys Tyr Met Phe Leu Ser Asp Thr Thr Asp Ile Thr Ser Ser Glu
3205 3210 3215
Ser Glu Tyr Glu Glu Leu Asp Ile Asn Asp Ile Tyr Val Pro Gly Ser
3220 3225 3230
Pro Lys Tyr Lys Thr Leu Ile Glu Val Val Leu Glu Pro Ser Lys Ser
3235 3240 3245
Asp Gly Asn Thr Pro Gly Lys Gly Asp Gly Asn Thr Leu Gly Asp Asp
3250 3255 3260
Met Val Pro Thr Thr Asn Thr Phe Thr Asp Glu Glu Trp Asn Glu Leu
3265 3270 3275 3280
Lys Gln Asp Phe Val Ser Gln Tyr Ile Gln Ser Arg Leu Pro Met Asp
3285 3290 3295
Val Pro Gln Tyr Asp Val Ser Thr Glu Ser Pro Met Asn Ile Gly Gly
3300 3305 3310
Asn Val Leu Asp Asp Gly Met Asp Glu Lys Pro Phe Ile Thr Ser Ile
3315 3320 3325
His Asp Arg Asp Leu Asn Ser Gly Glu Glu Ile Ser Tyr Asn Ile His
3330 3335 3340
Met Ser Thr Asn Thr Asn Asn Asp Ile Pro Lys Tyr Val Ser Asn Asn
3345 3350 3355 3360
Val Tyr Ser Gly Ile Asp Leu Ile Asn Asp Thr Leu Ser Asp Asn Lys
3365 3370 3375
His Ile Asp Ile Tyr Asp Glu Val Leu Lys Arg Lys Glu Asn Glu Leu
3380 3385 3390
Phe Gly Thr Asn Tyr Lys Lys Asn Thr Ser Asn Asn Ser Val Ala Lys
3395 3400 3405
Asn Thr Asn Ser Asp Pro Ile Met Asn Gln Leu Asp Leu Leu His Lys

3410 3415 3420
Trp Leu Asp Arg His Arg Asp Ile Cys Glu Asn Trp Gly Lys Lys Glu
3425 3430 3435 3440
Asp Ile Leu Asn Lys Leu Asn Glu Gln Trp Asn Lys Asp Asn Asp Gly
3445 3450 3455
Gly Asp Ile Pro Asn Asp Asn Lys Lys Leu Asn Thr Asp Val Ser Ile
3460 3465 3470
Gln Ile Asp Met Asp Glu Thr Lys Gly Lys Lys Glu Phe Ser Asn Met
3475 3480 3485
Asp Thr Ile Leu Asp Asp Met Glu Asp Asp Ile Tyr Tyr Asp Val Asn
3490 3495 3500
Asp Glu Asn Pro Ser Val Asp Asp Ile Pro Met Asp His Asn Lys Val
3505 3510 3515 3520
Asp Val Pro Lys Lys Val His Val Glu Met Lys Ile Leu Asn Asn Thr
3525 3530 3535
Ser Asn Gly Ser Leu Glu Gln Gln Phe Pro Ile Ser Asp Val Trp Asn
3540 3545 3550
Ile

<210> 3
<211> 8985
<212> DNA
<213> Plasmodium falciparum

<220>
<221> gene
<222> (0)...(0)
<223> PF11_0008

<400> 3
atggggtcac aaacatcaaa attttctaaa actgttgttg gaaatgaaac acacaacagt 60
gcccgaaatg ttttggaagg ttttgcaaaa gatataaaaa gggatgtatc aaataacgca 120
aaaagacatg gaaaagtttt gaagggaaat ttgagagatg ccaaatttta tcatgattat 180
tctaagttaa gagacatacc tagaagtccc tgtgatcttg atttttggtt tcatacgaat 240
gtttggaggg acaaagcata tgaaagagat ccttgttatg gcagacaagc aaaaaataat 300
tacaatttgg aaggagcagt atgtacgaat agtaaaataa aaggtaatga aaacaagata 360
aatgacattg gagcgtgtgc cccatataga agacgaaata tatgcgatta taatttagaa 420
catctaaatg aaagaaatgt tttaaatact catgatttat tgggaaatgt gttagttatg 480
gcaaaacgtg aaggtgaatc tattgttgag aaacatccaa atagaggatc ttcagaagta 540
tgtattgccc ttgcaagaag ttttgcagat ataggagata ttttaagagg aaaagacatg 600
tatgtcgggt atgatgaaaa agaaaaaaat cgaagaaaac aattagaaaa taagttgaaa 660
gatattttcg ataatatata taaggatttg acgaagaaga aggggaggaa tgggaagaag 720
tcggcgctac aagaacgcta caatgatcct aaaggagatt tttttcaatt acgagaagat 780
tggtgggcgc ttaatagaga agacgtatgg aaagcattaa catgttctgc ggatgacagt 840
gaagattatt tcatacaatc agaaggtgtt acaaaatcat ttacaaatcc taaatgtggc 900
catggtgaca atgaggttct tacaaatctt gattatgtcc ctcaattttt acgttggttc 960
accgaatggg cagaagagtt ttgtaggata agaaaaatta aattaggaaa ggttaaaaac 1020
gaatgtcgtg gtgagacatc aggtaaaagg tattgtagtg gcgatggtta tgattgtact 1080
aaaacagata tatcacgtaa tatttttat atggatttag attgcccacg ttgtgaagaa 1140
gaatgtagaa aatatgatga atggattgaa aataaagaaa atgaattaga taaacaaaaa 1200
aataaataca ctaaagaaat tgaaaaatta aaagataatt ctaagagcaa ttatgataaa 1260
aatttttatt taacacttac taaaaaatat ggttcaatta acttatttt agatacatta 1320
aaagaaggat cacattgtag ctacaatacc atagaagata aaatagattt taacaaagca 1380
aatcaaacat ttactagttc gaaattttgt ggggcatgtc ctttttatgg agttaaatgc 1440
aattggaaaa catgtacaga ggttaaggaa aatgagtaca aaaaaaaaaa taaggttgat 1500
agtacacata cgacagaaca acctactgct attgatgtac tagttactca tattagagga 1560
acaaatattc ccgaagattt aaaggattgt aaaaaatatg gtctttttaa aggtatgcga 1620

aaacaagcgt ggaaatgtca atatataaat ccatatgatg aatgcaagtt gagtcctttt 1680
gtgaaagata tagatgttga tgatcgtatt ttatttaaag tattgtttga gcgttggtta 1740
aaatatttca tacaagattt taataatgtt aaggacaaaa ttaatagatg tacaaaattc 1800
gaaaagggaa aagataatac atgtattaaa ggttgtaaac ataaatgcga atgtgtggaa 1860
aaatggataa aaataaagga agcagaatgg aaaaaaataa atcaacatta taaccaacaa 1920
aaaaaacatt atacctatag tgttcctcgt tgggttaata gttatttgac gcaccagcac 1980
ttctctagtg attttattaa tgcattagaa gcttttaaaa atatacgggg attagaaaat 2040
ttgaaggaat gtagtagtga cacttgtaaa attgaaaaaa ttagaactat agatgatgat 2100
ttaataaaag aattaatttc taaacttaaa gataaatgtg ctatgtgtaa aaaccaacat 2160
aaagcaacca aaggtaaaga atgttgtggt aaattaccta aaactctaaa tgatcaagat 2220
gatgaagaag acgaagaata cgaagcacca ccaccaccaa cacctcctcg cacccaaaaa 2280
aacccctgcg ttaatggtca aaaccagaag gttcgtaaaa tcaggagcgt gagacgagtg 2340
ccgaaaagga tgcaaaaaca agcaagtgtt cgtgttcctc gtgctcggca gggaggggag 2400
agggagcagg ttgtaaagaa cgggcgccag gaccaccacc tccagcgggt gcttttggtg 2460
ggggaggcgg aggcggagga gccggagacg gcggaggaaa agaaggagga ggaaaaggag 2520
gaagacacgg acgggaaggt acagccacca ccagcagcaa caacacccgg ggtgaagccg 2580
ccatgtgaca tagttgaaaa acactttaaa gataagcacg ataatactgg tgcaatagat 2640
cattgtaatc caaaaaagga ttatcctcca tggaaaaacg acaaaagttt agtggatgaa 2700
gatggtgtgt atatgcctcc tagaagacaa aaattatgtg taattaattt agaacatttt 2760
aaagagaata catcagatga tttgagagaa gcattcatta aatgcgctgc cgcagaaact 2820
tatttgttat ggcaaaaata taaagaggat aacaatggtg gtgaagatct acaaaaccaa 2880
ttaaaaagtg gaaaaattcc tgaagatttt aaacgtcaaa tgttctacac atttggagat 2940
tatagagatt tcttatttgg aacagatata tcaaaattaa ataaacatac agaagctgtt 3000
aaaactaata tagatagaat tttcccacca actgagcgaa caaatgatac aatacgtaaa 3060
gaatttgggg aaaaaaacgc agaatctatt tggcaaggaa tgttatgtgc tttaagttat 3120
aatagtaatg acaaaaaaat ggatccagat gtacaaaaag aactaaactc cacctacaac 3180
tacgatacca taaaaaataa tctagaagac tttgcgaaca gacctcaatt cttacgatgg 3240
tttattgaat ggagtgatga attttgtcgt gaacggaaga agaaggaaga aaaggtagga 3300
tcagcttgta agaatgatta tgagggatgt gcaaacacta aggataatgg taatggtaat 3360
tgtgttaacg catgtaatgc atataaaaaa tacattacag acaaaaaaga acaatatgaa 3420
aaacaagcaa agaaatttga tattgataaa agtcagaata aaccaggata tgaagattat 3480
tctggcaaaa aggcttctga atatttgaaa gaaaaatgta taaactcatc atgtgattat 3540
atgctaaaat taaaagataa ttccaattac tgggaaaaac ctcatacaac atacgacgat 3600
aattcacttc aaaacaaatg tagctgcccc ctttctccct gcgaaatcgt ggataaaaca 3660
ctgggcgaca aaacctcaaa gtcttacgcc gaagggtgca aatggaaata tgggaagatg 3720
ccactaggtt tgggatggtt atgtaatgac aaagagggtg agaagggtaa ggaggacggt 3780
ttatgtatac cgccaaggag aaagagatta tatgtaaaag atttagagac attcagcgat 3840
cacacaacag taggtctccg agaagctttt attaaatgtg ctgctgtaga aacttttttt 3900
gcttggcatg aatttacaaa ggaaaaagaa agagagtata aagaagaaaa acaaagaaat 3960
ggagaacttg gatttatcga cgaaaacgat caaataccaa aggacccaga taatccacag 4020
aacaaaataa gaaaaaatgg agaaatacat gaagagttta aaagtcaaat gttctatacc 4080
cttgcagatt atagagatat attatttggg aataatatag gtattggtaa cgacatgggg 4140
aaagttaaaa gtaatataga taaggttttc gcaaatagta gtggcaaaac acctactgcc 4200
aaaaaaacaa caccaaaaga atggtgggaa aaaaatgcaa aagatatatg ggaaggaatg 4260
ttatgtgctt taagttatga tacgaaaaca aaaattaaga atgaagaact gcgcaagaaa 4320
cttatagatc caaagaacag caactacatg tacgaaaaag ttacatttag tagtgataat 4380
aacacaaatt tgtcaaaatt tacagaaaga cccccgtttt ttcgatggtt tcaggaatgg 4440
ggagaagagt tttgtcgaaa aaaaaaaata aaaattgata aaattgaaaa agaatgtcgt 4500
ggaccatatg gtcgaaatca ttgtgatggc gatggattcg actgtagtga aataggccca 4560
aatgagaatg gaagttttgc gatttttaaa tgtccaagtt gtgcaatttc ttgtcgatct 4620
tataaaacgt ggataaacac aaaaaaagac gaatttaaaa aacaagaaaa actatataat 4680
aaagaaatta aggataataa aagtaattat gataatatat atgataaaga atttgttaaa 4740
aacctttgta cagattataa gtctgttgac tcatttttaa aaaagttaaa agaaggccca 4800
tgttgtaaca aaaatactaa agacagtaaa atagatttta aggatacaga ggagacattt 4860
agaaacgctg aatattgcga tccatgtcct gtatttggag ttatttgtaa taacggtgat 4920
tgcagtaatt ctacagaaaa gaagtgtgat gcacaagaat ttaaggttac atatgatgta 4980
aaaaataagg aaaaccctaa taaagaagta aatatgcttg tcagtgataa aacagcaaag 5040
aaatacccag gtgatttaaa cggtgtttgc gaaaattcaa gtatctttga aggtattaga 5100
gaagataaat ggtcatgtgg ttatttctgt ggtttagata tatgtacacc caacaaaact 5160

acaggtgata tacatgataa acaaaatgca ccaattagag tactgtttaa acgatggata 5220
gaaaattttt taaaagatca taacaaaatt aaagacaaaa tttctttatg tataaataat 5280
gaaaacagaa atatatgtac agatgtttgc agaaaaaatt gtgaatgtat agataaatgg 5340
atagagatga aaatgaaaga atggaaaata gtacgcgatc gttacgtcaa acaatataat 5400
gttgctgatt cagtagttta cgaagtgaga agatttttag agggcttgca acctcaaaat 5460
gaccttgaaa aagttaaagg agatgttaat gatttacgtg atttagagga actaagtgaa 5520
tgtactaata ctgtatcaac agaaaataga aaatgtagaa aaaaggatgt agtagaaagt 5580
ttgcttaata aacttaaaaa tgaaatacgt cattgtaaaa atgaacgtga cgatagtatg 5640
ggcaaggaaa gttgcaaaac attacccgaa cctacagacg atccacaaac agatagtgat 5700
acccacgaca cacctgacat accaccaggt gacgttgcac ccacttttg taatgttcca 5760
gcaaatccat gtggcgacaa aagcgccacc aatgtggtaa atgtgacaga ggtggcgaag 5820
gaaatgcacg aagaggcaca caaggatatg ttagagagga gtgttaaaaa ggttgagagt 5880
aaggttaagg atagtacggt tgagagtgtg ttaagggctg atgcatcaaa aggtgaatat 5940
aaacatgaag gtaatccaga tgacttgaaa cacaacatgt gcaatataac gaaggaacat 6000
accaattatc aaaaacgtgg tggttataat tatcgaggac catgtacggg taaaggtaat 6060
ggtaaagaca caagatttgt cataggaacc atatggaaag atgaagacga aaaagatgaa 6120
accattaaag ttctgttgcc tccgcgacgt cgtcatatgt gtacatcaaa tttagaatat 6180
ttacttcatg ttaataaggg cccacttcta aaagttgaac ctgataaaat taatcattcc 6240
ttttggggg atgttttgct tgcagcaaaa tatgaagcag aattcataaa aaccaattat 6300
acgagattaa atggccaaaa tgacaatgga gctaaatgta gagctatgaa atatagtttt 6360
gctgatatag gtgatattat acgaggaaaa gatctgtggg gaattcagga cttcaaggat 6420
ctacaaacta agttagtaac aatatttggt aaaattaaag aggaaattcc cgatattaaa 6480
aaaaaatata gtagtgaaaa tcccccatat acgacattac gtgaacattg gtgggaagca 6540
aatcgagcca aagtatggga agcaatgcaa tgtccaacaa taccaccagt caccacaagt 6600
tgtgatacta ccactgttac ccctcttgtg gattacatcc cacaaagatt acgttggatg 6660
accgaatggg ccgaatggtt ctgcaaaatg cagtcacagg agtatgaggt gttagtgaaa 6720
cagtgtagga attgtaggag tggaatatgt gagaatggta aggatgactg tgtcaagtgc 6780
acacaagctt gtaatacata taaacaaaaa ataaaaaaat gggaagatca atggaaggaa 6840
atatcaaaaa aatacaaaac attataccaa caagcaaaag gcagtgttaa tggtgctact 6900
actagtagta ctacagatga gaaagacaaa gatgtcgttg atttcttgaa aatgttacac 6960
caaaaaaata ctgataatac catatatact actgctgcag gatttataca tcaagaagca 7020
catatgactg attgtcaaaa acaaacaatt ttttgtaaaa acactagtta taacgacaag 7080
aagaaatatg cttttcgtca tccaccacat gatcatgatg atgcgtgtgc ttgcaggcca 7140
ccatcaacgc cagtagacgt ctcccgcaaa ctagacaccc aacgtgaccc caaaaaagag 7200
gaatctgaac ctgaatccga agaagaagaa gacgatgccg aagaggagga ggagccggca 7260
aaggagacgg ctaccacaga gacaacacaa ccagcagcac cagcgggacc accggtaaca 7320
ccagtaccag aactaccggg accacccgca ccagcgggac cagcagctga tggccccatt 7380
gaggatgacg aagacgccga aaacgaagac gatgatgacg tcggctccgc caccggcaca 7440
gaagacgatg acgacgacga agatgacgac gacgaagacg aagaggactc agcagacgaa 7500
ggtgaaggtg aaggcgacgg cggtgacgtc ggcgaggagg aagatgaaga tcacggcggc 7560
caggaggcgg agggggtggt accacaacca gcagcaccac aaccaccaac cccacaactc 7620
ttggatgacc ccctccttaa aaccgccctc atgtcttcta ccatcctctg gatggtaggt 7680
atcggttttg cggcgttgac ttacttttta ctcaagaaaa aatccaaatc ttctgttgac 7740
ttgttgcgtg tactgaatat cccgaaagga gattatgaaa tgcctacgtt gaaatccaaa 7800
aataggtaca taccatatag aagtggttca tataaaggca aaacatatat atatatggaa 7860
ggagatagtg atagtggaca ctactacgaa gatacaactg atattacttc atccgaaagt 7920
gaatatgaag aattggatat taatgagata tatccgtatc agtcaccaaa atacaaaaca 7980
ttgattgaag tggtactaga accatccaaa agtaatggta acacaccaag taagggtgat 8040
ggtaacacac taggtgatga tatggtacct accacgaata catttacaga tgaggaatgg 8100
agtgaattga aacatgattt tatatcacaa tatatacaaa gtgaaccact ggatgtacca 8160
aaagttggtg tatcaaagga attaccaatg aatataggag gtaatgtttt agatgatggt 8220
ataaacgaaa aacctttttat tacttctatt catgataggg atttatatac tggggaagaa 8280
attaaatata atattaatat gggtactaat agtatggacg atccaacata tgtatcaaat 8340
aatgtatatt ctggtatcga tttaattaat gacacattaa gtggtaatca acatattgat 8400
atatatgatg aagtgctaaa aagaaaagaa aatgaattat ttggaacaaa ttataagaaa 8460
aatacatcaa ataacaatgt agctaaatta acaaatagtg atcctattat gaaccaatta 8520
gatttgttac atacatggtt agatagacat agagatatgt gtgagaagtg gaataaaaag 8580
gaagaattgt tagataaatt aaatgaacaa tggaataaag ataatgatgg tggtgatata 8640
ccaaatgata acaaaaagtt gaatacggat gtttctatac aaatagatat agatgaaaat 8700

aaaggaaaga aagaatttag taatatggat acaaacgtgg atacacctac tatggatagt 8760
atattggatg atttggaaac atataatgaa ccttttttatg atatatttga ggatgatgtg 8820
tattatgatg tatatgatga aaacccattt gtggatgata tacctatgga tcataataaa 8880
gtagatgtac ctaagaaagt acatattgaa atgaaaatcc ttaataatac atccaatgga 8940
tcgttggaac aacaatttcc tatatcggat gtatggaata tataa 8985

<210> 4
<211> 2994
<212> PRT
<213> Plasmodium falciparum

<400> 4

Met Gly Ser Gln Thr Ser Lys Phe Ser Lys Thr Val Val Gly Asn Glu
1 5 10 15
Thr His Asn Ser Ala Arg Asn Val Leu Glu Gly Phe Ala Lys Asp Ile
20 25 30
Lys Arg Asp Val Ser Asn Asn Ala Lys Arg His Gly Lys Val Leu Lys
35 40 45
Gly Asn Leu Arg Asp Ala Lys Phe Tyr His Asp Tyr Ser Lys Leu Arg
50 55 60
Asp Ile Pro Arg Ser Pro Cys Asp Leu Asp Phe Trp Phe His Thr Asn
65 70 75 80
Val Trp Arg Asp Lys Ala Tyr Glu Arg Asp Pro Cys Tyr Gly Arg Gln
85 90 95
Ala Lys Asn Asn Tyr Asn Leu Glu Gly Ala Val Cys Thr Asn Ser Lys
100 105 110
Ile Lys Gly Asn Glu Asn Lys Ile Asn Asp Ile Gly Ala Cys Ala Pro
115 120 125
Tyr Arg Arg Arg Asn Ile Cys Asp Tyr Asn Leu Glu His Leu Asn Glu
130 135 140
Arg Asn Val Leu Asn Thr His Asp Leu Leu Gly Asn Val Leu Val Met
145 150 155 160
Ala Lys Arg Glu Gly Glu Ser Ile Val Glu Lys His Pro Asn Arg Gly
165 170 175
Ser Ser Glu Val Cys Ile Ala Leu Ala Arg Ser Phe Ala Asp Ile Gly
180 185 190
Asp Ile Leu Arg Gly Lys Asp Met Tyr Val Gly Tyr Asp Glu Lys Glu
195 200 205
Lys Asn Arg Arg Lys Gln Leu Glu Asn Lys Leu Lys Asp Ile Phe Asp
210 215 220
Asn Ile Tyr Lys Asp Leu Thr Lys Lys Lys Gly Arg Asn Gly Lys Lys
225 230 235 240
Ser Ala Leu Gln Glu Arg Tyr Asn Asp Pro Lys Gly Asp Phe Phe Gln
245 250 255
Leu Arg Glu Asp Trp Trp Ala Leu Asn Arg Glu Asp Val Trp Lys Ala
260 265 270
Leu Thr Cys Ser Ala Asp Asp Ser Glu Asp Tyr Phe Ile Gln Ser Glu
275 280 285
Gly Val Thr Lys Ser Phe Thr Asn Pro Lys Cys Gly His Gly Asp Asn
290 295 300
Glu Val Leu Thr Asn Leu Asp Tyr Val Pro Gln Phe Leu Arg Trp Phe
305 310 315 320
Thr Glu Trp Ala Glu Glu Phe Cys Arg Ile Arg Lys Ile Lys Leu Gly
325 330 335
Lys Val Lys Asn Glu Cys Arg Gly Glu Thr Ser Gly Lys Arg Tyr Cys
340 345 350
Ser Gly Asp Gly Tyr Asp Cys Thr Lys Thr Asp Ile Ser Arg Asn Ile

355 360 365
Phe Tyr Met Asp Leu Asp Cys Pro Arg Cys Glu Glu Glu Cys Arg Lys
370 375 380
Tyr Asp Glu Trp Ile Glu Asn Lys Glu Asn Glu Leu Asp Lys Gln Lys
385 390 395 400
Asn Lys Tyr Thr Lys Glu Ile Glu Lys Leu Lys Asp Asn Ser Lys Ser
405 410 415
Asn Tyr Asp Lys Asn Phe Tyr Leu Thr Leu Thr Lys Lys Tyr Gly Ser
420 425 430
Ile Asn Leu Phe Leu Asp Thr Leu Lys Glu Gly Ser His Cys Ser Tyr
435 440 445
Asn Thr Ile Glu Asp Lys Ile Asp Phe Asn Lys Ala Asn Gln Thr Phe
450 455 460
Thr Ser Ser Lys Phe Cys Gly Ala Cys Pro Phe Tyr Gly Val Lys Cys
465 470 475 480
Asn Trp Lys Thr Cys Thr Glu Val Lys Glu Asn Glu Tyr Lys Lys Lys
485 490 495
Asn Lys Val Asp Ser Thr His Thr Thr Glu Gln Pro Thr Ala Ile Asp
500 505 510
Val Leu Val Thr His Ile Arg Gly Thr Asn Ile Pro Glu Asp Leu Lys
515 520 525
Asp Cys Lys Lys Tyr Gly Leu Phe Lys Gly Met Arg Lys Gln Ala Trp
530 535 540
Lys Cys Gln Tyr Ile Asn Pro Tyr Asp Glu Cys Lys Leu Ser Pro Phe
545 550 555 560
Val Lys Asp Ile Asp Val Asp Asp Arg Ile Leu Phe Lys Val Leu Phe
565 570 575
Glu Arg Trp Leu Lys Tyr Phe Ile Gln Asp Phe Asn Asn Val Lys Asp
580 585 590
Lys Ile Asn Arg Cys Thr Lys Phe Glu Lys Gly Lys Asp Asn Thr Cys
595 600 605
Ile Lys Gly Cys Lys His Lys Cys Glu Cys Val Glu Lys Trp Ile Lys
610 615 620
Ile Lys Glu Ala Glu Trp Lys Lys Ile Asn Gln His Tyr Asn Gln Gln
625 630 635 640
Lys Lys His Tyr Thr Tyr Ser Val Pro Arg Trp Val Asn Ser Tyr Leu
645 650 655
Thr His Gln His Phe Ser Ser Asp Phe Ile Asn Ala Leu Glu Ala Phe
660 665 670
Lys Asn Ile Arg Gly Leu Glu Asn Leu Lys Glu Cys Ser Ser Asp Thr
675 680 685
Cys Lys Ile Glu Lys Ile Arg Thr Ile Asp Asp Asp Leu Ile Lys Glu
690 695 700
Leu Ile Ser Lys Leu Lys Asp Lys Cys Ala Met Cys Lys Asn Gln His
705 710 715 720
Lys Ala Thr Lys Gly Lys Glu Cys Cys Gly Lys Leu Pro Lys Thr Leu
725 730 735
Asn Asp Gln Asp Asp Glu Glu Asp Glu Glu Tyr Glu Ala Pro Pro Pro
740 745 750
Pro Thr Pro Pro Arg Thr Gln Lys Asn Pro Cys Val Asn Gly Gln Asn
755 760 765
Gln Lys Val Arg Lys Ile Arg Ser Val Arg Arg Val Pro Lys Arg Met
770 775 780
Gln Lys Gln Ala Ser Val Arg Val Pro Arg Ala Arg Gln Gly Gly Glu
785 790 795 800
Arg Glu Gln Val Val Lys Asn Gly Arg Gln Asp His His Leu Gln Arg
805 810 815
Val Leu Leu Val Gly Glu Ala Glu Ala Glu Glu Pro Glu Thr Ala Glu
820 825 830

Glu Lys Lys Glu Glu Glu Lys Glu Glu Asp Thr Asp Gly Lys Val Gln
835 840 845
Pro Pro Pro Ala Ala Thr Thr Pro Gly Val Lys Pro Pro Cys Asp Ile
850 855 860
Val Glu Lys His Phe Lys Asp Lys His Asp Asn Thr Gly Ala Ile Asp
865 870 875 880
His Cys Asn Pro Lys Lys Asp Tyr Pro Pro Trp Lys Asn Asp Lys Ser
885 890 895
Leu Val Asp Glu Asp Gly Val Tyr Met Pro Pro Arg Arg Gln Lys Leu
900 905 910
Cys Val Ile Asn Leu Glu His Phe Lys Glu Asn Thr Ser Asp Asp Leu
915 920 925
Arg Glu Ala Phe Ile Lys Cys Ala Ala Ala Glu Thr Tyr Leu Leu Trp
930 935 940
Gln Lys Tyr Lys Glu Asp Asn Asn Gly Gly Glu Asp Leu Gln Asn Gln
945 950 955 960
Leu Lys Ser Gly Lys Ile Pro Glu Asp Phe Lys Arg Gln Met Phe Tyr
965 970 975
Thr Phe Gly Asp Tyr Arg Asp Phe Leu Phe Gly Thr Asp Ile Ser Lys
980 985 990
Leu Asn Lys His Thr Glu Ala Val Lys Thr Asn Ile Asp Arg Ile Phe
995 1000 1005
Pro Pro Thr Glu Arg Thr Asn Asp Thr Ile Arg Lys Glu Phe Trp Glu
1010 1015 1020
Lys Asn Ala Glu Ser Ile Trp Gln Gly Met Leu Cys Ala Leu Ser Tyr
1025 1030 1035 1040
Asn Ser Asn Asp Lys Lys Met Asp Pro Asp Val Gln Lys Glu Leu Asn
1045 1050 1055
Ser Thr Tyr Asn Tyr Asp Thr Ile Lys Asn Asn Leu Glu Asp Phe Ala
1060 1065 1070
Asn Arg Pro Gln Phe Leu Arg Trp Phe Ile Glu Trp Ser Asp Glu Phe
1075 1080 1085
Cys Arg Glu Arg Lys Lys Lys Glu Glu Lys Val Gly Ser Ala Cys Lys
1090 1095 1100
Asn Asp Tyr Glu Gly Cys Ala Asn Thr Lys Asp Asn Gly Asn Gly Asn
1105 1110 1115 1120
Cys Val Asn Ala Cys Asn Ala Tyr Lys Lys Tyr Ile Thr Asp Lys Lys
1125 1130 1135
Glu Gln Tyr Glu Lys Gln Ala Lys Lys Phe Asp Ile Asp Lys Ser Gln
1140 1145 1150
Asn Lys Pro Gly Tyr Glu Asp Tyr Ser Gly Lys Lys Ala Ser Glu Tyr
1155 1160 1165
Leu Lys Glu Lys Cys Ile Asn Ser Ser Cys Asp Tyr Met Leu Lys Leu
1170 1175 1180
Lys Asp Asn Ser Asn Tyr Trp Glu Lys Pro His Thr Thr Tyr Asp Asp
1185 1190 1195 1200
Asn Ser Leu Gln Asn Lys Cys Ser Cys Pro Leu Ser Pro Cys Glu Ile
1205 1210 1215
Val Asp Lys Thr Leu Gly Asp Lys Thr Ser Lys Ser Tyr Ala Glu Gly
1220 1225 1230
Cys Lys Trp Lys Tyr Gly Lys Met Pro Leu Gly Leu Gly Trp Leu Cys
1235 1240 1245
Asn Asp Lys Glu Gly Glu Lys Gly Lys Glu Asp Gly Leu Cys Ile Pro
1250 1255 1260
Pro Arg Arg Lys Arg Leu Tyr Val Lys Asp Leu Glu Thr Phe Ser Asp
1265 1270 1275 1280
His Thr Thr Val Gly Leu Arg Glu Ala Phe Ile Lys Cys Ala Ala Val
1285 1290 1295
Glu Thr Phe Phe Ala Trp His Glu Phe Thr Lys Glu Lys Glu Arg Glu

1300 1305 1310
Tyr Lys Glu Glu Lys Gln Arg Asn Gly Glu Leu Gly Phe Ile Asp Glu
1315 1320 1325
Asn Asp Gln Ile Pro Lys Asp Pro Asp Asn Pro Gln Asn Lys Ile Arg
1330 1335 1340
Lys Asn Gly Glu Ile His Glu Glu Phe Lys Ser Gln Met Phe Tyr Thr
1345 1350 1355 1360
Leu Ala Asp Tyr Arg Asp Ile Leu Phe Gly Asn Asn Ile Gly Ile Gly
1365 1370 1375
Asn Asp Met Gly Lys Val Lys Ser Asn Ile Asp Lys Val Phe Ala Asn
1380 1385 1390
Ser Ser Gly Lys Thr Pro Thr Ala Lys Lys Thr Thr Pro Lys Glu Trp
1395 1400 1405
Trp Glu Lys Asn Ala Lys Asp Ile Trp Glu Gly Met Leu Cys Ala Leu
1410 1415 1420
Ser Tyr Asp Thr Lys Thr Lys Ile Lys Asn Glu Glu Leu Arg Lys Lys
1425 1430 1435 1440
Leu Ile Asp Pro Lys Asn Ser Asn Tyr Met Tyr Glu Lys Val Thr Phe
1445 1450 1455
Ser Ser Asp Asn Asn Thr Asn Leu Ser Lys Phe Thr Glu Arg Pro Pro
1460 1465 1470
Phe Phe Arg Trp Phe Gln Glu Trp Gly Glu Glu Phe Cys Arg Lys Lys
1475 1480 1485
Lys Ile Lys Ile Asp Lys Ile Glu Lys Glu Cys Arg Gly Pro Tyr Gly
1490 1495 1500
Arg Asn His Cys Asp Gly Asp Gly Phe Asp Cys Ser Glu Ile Gly Pro
1505 1510 1515 1520
Asn Glu Asn Gly Ser Phe Ala Ile Phe Lys Cys Pro Ser Cys Ala Ile
1525 1530 1535
Ser Cys Arg Ser Tyr Lys Thr Trp Ile Asn Thr Lys Lys Asp Glu Phe
1540 1545 1550
Lys Lys Gln Glu Lys Leu Tyr Asn Lys Glu Ile Lys Asp Asn Lys Ser
1555 1560 1565
Asn Tyr Asp Asn Ile Tyr Asp Lys Glu Phe Val Lys Asn Leu Cys Thr
1570 1575 1580
Asp Tyr Lys Ser Val Asp Ser Phe Leu Lys Lys Leu Lys Glu Gly Pro
1585 1590 1595 1600
Cys Cys Asn Lys Asn Thr Lys Asp Ser Lys Ile Asp Phe Lys Asp Thr
1605 1610 1615
Glu Glu Thr Phe Arg Asn Ala Glu Tyr Cys Asp Pro Cys Pro Val Phe
1620 1625 1630
Gly Val Ile Cys Asn Asn Gly Asp Cys Ser Asn Ser Thr Glu Lys Lys
1635 1640 1645
Cys Asp Ala Gln Glu Phe Lys Val Thr Tyr Asp Val Lys Asn Lys Glu
1650 1655 1660
Asn Pro Asn Lys Glu Val Asn Met Leu Val Ser Asp Lys Thr Ala Lys
1665 1670 1675 1680
Lys Tyr Pro Gly Asp Leu Asn Gly Val Cys Glu Asn Ser Ser Ile Phe
1685 1690 1695
Glu Gly Ile Arg Glu Asp Lys Trp Ser Cys Gly Tyr Phe Cys Gly Leu
1700 1705 1710
Asp Ile Cys Thr Pro Asn Lys Thr Thr Gly Asp Ile His Asp Lys Gln
1715 1720 1725
Asn Ala Pro Ile Arg Val Leu Phe Lys Arg Trp Ile Glu Asn Phe Leu
1730 1735 1740
Lys Asp His Asn Lys Ile Lys Asp Lys Ile Ser Leu Cys Ile Asn Asn
1745 1750 1755 1760
Glu Asn Arg Asn Ile Cys Thr Asp Val Cys Arg Lys Asn Cys Glu Cys
1765 1770 1775

Ile Asp Lys Trp Ile Glu Met Lys Met Lys Glu Trp Lys Ile Val Arg
1780 1785 1790
Asp Arg Tyr Val Lys Gln Tyr Asn Val Ala Asp Ser Val Val Tyr Glu
1795 1800 1805
Val Arg Arg Phe Leu Glu Gly Leu Gln Pro Gln Asn Asp Leu Glu Lys
1810 1815 1820
Val Lys Gly Asp Val Asn Asp Leu Arg Asp Leu Glu Glu Leu Ser Glu
1825 1830 1835 1840
Cys Thr Asn Thr Val Ser Thr Glu Asn Arg Lys Cys Arg Lys Lys Asp
1845 1850 1855
Val Val Glu Ser Leu Leu Asn Lys Leu Lys Asn Glu Ile Arg His Cys
1860 1865 1870
Lys Asn Glu Arg Asp Asp Ser Met Gly Lys Glu Ser Cys Lys Thr Leu
1875 1880 1885
Pro Glu Pro Thr Asp Asp Pro Gln Thr Asp Ser Asp Thr His Asp Thr
1890 1895 1900
Pro Asp Ile Pro Pro Gly Asp Val Ala Pro Thr Phe Cys Asn Val Pro
1905 1910 1915 1920
Ala Asn Pro Cys Gly Asp Lys Ser Ala Thr Asn Val Val Asn Val Thr
1925 1930 1935
Glu Val Ala Lys Glu Met His Glu Glu Ala His Lys Asp Met Leu Glu
1940 1945 1950
Arg Ser Val Lys Lys Val Glu Ser Lys Val Lys Asp Ser Thr Val Glu
1955 1960 1965
Ser Val Leu Arg Ala Asp Ala Ser Lys Gly Glu Tyr Lys His Glu Gly
1970 1975 1980
Asn Pro Asp Asp Leu Lys His Asn Met Cys Asn Ile Thr Lys Glu His
1985 1990 1995 2000
Thr Asn Tyr Gln Lys Arg Gly Gly Tyr Asn Tyr Arg Gly Pro Cys Thr
2005 2010 2015
Gly Lys Gly Asn Gly Lys Asp Thr Arg Phe Val Ile Gly Thr Ile Trp
2020 2025 2030
Lys Asp Glu Asp Glu Lys Asp Glu Thr Ile Lys Val Leu Leu Pro Pro
2035 2040 2045
Arg Arg Arg His Met Cys Thr Ser Asn Leu Glu Tyr Leu Leu His Val
2050 2055 2060
Asn Lys Gly Pro Leu Leu Lys Val Glu Pro Asp Lys Ile Asn His Ser
2065 2070 2075 2080
Phe Leu Gly Asp Val Leu Leu Ala Ala Lys Tyr Glu Ala Glu Phe Ile
2085 2090 2095
Lys Thr Asn Tyr Thr Arg Leu Asn Gly Gln Asn Asp Asn Gly Ala Lys
2100 2105 2110
Cys Arg Ala Met Lys Tyr Ser Phe Ala Asp Ile Gly Asp Ile Ile Arg
2115 2120 2125
Gly Lys Asp Leu Trp Gly Ile Gln Asp Phe Lys Asp Leu Gln Thr Lys
2130 2135 2140
Leu Val Thr Ile Phe Gly Lys Ile Lys Glu Glu Ile Pro Asp Ile Lys
2145 2150 2155 2160
Lys Lys Tyr Ser Ser Glu Asn Pro Pro Tyr Thr Thr Leu Arg Glu His
2165 2170 2175
Trp Trp Glu Ala Asn Arg Ala Lys Val Trp Glu Ala Met Gln Cys Pro
2180 2185 2190
Thr Ile Pro Pro Val Thr Thr Ser Cys Asp Thr Thr Thr Val Thr Pro
2195 2200 2205
Leu Val Asp Tyr Ile Pro Gln Arg Leu Arg Trp Met Thr Glu Trp Ala
2210 2215 2220
Glu Trp Phe Cys Lys Met Gln Ser Gln Glu Tyr Glu Val Leu Val Lys
2225 2230 2235 2240
Gln Cys Arg Asn Cys Arg Ser Gly Ile Cys Glu Asn Gly Lys Asp Asp

2245 2250 2255
Cys Val Lys Cys Thr Gln Ala Cys Asn Thr Tyr Lys Gln Lys Ile Lys
2260 2265 2270
Lys Trp Glu Asp Gln Trp Lys Glu Ile Ser Lys Lys Tyr Lys Thr Leu
2275 2280 2285
Tyr Gln Gln Ala Lys Gly Ser Val Asn Gly Ala Thr Thr Ser Ser Thr
2290 2295 2300
Thr Asp Glu Lys Asp Lys Asp Val Val Asp Phe Leu Lys Met Leu His
2305 2310 2315 2320
Gln Lys Asn Thr Asp Asn Thr Ile Tyr Thr Thr Ala Ala Gly Phe Ile
2325 2330 2335
His Gln Glu Ala His Met Thr Asp Cys Gln Lys Gln Thr Ile Phe Cys
2340 2345 2350
Lys Asn Thr Ser Tyr Asn Asp Lys Lys Lys Tyr Ala Phe Arg His Pro
2355 2360 2365
Pro His Asp His Asp Asp Ala Cys Ala Cys Arg Pro Pro Ser Thr Pro
2370 2375 2380
Val Asp Val Ser Arg Lys Leu Asp Thr Gln Arg Asp Pro Lys Lys Glu
2385 2390 2395 2400
Glu Ser Glu Pro Glu Ser Glu Glu Glu Glu Asp Asp Ala Glu Glu Glu
2405 2410 2415
Glu Glu Pro Ala Lys Glu Thr Ala Thr Thr Glu Thr Thr Gln Pro Ala
2420 2425 2430
Ala Pro Ala Gly Pro Pro Val Thr Pro Val Pro Glu Leu Pro Gly Pro
2435 2440 2445
Pro Ala Pro Ala Gly Pro Ala Ala Asp Gly Pro Ile Glu Asp Asp Glu
2450 2455 2460
Asp Ala Glu Asn Glu Asp Asp Asp Asp Val Gly Ser Ala Thr Gly Thr
2465 2470 2475 2480
Glu Asp Asp Asp Asp Asp Glu Asp Asp Asp Asp Glu Asp Glu Glu Asp
2485 2490 2495
Ser Ala Asp Glu Gly Glu Gly Glu Gly Asp Gly Gly Asp Val Gly Glu
2500 2505 2510
Glu Glu Asp Glu Asp His Gly Gly Gln Glu Ala Glu Gly Val Val Pro
2515 2520 2525
Gln Pro Ala Ala Pro Gln Pro Pro Thr Pro Gln Leu Leu Asp Asp Pro
2530 2535 2540
Leu Leu Lys Thr Ala Leu Met Ser Ser Thr Ile Leu Trp Met Val Gly
2545 2550 2555 2560
Ile Gly Phe Ala Ala Leu Thr Tyr Phe Leu Leu Lys Lys Lys Ser Lys
2565 2570 2575
Ser Ser Val Asp Leu Leu Arg Val Leu Asn Ile Pro Lys Gly Asp Tyr
2580 2585 2590
Glu Met Pro Thr Leu Lys Ser Lys Asn Arg Tyr Ile Pro Tyr Arg Ser
2595 2600 2605
Gly Ser Tyr Lys Gly Lys Thr Tyr Ile Tyr Met Glu Gly Asp Ser Asp
2610 2615 2620
Ser Gly His Tyr Tyr Glu Asp Thr Thr Asp Ile Thr Ser Ser Glu Ser
2625 2630 2635 2640
Glu Tyr Glu Glu Leu Asp Ile Asn Glu Ile Tyr Pro Tyr Gln Ser Pro
2645 2650 2655
Lys Tyr Lys Thr Leu Ile Glu Val Val Leu Glu Pro Ser Lys Ser Asn
2660 2665 2670
Gly Asn Thr Pro Ser Lys Gly Asp Gly Asn Thr Leu Gly Asp Asp Met
2675 2680 2685
Val Pro Thr Thr Asn Thr Phe Thr Asp Glu Glu Trp Ser Glu Leu Lys
2690 2695 2700
His Asp Phe Ile Ser Gln Tyr Ile Gln Ser Glu Pro Leu Asp Val Pro
2705 2710 2715 2720

Lys Val Gly Val Ser Lys Glu Leu Pro Met Asn Ile Gly Gly Asn Val
2725 2730 2735
Leu Asp Asp Gly Ile Asn Glu Lys Pro Phe Ile Thr Ser Ile His Asp
2740 2745 2750
Arg Asp Leu Tyr Thr Gly Glu Glu Ile Lys Tyr Asn Ile Asn Met Gly
2755 2760 2765
Thr Asn Ser Met Asp Asp Pro Thr Tyr Val Ser Asn Asn Val Tyr Ser
2770 2775 2780
Gly Ile Asp Leu Ile Asn Asp Thr Leu Ser Gly Asn Gln His Ile Asp
2785 2790 2795 2800
Ile Tyr Asp Glu Val Leu Lys Arg Lys Glu Asn Glu Leu Phe Gly Thr
2805 2810 2815
Asn Tyr Lys Lys Asn Thr Ser Asn Asn Asn Val Ala Lys Leu Thr Asn
2820 2825 2830
Ser Asp Pro Ile Met Asn Gln Leu Asp Leu Leu His Thr Trp Leu Asp
2835 2840 2845
Arg His Arg Asp Met Cys Glu Lys Trp Asn Lys Lys Glu Glu Leu Leu
2850 2855 2860
Asp Lys Leu Asn Glu Gln Trp Asn Lys Asp Asn Asp Gly Gly Asp Ile
2865 2870 2875 2880
Pro Asn Asp Asn Lys Lys Leu Asn Thr Asp Val Ser Ile Gln Ile Asp
2885 2890 2895
Ile Asp Glu Asn Lys Gly Lys Lys Glu Phe Ser Asn Met Asp Thr Asn
2900 2905 2910
Val Asp Thr Pro Thr Met Asp Ser Ile Leu Asp Asp Leu Glu Thr Tyr
2915 2920 2925
Asn Glu Pro Phe Tyr Asp Ile Phe Glu Asp Asp Val Tyr Tyr Asp Val
2930 2935 2940
Tyr Asp Glu Asn Pro Phe Val Asp Asp Ile Pro Met Asp His Asn Lys
2945 2950 2955 2960
Val Asp Val Pro Lys Lys Val His Ile Glu Met Lys Ile Leu Asn Asn
2965 2970 2975
Thr Ser Asn Gly Ser Leu Glu Gln Gln Phe Pro Ile Ser Asp Val Trp
2980 2985 2990
Asn Ile

<210> 5
<211> 10041
<212> DNA
<213> Plasmodium falciparum

<220>
<221> gene
<222> (0)...(0)
<223> PF13_0003

<400> 5
atggggaata cacaatcatc agaggaagag gaagctaaaa gccctagttt aacagaaagt 60
cacaacagtg caaggggtgt tttggaagaa attggaaaaa agataaaaga taagacagaa 120
aaagagagta aacatgtaag gcaattgaaa ggaaaattat caaatgcaaa atttgctgat 180
cgattgtata aggaatctgg tggtgattta aggtctgctt attcagatgc ttgttcactt 240
acatacaaat ttcatactaa tataacaact gatgggggg atggaaggca tccttgtcat 300
ggtagggaaa acaatcgttt ttctgaaagt caagaatatg gatgtagtaa tgtatacata 360
aaaggaaatg aaaataacag taatggtaca gcatgtgtac caccaagaag aagacatata 420
tgtgatcaaa atttagaatt tttagataat cctcacactg atgatactga tgatttgttg 480
ggaaatgtgt tagttacagc aaaatacgaa ggtaattata ttgttagtaa tcatccagat 540
aaaaacagca atggaaataa atcaggaata tgtacttctc ttgcacgcag ttttgcagat 600

ataggagata ttgtaagagg aagagatatg tttaaatcta atgaaaaggt agaaatcggt 660
ctaaaaaagg ttttcgagaa aataaataat ggattgaaga aaataggaat taatgattat 720
aatgatatat ctggaaatta ttataaatta agggaagctt ggtggacggc taaccgcgat 780
caagtatgga aagccataac atgtagagcc ccaaacgggg ctaattattt tagaaaaggt 840
ttagatggaa aaataatttt ttcagataat ggaccatgtg gtcgtaagga actaatcgtt 900
cctacctatt tagattatgt ccctcaattt ttaagatggt taaatgaatg gtcggaagag 960
ttttgtcgaa taaaaaatat aaaaatagga aatattaaga aatcctgtac tggagaaagt 1020
aataataaac attgtagtcg tgagggttac gattgtaata aaacaaatct aagacttaat 1080
gaaatttta tggatctaga atgtccacgt tgtgcagatg attgtaaatc gtatgaaaca 1140
tgggtagaaa aaaaaaaaaa agaatttaat aaacaaaaga aaaaatacga aaaagaagtt 1200
gatgctacac aaaataatga taataacgaa aatggaatct ataataaaaa attttatgat 1260
gaactaaaaa gttcatataa agaagttaat agtttttttg aattattgaa taaaggacca 1320
atatgtgaac atattgataa aaaaattcca atggactata ataatactga gaaaacattt 1380
tcccgttcag agtattgtaa atcatgtcct ataacagata ttttatgtga tgataatgaa 1440
tgtaaaacca ttaatgaatt taaatgtaga gaaataaaaa gtatgcctaa tataagaaaa 1500
aacgaaaatg aaacccctat tgatattgat attctggtta atgttaataa caaaaaggtt 1560
attacgcatg atttaaagaa taattacgaa aactgtgatc tttttaaaaa actaggagaa 1620
caaaaatgga aatgtaaata taaatgttac ttagatgtat gtgaaccgag aaatttggat 1680
agtaatatat ataatgaacg atatatctca attaaagtac tatttaaacg gtggttagaa 1740
tatttcttag aagattacaa taaattaaag gaaaaattga acccatgcat gtataatgta 1800
caagaaatcg tatgtataaa tgaatgtaag caaaattgtg aatgcgtaga aaaatggata 1860
aaagaaaaaa gggaagaatg gaaaaaaata aaagatcgtt acgtacaaca atatgaaagt 1920
aaagatgaag atgtttcttc taaacttaaa aaatttttga aacaggaact gtttactaat 1980
tatgttaaaa atgccttgga caaggatgaa acgttagata gtatgaaaga atctactgaa 2040
tgcattgatc ctaataaacc caaaggaaaa ccatgtaaca ataacgatgt cataaatatt 2100
ttacttaata gacttgaaaa acaaatcgat aattgcaaaa agaagcacga agaaaaggga 2160
gaaaaacctt gtgttgatat acctaaactt ctaaatgatg aagatgagga cgaagatgac 2220
gacgaaacac cacgcgccca taatccgtgt gtagataaaa atgattctca acccactaaa 2280
actgtgagtt atatcgctag acaaatgcat cgaagggcaa aagcacaaat gacaaaaaat 2340
agtgttgttg atggtgataa taagttggaa ggcgatatat ttaaggttac atttagaaat 2400
ggcggggtcg gaaaaaacct gaatggagat atttgcaaga ttgacaaaac gtattccaat 2460
gacagtcgtg gtactcctac agatggacct tgtgaaggca aaggcgatcg gtttaaaata 2520
ggaacggact ggcaaggtga tagtttcgta aacccacaat accgtgggat ttatatgcct 2580
cctagacgtc aacatttttg tacatcgaat ttagaaaaat tagatgttag tagagtcata 2640
agaaatggta atgctagcaa ttcattattg ggtgatgtgc tgctcgcagc aaagtatgaa 2700
gcagaacgaa caaagaacca ttatgtatct aaaaaggaag aacattccga agcttgtcgt 2760
gctgtgcgtt acagttttgc cgatttagga gatattatac gaggaaaaga catgtgggat 2820
aaaaatcatg gcgagaagaa aacacaagaa aatttagaaa gaatatttgc taaaattaaa 2880
gagcaacttc ttaatagcag tatcaaagat aaatataagg atgatgacaa agcaacaccc 2940
aaatataaac aattaagaga agattggtgg gaagccaatc gttcacaggt atgggaagca 3000
atgcaatgcc caccaaaaaa cggtactttc ccatgtaaaa gtgatcatac accgctacat 3060
gactacatcc cccaaagatt aagatggatg accgaatggg cagaatggta ctgtaaagaa 3120
cagtcacggc tgtatggaga gttggtggag acgtgtggta agtgtatgca taagggaaaa 3180
tgtaagcaag gtaatggcca ttgtgtaacg tgcaagccag catgtgaaaa atataaaaaa 3240
tttattaata catggcaacc tcaatggaaa caaatggaac aaaaatactc ccagttatac 3300
gaagaagcaa aaaagtataa tgatagtagc agaaaagata ccacaaacaa agacgattat 3360
gtccttcaat tcttgaacaa attactcacg caaaacaaag gaaataaaac atatgatact 3420
gctgaaggat atgtacacca agaagcacat attagtgatt gtcagaaaca aacacaattt 3480
tgtaaaaaaa gaaatggtga gatcccaagt agtgatacag agaccgacaa caattatgcc 3540
tttcgtcctc aaccacacga ccatgatgag gtgtgtgagt gtaatactag acagaagacg 3600
aaggtacgga aaaaaaaaaa aaaagttgat gcatgtgaaa tggcaaaaac acttttgcac 3660
aacaacgatg gaaccataag aataggacaa tgcaaacgta aagatgaagg aaatgcagaa 3720
tatccaaaat gggattgtaa ttctcagatt catacaacac ataatggagc atgtatgcct 3780
cctagaagac aaaaattatg cgtatatttt tttgcaaatc catctcaaat aggaagtata 3840
aataaacaag ataatttaag aaaagcattt attatatctg cagcagcaga aacatttcgt 3900
tcatggcagt attataagag taagaatggt ggtgaaaacc tccaaactca attaaaagat 3960
ggaactattc ctgacgattt taaacgtcaa atgttctata catatggaga ttatagagat 4020
tttttatttg gaaccgatat atcaaaaggt cttggtgaag ggactgccct agaaaagcaa 4080
ataaatattc ttttcccaaa tggtgtccga aaaattccta atgaaaaaac acgtgaaaag 4140

tggtggacag atcacggacc tgagatatgg aaaggtatgt tatgcgccct aacaaatggt 4200
ctcagtgaaa gcgaaaaaaa aacaaaaata ttcgacgact actcacacga caaagtcaac 4260
caatccaaaa atggtaaccc ttcgctcgag gatttcgcaa aaaaacctca atttttcaga 4320
tggtttattg aatggagtga tgaatttttgt cgggaaagga agaagaagga agaggaggtg 4380
gaaagggatt gtaaggatga atatgaggga tgtgaaaagg agaaaaatgg taaatgtgtt 4440
accgcatgta aagcatataa agaatacatt acaaacaaaa aagaagaata tgatagtcaa 4500
aaagggaaat ttgacgttga aaaaacagag aagaaacaag gatatgaaga ttattctgag 4560
aaacaggctt ctgaatattt gaaagaaaaa tgtataaaat catcatgtaa ttgtatgaag 4620
aaagttacag aaatttccaa ttactggacc aaccctcata aaacctacga caccgaaaat 4680
cttggaatca aatgtgaatg ccccccttca ccctgcacca tcgtggatgg catcctcagc 4740
ccacaaaatt cgagttcgta cgccgaaggg tgtaaatgga aatatgggaa gatgtcacaa 4800
gggggtacgg aatgggattg tagtaaaaaa agtgggggtg aaggtggtaa tgaggacggt 4860
gatgttgtat gtatacctcc aaggagaagg agattatatg taaagaattt acaggatttg 4920
actggtgaag aatcactagt ggatttacga aaagctttta ttaagtgtgc tgctatagaa 4980
acatttttg cttggcatga atttaaaaaa gaaaaagaaa gagaggaaaa agaaaaaaat 5040
gaacaagatg tacaatataa atcatctgtc ttagaaaatc ttcaaaagca gttaaaaaat 5100
ggagaaatag atgatgagtt taaaagacaa atgttctata catttgcaga ttatagagat 5160
atatgtttag ggaaggatat aggtaacgac gtggatggaa ttaatgaaaa aatagataca 5220
attttgcaaa aaaatggaaa acctaataat atcgaagaat ataaaaaatg gtggcaaaaa 5280
catggtcatg agatatggga aggaatgtta tgtgctctaa gctacaatac cgaaacaaaa 5340
gagatggata aagaacttcg caacaaatta accgaacaaa agaacggtaa caaaaacacg 5400
tacgacaccg tcacaattag tggtggtccc attggtaata ccaaattgga gaaatttgca 5460
tctaggcccc catttttcg ttggttagaa gaatgggcag atgagttttg tagaaaacga 5520
acacataaat tggaaaaaat tcaaaatgaa tgtaagggag taagtggtac aaatcagtgt 5580
gatgatgatg gttttgactg cgatgaaatg tgtccaaaaa aggatgggag ttttgaaacg 5640
tttaaatgtc tgagttgtgc caaatcttgt agattttata aaaagtggat aagtagaaaa 5700
aaagaggaat ttgataaaca aagcaaaaaa tacgaaaacg aaattgacga tgttaaacat 5760
aattctgata acatatatgg aaaagacttt cttgaaactc ttgatcaaca atataagtct 5820
gttgaattat ttttagaaaa agtaaaagga ccatgttcta ttaataataa taatgaagaa 5880
tgtaaaatag attttaataa accaaaggat acatttggtc atgcaaaaaa ttgtggtcca 5940
tgttctgaaa ttagattcaa gtgtatagag gataatagca attgggttac tacaaataca 6000
tgcaataaaa caacttttaa gtttacagaa gataataaag atacgaaaga agatagtgaa 6060
caattaggta tgcttattag tgataataca gtacaaaatt ttgcagatgg tttacagaat 6120
gattgtaaag atgcagatat ctttaaaggt cttagaaaag accaatggtc atgtggttat 6180
ttttgtaatt tagatatatg tagtctgaaa acttctcatg gggaaaacaa ttataaacaa 6240
aatatattaa ttagggcatt gtttaaacga tggttagaac atttttaga agactataat 6300
aaaattaatg acaaaatttc acattgtatg aaaaatggtg aaggatccac atgtataaaa 6360
ggatgtgaaa taaaatgtaa ttgtgtaagt aattggataa agaagaaaac gttagaatgg 6420
gaaatagtac gagatcgttt ctttaaacaa tataatgttg attcagaaaa atcttttaca 6480
gtgaaaagtt ttttagagca ggctccattt gacagtgatg ttcaaaaagc tataaaacct 6540
tttgaaaaat tacgtgactt cgaggattca attgtatgta atggaactac gagcgcacga 6600
aaggaaaaag gtacagaaaa ggatgtcgta atatgtttgc ttgataaact tcaaaaacaa 6660
atagaaactt gtcaaacgaa acataaagaa acatctggaa atacatgttc cccaccccca 6720
aaccccgaca cacaaacaga cacaccatta ccacttgagt cttttcctcc ccctttttgt 6780
aacgttcctc ctaatccatg tggcgacaaa gatgcgacca acgtggttgg agttgaagtg 6840
ctggcgaagg aaatgcagga ggcggcacat aaaagcatgt taagtcgtag tgctgttgat 6900
agtggtaagg gtgataaggg tgagagtagt agtggtaaga gtagtttgga aggagatata 6960
tccttagcag aatttaaaaa tggctttaat ccaagtgggt tgaagaacgt atgtcaaata 7020
acggaaaaac attcctatgc taatggtgca tcaaaggatc cttgtaatgg aaaaggaaac 7080
ggcaaggacc agagatttaa aatagaaacc caatggaaag atacaggcaa aagcggtaaa 7140
cacgttgacg tctatttacc tccacgacgc gaacatatat gtacctcaaa tttggaatat 7200
ttacttaagg gtaatagtga tcagattatg aaggttggaa ataacaaaat taatcattcc 7260
tttttgggag aggtattgct agcagcaaaa tatgaagcag aattcataaa aaccaattat 7320
acgagattaa atggccaaaa tgacaatgga gctaaatgta gagctatgaa atatagtttt 7380
gctgatatag gagatattgt acgaggaaga gatctgtggg aacataatga ttttaaaaag 7440
ctagaacgag atttggtaaa aatatttggt aaaattaaag agggaattac tgatgagaca 7500
accaaaaaac aatatgaaaa ggatgacaca gacaataaac aattacgttg tgattggtgg 7560
gaagctaacc gtgatcaagt atgggaagca atgcagtgta aaacaacaat accaccagtc 7620
accacaagtt gtgatactac cactgttacc cctcttgtgg attacatccc ccaaagatta 7680

cgttggatga tggaatgggc agaatggtat tgtaaatatc aatcgaaggc atatagtgag 7740
ttgaggaagg ggtgtgagga ttgtaggagt tggaaatgta tgaagggtga tagtaaatgt 7800
gagaattgca caaaagcttg taaagactat aatagtaaaa tagaaccatg gaaacagcaa 7860
tggacaaaaa taaaagaaaa atacgaagaa ttatacaaaa aagcacaaaa tagtgatacc 7920
tctaatagtg gtacaacata tcccaaagat gagaaagatg tcgtttcttt tttgtcaaaa 7980
ttacacgaaa aaaataaaga caataagata tattatactg ctgcaggata tatacatcaa 8040
caagcaaaat atttagattg tacacaacaa acacattttt gtgataaaaa aaatggcgag 8100
acattaccta gcggtagaga caatgacaaa tatgctttta agaaaccgcc aaaaaaatat 8160
gaacgagcat gtaaatgtca cgagaaacag gaaccaccac ctcctaaggt accagaagat 8220
tcagaggacg atagagaacg atcagaacct ggtgaagatg cactccctgt actcccacca 8280
gaagaaatag aacaagagga agaacccgaa gaaacttccg tagacactac acaagatgag 8340
gaggaaccag catccgaagg aggtggccca tcgggatcac caacagaaga aagtggggaa 8400
ccaagagaaa atagtgatag ctccgacccc aaacctgacc aaaaccccga agccaacccc 8460
gaacaaacac cgatactcaa acccgaagaa gaagcaccac caaaatcaaa accacccgat 8520
ggagatcgtg gcgtaggacg ttctttagga ccaaccccac gttctgaagt tgaacccgag 8580
gaatccgaaa acgaagacgt cgaagacgaa gatgacgaag aggaggaaga agaccccgac 8640
gacgaccccg aggcggagtc ggaggaggaa gatgaagatc acggcggcca ggaggcggag 8700
gcggtaccac cacaacccca agcaccagca cctctacccc ctcctccacc acctttaccc 8760
ccccttaaaa ccgccctcat gtcttctacc atcatgtgga gtgtaggtat cggttttgcg 8820
gccatcagtt acttttttact aaagaaaaaa ccgaaatcac ctgttgacct catacgtgta 8880
attgatatcc ataaaggcga ttatggaata cctacattgg aatccaaaaa tagatatatc 8940
ccctatgtga gtgatacata caaaggcaaa acatatatat atatggaagg agatactagt 9000
ggagatgaaa aatatggatt tatgtctgat actactgata taacttcctc cgaaagtgag 9060
tatgaagaat tggatattaa tgatatatat gtaccaggta gtcctaaata taaaacattg 9120
atagaagtag tattggaacc atcaaaaagt aatggtaaca cactaggtga tgatatggta 9180
cctaccacga atacatttac agatgaggaa tggaatgaat tgaaacacga ttttatatca 9240
caatatatac aaagtgaacc actgaatgta ccacaatatg atgtattaaa ggagttacca 9300
atgaatatag taggtaatgt tttagatgat ggtataaacg aaaaaccttt tattacttct 9360
attcatgata gggatttaaa tagtggagaa gaaattagtt ataatattaa tatgagtact 9420
aatagtatgg atgatccaaa atatgtatca aataatgtat attctggtat agatttaatt 9480
aatgattcac taagtggtgg taaacctatt gatatatatg atgaagtgct aaaaagaaaa 9540
gaaaatgaat tatttggaac aaattataag aaaaatacat caaataacaa tgtagctaaa 9600
ttaacaaata gtgatccaat tatgaaccaa ttagatttgt tacataaatg gttagataga 9660
catagagata tgtgtgagat gtggaataat aaagaggaag tattagataa attaaaagaa 9720
caatggaata aagataatga tggtggtgat atatcaagtg atagtaacaa aaggttgaat 9780
acggatgttt cgattgaaat agatatggat gatcctaaag gaaagaagga atttagtaat 9840
atggatacta tcttggataa tatagaagat gatatatatt atgatgtaaa tgatgaaaac 9900
ccatctgtga atgatatacc tatggatcat aataaagtag atgtacctaa gaaagtacat 9960
gttgaaatga aaatccttaa taatacatcc actggatcct tggaacaaca atttcctata 10020
tcggatgtat ggaatatata a 10041

<210> 6
<211> 3346
<212> PRT
<213> Plasmodium falciparum

<400> 6

```
Met Gly Asn Thr Gln Ser Ser Glu Glu Glu Glu Ala Lys Ser Pro Ser
 1               5                  10                  15
Leu Thr Glu Ser His Asn Ser Ala Arg Gly Val Leu Glu Glu Ile Gly
            20                  25                  30
Lys Lys Ile Lys Asp Lys Thr Glu Lys Glu Ser Lys His Val Arg Gln
        35                  40                  45
Leu Lys Gly Lys Leu Ser Asn Ala Lys Phe Ala Asp Arg Leu Tyr Lys
    50                  55                  60
Glu Ser Gly Gly Asp Leu Arg Ser Ala Tyr Ser Asp Ala Cys Ser Leu
65                  70                  75                  80
```

```
Thr Tyr Lys Phe His Thr Asn Ile Thr Thr Asp Gly Gly Asp Gly Arg
                85                  90                  95
His Pro Cys His Gly Arg Glu Asn Asn Arg Phe Ser Glu Ser Gln Glu
            100                 105                 110
Tyr Gly Cys Ser Asn Val Tyr Ile Lys Gly Asn Glu Asn Asn Ser Asn
        115                 120                 125
Gly Thr Ala Cys Val Pro Pro Arg Arg Arg His Ile Cys Asp Gln Asn
    130                 135                 140
Leu Glu Phe Leu Asp Asn Pro His Thr Asp Asp Thr Asp Asp Leu Leu
145                 150                 155                 160
Gly Asn Val Leu Val Thr Ala Lys Tyr Glu Gly Asn Tyr Ile Val Ser
                165                 170                 175
Asn His Pro Asp Lys Asn Ser Asn Gly Asn Lys Ser Gly Ile Cys Thr
            180                 185                 190
Ser Leu Ala Arg Ser Phe Ala Asp Ile Gly Asp Ile Val Arg Gly Arg
        195                 200                 205
Asp Met Phe Lys Ser Asn Glu Lys Val Glu Ile Gly Leu Lys Lys Val
    210                 215                 220
Phe Glu Lys Ile Asn Asn Gly Leu Lys Lys Ile Gly Ile Asn Asp Tyr
225                 230                 235                 240
Asn Asp Ile Ser Gly Asn Tyr Tyr Lys Leu Arg Glu Ala Trp Trp Thr
                245                 250                 255
Ala Asn Arg Asp Gln Val Trp Lys Ala Ile Thr Cys Arg Ala Pro Asn
            260                 265                 270
Gly Ala Asn Tyr Phe Arg Lys Gly Leu Asp Gly Lys Ile Ile Phe Ser
        275                 280                 285
Asp Asn Gly Pro Cys Gly Arg Lys Glu Leu Ile Val Pro Thr Tyr Leu
    290                 295                 300
Asp Tyr Val Pro Gln Phe Leu Arg Trp Leu Asn Glu Trp Ser Glu Glu
305                 310                 315                 320
Phe Cys Arg Ile Lys Asn Ile Lys Ile Gly Asn Ile Lys Lys Ser Cys
                325                 330                 335
Thr Gly Glu Ser Asn Asn Lys His Cys Ser Arg Glu Gly Tyr Asp Cys
            340                 345                 350
Asn Lys Thr Asn Leu Arg Leu Asn Glu Ile Phe Met Asp Leu Glu Cys
        355                 360                 365
Pro Arg Cys Ala Asp Asp Cys Lys Ser Tyr Glu Thr Trp Val Glu Lys
    370                 375                 380
Lys Lys Lys Glu Phe Asn Lys Gln Lys Lys Lys Tyr Glu Lys Glu Val
385                 390                 395                 400
Asp Ala Thr Gln Asn Asn Asp Asn Asn Glu Asn Gly Ile Tyr Asn Lys
                405                 410                 415
Lys Phe Tyr Asp Glu Leu Lys Ser Ser Tyr Lys Glu Val Asn Ser Phe
            420                 425                 430
Phe Glu Leu Leu Asn Lys Gly Pro Ile Cys Glu His Ile Asp Lys Lys
        435                 440                 445
Ile Pro Met Asp Tyr Asn Asn Thr Glu Lys Thr Phe Ser Arg Ser Glu
    450                 455                 460
Tyr Cys Lys Ser Cys Pro Ile Thr Asp Ile Leu Cys Asp Asp Asn Glu
465                 470                 475                 480
Cys Lys Thr Ile Asn Glu Phe Lys Cys Arg Glu Ile Lys Ser Met Pro
                485                 490                 495
Asn Ile Arg Lys Asn Glu Asn Glu Thr Pro Ile Asp Ile Asp Ile Leu
            500                 505                 510
Val Asn Val Asn Asn Lys Lys Val Ile Thr His Asp Leu Lys Asn Asn
        515                 520                 525
Tyr Glu Asn Cys Asp Leu Phe Lys Lys Leu Gly Glu Gln Lys Trp Lys
    530                 535                 540
Cys Lys Tyr Lys Cys Tyr Leu Asp Val Cys Glu Pro Arg Asn Leu Asp
```

```
545                 550                 555                 560
Ser Asn Ile Tyr Asn Glu Arg Tyr Ile Ser Ile Lys Val Leu Phe Lys
            565                 570                 575
Arg Trp Leu Glu Tyr Phe Leu Glu Asp Tyr Asn Lys Leu Lys Glu Lys
        580                 585                 590
Leu Asn Pro Cys Met Tyr Asn Val Gln Glu Ile Val Cys Ile Asn Glu
    595                 600                 605
Cys Lys Gln Asn Cys Glu Cys Val Glu Lys Trp Ile Lys Glu Lys Arg
610                 615                 620
Glu Glu Trp Lys Lys Ile Lys Asp Arg Tyr Val Gln Gln Tyr Glu Ser
625                 630                 635                 640
Lys Asp Glu Asp Val Ser Ser Lys Leu Lys Lys Phe Leu Lys Gln Glu
                645                 650                 655
Leu Phe Thr Asn Tyr Val Lys Asn Ala Leu Asp Lys Asp Glu Thr Leu
            660                 665                 670
Asp Ser Met Lys Glu Ser Thr Glu Cys Ile Asp Pro Asn Lys Pro Lys
        675                 680                 685
Gly Lys Pro Cys Asn Asn Asn Asp Val Ile Asn Ile Leu Leu Asn Arg
    690                 695                 700
Leu Glu Lys Gln Ile Asp Asn Cys Lys Lys Lys His Glu Glu Lys Gly
705                 710                 715                 720
Glu Lys Pro Cys Val Asp Ile Pro Lys Leu Leu Asn Asp Glu Asp Glu
                725                 730                 735
Asp Glu Asp Asp Asp Glu Thr Pro Arg Ala His Asn Pro Cys Val Asp
            740                 745                 750
Lys Asn Asp Ser Gln Pro Thr Lys Thr Val Ser Tyr Ile Ala Arg Gln
        755                 760                 765
Met His Arg Arg Ala Lys Ala Gln Met Thr Lys Asn Ser Val Val Asp
    770                 775                 780
Gly Asp Asn Lys Leu Glu Gly Asp Ile Phe Lys Val Thr Phe Arg Asn
785                 790                 795                 800
Gly Gly Val Gly Lys Asn Leu Asn Gly Asp Ile Cys Lys Ile Asp Lys
                805                 810                 815
Thr Tyr Ser Asn Asp Ser Arg Gly Thr Pro Thr Asp Gly Pro Cys Glu
            820                 825                 830
Gly Lys Gly Asp Arg Phe Lys Ile Gly Thr Asp Trp Gln Gly Asp Ser
        835                 840                 845
Phe Val Asn Pro Gln Tyr Arg Gly Ile Tyr Met Pro Pro Arg Arg Gln
    850                 855                 860
His Phe Cys Thr Ser Asn Leu Glu Lys Leu Asp Val Ser Arg Val Ile
865                 870                 875                 880
Arg Asn Gly Asn Ala Ser Asn Ser Leu Leu Gly Asp Val Leu Leu Ala
                885                 890                 895
Ala Lys Tyr Glu Ala Glu Arg Thr Lys Asn His Tyr Val Ser Lys Lys
            900                 905                 910
Glu Glu His Ser Glu Ala Cys Arg Ala Val Arg Tyr Ser Phe Ala Asp
        915                 920                 925
Leu Gly Asp Ile Ile Arg Gly Lys Asp Met Trp Asp Lys Asn His Gly
    930                 935                 940
Glu Lys Lys Thr Gln Glu Asn Leu Glu Arg Ile Phe Ala Lys Ile Lys
945                 950                 955                 960
Glu Gln Leu Leu Asn Ser Ser Ile Lys Asp Lys Tyr Lys Asp Asp Asp
                965                 970                 975
Lys Ala Thr Pro Lys Tyr Lys Gln Leu Arg Glu Asp Trp Trp Glu Ala
            980                 985                 990
Asn Arg Ser Gln Val Trp Glu Ala Met Gln Cys Pro Pro Lys Asn Gly
        995                 1000                1005
Thr Phe Pro Cys Lys Ser Asp His Thr Pro Leu His Asp Tyr Ile Pro
    1010                1015                1020
```

Gln Arg Leu Arg Trp Met Thr Glu Trp Ala Glu Trp Tyr Cys Lys Glu
1025 1030 1035 1040
Gln Ser Arg Leu Tyr Gly Glu Leu Val Glu Thr Cys Gly Lys Cys Met
1045 1050 1055
His Lys Gly Lys Cys Lys Gln Gly Asn Gly His Cys Val Thr Cys Lys
1060 1065 1070
Pro Ala Cys Glu Lys Tyr Lys Lys Phe Ile Asn Thr Trp Gln Pro Gln
1075 1080 1085
Trp Lys Gln Met Glu Gln Lys Tyr Ser Gln Leu Tyr Glu Glu Ala Lys
1090 1095 1100
Lys Tyr Asn Asp Ser Ser Arg Lys Asp Thr Thr Asn Lys Asp Asp Tyr
1105 1110 1115 1120
Val Leu Gln Phe Leu Asn Lys Leu Leu Thr Gln Asn Lys Gly Asn Lys
1125 1130 1135
Thr Tyr Asp Thr Ala Glu Gly Tyr Val His Gln Glu Ala His Ile Ser
1140 1145 1150
Asp Cys Gln Lys Gln Thr Gln Phe Cys Lys Lys Arg Asn Gly Glu Ile
1155 1160 1165
Pro Ser Ser Asp Thr Glu Thr Asp Asn Asn Tyr Ala Phe Arg Pro Gln
1170 1175 1180
Pro His Asp His Asp Glu Val Cys Glu Cys Asn Thr Arg Gln Lys Thr
1185 1190 1195 1200
Lys Val Arg Lys Lys Lys Lys Lys Val Asp Ala Cys Glu Met Ala Lys
1205 1210 1215
Thr Leu Leu His Asn Asn Asp Gly Thr Ile Arg Ile Gly Gln Cys Lys
1220 1225 1230
Arg Lys Asp Glu Gly Asn Ala Glu Tyr Pro Lys Trp Asp Cys Asn Ser
1235 1240 1245
Gln Ile His Thr Thr His Asn Gly Ala Cys Met Pro Pro Arg Arg Gln
1250 1255 1260
Lys Leu Cys Val Tyr Phe Phe Ala Asn Pro Ser Gln Ile Gly Ser Ile
1265 1270 1275 1280
Asn Lys Gln Asp Asn Leu Arg Lys Ala Phe Ile Ile Ser Ala Ala Ala
1285 1290 1295
Glu Thr Phe Arg Ser Trp Gln Tyr Tyr Lys Ser Lys Asn Gly Gly Glu
1300 1305 1310
Asn Leu Gln Thr Gln Leu Lys Asp Gly Thr Ile Pro Asp Asp Phe Lys
1315 1320 1325
Arg Gln Met Phe Tyr Thr Tyr Gly Asp Tyr Arg Asp Phe Leu Phe Gly
1330 1335 1340
Thr Asp Ile Ser Lys Gly Leu Gly Glu Gly Thr Ala Leu Glu Lys Gln
1345 1350 1355 1360
Ile Asn Ile Leu Phe Pro Asn Gly Val Arg Lys Ile Pro Asn Glu Lys
1365 1370 1375
Thr Arg Glu Lys Trp Trp Thr Asp His Gly Pro Glu Ile Trp Lys Gly
1380 1385 1390
Met Leu Cys Ala Leu Thr Asn Gly Leu Ser Glu Ser Glu Lys Lys Thr
1395 1400 1405
Lys Ile Phe Asp Asp Tyr Ser His Asp Lys Val Asn Gln Ser Lys Asn
1410 1415 1420
Gly Asn Pro Ser Leu Glu Asp Phe Ala Lys Lys Pro Gln Phe Phe Arg
1425 1430 1435 1440
Trp Phe Ile Glu Trp Ser Asp Glu Phe Cys Arg Glu Arg Lys Lys Lys
1445 1450 1455
Glu Glu Glu Val Glu Arg Asp Cys Lys Asp Glu Tyr Glu Gly Cys Glu
1460 1465 1470
Lys Glu Lys Asn Gly Lys Cys Val Thr Ala Cys Lys Ala Tyr Lys Glu
1475 1480 1485
Tyr Ile Thr Asn Lys Lys Glu Glu Tyr Asp Ser Gln Lys Gly Lys Phe

1490 1495 1500
Asp Val Glu Lys Thr Glu Lys Lys Gln Gly Tyr Glu Asp Tyr Ser Glu
1505 1510 1515 1520
Lys Gln Ala Ser Glu Tyr Leu Lys Glu Lys Cys Ile Lys Ser Ser Cys
1525 1530 1535
Asn Cys Met Lys Lys Val Thr Glu Ile Ser Asn Tyr Trp Thr Asn Pro
1540 1545 1550
His Lys Thr Tyr Asp Thr Glu Asn Leu Gly Ile Lys Cys Glu Cys Pro
1555 1560 1565
Pro Ser Pro Cys Thr Ile Val Asp Gly Ile Leu Ser Pro Gln Asn Ser
1570 1575 1580
Ser Ser Tyr Ala Glu Gly Cys Lys Trp Lys Tyr Gly Lys Met Ser Gln
1585 1590 1595 1600
Gly Gly Thr Glu Trp Asp Cys Ser Lys Lys Ser Gly Gly Glu Gly Gly
1605 1610 1615
Asn Glu Asp Gly Asp Val Val Cys Ile Pro Pro Arg Arg Arg Arg Leu
1620 1625 1630
Tyr Val Lys Asn Leu Gln Asp Leu Thr Gly Glu Glu Ser Leu Val Asp
1635 1640 1645
Leu Arg Lys Ala Phe Ile Lys Cys Ala Ala Ile Glu Thr Phe Phe Ala
1650 1655 1660
Trp His Glu Phe Lys Lys Glu Lys Glu Arg Glu Glu Lys Glu Lys Asn
1665 1670 1675 1680
Glu Gln Asp Val Gln Tyr Lys Ser Ser Val Leu Glu Asn Leu Gln Lys
1685 1690 1695
Gln Leu Lys Asn Gly Glu Ile Asp Asp Glu Phe Lys Arg Gln Met Phe
1700 1705 1710
Tyr Thr Phe Ala Asp Tyr Arg Asp Ile Cys Leu Gly Lys Asp Ile Gly
1715 1720 1725
Asn Asp Val Asp Gly Ile Asn Glu Lys Ile Asp Thr Ile Leu Gln Lys
1730 1735 1740
Asn Gly Lys Pro Asn Asn Ile Glu Glu Tyr Lys Lys Trp Trp Gln Lys
1745 1750 1755 1760
His Gly His Glu Ile Trp Glu Gly Met Leu Cys Ala Leu Ser Tyr Asn
1765 1770 1775
Thr Glu Thr Lys Glu Met Asp Lys Glu Leu Arg Asn Lys Leu Thr Glu
1780 1785 1790
Gln Lys Asn Gly Asn Lys Asn Thr Tyr Asp Thr Val Thr Ile Ser Gly
1795 1800 1805
Gly Pro Ile Gly Asn Thr Lys Leu Glu Lys Phe Ala Ser Arg Pro Pro
1810 1815 1820
Phe Phe Arg Trp Leu Glu Glu Trp Ala Asp Glu Phe Cys Arg Lys Arg
1825 1830 1835 1840
Thr His Lys Leu Glu Lys Ile Gln Asn Glu Cys Lys Gly Val Ser Gly
1845 1850 1855
Thr Asn Gln Cys Asp Asp Asp Gly Phe Asp Cys Asp Glu Met Cys Pro
1860 1865 1870
Lys Lys Asp Gly Ser Phe Glu Thr Phe Lys Cys Leu Ser Cys Ala Lys
1875 1880 1885
Ser Cys Arg Phe Tyr Lys Lys Trp Ile Ser Arg Lys Lys Glu Glu Phe
1890 1895 1900
Asp Lys Gln Ser Lys Lys Tyr Glu Asn Glu Ile Asp Asp Val Lys His
1905 1910 1915 1920
Asn Ser Asp Asn Ile Tyr Gly Lys Asp Phe Leu Glu Thr Leu Asp Gln
1925 1930 1935
Gln Tyr Lys Ser Val Glu Leu Phe Leu Glu Lys Val Lys Gly Pro Cys
1940 1945 1950
Ser Ile Asn Asn Asn Asn Glu Glu Cys Lys Ile Asp Phe Asn Lys Pro
1955 1960 1965

Lys Asp Thr Phe Gly His Ala Lys Asn Cys Gly Pro Cys Ser Glu Ile
1970 1975 1980
Arg Phe Lys Cys Ile Glu Asp Asn Ser Asn Trp Val Thr Thr Asn Thr
1985 1990 1995 2000
Cys Asn Lys Thr Thr Phe Lys Phe Thr Glu Asp Asn Lys Asp Thr Lys
2005 2010 2015
Glu Asp Ser Glu Gln Leu Gly Met Leu Ile Ser Asp Asn Thr Val Gln
2020 2025 2030
Asn Phe Ala Asp Gly Leu Gln Asn Asp Cys Lys Asp Ala Asp Ile Phe
2035 2040 2045
Lys Gly Leu Arg Lys Asp Gln Trp Ser Cys Gly Tyr Phe Cys Asn Leu
2050 2055 2060
Asp Ile Cys Ser Leu Lys Thr Ser His Gly Glu Asn Asn Tyr Lys Gln
2065 2070 2075 2080
Asn Ile Leu Ile Arg Ala Leu Phe Lys Arg Trp Leu Glu His Phe Leu
2085 2090 2095
Glu Asp Tyr Asn Lys Ile Asn Asp Lys Ile Ser His Cys Met Lys Asn
2100 2105 2110
Gly Glu Gly Ser Thr Cys Ile Lys Gly Cys Glu Ile Lys Cys Asn Cys
2115 2120 2125
Val Ser Asn Trp Ile Lys Lys Lys Thr Leu Glu Trp Glu Ile Val Arg
2130 2135 2140
Asp Arg Phe Phe Lys Gln Tyr Asn Val Asp Ser Glu Lys Ser Phe Thr
2145 2150 2155 2160
Val Lys Ser Phe Leu Glu Gln Ala Pro Phe Asp Ser Asp Val Gln Lys
2165 2170 2175
Ala Ile Lys Pro Phe Glu Lys Leu Arg Asp Phe Glu Asp Ser Ile Val
2180 2185 2190
Cys Asn Gly Thr Thr Ser Ala Arg Lys Glu Lys Gly Thr Glu Lys Asp
2195 2200 2205
Val Val Ile Cys Leu Leu Asp Lys Leu Gln Lys Gln Ile Glu Thr Cys
2210 2215 2220
Gln Thr Lys His Lys Glu Thr Ser Gly Asn Thr Cys Ser Pro Pro Pro
2225 2230 2235 2240
Asn Pro Asp Thr Gln Thr Asp Thr Pro Leu Pro Leu Glu Ser Phe Pro
2245 2250 2255
Pro Pro Phe Cys Asn Val Pro Pro Asn Pro Cys Gly Asp Lys Asp Ala
2260 2265 2270
Thr Asn Val Val Gly Val Glu Val Leu Ala Lys Glu Met Gln Glu Ala
2275 2280 2285
Ala His Lys Ser Met Leu Ser Arg Ser Ala Val Asp Ser Gly Lys Gly
2290 2295 2300
Asp Lys Gly Glu Ser Ser Ser Gly Lys Ser Ser Leu Glu Gly Asp Ile
2305 2310 2315 2320
Ser Leu Ala Glu Phe Lys Asn Gly Phe Asn Pro Ser Gly Leu Lys Asn
2325 2330 2335
Val Cys Gln Ile Thr Glu Lys His Ser Tyr Ala Asn Gly Ala Ser Lys
2340 2345 2350
Asp Pro Cys Asn Gly Lys Gly Asn Gly Lys Asp Gln Arg Phe Lys Ile
2355 2360 2365
Glu Thr Gln Trp Lys Asp Thr Gly Lys Ser Gly Lys His Val Asp Val
2370 2375 2380
Tyr Leu Pro Pro Arg Arg Glu His Ile Cys Thr Ser Asn Leu Glu Tyr
2385 2390 2395 2400
Leu Leu Lys Gly Asn Ser Asp Gln Ile Met Lys Val Gly Asn Asn Lys
2405 2410 2415
Ile Asn His Ser Phe Leu Gly Glu Val Leu Leu Ala Ala Lys Tyr Glu
2420 2425 2430
Ala Glu Phe Ile Lys Thr Asn Tyr Thr Arg Leu Asn Gly Gln Asn Asp

```
          2435                2440                2445
Asn Gly Ala Lys Cys Arg Ala Met Lys Tyr Ser Phe Ala Asp Ile Gly
     2450                2455                2460
Asp Ile Val Arg Gly Arg Asp Leu Trp Glu His Asn Asp Phe Lys Lys
2465                2470                2475                2480
Leu Glu Arg Asp Leu Val Lys Ile Phe Gly Lys Ile Lys Glu Gly Ile
                2485                2490                2495
Thr Asp Glu Thr Thr Lys Lys Gln Tyr Glu Lys Asp Asp Thr Asp Asn
           2500                2505                2510
Lys Gln Leu Arg Cys Asp Trp Trp Glu Ala Asn Arg Asp Gln Val Trp
     2515                2520                2525
Glu Ala Met Gln Cys Lys Thr Thr Ile Pro Pro Val Thr Thr Ser Cys
     2530                2535                2540
Asp Thr Thr Thr Val Thr Pro Leu Val Asp Tyr Ile Pro Gln Arg Leu
2545                2550                2555                2560
Arg Trp Met Met Glu Trp Ala Glu Trp Tyr Cys Lys Tyr Gln Ser Lys
                2565                2570                2575
Ala Tyr Ser Glu Leu Arg Lys Gly Cys Glu Asp Cys Arg Ser Trp Lys
           2580                2585                2590
Cys Met Lys Gly Asp Ser Lys Cys Glu Asn Cys Thr Lys Ala Cys Lys
     2595                2600                2605
Asp Tyr Asn Ser Lys Ile Glu Pro Trp Lys Gln Gln Trp Thr Lys Ile
     2610                2615                2620
Lys Glu Lys Tyr Glu Glu Leu Tyr Lys Lys Ala Gln Asn Ser Asp Thr
2625                2630                2635                2640
Ser Asn Ser Gly Thr Thr Tyr Pro Lys Asp Glu Lys Asp Val Val Ser
                2645                2650                2655
Phe Leu Ser Lys Leu His Glu Lys Asn Lys Asp Asn Lys Ile Tyr Tyr
           2660                2665                2670
Thr Ala Ala Gly Tyr Ile His Gln Gln Ala Lys Tyr Leu Asp Cys Thr
     2675                2680                2685
Gln Gln Thr His Phe Cys Asp Lys Lys Asn Gly Glu Thr Leu Pro Ser
     2690                2695                2700
Gly Arg Asp Asn Asp Lys Tyr Ala Phe Lys Lys Pro Pro Lys Lys Tyr
2705                2710                2715                2720
Glu Arg Ala Cys Lys Cys His Glu Lys Gln Glu Pro Pro Pro Pro Lys
                2725                2730                2735
Val Pro Glu Asp Ser Glu Asp Asp Arg Glu Arg Ser Glu Pro Gly Glu
           2740                2745                2750
Asp Ala Leu Pro Val Leu Pro Pro Glu Glu Ile Glu Gln Glu Glu Glu
     2755                2760                2765
Pro Glu Glu Thr Ser Val Asp Thr Thr Gln Asp Glu Glu Glu Pro Ala
     2770                2775                2780
Ser Glu Gly Gly Gly Pro Ser Gly Ser Pro Thr Glu Glu Ser Gly Glu
2785                2790                2795                2800
Pro Arg Glu Asn Ser Asp Ser Ser Asp Pro Lys Pro Asp Gln Asn Pro
                2805                2810                2815
Glu Ala Asn Pro Glu Gln Thr Pro Ile Leu Lys Pro Glu Glu Glu Ala
           2820                2825                2830
Pro Pro Lys Ser Lys Pro Pro Asp Gly Asp Arg Gly Val Gly Arg Ser
     2835                2840                2845
Leu Gly Pro Thr Pro Arg Ser Glu Val Glu Pro Glu Glu Ser Glu Asn
     2850                2855                2860
Glu Asp Val Glu Asp Glu Asp Asp Glu Glu Glu Glu Glu Asp Pro Asp
2865                2870                2875                2880
Asp Asp Pro Glu Ala Glu Ser Glu Glu Glu Asp Glu Asp His Gly Gly
                2885                2890                2895
Gln Glu Ala Glu Ala Val Pro Pro Gln Pro Gln Ala Pro Ala Pro Leu
           2900                2905                2910
```

Pro Pro Pro Pro Pro Pro Leu Pro Pro Leu Lys Thr Ala Leu Met Ser
2915 2920 2925
Ser Thr Ile Met Trp Ser Val Gly Ile Gly Phe Ala Ala Ile Ser Tyr
2930 2935 2940
Phe Leu Leu Lys Lys Lys Pro Lys Ser Pro Val Asp Leu Ile Arg Val
2945 2950 2955 2960
Ile Asp Ile His Lys Gly Asp Tyr Gly Ile Pro Thr Leu Glu Ser Lys
2965 2970 2975
Asn Arg Tyr Ile Pro Tyr Val Ser Asp Thr Tyr Lys Gly Lys Thr Tyr
2980 2985 2990
Ile Tyr Met Glu Gly Asp Thr Ser Gly Asp Glu Lys Tyr Gly Phe Met
2995 3000 3005
Ser Asp Thr Thr Asp Ile Thr Ser Ser Glu Ser Glu Tyr Glu Glu Leu
3010 3015 3020
Asp Ile Asn Asp Ile Tyr Val Pro Gly Ser Pro Lys Tyr Lys Thr Leu
3025 3030 3035 3040
Ile Glu Val Val Leu Glu Pro Ser Lys Ser Asn Gly Asn Thr Leu Gly
3045 3050 3055
Asp Asp Met Val Pro Thr Thr Asn Thr Phe Thr Asp Glu Glu Trp Asn
3060 3065 3070
Glu Leu Lys His Asp Phe Ile Ser Gln Tyr Ile Gln Ser Glu Pro Leu
3075 3080 3085
Asn Val Pro Gln Tyr Asp Val Leu Lys Glu Leu Pro Met Asn Ile Val
3090 3095 3100
Gly Asn Val Leu Asp Asp Gly Ile Asn Glu Lys Pro Phe Ile Thr Ser
3105 3110 3115 3120
Ile His Asp Arg Asp Leu Asn Ser Gly Glu Glu Ile Ser Tyr Asn Ile
3125 3130 3135
Asn Met Ser Thr Asn Ser Met Asp Asp Pro Lys Tyr Val Ser Asn Asn
3140 3145 3150
Val Tyr Ser Gly Ile Asp Leu Ile Asn Asp Ser Leu Ser Gly Gly Lys
3155 3160 3165
Pro Ile Asp Ile Tyr Asp Glu Val Leu Lys Arg Lys Glu Asn Glu Leu
3170 3175 3180
Phe Gly Thr Asn Tyr Lys Lys Asn Thr Ser Asn Asn Asn Val Ala Lys
3185 3190 3195 3200
Leu Thr Asn Ser Asp Pro Ile Met Asn Gln Leu Asp Leu Leu His Lys
3205 3210 3215
Trp Leu Asp Arg His Arg Asp Met Cys Glu Met Trp Asn Asn Lys Glu
3220 3225 3230
Glu Val Leu Asp Lys Leu Lys Glu Gln Trp Asn Lys Asp Asn Asp Gly
3235 3240 3245
Gly Asp Ile Ser Ser Asp Ser Asn Lys Arg Leu Asn Thr Asp Val Ser
3250 3255 3260
Ile Glu Ile Asp Met Asp Asp Pro Lys Gly Lys Lys Glu Phe Ser Asn
3265 3270 3275 3280
Met Asp Thr Ile Leu Asp Asn Ile Glu Asp Asp Ile Tyr Tyr Asp Val
3285 3290 3295
Asn Asp Glu Asn Pro Ser Val Asn Asp Ile Pro Met Asp His Asn Lys
3300 3305 3310
Val Asp Val Pro Lys Lys Val His Val Glu Met Lys Ile Leu Asn Asn
3315 3320 3325
Thr Ser Thr Gly Ser Leu Glu Gln Gln Phe Pro Ile Ser Asp Val Trp
3330 3335 3340
Asn Ile
3345